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i Abstract 
Several series of photo-activated carbon monoxide-releasing molecules have been synthesised 
and characterised for use as potential pharmaceutical molecules. 
Initial CO-RMs synthesised were based on a tetracarbonyl phenylpyridine(I) complex, with 
substitutions in the para-phenyl position. All were shown to release CO when irradiated with 
light of wavelength 365 nm.  
An LED system was developed to irradiate samples in CO-release quantification assays. 
 A carboxylic acid-containing CO-RM was then developed to improve solubility. The new CO-
RM is water compatible and releases three molecules of CO per molecule of CO-RM. It has been 
shown to be viable with sensitive RAW 264.7 macrophage cells, and to exhibit a toxic effect on 
E. coli in combination with light of wavelength 400 nm. 
 An L tryptophan-containing CO-RM was synthesised and is water compatible; and releases CO 
when irradiated at 465 nm light. It is viable with RAW 264.7 cells and is capable of suppressing 
an inflammatory response initiated by LPS and IFN-γ and been shown to have a detrimental 
effect on E. coli, S. aureus, and N. gonorrhoeae.  
An alkyne-containing CO-RM was designed so that it could be used in Huisgen [3+2] 
cycloaddition chemistry. This CO-RM was functionalised using 4-azidobenzoic and biotin to 
give two new triazole-containing CO-RMs. The biotin-containing CO-RM has been shown to 
release CO and bind strongly with an avidin target. 
Bacterial studies with a tryptophan-containing CO-RM show that increased optical density of 
cultures decreases the effectiveness of the CO-RM, due to reduced light penetration. This lead to 
the development of dye-containing CO-RM, which is based on a benzothiazole azodye. This dye-
CO-RM contains a UV-band associated with CO-release that tails out to a higher wavelength 
than any of the previous CO-RMs prepared in this project. 
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1 Introduction 
1.1 Carbon monoxide (CO) as a ligand 
Carbon monoxide (CO) is a di-atomic species consisting of one carbon and oxygen atom with a 
double bond and a dative bond. The bonding in carbon monoxide can be considering in the 
following way (Figure 1). 
 
Figure 1. The structure of carbon monoxide  
There are two covalent bonds between the carbon and oxygen with an additional dative bond 
from the oxygen. This makes the bond very strong compared to a typical CO or CC double 
bond.1  Carbon monoxide is relatively inert compared to triplet dioxygen (O2) which has two 
unpaired electrons. However this is situational and carbon monoxide can still undergo many 
reactions. In particular, it can bond strongly to metal centres.2-3 CO bonds strongly to metal 
centres because it can donate and receive electron density into different orbitals. The two types of 
bonding are shown in Figure 2. 
 
Figure 2. The bonding of carbon monoxide with a metal centre. Left: σ-donation into an empty 
metal d-orbital, Right: pi-back donation from a full metal d-orbital into the CO pi* anti bonding 
orbital.  
The use of d-orbitals with a 45° rotation respective to each other allows for this synergistic 
bonding, giving a strong interaction. This bonding could involve dxy and dx2−y2 orbitals to give the 
correct orientation. To demonstrate how a metal centre binds with CO, a molecular orbital 
diagram of CO needs to be considered (Figure 3). 
30 
 
 
Figure 3. The molecular orbital diagram for carbon monoxide. 
The diagram in Figure 3 shows that in carbon monoxide, the pi* anti-bonding orbital is empty, 
which explains why a metal centre dxy orbital can donate electron density into this orbital. The 
dxy–pi* interaction is bonding with respect to a metal carbonyl bond but anti-bonding with respect 
to the C–O bond. This is why metal carbonyl stretching frequencies typically come at lower 
wavenumber than free CO due to a weaker C–O bond because of the pi-back-bonding. The full σ 
orbital on CO can donate electron density into the empty dx2−y2 on a metal centre. Figure 4 shows 
how a metal centre can bind with carbonyl ligands in an octahedral configuration. This 
demonstrates how the resulting molecular orbitals are filled with electrons.4 
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Figure 4. The bonding of a manganese(I) centre with carbon monoxide with octahedral geometry 
Considering a manganese(I) metal centre it has a d6 electron shell configuration. The six CO 
ligands will donate two electrons each to the metal centre giving 12 electrons from these in total. 
The atomic orbitals on the metal and carbonyl ligands of matching symmetry overlap to form the 
molecular orbitals. The 18 electrons are situated in the lowest energy orbitals available. Due to 
the large splitting of the t2g and eg orbitals by the strong field CO ligands; the six highest energy 
electrons are situated in orbitals of t2g symmetry (dxy, dxz, and dyz). The ∆o is too large to allow for 
electron promotion to the eg orbitals (dz2 and dx2-y2). The highest occupied molecular orbitals are 
the t2g orbitals which are involved in the donation of electron density to the pi* orbital on the CO 
ligand. The lowest unoccupied molecular eg orbitals can accept electron density from σ orbitals 
on the CO ligand. Irradiation of a metal complex with light of energy ∆o can result in promotion 
of an electron in to the eg anti-bonding orbital. This can result in the loss of CO photolytically. 
Nitric oxide (NO) is another diatomic ligand which is similar to carbon monoxide and can also 
bind to metal centres. The structure of NO is shown in Figure 5. 
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Figure 5. The structure of nitric oxide. 
NO contains a double bond between its two atoms is a radical. This makes the ligand much more 
reactive and opens up more modes of binding. When NO bonds to a metal it can bind in a linear 
or bent fashion as shown in Figure 6.5 
 
Figure 6. Binding modes of NO to a metal centre. Left: linear binding, Right: bent NO binding.  
With linear NO binding, the unpaired electron is donated to the metal giving M-NO+. With NO+ 
now being isoelectronic to CO, it donates a further two electrons via σ-donation just like CO does 
making it a three-electron donor. 
With bent NO binding to a metal centre, the metal donates an electron in to the same orbital as 
the radical creating a lone pair, giving NO−, which is isoelectronic with di-oxygen (O2). This then 
donates two electrons to the metal centre and therefore is overall a one-electron donor. O2 also 
typically binds to metal centres in a bent fashion and it is clear why NO does this too when it 
becomes NO−.6 
 
1.2 Carbon monoxide and nitric oxide in biology 
Carbon monoxide and nitric oxide both play an important role in biological systems.7-8 Both of 
these are signalling molecules and it is not surprising considering their similar structures, that the 
signalling pathway of these molecules overlaps significantly.8 This could be considered to be 
counter-intuitive as in relatively high concentrations CO is toxic to many organisms.9 At lower 
concentrations, both of these molecules are involved in: the regulation of the immune system, 
muscle relaxation, vasodilation, blood pressure regulation, and healing processes such as 
thrombosis.7, 10 
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1.2.1 Carbon monoxide binding targets and protein regulation 
1.2.1.1 Carbon monoxide toxicity 
It is well known that CO can induce negative symptoms in humans. These effects start to occur at 
levels above 70 ppm.9 At these levels, the concentration of CO-Hb in the blood can reach 10-
15%. When the CO-Hb concentration is much higher than this, more severe symptoms are 
observed.  
There are two main reasons for CO toxicity with the first being that CO has a high affinity for 
myoglobin and haemoglobin. CO will bind strongly to the haem group in both of these proteins. 
This reduces the amount of oxygen available to the organism, inducing symptoms such as fatigue 
and headaches but is not the main reason for its toxicity. 
 CO can also inhibit the action of cytochrome c oxidase.11 This protein is found in mitochondria 
and is an essential part of the respiratory chain. If this chain is severely damaged, the cells cannot 
produce ATP and therefore cannot survive. One can consider this to be like having no fuel in the 
tank of a vehicle. 
Cytochrome c oxidase is a large integral membrane protein consisting of 13 subunits.12 The 
enzyme contains two haem centres.13 The haem centres can bind oxygen which is essential to the 
transfer of electrons into the mitochondria. Carbon monoxide can compete with oxygen with 
respect to haem centre binding. This competition interrupts the smooth operation of this enzyme 
resulting in significant inhibition. 
Miró carried out experiments using human muscle tissue to demonstrate the discussed 
mechanism of action.11 Mitochondria were isolated and each complex of the mitochondrial 
respiratory chain was assayed for enzyme activity at different CO concentrations. Table 1 shows 
the results obtained for cytochrome c oxidase. 
Table 1. The variation in cytochrome c oxidase activity in human mitochondria at varying CO 
concentrations. 
CO concentration / ppm Cytochrome c oxidase activity/ nmol min-1
 
mg
 
-1
 
Air 836 ± 439 
50 670 ± 401 
100 483 ± 182 
500 379 ±131 
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The results obtained shows statistical significance despite the large error in the measurements 
obtained. All the other protein complexes in the respiratory chain tested did not show any 
statistical significance and did not vary with CO concentration. This is an important study and it 
shows the site of action of carbon monoxide at higher concentrations. 
Interestingly, despite the high binding affinity of CO for haem proteins such as haemoglobin and 
cytochrome c oxidase, Killick and Marchant showed that dogs could be rescued under certain 
conditions.14 Dogs which had been poisoned with CO, giving rise to CO-Hb levels of up to 70%, 
could be rescued by immediate breathing of CO2/O2 mixtures. This work shows that with 
significant flushing of the system with fresh gas that the CO bound to various proteins is actually 
reversible. Figure 7 shows the reduction of CO-Hb within the experiment dogs while breathing 
various gas mixtures. 
 
Figure 7. The percentage of CO-Hb in dogs acutely poisoned with CO. Reduction over time 
when breathing various gas mixtures. Square - dogs breathing air, Cross - dogs breathing 100% 
O2, Circle - dogs breathing 5:95% CO2:O2 mixture. (Figure taken from ref. 14: Resuscitation of 
dogs from severe acute carbon monoxide poisoning, Killick, E. M.; Marchant, J. V. J. Physiol. 
1959, 147, 274-98, Copyright Wiley 1959) 
It is clear that the recovery of the dogs is improved when breathing pure oxygen or a CO2/O2 
mixture. This is expected as nitrogen in the air does not have any affinity for these proteins so 
cannot compete with the bound CO at all. It is interesting to see that results like this were 
obtained in the late 1950s, yet these kind of gas mixtures are not readily available where CO 
poisoning is a possible risk. Immediate access to gas mixtures like this could save someone’s life. 
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1.2.1.2 Haem degradation pathway - Natural CO production 
As a signalling molecule, CO can bind strongly with various proteins, which triggers regulation 
of further proteins. CO could be considered to be a signalling molecule early on in many 
pathways as it is produced during the degradation of haem. Scheme 1 shows how carbon 
monoxide is produced naturally within mammals and fish.15-17  
 
Scheme 1. The conversion of haem to Bilirubin. Side chains: M= Methyl,V= Vinyl, P= 
Proprionate.  
Haems like in Scheme 1 are present within many proteins such as haemoglobin, myoglobin, and 
many other enzymes. The haem is essential for protein function and as proteins break down the 
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haem material needs to be recycled/excreted. The haem also contributes to significant absorption 
in the 500-600 nm region of the spectrum and is often responsible for observed Q-bands. 
Carbon monoxide is released in the first step of the haem degradation pathway. Haem oxygenase 
cleaves a carbon-carbon bond and introduces two carbonyl groups to form amides, giving 
ferribiliverdin. This molecule of CO can then go on to up-regulate many enzymes including the 
ones in this cycle.  
Cytochrome p450 then removes the iron centre from the biliverdin structure by reducing it to 
iron(II). Biliverdin reductase then reduces a double bond in the structure introducing another 
pyrrole ring to giving the unconjugated bilirubin. If unconjugated bilirubin accumulates it can 
cause jaundice, particular in babies, which can cause serious health problems and can be 
potentially fatal.18 This highlights how important this pathway is and that smooth catalysis is 
constantly required. This could occur for many reasons but could potentially be due to the lack of 
glucuronidation leading to a lack of excretion because of poor solubility. 
 
1.2.1.3 Haem oxygenases and their importance 
As mentioned in section 1.2.1.2, haem oxygenases are essential to the haem degradation pathway. 
They catalyse the natural production of CO, and this then up regulates many further enzymes.10 
Haem oxygenase is present in three forms: HO-1, HO-2 and HO-3.19 HO-1 is an inducible form 
of the enzyme, which is activated in the presence of increased CO levels and various forms of 
stress including H2O2 and cytokines.20 HO-2 is a constitutive form of the enzyme that is present 
in lower levels and is not regulated by CO.21 HO-1 carries out the majority of the catalysis in this 
pathway; however both HO-1 and 2 are expressed at higher levels than each other in certain 
organs. For example, HO-2 is strongly expressed in the testes and HO-1 tends to be expressed 
strongly in areas of erythrocyte and haem degradation. HO-3 has a very similar structure to HO-2 
but little is known about what regulates HO-3 expression.19  
HO-1 is very important during times of injury and stress. Chen and co-workers showed that aortic 
transplant in mice without the HO-1 enzyme resulted in death within four days in all cases due to 
arterial thrombosis. Mice able to produce HO-1 survived the operation for at least 56 days.22 The 
low concentrations of CO due to the absence of HO-1 then results in many further enzymes not 
being up-regulated. This then results in: blood clotting, slow healing, and poor resistance to 
infection.  
The presence of HO-2 which is constitutive allows initial haem decomposition. This enzyme is 
important as cells are dying continually within a biological system and a mechanism is needed 
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for constant decomposition. During periods of physical and oxidative stress, an increased haem 
decomposition rate is essential and the up regulation of HO-1 from increase CO levels then 
provides this. 
Initial studies have shown the importance of the two haem oxygenase enzymes. A study by 
Gronert and co-workers compares injury repair rates in mice.23 HO-2 wild type and knockout 
mice were wounded and the cornea was stained with fluorescein; the rates and quality of healing 
was then compared. Figure 8 shows the results from this study. 
 
Figure 8. Results from a healing rate study in wild type and HO-2 null mice. A - Fluorescein 
stained cornea in wild type and HO-2 null mice. B - Study of re-epithelialisation, C - Photograph 
of specimens D - Neovascularisation study expressed as total length of penetrating vessels. 
(Figure taken from ref. 23: Heme Oxygenase-2 Is a Critical Determinant for Execution of an 
Acute Inflammatory and Reparative Response, Gronert, K.; Seta, F.; Bellner, L.; Rezzani, R.; 
Regan, R. F.; Dunn, M. W.; Abraham, N. G.; Laniado-Schwartzman, M. Am. J. Pathol. 2006, 
169, 1612-1623. Copyright Elsevier 2006). 
The study shows that the constitutive HO-2 enzyme is essential in initialising haem breakdown. 
Without this initial breakdown, the up-regulation of HO-1 due to CO release is not possible. 
Many other enzymes cannot be appropriately regulated, and this is evident from the slower 
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healing observed in the HO-2-null mice. The study also shows that healing in HO-2 null mice can 
be improved by administration of biliverdin. This shows that even though the CO released from 
the initial cleavage is important in homeostasis but there are many interlinked pathways which 
evolution has created to bypass certain situations. 
 
1.2.1.4 Guanylyl cyclase - regulation and implications 
Guanylyl cyclase is an important enzyme that is regulated by both CO and NO.20, 24 This links 
back to the similarity between NO and CO, and explains why they work in tandem in regulation 
and communication. Guanylyl cyclase catalyses the conversion of guanosine triphosphate (GTP) 
to cyclic guanosine monophosphate (cGMP). The structures of these two compounds are shown 
in Scheme 2.25 
 
Scheme 2. The conversion of GTP to cGMP by guanylyl cyclase 
This is an important process associated with key biological pathways in homeostasis. The cGMP 
molecule produced by guanylyl cyclase is involved in the regulation of vasodilation, immune 
responses and neurotransmission. Zhang and co-workers have shown that guanylyl cyclase is 
involved in platelet synthesis and activation.25 The group have prepared mice that were guanylyl 
cyclase deficient only in the megakaryocytes and platelets. The platelets in these mice did not 
efficiently aggregate when required. These mice also showed extended bleeding times due to 
poor thrombosis when exposed to low doses of agonist.   
cGMP produced by guanylyl cyclase has been found to activate cGMP-dependent protein kinase 
I.10, 26 This protein is involved in a long chain of regulation pathways, including myosin 
phosphatase and vasodilator-stimulated phosphoprotein(VASP).27-28 The end of this chain results 
in platelet inhibition and aggregation does not occur. Gawaz and co-workers have shown that 
platelets deficient in VASP show increased aggregation, highlighting how guanylyl cyclase and 
VASP work together to control aggregation. This will depend on many factors and stimuli. 
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This pathway explains why lack of CO results in thrombosis; due to low guanylyl cyclase 
concentrations, which then interrupts the rest of this regulatory pathway. The end of this pathway 
is also significantly involved in smooth muscle relaxation and vasodilation and can be a strong 
contributor to blood pressure regulation. 
 
1.2.1.5 Inducible nitric oxide synthase (iNOS): Suppression by CO 
iNOS is a cytochrome p450 type protein, and is responsible for the synthesis of nitric oxide (NO), 
which is known to cause an inflammatory response.29-30 Carbon monoxide has been shown to 
suppress the activity of this enzyme. It is clear that the CO binds to the haem in this protein and 
inhibits the two step reaction that occurs at the protein haem centre.31 CO can be considered as an 
anti inflammatory molecule as it can suppress the production of a molecule associated with pro-
inflammatory action. This is useful and important when potentially using CO as a therapeutic 
molecule. 
 
1.2.1.6 Calcium-activated potassium channels 
Calcium-activated potassium channels are important membrane proteins associated with a wide 
range of biological functions including: smooth muscle tone,32-33 neurotransmitter release,34 
proliferation of white blood cells,35 red blood cell size, and many more.36-37 This channels 
functions by pumping out K+ ions when they detect Ca2+ ions, resulting in hyperpolarisation due 
to subsequent calcium channel deactivation. 
Carbon monoxide and other small signalling molecules such as H2S are known to target these 
channels and are associated with activating them.38 This information emphasises the wide range 
of processes that CO is associated with regulating. The single molecule of carbon monoxide 
released from haem degradation could be extremely important in regulating all of the biological 
processes discussed. 
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1.3 Carbon Monoxide as a therapeutic molecule 
1.3.1 Direct administration 
With all the knowledge in the literature about how carbon monoxide interacts in biological 
systems, it is clear that this molecule could be exploited for use in medicine. Carbon monoxide 
regulates many biological functions and the introduction of CO from an external source could 
potentially remediate many diseases and conditions. 
Within the past two decades, a significant amount of research has been carried out on the use of 
carbon monoxide as a therapeutic molecule. The direct administration of carbon monoxide has 
been used in a variety of cases. 
 
1.3.2 Covox DS™ system for CO delivery 
The Covox DS™ system is a complex machine consisting of pumps and safety valves; which can 
repeatedly control the amount of carboxy-haemoglobin (CO-Hb) within healthy human patients. 
The problem with administering CO as a gas is that the CO can freely diffuse throughout the 
blood stream to all areas of the patient and can pass through all cell membranes.7 It seems 
somewhat inefficient to have compound evenly distributed throughout an entire system, when it 
may only be required in localised environments. The Covox DS™ system was used on healthy 
patients, and it is not known if CO delivered in this way could be beneficial. 
 
1.3.3 Small intestine preservation and transplantation improvements 
A trial carried out by Nakao and co-workers using Lewis rats has shown that CO in a University 
of Wisconsin solution (UW) can significantly improve the preservation of a small intestine prior 
to transplantation.39 This includes reducing the amount of erosion to mucus, and helping to 
maintain sufficient membrane permeability. 
Carbon monoxide can also improve the percentage survival of the rats after a transplantation 
operation was performed. Suitable controls show that the UW solution without CO does not give 
the same beneficial effects. Carbon monoxide also prevents reperfusion injury after an innate 
blood supply returns to the organ. The work also shows that the CO infused into the intestine 
41 
 
before transplantation then circulates around the animal when blood supply is restored. This CO 
could also have beneficial effects elsewhere in the animal. 
There is also significantly reduced weight loss when CO is used in this experiment, which also 
links to the improved preservation of the intestine. The weight loss without CO treatment 
following transplantation could be due to poor nutrient absorption. This research also indicates 
that when CO is used, there is a significant reduction in concentration of several inflammatory 
cytokines. This is a strong indication that CO exhibits anti-inflammatory activity. This is a very 
promising study and is significant progress towards the use of CO in human medicine; it is 
impressive to see CO acting on several factors all at once. 
 
1.3.4 CO and its potential to treat liver disease 
The number of liver disease cases in the UK has been on the increase for many years. There is an 
increasing requirement to find treatments to prevent and treat liver failure; as thousands of people 
are dying every year due to this condition.40 Otterbein and co-workers have shown that apoptosis 
in liver cells can be prevented by the administration of 250 ppm CO.41 This is because the 
production of apoptosis inducing cytokines such as TNF-α, are reduced. 
Tsui and co-workers have carried out similar research, and found that TNF-α induced apoptosis 
of liver cells also occurs when mice are sensitised with D-galactosamine.42 The survival of these 
mice to this treatment can be significantly improved by the administration of CO. The work also 
shows that HO-1 deficiency increases sensitivity to liver damage. This work is in agreement with 
the research of Nakao and co-workers, and shows a key link between haem oxygenase and CO in 
cytoprotective action.  
 
1.3.5 Carbon monoxide as an antimicrobial agent 
There is an urgent need for new potent antimicrobial agents. There has been a significant increase 
in antibiotic resistance and some species are becoming untreatable with current medicines.43 
There has been significant interest in using carbon monoxide as an anti bacterial agent, as 
bacteria contain CO-binding proteins.44-47 Binding these proteins with CO may interrupt many 
functions including electron transport and could increase bacterial susceptibility to attack from 
host immune systems. CO under the right circumstances is beneficial to the mammalian host, and 
this presents a multitude of potential uses for carbon monoxide. 
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The direct use of CO against Escherichia coli and Staphylococcus aureus was investigated by 
Saraiva and co-workers. It was found that a flux of gas could kill both strains of bacteria after a 
15 minute CO gas flux.48 Figure 9 shows how the percentage survival of bacteria decreases after 
exposure to a flux of CO gas. 
 
Figure 9. A: Percentage survival of E. coli and S. aureus over a five hour period after exposure to 
CO gas for 15 minutes. B: Sensitivity tests by spreading out diluted aliquots after four hours 
exposure to CO gas (+) and N2 gas (-). (Figure taken from ref. 48, Antimicrobial Action of 
Carbon Monoxide-Releasing Compounds, Nobre, L. S.; Seixas, J. D.; Romao, C. C.; Saraiva, L. 
M., Antimicrob. Agents Ch. 2007, 51, 4303-4307) Copyright American Society for Microbiology 
2007 
The data in Figure 9 shows that CO has a toxic effect on both strains of bacteria and there is a 
significant decrease in the percentage survival. The question is, with a ‘flux’ of CO gas, how 
much CO was actually delivered? This highlights the problem with directly delivering CO as gas 
or a solution that it can be difficult to administer accurate concentrations. This links in with the 
problems associated with the Covox DS™ system used to deliver CO into humans. It is clear there 
is a toxic effect but CO is also toxic to mammalian cells at a high enough concentration. This 
initial study highlights the need for a better method of delivering CO, so that accurate 
concentrations of CO can be delivered where they are required. This is why carbon monoxide-
releasing molecules (CO-RMs) were developed. 
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1.4 Carbon monoxide-releasing molecules as therapeutics 
The problems with the administration of CO gas are currently being addressed by the 
development of CO releasing pro-drugs. These take advantage of the reactivity of inorganic metal 
carbonyl complexes. There are some organic reactions that will liberate CO but most of these 
conditions are biologically incompatible and reagents can react very violently at room 
temperature.49 An example of this is the reaction of oxalyl chloride with DMSO. The reaction is 
explosive at room temperature and has to be carried out at −60 °C. This temperature is too low 
and makes this kind of molecule unsuitable for CO release applications. 
CO-RMs can be thought of as a pro-drug, a means of delivering CO to a target. This typically 
requires a transition metal carbonyl complex stabilised by a multidentate ligand.50 The ligand 
could then be functionalised to enable the molecule to accumulate at a desired location.  
 
1.4.1 Methods of CO-RM activation 
CO-RMs require a method of activation and there are three key ways this can be achieved. These 
three methods include: thermal, enzyme-triggering, and photo-activation. 
 
1.4.1.1 Thermal CO-RM activation 
This method of CO-release involves a molecule that releases CO when in solution without any 
complicated stimulation.51  
Lynam and co-workers reported a series of tricarbonyl iron(0) complexes. Some of these release 
CO rapidly on dissociation of the norbornadiene ligand in solution, without the need of a target 
such as myoglobin. This presents advantages such as definitely getting CO-release from the 
molecule on administration. The issue is that the CO-release rate is fixed at a given 
concentration. The CO-release begins immediately and could all be released before it reaches a 
desired target. With careful tuning of the norbornadiene ligand, optimal CO-release rates could 
still be obtained in a system like this. 
Motterlini and co-workers have also developed a thermally-activiated CO-RM known as CO-RM 
A1.52 The structure of this compound is shown in Figure 10. 
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Figure 10. The structure of boron based CO-RM A1 
In contrast to the majority of CO-RMs in the literature CO-RM A1 does not contain any 
transition metals, but contains two sodium atoms. A previously reported myoglobin assay was 
used to assess if this compound could release CO at different pH.53  Figure 11 shows the details 
of the experiments performed. 
 
Figure 11. The conversion of deoxy-Mb to carboxy-Mb at varying pH. pH 7.4 (A), 7.0 (B), 6.5 
(C), and 5.5 (D) after addition of 60 µM CO-RM A1.(Figure taken from ref. 52, CORM-A1: a 
new pharmacologically active carbon monoxide-releasing molecule, Motterlini, R.; Sawle, P.; 
Hammad, J.; Bains, S.; Alberto, R.; Foresti, R.; Green, C. J.,  FASEB J., 2005, 19, 284-6) 
Copyright FASEB 2014. 
CO-RM A1 releases CO faster at pHs 5.5 and 6.5, but is much slower at physiological pH. This 
could present problems under certain circumstances where higher concentrations of CO are 
required. This also means that there could be problems with administering this CO-RM orally. 
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The pH in the stomach may promote extremely fast CO release before the CO-RM gets to the 
desired location. 
CO-RM A1 was also used in an assay which employed amperometric electrodes to measure the 
amount of CO-released in solution at various pHs and temperatures. The performed assay is in 
agreement with the results of the myoglobin assays that were carried out. CO is released faster at 
lower pH and with increasing temperature. The amperometric assay works in the absence of 
myoglobin showing that CO-RM A1 is a true thermally activated CO-RM.  
It is also important to highlight that both of the CO release assays also employed i-CO-RM A1 as 
a control. i-CO-RM A1 is a collection of the by-products generated by the CO release from the 
original CO-RM. i-CO-RM A1 did not show any signs of CO release in any of these experiments. 
The group also used NaBH4 as a control in this experiment to assess if a boron reagent could 
cause any of the effects observed. However, this is not really an appropriate control as the 
concentration of by-products is not likely to be reflected by the concentration used in the 
experiments. In a biological system, the concentration of many metabolites will be varying over 
time, and the addition of a single by product is not the best control. The i-CO-RM experiments 
employed here are close to giving by-products like what is observed from fresh CO-RM. 
However, in a biological system, enzymes may accelerate degradation and produce different 
metabolites to simple thermal decomposition. 
CO-RM A1 has been employed in biological studies which show significant vasorelaxation on 
aortic rings isolated from rats. This effect can also be exaggerated if 1 µM YC-1 is administered 
alongside CO-RM A1. YC-1 is a stimulator of guanylyl cyclase and this is in agreement with the 
regulatory pathways discussed previously. 
Other research groups have also carried out research on CO-RM A1. Stec and co-workers have 
shown that CO-RM A1 increases the blood flow to the kidneys after administration to mice.54 
The work also shows that inhibition of sGC with ODQ significantly reduces the CO-RM A1 
mediated renal blood flow. This suggests that the effects observed are linked to carbon monoxide 
released from CO-RM A1. Nicoletti and co-workers have also carried out experiments with CO-
RM A1 on mice investigating its medicinal capabilities at treating experimental allergic 
encephalomyelitis (EAE).55 EAE is a good model for multiple sclerosis which affects the lives 
thousands of people worldwide. This study shows that prolonged administration of CO-RM A1 to 
mice with EAE show improvement in many areas including: reduced incidence of the disease, 
less inflammation of the brain and nervous system, and improved clinical and histopathological 
signs of the disease. This research is extremely promising and all the research discussed above 
shows CO-RM A1 is a potential treatment for multiple sclerosis and many other ailments. 
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There are also many other thermo-CO-RMs reported in the literature such as molybdenum based 
CO-RMs ALF062 and ALF186, developed by Alfama.7, 56-57 The structure of these CO-RMs are 
shown in Figure 12. 
 
Figure 12. The structure of CO-RMs ALF062(left) and ALF186(right). 
These CO-RMs are unstable in the presence of air. ALF186 is stable in an anaerobic aqueous 
solution but not in the presence of O2 and under these conditions spontaneously releases CO. 
CO-RM ALF186 has been employed in experiments with rats to prevent gastric ulcery which 
arises from treatment with non-steroidal anti-inflammatory drugs (NSAIDs). ALF186 was shown 
to significantly reduce the formation and severity of ulcers that were induced by ethanol 
administration. ALF186 was also found to have the same effect in the presence of indomethacin, 
without significantly reducing the effectiveness of the anti-inflammatory drug. The potential of 
CO-RM conjugation to known NSAIDs is certainly a possibility. 
CO-RM ALF186 has a similar half-life to CO-RM A1 in aqueous solution at aqueous pH. 
However, in vivo ALF186 releases its CO very quickly. This could present problems as high 
concentrations of CO could be released quickly in the stomach and intestine preventing 
peristalsis. It is suggested that a more gradual CO-RM such as CO-RM A1 may be more 
appropriate for this kind of treatment. On the other hand, the quick CO release from this CO-RM 
may still have its uses to treat conditions such as blood pressure reduction.  
A large number of CO-RMs in the literature typically adopt an octahedral type structure, often 
with a metal(CO)n motif commonly reappearing.58-62 Fairlamb and co-workers developed a new 
series of CO-RMs based on a µ2-alkyne dicobalt(0)hexacarbonyl motif (Figure 13), with some 
distinctly different structural features compared to many other CO-RMs in the literature.63 
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Figure 13. The structure of a new alkyne cobalt(0) complexes 1-6. 
This series presents some of the first examples where a CO-RM uses a bimetallic centre to bind 
the CO ligands. It is beneficial to the pharmaceutical industry as a whole if interesting/unusual 
functionality is explored. Exploring a wide range of ‘structural space’ is likely to bring about 
interesting effects. If research is carried out within a narrow range of structural space then wide 
ranging bacterial resistance/allergies, and all sorts of other issues could become common.  
The bi-metallic hexacarbonyl dicobalt(0) motif has been functionalised with a variety of 
substituted alkyne ligands. This structural set up provides the potential to functionalise this CO-
RM with a wide variety of functionality in the future as any alkyne could be potentially 
introduced into the structure of a CO-RM using this chemistry.  
This series of CO-RMs demonstrates how the electronics of the ligand (the alkyne) can be tuned 
to alter the rate of the CO-release drastically. All the CO-RMs in Figure 13 were used in 
myoglobin CO-release quantification assays, and were all found to release-CO without the need 
for irradiation. The CO-RMs were also found to thermally release CO in DMSO. These CO-RMs 
do not need myoglobin to induce CO-release.  Complex 2 has a t½ of 1-2 minutes depending on 
concentration whereas 3 had a t¼  of 67 minutes which is considerably longer considering there is 
not that much different in the structure: Increasing the the electron density of the alkyne increases 
the ability of the metal to back-bond into the pi* orbital on CO. Less back-bonding into this orbital 
results in a stronger C–O bond. This explains why Complex 2 releases so quickly due to strong 
electron withdrawing ester groups. This demonstrates a really good way to tune a CO-RM to get 
difference types of CO-release. As discussed previously, different rates of CO-release are 
required to treat different conditions. 
Fairlamb and co-workers have carried out some detailed mechanistic investigations into the 
mechanism of CO-release from 2 in DMSO. ReactIR™ instrumentation which takes regular real 
time IR spectroscopic measurements shows that 2 is clearly unstable in DMSO. The IR spectra 
obtained over time show depletion of many of the M–CO vibration bands. A new strong band at 
1890 cm−1 appears on degradation which remains present and it is likely that was due to the 
formation of [Co(CO)4]−. Scheme 3 shows the proposed CO-release pathways devised from the 
degradation studies obtained. 
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Scheme 3. Proposed degradation/CO-release pathway for CO-RM 2 in DMSO. 
It is proposed that a molecule of DMSO solvent can either displace a CO ligand via coordination 
to the cobalt centre in 2 to produce 2a. It could also coordinate to the cobalt centre without CO 
displacement to produce 2d. Both of these species can then bind more DMSO, eventually 
resulting in cleavage of the Co–Co bond. This gives an oxidised cobalt carbonyl species with 
DMSO ligands, and a reduced [Co(CO)4]− species. This then acts as a counter ion to fragments 2c 
and 2e. One may want to think carefully about how much of this mechanism occurs in aqueous 
solution rather than in DMSO. Breakdown in aqeuous solution is much more relevant considering 
that these compounds are potential pharmaceutical agents. However, one could imagine that 
water could act as a two electron donor in the same fashion as DMSO, and similar pathways 
using H2O are likely. Carrying out mechanistic studies in water can be problematic as water can 
reduce the sensitivity in IR and NMR measurements making it difficult to follow what species a 
present. The development of better techniques to carry out detailed CO-RM degradation analysis 
in aqueous would be of great intrest to CO-RM researchers. 
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This series of CO-RMs is interesting from a structural and future synthetic perspective. This 
initial CO-RM series does not contain much polar functionality and structural diversity. However 
with the alkyne system with an R group that can be varied, many new interesting CO-RMs could 
be developed based on this alkyne dicobalt(0) hexacarbonyl motif. 
 
1.4.1.2 Enzyme-triggered/chemically triggered CO-RMs 
The second method of CO-RM activation is by a chemical trigger such as an enzyme.64 These 
CO-RMs in contrast to thermo-CO-RMs have long-term stability in aqueous solution. The CO-
release is induced by a chemical trigger, and it typically can be a haem-containing 
protein/enzyme which can tightly bind the CO.  
CO-RM-2 is a di-nuclear ruthenium complex with bridging chloride ligands and is sparingly 
water soluble. The structure of CO-RM-2 is shown in Figure 14. 
 
Figure 14. The structure of ruthenium-containing CO-RM-2 
CO-RM-2 is classed as an enzyme-triggered CO-RM (ET-CO-RM) as no CO can be detected by 
GC from the headspace of an aqueous solution. However in the presence of myoglobin in vitro, 
CO is transferred to the myoglobin with a half-life of one minute. This is exceptionally rapid CO-
release in comparison with CO-RMs such as CO-RM A1 and ALF186. 
For biological studies CO-RM-2 typically requires pre-dissolution in DMSO or another polar 
solvent due to solubility issues.65 However, this compound can exhibit various beneficial effects 
within a biological system. Chen and co-workers have shown that mice unable to produce HO-1 
undergoing aortic transplants can be rescued by administering CO-RM-2.22 The CO-RM provides 
the CO that the mice cannot naturally produce without HO-1, restoring CO regulatory pathways 
and preventing severe thrombosis. Figure 15 shows cross-sections of the aorta after the aortic 
transplantations were performed under various conditions. 
50 
 
 
Figure 15. Aortic across sections from HO-1+/+ and −/− mice having undergone an aortic graft. 
Administration of CO-RM-2 and inactive CO-RM-2 in both cases.(Image taken with permissions 
from ref. 22) Carbon Monoxide Rescues Heme Oxygenase-1-Deficient Mice from Arterial 
Thrombosis in Allogenic Aortic Transplantation, George, J. F.; Chen, B.; Guo, L. L.; Fan, C. L.; 
Bolisetty, S.; Joseph, R.; Wright, M. M.; Agarwal, A., Am. J. Pathol. 2009, 175, 422-429 
Copyright Elsevier 2009. Note : HO-1+/+ indicates a mouse group that can naturally produce HO-
1, and HO-1−/− indicates a group that cannot produce the enzyme. 
When a HO-1+/+ mouse is administered CO-RM-2, the artery shows clear signs of vaso-dilation, 
typical of CO action. However with the i-CO-RM-2 as a control, this vasodilation effect is not 
observed, showing that some of the ruthenium degradation species are not responsible for the 
effect. 
When a HO-1−/− mouse is given the i-CO-RM-2 control, the same arterial thrombosis occurs as 
when no CO-RM is administered at all. When these mice are given fresh CO-RM-2, the platelet 
rich thrombosis does not occur and normal conditions are restored. This is an excellent 
demonstration of how a CO-RM  can be used to restore normal function. 
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Ruthenium-based CO-RM-2 has also been employed in anti bacterial studies with E. coli and S. 
aureus.
48
 Viability studies were performed in the same fashion as was done with CO gas. Figure 
16 shows the results of bacterial viability studies with CO-RM-2. 
 
Figure 16. A: Use of CO-RM-2 to assess percentage survival of E. coli and S. aureus under 
aerobic and anaerobic conditions. B: Plating studies with haemoglobin controls to assess bacterial 
viability. (Figure taken from ref. 48, Antimicrobial Action of Carbon Monoxide-Releasing 
Compounds, Nobre, L. S.; Seixas, J. D.; Romao, C. C.; Saraiva, L. M., Antimicrob. Agents Ch. 
2007, 51, 4303-4307. Copyright 2007 American Society for Microbiology. 
The studies illustrated in Figure 9 and Figure 16 show that the use of ruthenium CO-RM-2 
shows improved anti-bacterial activity compared to using CO gas alone. The addition of 
haemoglobin as a control prevents the anti-bacterial effect observed by the CO-RM, suggesting 
that CO produced from the CO-RM is causing the effect.  
There are also other studies that have been carried out that show the potential problems with CO-
RM-2.66 Dong and co-workers have shown that ruthenium-based CO-RM-2 activates K+ channels 
in an inselective manner in human endothelial cells. Experiments carried out with ruthenium 
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monomer CO-RM-3 also induced currents by activating the K+
 
channels in the cells. The current 
generated by CO-RM-3 matches that of the currents generated by CO gas. The currents generated 
by CO-RM 2 show a different profile. The CO-RM-2 induced current generated was not 
diminished even after administration of 2-aminoethoxydiphenyl borate, which is a selective K+ 
channel blocker. More experiments would need to be carried out to discover why CO-RM-2 is 
activating the channels in this fashion. It is undesirable for a CO-RM to bind to a target in this 
way as it is unselective. On the other hand it is difficult to tell what the true consequences of this 
channel activation are, because there are many in vivo studies with mice that show very positive 
and promising properties from CO-RM-2.  
CO-RM-3 is a water soluble CORM that has attracted considerable research interest within the 
past few years. CO-RM-3 is a ruthenium complex containing a glycinato ligand, one chloride 
ligand and three CO ligands. It is synthesised from ruthenium dimer CO-RM-2 and the details are 
shown in Scheme 4.53 
 
Scheme 4. Synthesis of tricarbonylchloro(glycinato)ruthenium(II) (CORM-3)  
CO-RM-3 is an protein-triggered CO-RM, and is stable in aqueous solution with minimal 
degradation. In the presence of myoglobin the CO-RM has a half-life for CO-release of only one 
minute . This is a rapid rate of CO-release and is similar to the half-life of CO-RM-2. 
Studies by Desmard and co-workers have shown that CO-RM-3 is a potential treatment for 
Pseudomonas aeruginosa infection.67 Infected mice treated with CO-RM-3 show increased 
survival rates. Clark and co-workers have shown that administration of CO-RM-3 to mice that 
have had a heart transplant enables them to survive longer than ones that receive no CO-RM-3. In 
addition to this, i-CO-RM-3 is a solution of CO-RM-3 that has been allowed to release one CO 
thermally and this solution shows no improvement compared to the control, suggesting the effect 
is due to the action of CO. There are however some problems with i-CO-RM-3. Only one CO 
from CO-RM-3 is released thermally and the exact composition of the material after release is 
unknown. There may not be any significant thermal release from i-CORM-3 but there could be 
further interactions of the remaining complexes with the host proteins and other targets. 
Even though a lot of research into the effect of CORM-3 has been carried out, and the results are 
very promising, the synthesis and characterisation does not exhibit defined stereoselectivity. It is 
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possible to have the chloride ligand trans- to a carbonyl ligand, oxygen ligand or an amine 
ligand. Differences in the isomers within the compounds produced could easily affect the CO 
release rates and even the way that the compound binds to proteins. 
It has also been shown by X-ray diffraction that CORM-3 forms ruthenium adducts with various 
proteins, including hen egg white lysozyme (HEWL). The structure of these adducts are shown in 
Figure 17.64 
 
Figure 17. The structure of a ruthenium CO-RM 3/ HEWL protein adduct. (Image taken from 
ref. 64, CORM-3 Reactivity toward Proteins: The Crystal Structure of a Ru(II) 
Dicarbonyl−Lysozyme Complex, Bernardes, G. J. L.; Santos-Silva, T.; Mukhopadhyay, A.; 
Seixas, J. D.; Romão, C. C.; Romão, M. J. J. Am. Chem. Soc. 2011, 133, 1192-1195) Copyright 
2011, American Chemical Society. 
The ruthenium moiety bound to the protein is a triaqua, dicarbonyl species. Even though 80% of 
the ruthenium is bound to a histidine residue, it also can bind to many other sites on protein such 
as Glu35. This binding is unselective and it is likely that this ruthenium species could bind to 
many other proteins in a similar fashion and this could give rise to undesirable side effects. More 
investigations into how CO-RM-3 interacts with proteins to distinguish the difference between 
CO release effects and the newly discovered ruthenium binding. This binding could be 
responsible for some of the biological effects observed in recent studies and it may be difficult to 
differentiate between the two. 
An efficient CO-RM would interact selectively with proteins for targeting purposes only, 
providing that the CO is responsible for the observed therapeutic effects. Once CO-release is 
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complete, any degradation products need to be non toxic and it would be ideal if they did not 
bind to unwanted targets. The purpose of the metal centre and ligands are for selectivity and CO 
transportation. Multidentate ligands can prevent leeching of any toxic metal species by keeping 
them tightly bound as a soluble complex.  
CO-RM-3 has been employed in many in vivo experiments and it has been shown to exhibit 
many positive effects. Drago and co-workers have carried out experiments with rabbits, showing 
that administration of CO-RM-3 lowers intraocular pressure induced by α-chymotrypsin.68 The 
inactive form of CO-RM-3 does not lower intraocular pressure, suggesting the action of carbon 
monoxide in this treatment. These studies demonstrate a potential use of CO-RM-3 for the 
treatment of ocular hypertension. 
Chlopicki and co-workers have carried out experiments on human platelets with CO-RM-3 and 
demonstrated that it inhibits platelet aggregation in a concentration-dependent manner.69 The 
administration of a guanylate cyclase inhibitor increases the effect observed by the CO-RM. 
Considering the X-ray structure in Figure 17, it could be possible that CO-RM-3 is having its 
effect by binding to a protein and altering its function. i-CO-RM-3 would not be a suitable 
control here as fresh complex might be required to get transfer of the ruthenium centre on to a 
protein.  It is also important to note that addition of an sGC activator did not affect the outcome 
of CO-RM-3 administration. This suggests a guanylate cyclase independent mechanism is 
involved in inhibition of platelet aggregation. However this study was carried out with washed 
platelets in vitro, and the lack of other cells types and proteins that are present in vivo could 
significantly alter how the platelets aggregate. It is worth questioning how comparable an in vitro 
study is to what occurs in a live organism. 
[Mn(CO)4{S2CNMe(CH2CO2H)}](7), a CO-RM developed by Mann and co-workers, is stable in 
phosphate buffered saline for several hours (Figure 18).58  
 
Figure 18. The structure of CO-RM 7 
In the presence of myoglobin, CO is rapidly released from CO-RM 7 to the haem. One of the real 
advantages of this molecule in comparison with previous CO-RMs, is that it can release several 
molecules of CO per molecule of CO-RM. This was determined by the myoglobin assay data 
shown in Figure 19. 
55 
 
 
Figure 19.[Mn(CO)4{S2CNMe(CH2CO2H)}] (7) at a concentration of 10 µM in a myoglobin 
assay.(Image taken from ref. 58, [Mn(CO)4({S2CNMe(CH2CO2H})], a new water-soluble CO-
releasing molecule, Crook, S. H.; Mann, B. E.; Meijer, A. J.; Adams, H.; Sawle, P.; Scapens, D.; 
Motterlini, R., Dalton Trans. 2011, 40, 4230-5. Copyright The Royal Society of Chemistry 2011. 
Only 10 µM of CO-RM 7 can produce around 30 µM of CO-Mb, meaning that this molecule 
releases three molecules of CO per molecule of CO-RM. This is advantageous as less of the 
original molecule is required to get the same amount of CO that can be released from ruthenium-
based CO-RM-3. [Mn(CO)4{S2CNMe(CH2CO2H)}] (7) has been used in viability tests with 
RAW 264.7 cells, a macrophage cell line. An Alamar blue assay which detects the metabolism of 
live cells indicates that there is a 25% reduction in cell viability at 50 and 100 µM concentrations 
of this complex. An LDH assay that detects the release of LDH from dead cells shows only 10% 
cytotoxicity. CO-RM 7 is only killing 10% of cells, but is clearly interfering with the metabolism 
of the cells. This is potentially concerning from a pharmacological point of view.  
It is known that CO can suppress the production of nitric oxide (NO) in cells.70 It is also known 
that NO can exhibit an anti-inflammatory response,29 and if NO is suppressed then an anti-
inflammatory response can be observed. NO2− (nitrite) is a stable degradation product of NO and 
so it can be used as a way of quantifying the amount of NO produced by cells. This means that by 
using carefully designed controls, it is possible to determine if the CO released by CO-RMs is 
causing a suppression of NO production in RAW 264.7 cells and thus anti-inflammatory action. 
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A nitrite assay was performed to assess if [Mn(CO)4{S2CNMe(CH2CO2H})] (7) could be used to 
induce an anti-inflammatory response in RAW 264.7 macrophages, and results are shown in 
Figure 20. 
 
Figure 20. Nitrite quantification assay to assay NO suppression on administration of CO-RM 7 
to RAW 264.7 cells. LPS (1 µl) was used to stimulate an initial inflammatory response.(Image 
from ref. 58, [Mn(CO)4{S2CNMe(CH2CO2H)}], a new water-soluble CO-releasing molecule, 
Crook, S. H.; Mann, B. E.; Meijer, A. J.; Adams, H.; Sawle, P.; Scapens, D.; Motterlini, R. 
Dalton Trans. 2011, 40, 4230-5) Copyright The Royal Society of Chemistry 2011 
Results in Figure 20 show a larger percentage reduction in nitrite compared to the drop in 
viability, and toxicity. This suggests that CO-RM 7 can induce an anti-inflammatory response, 
although the percentage cell viability in these studies is of some concern. Testing cells in a plate 
is not always likely to be representative of what may happen in vivo and further studies are 
required with this molecule. 
Fairlamb and co-workers have also developed a series of CO-RMs based on an η4-2-pyrone motif 
coordinated to a tricarbonyl iron(0) centre.71-74 One could think of these CO-RMs being similar to 
the norbornadiene iron complexes prepared by Lynam and co-workers due to the η4-diene mode 
of coordination.51 The pyrone ligand is a planar molecule where as the norbornadiene ligand has 
a bent structure with the two parallel alkenes being forced closer together in space. Pyrone based 
CO-RMs are of particular importance as this type of free ligand is known to possess anti-bacterial 
activity.75 One could imagine administering the CO-RM which will release CO and the 
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antibacterial pyrone at the same time, which has great potential. The structure of the 2-pyrone 
CO-RMs from this research are shown in Figure 21.  
 
Figure 21. The structure of 2-pyrone containing CO-RMs prepared by Fairlamb and co-workers. 
Parent CO-RM 8 was the first pyrone compound to be tested in a myoglobin assay and it was 
unfortunately discovered that it did not release-CO in a myoglobin assay. This shows that this 
particular CO-RM is stable in aqueous solution and in the presence of myoglobin. It was not 
tested for CO-release using irradiation but it is certainly possible that it could.  
CO-RM F8 was tested at 60 µM in a myoglobin assay and was found to release only 3 µM of CO 
in the presence of myoglobin without irradiation. This is slow release compared to other CO-
RMs such as CO-RM-3. This CO-RM could still be used if a steady release of CO is required. It 
was not established whether the gradual CO-release from CO-RM F8 was due to myoglobin 
extraction or thermal degradation. However, it is clear that the introduction of a halogen in the 4-
position on the ring alters the properties of the molecule. It either alters the electronics of the Fe–
CO bonds allowing for some thermal release, or it could alter the binding constant of the pyrone 
ring to the Fe(CO)3 moeity. Dissociation of the pyrone ring from the metal centre could then 
result in spontaneous CO-release from the resulting fragment just like what occurs when 
substituents are changed in norbornadiene complexes.51 
CO-RM F8 was tested for viability/toxicity with RAW 264.7 cells as has been done with 
previous CO-RMs. It was found to be viable up to a concentration of 100 µM which is 
encouraging. Considering that previous Fe(CO)3-based CO-RMs have been shown to release two 
molecules of CO per molecule of CO-RM, it is likely that this CO-RM could do the same. The 
production of 200 µM CO from 100 µM CO-RM is likely to be more than enough CO to exhibit 
many of the effects previously discussed, although the CO-release rate is rather slow for CO-RM 
F8. 
The pyrone ring was also substituted with a bromine atom in the 4-position to give CO-RM F3. 
This CO-RM was tested in a myoglobin assay and was found to release 11 µM of CO over one 
hour. This is a relatively slow release but is almost four times faster than CO-RM F8. There is 
something significant about substituent 4 position on the ring. Exchanging a chlorine atom for a 
bromine atom in this structure has significantly increased the rate of CO-release. CO-RM F3 was 
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also shown to be just as viable as CO-RM F8 with RAW 264.7 cells despite the increased rate of 
CO-release. It is important to be aware of the fact that a higher rate of CO-release also means a 
higher rate of production of by-products which could be potentially toxic. Figure 22 shows the 
details of the CO-release studies and some biological work carried out on CO-RM F3. 
 
Figure 22. A: Reference UV-Vis spectra of deoxy-Mb and carboxy-Mb. B: UV showing clear 
conversion of deoxy-Mb to carboxy-Mb using CO released from CO-RM F3. C: Calculated 
concentrations of carboxy-Mb on CO-release from CO-RM F3. D: Demonstration of 
vasorelaxation on isolated aortic rings from rats using CO-RM F3, rings were pre-contracted with 
administration of phenyl ephedrine (Phe). (Figure taken from ref. 72, η4-Pyrone iron(0)carbonyl 
complexes as effective CO-releasing molecules (CO-RMs), Fairlamb, I. J. S.; Duhme-Klair, A. 
K.; Lynam, J. M.; Moulton, B. E.; O'Brien, C. T.; Sawle, P.; Hammad, J.; Motterlini, R. Bioorg. 
Med. Chem. Lett. 2006, 16, 995-8).Copyright Elsevier 2006 
CO-RM F3 is a promising CO-releasing molecule, and a smooth conversion to carboxy-Mb is 
observed over a three hour period. This CO-RM was also shown to induce vasodilation to aortic 
rings when 100 µM portions of the CO-RM were administered. There is a change in gradient in 
the tension in the aortic ring on addition of CO-RM F3, which had been deliberately contracted 
prior to starting the experiment. The vasodilatory properties of CO-RM F3 are likely to be due to 
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the CO that is released from this CO-RM. Considering that there is an immediate drop in tension 
on CO-RM addition, is it also suggesting that low concentrations CO are required to induce this 
effect. This CO-RM releases CO as a slow rate so a small amount of CO will have been released 
on the time scale of this vasodilation experiment.  
CO-RM F3 has also been used in Greiss assay experiments as was performed with 
[Mn(CO)4({S2CNMe(CH2CO2H})] (7). CO-RM F3 shows a concentration-dependent reduction 
in nitrite production from RAW 264.7 cells. This occurs at concentrations which are significantly 
below signs of any toxicity, strongly suggesting CO-RM F3 can induce an anti-inflammatory 
response. CO-RM F3 is a promising CO-releasing molecule and further studies into its action, is 
justified by the discussed research. It would be important to determine whether this CO-RM is a 
thermo- or enzyme-triggered-CO-RM as this has not yet been established.  
Schatzschneider and co-workers have also developed CO-RMs which are activated by enzymes.76 
CO-RMs 9-12 are based on an tricarbonyl iron(0) motif bound by an acyloxybutadiene ligand. 
The structures of these CO-RMs are shown in Figure 23.77 
 
 
Figure 23. The structure of tricarbonyl iron(0) acyloxybutadiene complexes 9-12. 
The four complexes above including 12, which was previously prepared by Boháč and co-
workers for non medicinal purposes, have been utilised in this enzyme-triggered CO-RM study. 
It was determined that these CO-RMs 9-12 are relatively stable compared to many thermo-CO-
RMs, which made them suitable ET-CO-RMs candidates. It was found that these complexes 
could be activated by the use of esterase enzymes. Interestingly each CO-RM could be 
hydrolysed by some esterase enzymes but not others. This creates a fantastic platform for 
selectively activated ET-CO-RMs. Table 2 shows which of the CO-RMs above degrade when 
treated with two different esterase enzymes. 
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Table 2. Esterase ability to activate CO-RM 9-12.PLE = Pig-liver esterate.LCR = Lipase from 
Candida rugosa. + indicates activity, − indicates no activity. 
Enzyme 9
 
10 11 12 
PLE − − + + 
LCR + + + - 
 
It was found through kinetic resolution experiments that PLE could not degrade 9 and 10 but 
could degrade 11 and 12. Conversely, LCR could degrade 9-11 but not 12. This variation in 
selectivity is useful when thinking about administering a CO-RM in vivo. Understanding which 
enzymes are degrading/activating a drug is essential for compounds to progress as medicinal 
candidates. 
Interestingly a myoglobin assay was used with these CO-RMs as standard to assess their CO 
releasing ability and it was found that without esterase, there was no significant CO release from 
these CO-RMs with myoglobin present. This is a key result as many CO-RMs are readily 
degraded by myoglobin as CO is transferred to them very quickly. In the presence of the 
appropriate enzyme, CO-release to myoglobin can then be observed. Cleavage of the ester bond 
in CO-RMs 9-12 leaving an alcohol significantly alters the ability of the diene ligand to donate 
and receive electron density from the iron centre. Figure 24 shows details of esterase-mediated 
CO release to myoglobin from CO-RM 11. 
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Figure 24. CO-release from 99 µM CO-RM 11 indicated by a clean deoxy-Mb to carboxy-Mb 
transition. 0.01 eq. PLE used as a CO-RM activation agent.(Image taken from Ref. 77, 
Acyloxybutadiene Iron Tricarbonyl Complexes as Enzyme-Triggered CO-Releasing Molecules 
(ET-CORMs), Romanski, S.; Kraus, B.; Schatzschneider, U.; Neudorfl, J. M.; Amslinger, S.; 
Schmalz, H. G., Angew. Chem. Int. Ed. 2011, 50, 2392-6) Copyright Wiley 2011. 
In the presence of PLE, CO from CO-RM 11 results in clean conversion of reduced myoglobin to 
carboxy myoglobin over a period of eight hours. This slow release is similar to the CO-RM A1 
release rate. The kinetic rates of CO release here could be easily controlled by varying the 
concentrations of esterase in the solution. This gives a very strong degree of control.  
CO-RMs 9-12 were all tested for cell viability with RAW 264.7 macrophages. The CO-RMs 
show varying degrees of toxicity in the presence of LPS. 10 showed the most promising results 
with no signs of toxicity within the 100 µM range. However, 11 shows an IC50 of only 39 µM 
which is relatively toxic with respect to 10. Unfortunately the authors did not carry out any sub-
stoichiometric myoglobin assays to determine how many CO molecules were released per 
molecule of CO-RM. With an iron tricarbonyl CO-releasing moeity, it would be reasonable to 
expect more than one CO molecule released per molecule of CO-RM.  
The authors did however test the four CO-RMs for their ability to suppress NO production in 
RAW 264.7 cells, thus eliciting an anti-inflammatory response as described previously. All the 
CO-RMs were found to suppress the production of NO by a greater percentage than their toxicity 
at the same CO-RM concentration. 11 and 12 were found to be the best NO suppressors with 
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reduction values of 33% at only 5 µM CO-RM concentrations. This is one of the most potent 
anti-inflammatory responses from a CO-RM in the literature and is promising.  
Future research with these acyloxybutadiene complexes could focus around its enzyme related 
activation. Screening needs to be carried out with a larger variety of enzymes to find out which in 
vivo esterases could activate the CO-RMs. There are also many other enzymes which could 
activate this CO-RM and this is clearly going to be important when calculating in vivo CO release 
kinetics. One could also think about the co-administration of a CO-RM with an esterase enzyme 
to aid its degradation under certain circumstances. The CO-RM could be administered first, and 
allowed to accumulate at its required location. The appropriate enzymes could then be 
administered to trigger controlled CO-release. Careful selection would have to be made to find an 
enzyme that would not interfere with other biological processes. 
 
1.4.1.3 Photo-activated CO-RMs 
The final method of CO-RM activation is by photo-irradiation. There are now many new photo 
CO-RMs being published in the literature.59-62, 78 This class of CO-RM does not degrade over a 
short period of time; either thermally or in the presence of a CO binder such as myoglobin. Using 
light to activate a CO-RM provides an extra degree of control to the CO-release kinetics. Both 
the light intensity and CO-RM concentration can be varied. There are issues with the wavelength 
of light in terms of getting effective tissue penetration, and research towards photo-CO-RMs that 
edge away from low wavelength UV light is desirable. 
One of the first photo-CO-RMs prepared was CO-RM-1 (Mn2(CO)10). CO-RM-1 is a di-
manganese compound containing a metal-metal bond with each manganese bearing five carbonyl 
ligands. This compound is an efficient photo-CO-RM with a short half-life, but is apolar. This 
gives rise to poor water solubility and therefore low bioavailability.79-80 This molecule is shown 
to release CO efficiently in organic solvent when irradiated as detected by myoglobin through a 
CO permeable membrane. Considering the wavelength of light being used to photolyse CO-RMs 
in the current literature; UV light is too high in energy for medical use and CO-RMs which 
release when irradiated at a higher wavelength are  more desirable. 
Arregui and co-workers have carried out some initial studies with CO-RM-1 in similar fashion to 
what has been carried out with previous CO-RMs.81 In rats, CO-RM-1 was shown to increase the 
level of CO-Hb in the blood and increase the levels of cGMP in urine. It was also shown to 
increase renal blood flow by a significant amount. This CO-RM was an important starting point 
in the development of CO quantification procedures and photo-activated CO release, however 
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this molecule does not contain interesting structural features for further modification to alter 
properties like in the case of the acyloxybutadiene complexes.76 New, more soluble and more 
structurally appropriate CO-RMs have now been prepared.  
Lynam and co-workers prepared a series of cyclopentadienyl molybdenum tricarbonyl complexes 
with varying alkynyl ligands. The synthesis and structure of the more promising CO-RMs from 
this work is shown in Scheme 5 .82 
 
Scheme 5. Cyclopentadienyl molybdenum tricarbonyl complexes with varying alkynyl ligands 
CO-RMs 14-18 are prepared by reaction of a terminal alkyne with a tricarbonyl chloro 
molybdenum complex (13) in the presence of CuI to activate the alkyne, with NHEt2 as a base. 
This reaction is very versatile and produces a structurally diverse selection of potentially 
therapeutic CO-RMs. The most promising of these CO-RMs is 16. This CO-RM is water soluble 
presumably because of the β-D-fructopyranose group. This group significantly increases the 
polarity and therefore water solubility of the complex.  
CO-RM 16 was used in a myoglobin assay and was found not to release CO to the myoglobin 
without any irradiation. However with irradiation from a 6 W TLC lamp, clean generation of CO-
Mb was observed. More studies into the cytotoxicity of this CO-RM and how it may breakdown 
in vivo would be essential if this CO-RM was to be taken forward. The use of a sugar to improve 
its solubility makes it structurally interesting. The method of attaching the ligand to the metal 
carbonyl moeity allows almost endless variation of the R group and further synthetic 
investigation could produce more interesting candidates.  
Westerhausen and co-workers developed another photo-CO-RM based on a cystamine iron 
structure.83 The synthesis and structure of CO-RM S1 is shown in Scheme 6. 
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Scheme 6. The synthesis of CO-RM S1 
CO-RM S1 is prepared by reaction of 6 eq. of cystamine with dodecyl carbonyl species 19, which 
forms three equivalents of CO-RM S1. This reaction is fairly efficient with the only waste 
products being small gasses. A myoglobin assay was used to assess and classify the CO-release 
behaviour of CO-RM S1. It was found that CO-RM S1 that was stored in solution in the dark for 
15 mins before addition to myoglobin only released marginal amounts of CO. When a repeat 
solution was irradiated for 15 mins with light of wavelength 470 nm. Complete conversion of 
deoxy-Mb to carboxy-Mb was observed. CO-RM S1 was also irradiated directly in the presence 
of myoglobin after an initial ‘dark’ period. No release was observed in the dark period followed 
by quick CO release with irradiation (Figure 25). 
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Figure 25. Myoglobin assay absorbance profile with CO-RM S1. Initially in the dark followed 
by 470 nm irradiation. (Graph taken from Ref. 83 with permissions, Dicarbonyl-
bis(cysteamine)iron(II): A light induced carbon monoxide releasing molecule based on iron 
(CORM-S1), Kretschmer, R.; Gessner, G.; Gorls, H.; Heinemann, S. H.; Westerhausen, M., J. 
Inorg. Biochem., 2011, 105, 6-9) Copyright Elsevier 2011.  
CO-RM S1 shows good stability in the dark in the presence of myoglobin and releases in a 
controlled an efficient manner on irradiation at 470 nm. This is one of the most promising photo-
activated CO-RMs in terms of wavelength in the literature. 470 nm is one of the highest 
wavelengths used the promote CO-release from a CO-RM and this wavelength will penetrate 
further in to tissue than some of the lower wavelengths used to activate previous CO-RMs. 
CO-RM S1 was also employed in a key study which shows that it can activate the Ca2+-
dependent K+ channels in the presence of irradiation. Figure 26 shows the results of this study. 
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Figure 26. Current measured across a membrane containing BK Slo1 Ca2+-activated K+ channels. 
Current measurements carried out in the presence (1mM) and absence of CO-RM S1(control). 
Light was also turned on after an initial dark period as indicated. (Image taken from Ref. 83, 
Dicarbonyl-bis(cysteamine)iron(II): A light-induced carbon monoxide releasing molecule based 
on iron (CORM-S1), Kretschmer, R.; Gessner, G.; Gorls, H.; Heinemann, S. H.; Westerhausen, 
M., J. Inorg. Biochem. 2011, 105, 6-9). Copyright Elsevier 2011  
There is negligible current detected with CO-RM S1 in the absence of light which matches with 
the control. When the light is turned on there is a statistically significant increase in the current 
measured across the membrane. This strongly suggests that the CO-RM is not releasing a 
significant amount of CO in the dark and then CO is being released on irradiation and causing a 
strong activation of the K+ channels. This is an encouraging result although using the CO-RM at 
1mM seems like a clinically irrelevant concentration. Cytotoxicity studies need to be carried out 
with macrophages such as RAW 264.7 cells. The CO-RM may activate the channel at 1mM but 
cell viability assays or in vivo studies have not being carried out to show that this complex is not 
toxic at 1 mM. Most CO-RMs are typically administered at a much lower concentration and it 
would be better to see if 1 mM is really necessary. The binding site on the K+ may be saturated at 
a much lower concentration of CO-RM. 
Mohr and co-workers have also developed a class of photo-CO-RM developed on unprotected L-
histidine.78 The synthesis and structure of CO-RM 21 is shown in Scheme 7. 
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Scheme 7. The synthesis and structure of CO-RM 21 
CO-RM 21 has a structurally desirable unprotected L-histidine ligand. L-histidine is a natural 
amino acid and is of course non-toxic. This is likely to reduce the chance of toxicity when 
developing a new CO-RM, because if free L-histidine is released then it is less likely to be a 
problem from a pharmacological point of view compared to an unknown newly designed ligand. 
Having said that, CO-RM 21 has not been tested for toxicity/viability yet which would need to be 
done if it were to be used in further studies.  
The molecule has been show to be stable in aqueous solution and in the presence of myoglobin. 
On irradiation at 365 nm with a 6 W TLC lamp there is CO-release observed with a half-life of 
93 mins. This is slow release for a photo-CO-RM and irradiation for such long periods of time in 
a clinic is impractical. Irradiation with light of wavelength 365 nm is now outdated, and there are 
better photo-CO-RMs in the literature such as CO-RM S1. In vivo experiments could be carried 
out to assess if there is any enzymatic activity that could degrade CO-RM 21. It could potentially 
have a role as an ET-CO-RM under the correct conditions. 
Zobi and co-workers have recently developed CO-RM 22 based on vitamin-B12 (Figure 27).60 
This is a clever strategy to take as the use of essential biological molecules is likely to decrease 
toxicity, as everyone needs vitamin-B12 to live and stay healthy. Vitamin-B12 is also water soluble 
and due to its porphyrin ring absorbs strongly in the visible region, making an excellent potential 
CO-RM tag. A similar strategy was also taken with the Mohr histidine CO-RM 21 by using 
unprotected L-histidine, which is a biologically essential compound. 
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Figure 27. The structure of Vitamin-B12 conjugate CO-RM 22 
The structure of CO-RM 22 is quite remarkable, and is one of the most structurally complex and 
diverse CO-RMs ever prepared. This is made possible by using an already complex naturally 
occurring compound. Trying to synthesise this compound from scratch would prove extremely 
difficult involving many steps. By using a natural compound and some clever linking chemistry it 
is possible to make this compound in only a few synthetic steps.  
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CO-RM 22 contains a tetraazacyclotetradecane (tacd) manganese(I) tricarbonyl species, which 
has been conjugated using carbamate functionality. Manganese carbonyl CO-release motifs are 
very commonly used and for good reasons. Many manganese(I) CO-RMs as discussed previously 
are not toxic, reducing the risk when developing new CO-RMs that contain this moeity. 
CO-RM 22 is soluble in water, which of course is due to the vitamin-B12 functionality with its 
primary amide functionality. CO-RM 22 is stable in aqueous solution for long periods of time 
setting up to be a promising photo-CO-RM. In a solution of methanol, the CO-RM is stable for a 
prolonged period, and on irradiation the M–CO bands in the IR spectrum slowly deplete showing 
that CO-RM 22 is acting as a photo-CO-RM. Myoglobin assays also show CO-release from this 
CO-RM on irradiation with a 470 nm LED and a green Ar Laser.  
A UV-Vis spectrum of the tetraazacyclotetradecane (tacd) manganese(I) tricarbonyl species prior 
to conjugation shows overlap of the LED and laser emission with the compound’s absorption 
band. This (tacd)Mn(CO)3 moeity has some interesting spectral properties with the absorption 
band tailing well into the visible region. Carrying out some detailed DFT calculations on this 
structure could be very beneficial in terms of finding out what features of this moeity shifts the 
absorption to such high wavelength. CO-RM 22 is one of the highest wavelength photo activated 
CO-RMs presented in the literature and this kind of conjugation is something that should be 
taken on board by other researchers with other interesting biological molecules.  
Schatzschneider and co-workers have taken complex 24 previously synthesised by Trofimenko 
and co-workers, and investigated its potential as a photo-CO-RM.62, 84 The synthesis of 24 is 
shown in Scheme 8.  
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Scheme 8. The synthesis and structure of CO-RM 24 
 
 Complex 20 has become a very useful metal carbonyl precursor for the preparation of CO-RMs. 
CO-RM 24 is prepared by reaction of 20 with tpm ligand 23 in the presence of NaPF6.  
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CO-RM 24 has been shown to be stable in aqueous buffer and in the presence of myoglobin in 
the dark. No spectroscopic changes were observed when 24 was mixed with myoglobin. 
However upon irradiation with a 365 nm TLC lamp conversion to carboxy-Mb was observed. It 
is important to note that the CO-release from this tricarbonyl manganese(I) species is much faster 
compared with the similar Histidine complex 21. With myoglobin in excess of CO-RM 24, it was 
found that 1.9 moles of CO per mole of 24 which is advantageous for pharmacological reasons. 
CO-RM 24 was also used in studies with HT29 colon cancer cells for cytotoxicity studies. The 
results from this study are shown in Figure 28.  
 
Figure 28. Cytotoxicity test of CO-RM 24 at 100 µM against HT29 colon cancer cell.(graph 
taken from ref.62: Photoinduced CO release, cellular uptake and cytotoxicity of a 
tris(pyrazolyl)methane (tpm) manganese tricarbonyl complex Niesel, J.; Pinto, A.; Peindy 
N'Dongo, H. W.; Merz, K.; Ott, I.; Gust, R.; Schatzschneider, U., Chem Comm. 2008, 1798-800) 
Copyright The Royal Society of Chemistry 2008. 
The controls in this experiment show that the DMSO is not causing any significant toxicity. The 
irradiation only causes a small reduction, but this is expected considering the wavelength of 
irradiation used. CO-RM 24 does not cause any cytotoxicity to the cancer cells in the dark but a 
large increase in cytotoxicity is observed when the cells are irradiated for 10 mins in the presence 
of 24. This reduction is comparable to 5-fluorouracil (FU) which is an established anti-cancer 
agent. These results are initially very promising but more investigations in to the mechanism of 
71 
 
toxicity need to be carried out. Pre-irradiation of 24 to generate a ‘photo-i-CO-RM’ would be a 
suitable starting point in assessing if photo products were responsible for toxicity.  
CO-RM 24 was also developed further by Schatzschneider and co-workers using some 
procedures developed by Regal and co-workers. The methane proton in tpm ligand 23 was 
removed using base to provide an anchor for further synthesis. Scheme 9 shows how CO-RM 25 
was synthesised, which can then be easily functionalised by various reactions. 
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Scheme 9. The synthesis of CO-RM 25, a substituted variant of CO-RM 24. 
The final step in the system of CO-RM 25 is prepared by the same complexation as with CO-RM 
24. However the ligand is pre-functionalised before the complexation step in this case. Alkyne 
functionality was introduced with a spacer which was used to keep the alkyne distanced from the 
metal complex. This would have been done so that any groups that are subsequently attached on 
to the alkyne are less likely to interfere with the CO-releasing properties of the manganese unit. 
Schatzschneider and co-workers then developed some synthetic peptides which could be 
conjugated with CO-RM 25 using either a Sonogashira reaction, or a Huisgen [3 + 2] 
cycloaddition reaction. Figure 29 shows the structures of the different peptides prepared. 
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Figure 29. The structure of synthetic peptides used for coupling with CO-RM 25 
Peptides 26 and 28 contain functionality at the N-terminus while 27 is functionalised on the 
phenylalanine side chain. This provides an excellent opportunity to functionalise on different 
areas in the molecule depending on what is required. The azides are used in the [3 + 2] 
cycloaddition reactions and the iodine is used for Sonogashira cross-coupling reactions.  
Scheme 10 shows reaction of 28 with CO-RM 25 to produce a peptide-CO-RM conjugate 29. 
 
Scheme 10. The synthesis of peptide-CO-RM conjugate 29 using [3 + 2] cycloaddition 
chemistry. 
The peptide sequence Thr-Phe-Ser-Asp-Leu is found in the transactivation domain of tumour 
suppression protein p5385 which binds with regulatory MDM2. If MDM2 gets over expressed due 
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to too much p53-MDM2 binding, then p53 activity gets reduced and cells with damaged DNA 
can divide and grow unchecked. This then leads to cancerous growth.85 The authors chose this 
peptide as a means of trying to interrupt this interaction and prevent MDM2 over expression. 
CO-RM 29 was successfully synthesised by conjugation of 25 and 28 using [3 + 2] cycloaddition 
chemistry. ESI-MS, IR spectroscopy and HPLC were used to indicate high purity. To date, CO-
RM 29 has only be employed in a myoglobin assay but acts as a photo-CO-RM and releases 1.7 
moles of CO per mole of CO-RM. This is encouraging considering the complex amount of 
functionalisation carried out with this molecule and that the uncoupled CO-RM 25 releases 1.9 
moles of CO. Despite the complex peptide attached, the CO-releasing moeity in 29 still remains 
stable and releases CO in a very similar fashion to the unfunctionalised CO-RM 25. 
It is clear that [3+2] cycloaddition chemistry and Sonogashira cross-coupling reactions are a 
powerful tool for the development of more complex CO-RMs and indeed other pharmaceuticals 
agents. Once a suitable CO-RM has been developed there are thousands of possible interesting 
structures that can then be attached on to the CO-releasing moeity. The cyclopentadienyl 
molybdenum tricarbonyl complexes shown in Scheme 3 could also be easily modified to give a 
complex with a terminal alkyne functionality which would allow the same sort of chemistry to be 
carried out on those too. 
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1.5 Potential for CO-RM use as a labelling/imaging agent 
Schatzschneider and co-workers have also developed CO-RMs for more than just use as a 
pharmaceutical agent. It is possible take advantage of the diagnostic infrared M–CO stretching 
frequencies and use a ‘CO-RM’ like moeity to act as a labelling or imaging agent.86 
The first way that a CO-RM like molecule was used as an imaging agent was to use CO-RM 24 
but with a chloride counter ion to provide increased solubility (24a). The work establishes that 
there is a diagnostic M–CO Raman stretch at 1963 cm−1 from the CO-RM which is not present 
when analysing cells without 24a present. This allows for images to be taken of the cells clearly 
showing where the CO-RM is located. Figure 30 shows the difference between an optical image 
and a Raman microspectroscopy image of a HT29 colon cancer cell taken in the presence CO-
RM 24a. 
 
Figure 30. A) Optical image of a HT29 human colon cancer cell incubated with an aqueous 
solution (2 mM) of 24a for 3 h. B, C) Raman images reconstructed from integrating the 
intensities of the CO and CH stretching peaks. The integration range was 2800–3050 cm−1 for (B) 
and 1945–1965 cm−1 for (C). The scale bar for the Raman images is 6 µm.(adapted image taken 
from Ref.86 with permissions, Label-Free Imaging of Metal–Carbonyl Complexes in Live Cells 
by Raman Microspectroscopy, Meister, K.; Niesel, J.; Schatzschneider, U.; Metzler-Nolte, N.; 
Schmidt, D. A.; Havenith, M., Angew. Chem. Int. Ed. 2010.) Copyright Wiley 2010. 
Image A shows little information about the cell and only an outline of the cell can be observed. 
However using Raman microspectroscopy in the presence of [Mn(tpm)(CO)3]Cl (24a) observing 
at 1945 cm−1 clearly shows an intense signal of the CO-RM around the cell and inside, especially 
within the nucleus. Using C–H frequencies (Image C) is much less selective and informative as 
many biological molecules will contain Raman active C-H vibration modes. The use of the C–O 
stretch can be attributed specifically to the CO-RM and shows important localisation information. 
One would imagine that many other CO-RMs could also be used in the same way. 
Schatzschneider and co-workers also developed a cyclopentadienyl tricarbonyl manganese(I) 
system which can be used to label biologically important peptides.87 The CpMn(CO)3 ‘tag’ 
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provides metal carbonyls which can be used for infrared imaging. This makes it possible to view 
where these biological important molecules are located inside a cell. Figure 31 shows the 
structure of cymantrene-peptide conjugate 30. 
 
Figure 31. The structure of 30, a cymantrene tagged biological probe. 
The ‘CO-RM’ like moeity was attached to the peptide with a succinic acid linker to space out the 
metal fragment from the rest of the peptide sequence. This could help prevent any interference 
with the peptide binding to its natural targets. 
Complex 30 has three diagnostic IR stretches at 1916, 1943 and 2016 cm−1, which are similar to 
the stretches observed in the tpm CO-RM system. These peaks give a strong signal that would 
not be naturally produced by cells. This molecule has been shown to be non toxic to MCF-7 
human breast cancer cells making it suitable for use as a probe. Any toxicity would be 
undesirable as it could strongly interfere with the location of the unconjugated peptide. This is a 
promising molecule but imaging studies with this peptide have yet to be carried out. 
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1.6 Overview and remarks 
In summary, CO has been shown to play an essential role in eukaryotic biology and is a key 
molecule with respect to homeostasis. Many researchers have shown that CO as a gas or locked 
within a CO-RM can be used as an extremely beneficial molecule to treat many conditions and 
diseases and to preserve organs. The multiple benefits that carbon monoxide-releasing molecules 
(CO-RMs) could potentially give present a large advantage over many traditional organic drugs, 
which may only treat one condition. A single CO-RM has the potential to treat a variety of 
ailments rather than needing a complex mixture of different drugs. CO-RMs also have the 
potential to alleviate harmful side effects from current drugs already on the market. 
The other great benefit of using CO-RMs as pharmaceuticals is that there are numerous different 
structures capable of releasing CO as previously described. This spans a wide variety of 
coordinating ligands, geometries, CO-release modes and transition metal centres. This means that 
if one particular CO-RM was toxic to a patient in the future, another one could be potentially 
used. 
It is important to remember that the CO is the drug and the ligand is a means of getting the CO 
where it is required. With the right ligand, the properties of CO-release and localisation can be 
fine tuned and modified, which can simply not be achieved using CO gas alone. This highlights 
the benefits of a CO-RM over the use of CO gas. Ramão and co-workers have shown that a 
[Mo(CO)3(CNR)3] CO-RM motif is an encouraging candidate for treating acute liver injury.88 
This CO-RM accumulates in the liver but it was not designed to do this. While this work is 
encouraging, developing more functionalised CO-RMs for less random localisation could be 
more beneficial. Rather than making a CO-RM in the hope that it accumulates where it is 
required; it would be more logical to bind to specific proteins that are at high concentrations 
within an organ/tissue.  
One of the other benefits is that CO is already produced in the body naturally. So providing that 
the CO dose is controlled carefully there are unlikely to be too many side effects due to the CO 
itself. Although great care needs to be taken in assessing the behaviour of the fragments that are 
left behind after CO release. Currently, there is not much detail in the literature about the 
characterisation of the fragments left behind after CO-release; even if they have shown that it is 
non-toxic and not responsible for the beneficial effects observed.   
CO-RMs clearly have the potential to become some of the most important pharmaceuticals 
invented to date. 
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2 Aims and Objectives 
The aims of this project are to: 
• Synthesise a new generation of photo-active CO-RMs that are water compatible, and 
release CO in a controlled manner 
• Increase the wavelength of light required to release CO while retaining stability. 
• Introduce a site for functionalisation to allow targeting 
• To prepare CO-RMs that can be used to exhibit detrimental effects on various bacterial 
strains, while being viable with eukaryotic cells 
• Carry out investigations to elucidate the mechanism of action of the CO-RMs on bacteria 
The objectives of this project are to: 
• To design new ligands based on initial research and then synthesise complexes of these  
new designs using synthetic chemistry 
• Carry out a wide variety of myoglobin assay experiments to establish CO release profiles 
for the CO-RMs synthesised. Water compatibility can be assessed with data from these 
assays 
• Carry out growth curves and plating studies with E. coli and S. aureus. Careful controls 
are required to confirm effects and to assess what is causing these 
• Carry out Alamar blue and LDH assays with RAW 264.7 macrophages using CO-RMs to 
assess their viability 
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3 Manganese(I) complexes as potential CO-RMs 
3.1 Synthesis and characterisation of new manganese(I) complexes 
The main aim of this project was to prepare a new class of photo-active CO-RMs. To do this, it 
was necessary to find a promising CO-releasing moeity that could be used as a basis for further 
studies. Tetracarbonyl phenylpyridine manganese(I) complexes have been prepared by Bruce and 
co-workers in the 1970’s, however they had not yet been reported for use in a medicinal 
context.89-90 The structure of parent complex 37 is shown in Figure 32. 
 
Figure 32. The structure of a potential CO-RM manganese(I) complex 37  
This octahedral structure consists of a 2-phenylpyridine bidentate ring system with a covalent 
bond to the manganese from the phenyl ring. There is also dative bond to the manganese from the 
nitrogen in the pyridine ring. The central manganese(I) atom has four carbon monoxide ligands. 
This structure was taken as a starting point for further research into using this moeity as a CO-
RM.  
It was known from work by Fairlamb and co-workers that this molecule was known to release 
CO in the presence of light on a nano-second time scale;91 but a more in-depth study of this 
potential CO-RM was required. Initial work was required to establish if the ‘Mn(CO)4’ motif 
attached to the 2-phenylpyridine ligand could be used in CO-RMs for further studies.  
The aim was to assess if simple structural variation on the phenyl ring would influence how the 
molecule behaves in terms of general stability and CO-release rates. If small structural variations 
caused dramatic changes in the rate/mode of the CO-release then this would make the CO-RM 
unsuitable when considering the aims of this project. The aim is to discover a CO-releasing 
moeity that can be functionalised with lots of different substituents to allow altering a variety of 
chemical properties. These include solubility, localisation, and wavelength of CO-release, and 
also for the potential to introduce fluorescence in to the structure. 
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Initial modification of CO-RM 37 involved synthesising a series of complexes substituted at the 
para-position on the phenyl ring. This position was chosen to avoid steric interaction of this 
group with the Mn(CO)4 moeity, and also to maintain symmetry in the molecule to avoid the 
potential for isomerism. The structure of the initial target molecules are shown in Figure 33. 
 
Figure 33. The target structures for initial CO-RM studies 
The series of structures includes halogen substituents and the introduction of a third aromatic 
ring. All of these substitutions could affect how each CO-RM releases CO. Different substituents 
could alter the amount of electron density within the aromatic rings, subsequently changing the 
electron density on the metal. This could then weaken the M–CO bond depending on the 
substituent, and alter CO-releasing properties. 
To synthesise these ligands, a two step linear strategy was developed based on the previous 
synthesis of the parent compound 37. Firstly the ligands were prepared by a series of palladium-
mediated Suzuki–Miyaura cross-coupling reactions in one step from commercially available 
materials. The general synthetic route to the substituted 2-phenylpyridine ligands required is 
shown in Scheme 11. 
 
Scheme 11. General reaction scheme for preparation of substituted phenyl pyridine ligands. (R = 
H (31) was purchased from Sigma Aldrich). 
The Suzuki–Miyaura cross-coupling reaction has long been established for synthesising linked 
aromatic systems,92 and this made it suitable for preparing ligands 32-35. The reactions use a 
palladium catalyst in low loading (0.7-2 mol%) to turn over the reaction using a THF/water 
system with the aqueous layer containing a base. The reactions were performed at 60-80 °C 
depending on the substrate, and the yields for the reactions are shown in Table 3. 
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Table 3. Percentage yields obtained from Suzuki–Miyaura cross-coupling reactions. 
Compound R Catalyst Base % Yield 
32 F AB cat (0.7 mol %) 1.9M Na2CO3(aq) 79 
33 Cl Pd(PPh3)4 (2 mol %) 2M K2CO3(aq) 83 
34 Br Pd(PPh3)4 (2 mol %) 1.9M Na2CO3(aq) 59 
35 Ph Pd(PPh3)4 (2 mol %) 1.9M Na2CO3(aq) 59 
 
Ligand 32 was synthesised using an alternative catalyst ABcat, which is a palladium dimer 
species bridged by 2-bromopyridine ligands (Figure 34).93 
 
Figure 34. The structure of palladium dimer pre-catalyst ABcat (36) 
Palladium dimer pre-catalyst 36 has been previously used in Suzuki–Miyaura reactions, and is 
particularly effective because it slowly degrades in solution to give mono-ligated Pd–PPh3, which 
is catalytically active in cross-coupling reactions.93 The slow release of active palladium into 
solution can prevent aggregate formation and subsequent turnover reduction. This catalyst had 
not been  previously used with an electron withdrawing substituent such as fluorine on a benzene 
ring before. ABcat (36) was used in this case to test if the reaction could tolerate different 
functionality. Pleasingly ABcat in this reaction gave compound 32 in 79% yield, which gave 
satisfactory material for further characterisation. 
Bromo-containing compound 34 had to be synthesised using a lower temperature of 60 °C. This 
was performed at 60 °C to prevent the para-bromophenylboronic acid from coupling with itself 
and the target product to give undesired tri-aromatic chains. ortho-Bromopyridines generally 
react faster than bromobenzene derivatives and 60 °C is low enough to efficiently promote the 
reaction of 2-bromopyridine, but low enough to avoid activation of the C–Br bond in the 
bromobenzene derivatives. The reaction in Scheme 11 gave product 34 in 59% yield. The chloro 
substituent in the starting material used to prepare 33 is much more suited to this reaction as these 
typically react at higher temperature. 80 °C gives a fast reaction of the 2-bromopyridine species 
with negligible cross-coupling observed from the chloro containing species in the reaction. This 
is reflected in the respectable 83% yield obtained for ligand 33.  
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Ligand 35 was only synthesised in 59% yield, which seems rather low considering that biphenyl 
boronic acid will not be coupling with itself like in the case of para-bromophenylboronic acid. 
The extended conjugation and larger system could slow down the reaction rate. However 
sufficient material was obtained to move forward with the synthesis of CO-RM 41. 
With all the synthesised ligands purified and fully characterised by: 1H/13C NMR, ESI mass 
spectrometry, elemental analysis and IR spectroscopy, the target CO-RMs 37-41 could then be 
prepared using the reaction presented in Scheme 12.89-90 
 
Scheme 12. The synthesis of CO-RMs 37-41 using BnMn(CO)5 
The phenylpyridine species react with BnMn(CO)5(42) to give a tetracarbonyl phenylpyridine 
manganese(I) species. Toluene is produced as a reaction by-product, which can easily be 
removed under reduced pressure. Figure 35 shows the 1H NMR of ligand 34 and its 
corresponding purified manganese complex 40. 
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Figure 35. The 400 MHz 1H NMR spectrum of ligand 34 (top) and CO-RM 40 (bottom) 
recorded in CDCl3 
In the 1H NMR spectra shown in Figure 35, it is clear that the pair of doublets (Ha-Ha′, Hb-Hb′ 
7.6–7.9 ppm, 3J = 8.3 Hz) due to the para-substituted aromatic starting material (34) are lost on 
reaction with BnMn(CO)5. This was a good indication that the cyclo-metallation had taken place. 
There is a resonance at 8.05 ppm (4J = 1.9 Hz), which is typical of long-range W-coupling 
between Ha and Ha′ as indicated in Figure 35. The removal of a proton Hb by the cyclo-
metallation reaction isolates Ha, which can then only couple to Ha′ at the other side of the ring. 
This also changes proton Hb′ in the product which can only couple to Ha′ (3J = 8.5 Hz). The 
nitrogen in the pyridine ring in CO-RM 40 coordinates to the manganese(I) centre and this results 
in shifting of the pyridine proton signals Hc-f. Protons Hc+d have shifted so that they are partially 
overlapping. These data together suggests the desired compound has been synthesised. 
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3.1.1 IR spectroscopic and group theory analysis of CO-RM 40 
Figure 36 shows the IR spectra of the starting material and product from the cyclo-metallation 
reaction of ligand 34 to produce 40. 
 
Figure 36. The solution IR spectra in THF of BnMn(CO)5 (black) and CO-RM 40 (blue) 
The IR spectrum of CO-RM 40 confirms that all the benzyl pentacarbonyl manganese(I) has been 
consumed in the reaction as there is no peak at 2107 cm−1. There are also new peaks at 2074 and 
1933 cm−1 corresponding to the new complex. It is possible to use group theory to analyse the 
symmetry of the complex, and determine the correct number of CO stretches that should be 
observed in the IR spectrum. A diagram of CO-RM 40 with appropriate axes is shown in Figure 
37. 
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Figure 37. The structure of a tetracarbonyl manganese(I) complex 40, with the axis relevant to 
the C2v point group. Note: y axis is perpendicular to the xz plain, as are the CO ligands with 
wedge and dashed bonds respectively. 
If complex 40 was treated purely by symmetry, it would belong to the Cs point group. If a C2 
operation is performed around the z axis considering the metal octahedron, only a carbon and 
nitrogen atom switch places. This means that this molecule may show pseudo C2v symmetry. In 
some cases pendant groups away from the central metal octahedral structure do not affect the 
number of IR stretches. 
The molecule contains four metal carbonyls and the symmetric stretches of each carbonyl can be 
represented as vectors pointing away from the molecule in the direction of the M-C≡O bond. The 
vectors can have each operation in the C2v point group performed on it. The number of vectors 
that move on performing an operation in the relevant point group are removed from the total 
number of vectors, and the reducible representation can be calculated. The irreducible 
representation can be calculated by finding which components of the C2v point group contribute 
to the reducible representation. Table 4 shows the reducible representation obtained for complex 
40 using the C2v point group. 
Table 4. The reducible representation for the CO symmetric stretches in complex 40 using the 
C2v point group. 
C2v E C2 σ(xz) σ(yz) 
Γ 4 0 2 2 
 
E is the identity operation and involves no movement and so no vectors move, hence giving a 
contribution of four. C2 is a 180° rotation about the z axis, and the two carbonyl vectors in the xz 
plain switch places. The two carbonyls trans to each other in the yz plane also switch places and 
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so the C2 operation contributes zero. The σ operation is a reflection in the plane indicated, and in 
both cases each plain dissects two of the vectors and these remain the same in each case. Both σ 
operations give a contribution of two each. Table 5 shows the point group C2v.  
Table 5. The C2v point group 
C2v E C2 σ(xz) σ(yz)  
A1 1 1 1 1 z, 
A2 1 1 -1 -1 Rz 
B1 1 -1 1 -1 x,Ry 
B2 1 -1 -1 1 y,Rx 
 
The irreducible representation components in the C2v point group that combine to give the 
reducible representation are 2 A1 + B1 + B2. All components are IR active and four stretches are 
expected. This is in agreement with the data obtained for the CO-RM 40.  
It may be possible that the complex could behave like it belongs to the Cs point group due to the 
bromine atom and the difference in mass between the C and N atoms. The reducible 
representation can be obtained by treating the compound in the same way as before but using the 
Cs point group operations. The new reducible representation is shown in Table 6 and the group 
table for the Cs point group is shown in Table 7. 
Table 6. The reducible representation for the CO symmetric stretches in complex 40 using the Cs 
point group. 
Cs E σh 
Γ 4 2 
 
Table 7. The Cs point group table 
Cs E σh  
A′ 1 1 x, y, Rz 
A′′ 1 -1 z, Rx, Ry 
 
The irreducible representation components in the Cs point group that combine to give the 
reducible representation are 2 A′ + 2 A′′. This would also give rise to four peaks. It could be 
possible that the molecule is behaving like either point group but it is difficult to assign it to one 
looking at the analysis given. The IR spectra of all the CO-RMs 37-41 all show very similar IR 
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spectra with four peaks all in almost identical positions. It is clear that this molecule is not 
affected significantly by the presence of a substituent in the para position on the phenyl ring. This 
can provide confidence that the pattern of IR signals observed in the metal carbonyl region is 
diagnostic and typical of a manganese tetracarbonyl species. 
 
3.1.2 X-ray crystal structure of CO-RM 40 
To confirm the structure of CO-RM 40, crystals have been obtained by diffusion of hexane in to a 
solution of 40 in CH2Cl2. The structure was confirmed by X-ray crystallography. The X-ray 
structure for complex 40 is shown in Figure 38. 
 
Figure 38. X-ray crystal structure of complex 40. Atoms displayed as ellipsoids at 50% 
probability. Hydrogen atoms omitted for clarity. Selected bond lengths (Å) and angles (°):Mn(1)-
C(11) = 2.0477(17) , Mn(1)-N(1) = 2.0638(14), Mn(1)-C(15) = 1.8007(18), Mn(1)-C(12) = 
1.8642(19), Mn(1)-C(13) = 1.8401(19), Mn(1)-C(14) = 1.8544(19); C(14)-Mn(1)-C(12) = 
168.51(8), C(13)-Mn(1)-C(12) = 95.58(8),C(11)-Mn(1)-C(15) = 93.25(7), C(13)-Mn(1)-N(1) 
=96.04(7), C(15)-Mn(1)-N(1) = 172.80(7), C(14)-Mn(1)-N(1) =90.03(7) , C(12)-Mn(1)-N(1) 
=88.03(7), N(1)-Mn(1)-C(11) = 79.55(6) 
It is interesting to note the C(14)-Mn(1)-C(12) bond angle of 168.51(8) ° is quite distorted from 
an ideal octahedron. This is due to the size of the phenylpyridine system, which forces the system 
due to the N-Mn-C(11) bond angle of only 79.55(6) °. This geometry could play an important 
role in the determining the properties of the CO-RM. The slight distortion could alter how 
electron density passes from the ligand to the metal, potentially altering the mode of CO-release. 
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3.1.3 Yields for CO-RMs 37-41 
Table 8 shows the yields obtained from the reaction of all the phenylpyridine ligands in the 
initial series with BnMn(CO)5 (42). 
Table 8. The isolated yields for CO-RMs 37-41 obtained from reactions using BnMn(CO)5. 
Compound R % Yield 
37 H 88 
38 F 43 
39 Cl 83 
40 Br 72 
41 Ph 72 
 
The complexes were all isolated in moderate to excellent yield following a simple filtration. 
Although further purification by column chromatography could be performed if required. Due to 
a slower rate of reaction in the synthesis of fluorinated CO-RM 38 (determined by 1H NMR 
analysis), a further 0.2 eq. of BnMn(CO)5 was added to react with any remaining ligand to give 
pure product. It is unknown why this reaction proceeded much slower than all the others; 
however enough material was obtained in all cases to carry out further testing. 
 
3.1.4 In situ infrared spectroscopic analysis (ReactIRTM) of CO-RM 41  
With five manganese(I) complexes that are potential releasers of CO, the first step was to assess 
if there was any short term degradation of the complexes in air. This was followed using 
ReactIR™ instrumentation (Mettler-Toledo). A 1 mM solution of CO-RM 41 was prepared in 
DMSO and was stirred ca. three hours with IR spectra being recorded every minute. Figure 39 
shows the results of this ReactIR™ experiment. This CO-RM was the only complex analysed by 
ReactIR™ in this series due to limited availability of the instrument. 
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Figure 39. ReactIR™ profile showing the stability of complex 41 in the dark, followed by 
continuous irradiation at 365 nm with a 4 W TLC hand lamp. 
Over a one hour 40 min period, The IR peaks associated with complex 41 do not significantly 
change in intensity. This suggests that this CO-RM is not a fast thermal CO-releaser at room 
temperature. When CO-RM 41 is irradiated after an initial period in the dark with light of 
wavelength 365 nm, many spectral changes occur. The most significant of these changes is the 
bleaching of the two peaks at 2076 and 1991 cm−1. This suggests that photolysis is initiating loss 
of carbon monoxide from the complex. However in this situation all the CO is not lost as a new 
species is formed which is suggested by a new peak forming at 2011 cm−1. The peak at 1932 cm−1 
does not decrease in intensity which suggests that there is a peak in the new formed species in the 
same position as a CO-RM peak. This IR spectroscopic data shows that 41 is a photo-CO-RM in 
DMSO but does not provide details concerning the degraded products of the CO-RM. This has 
however been done with other CO-RMs in this project. 
 
3.2 Correction details for the myoglobin assay 
It has been established by ReactIR™ experiments that CO-RM 41 is not a significant thermally 
promoted CO-RM in a solution of DMSO and can be activated with light of wavelength 365 nm. 
More experiments were required to show that the complex was definitely releasing CO, and to 
assess whether there was any promotion of CO release by myoglobin. The quantification of CO 
release and assessment of reactivity towards a protein can be done in the same experiment using a 
myoglobin assay. This assay will also assess thermal stability in an aqueous solution, better 
representing physiological type conditions compared to the initial DMSO studies. 
N
Mn(CO)4
41
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Myoglobin is a CO binding protein that shows clear spectroscopic changes when CO binds to the 
porphyrin metal centre.94 The spectra in Figure 40 shows myoglobin that has been deoxygenated 
with sodium dithionite, and then subsequently flushed with CO gas to generate Mb-CO. 
 
Figure 40. The UV spectra of 50 µM deoxy-Mb (green) and carboxy-Mb (red) in PBS buffer pH 
7.4. 
The data in Figure 40 shows that there are clear spectral changes on the binding of CO to deoxy-
Mb. The four isosbestic points suggest that there is a conversion from one species to another. 
Myoglobin has been used in an established assay to quantify the CO release from many reported 
CO-RMs.51, 53, 80, 94 
3.2.1 Correction of the myoglobin assay due to insolubility 
CO-RMs 37-41 are unfortunately only partially water soluble at 40 µM, and precipitation occurs 
when added to PBS buffer in a small amount of DMSO (0.5%). This is undesirable from a 
pharmacological point of view; however the main aim of this series of CO-RMs is to assess how 
varying the substituent affects the CO-release rates. Despite these CO-RMs being apolar, there 
are many water insoluble drugs on the market and solublising agents could be used to make them 
more compatible.95 
The assessment of CO-release can be still performed with myoglobin due to the complex still 
being partially soluble. As the CO-RM is irradiated more complex will be pulled in to solution 
and CO-release can be quantified. For the CO-release to be quantitative, a correction procedure 
has been developed by Fairlamb and co-workers, and has been further refined here.94 The full 
details of how the myoglobin assay is corrected is described in this section. It is not possible to 
discuss the CO-release data in detail until this correction has been performed. 
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Figure 41 shows the changes to the UV spectrum of a deoxy-myoglobin solution when a solution 
of CO-RM 37 in DMSO is added. 
 
Figure 41. The UV spectra of 50 µM deoxy-Mb (green) and carboxy-Mb (red) and deoxy-Mb 
with 40 µM CO-RM 37 in PBS buffer pH 7.4. 
On addition of CO-RM 37 to a solution of deoxy-Mb, there is a large increase in absorbance due 
to CO-RM precipitation. The important feature of this up-shifted spectrum is that it is still the 
same shape as the deoxy-Mb curve, suggesting that the complex has not released any CO on 
initial addition of CO-RM 37 to the myoglobin solution. The majority of additional absorbance 
from the CO-RM precipitation can be removed by fixing all the spectra at a reference point of 
510 nm. This reference point is at the position of one of the isosbestic points and was chosen in 
line with a published literature procedure.96 It is scientifically acceptable to fix all the spectra in 
the assay at this point, as regardless of how much CO is released, the absorbance will not change 
at 510 nm when considering the conversion of deoxy-Mb to carboxy-Mb. Figure 42 shows the 
spectra from Figure 41, after they have been corrected at 510 nm. 
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Figure 42. Spectra from Figure 41 after correction at 510 nm (spectra adjusted to match the 
absorbance of deoxy-Mb at 510 nm). 
After correction of the curves at 510 nm, the spectra just after addition of the CO-RM appears 
more like the deoxy-Mb curve that was taken without CO-RM. However there is a slight 
difference between them due to the precipitate from CO-RM 37. The 510 nm correction shifts the 
whole spectrum down by the same amount. This does not correct for any precipitate that 
scatters/absorbs light to varying degrees across the 500–600 nm region. This difference also 
needs to be subtracted and this can be done by mapping-out the difference at the isosbestic 
points. The difference at the four isosbestic points creates four positions to which a curve can be 
fitted. The equation of the curve can be used to calculate difference across the whole spectrum. 
These values can then be subtracted from the spectrum. Figure 43 shows the spectrum of the four 
isosbestic points representative of the difference between the two curves in Figure 42. 
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Figure 43. The difference between a deoxy-Mb spectra and a deoxy-Mb solution containing 40 
µM CO-RM 37 mapped out at the isosbestic points. 
Fitting a curve to the four points representing the difference between the two spectra, due to CO-
RM interference, can provide a good fit, from which an equation can be determined. The curve 
was fitted using Sigmaplot94 and new data points along the line between the first and last 
isosbestic point were generated at a 2 nm interval to match with the data obtained from the UV-
Vis spectrometer. The data is only valid within the isosbestic points because the curve for 
correction is only fitted to values within the 510-585 nm range.  
The relative absorbance here has ended up less than the original deoxy-Mb spectrum because it 
was originally higher up but has been pulled down during the correction at 510 nm. There 
happened to be less absorbance at the higher wavelength in the raw spectrum.  
Once this data has been subtracted from the spectrum representing deoxy-Mb and 40 µM CO-
RM 37, the data in Figure 44 was obtained. 
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Figure 44. Fully corrected data for 40 µM CO-RM 37 in a myoglobin assay at zero minutes. 
The myoglobin assay data that has been fully corrected fits the deoxy-myoglobin curve well as 
shown by Figure 44. The errors associated with this correction are calculated by taking the Mb-
CO concentration and calculating a theoretical Mb-CO concentration. This is done by combining 
the carboxy-Mb and deoxy-Mb reference spectra by the appropriate percentage and comparing 
this to the corrected spectrum containing the CO-RM. If the total concentration of myoglobin is 
50 µM, and at a particular time in the assay the measured value for Mb-CO is 25 µM, then 50% 
of the reference spectra for both deoxy-Mb and carboxy-Mb would be combined to provide a 
‘correct’ spectrum. The difference between the ‘correct’ and measured spectra gives the error. 
Figure 45 shows the error for the spectra acquired at zero minutes in the myoglobin assay for 
CO-RM 37. 
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Figure 45. The error in absorbance for a fully corrected UV-Vis spectrum at zero minutes in a 
myoglobin assay with 40 µM CO-RM 37. Error calculated as described above. 
The error in the measurement at zero minutes does not go above 0.0021. This error represents 
less than 1% of the absorbance values measured at these wavelengths, demonstrating that the 
corrected spectrum closely matches the calculated spectrum. For the full myoglobin assay with 
CO-RM 37, the aim was to assess if the CO-RM was stable in the presence of myoglobin. For 
this assay the solution was kept in the dark for a 45 minute period and then was irradiated with a 
6 W TLC hand lamp emitting irradiation of wavelength 365 nm from above the solution. This 
would then confirm if the CO-RM was releasing CO on irradiation at the given wavelength. 
The process described above for correcting the zero minute spectrum was then applied to all the 
spectra which were recorded every five minutes from this point. Figure 46 shows all the UV-Vis 
spectra from the myoglobin assay with CO-RM 37 corrected only at 510 nm. 
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Figure 46. Myoglobin assay UV spectra with 40 µM CO-RM 37 corrected at 510 nm. 
The data shows that all the isosbestic points for the experimental data do not yet match with the 
deoxy-Mb and Mb-CO reference curves. This is due to the difference in light scattering as 
previously discussed.  
Figure 47 shows the four points curves (like in Figure 43) for each spectrum in the myoglobin 
assay of CO-RM 37. 
 
Figure 47. The four point correction curves for every spectra in the myoglobin assay of CO-RM 
37 
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All of the four point curves shown in Figure 47 were put through the same non linear regression 
process as the four points shown in Figure 43. There were some problems with the curves 
towards the end of the assay (as Mb-CO evolves) due to a change in curve shape. The nature of 
turbidity changes as the assay progresses due to irradiation affecting the composition of the 
solution. The curves become more complex, and this makes it harder to fit a curve to the four 
points. Many different equations were used in the fitting process and the whole Sigmaplot™ 
equation library was used to find a curve with the most suitable fit. The most suitable fit was 
determined by how close the modelled curve was to the four isosbestic points. The key 
wavelength in these measurements is at 540 nm, as the absorbance at this wavelength is used to 
calculate the myoglobin concentrations. So the modelling between the first two isosbestic points 
(510 and 550 nm) was given priority. The non-linear regression curve for every spectrum is 
subtracted to generate a fully corrected curve and this is shown in Figure 48. 
 
Figure 48. Fully corrected myoglobin assay data using 40 µM CO-RM 37. 
The corrected data matches well with the deoxy-Mb and carboxy-Mb curves, and all the 
isosbestic points match closely throughout the assay. It is clear from this experiment that there is 
a smooth conversion from deoxy-Mb to carboxy-Mb. This is because the conversion matches 
tightly around the isosbestic points with only variation between these values. Figure 49 shows 
the errors for all the time points in the myoglobin assay of complex 37. 
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Figure 49. The error in absorbance for a fully corrected myoglobin assay using 40 µM CO-RM 
37. 
The data in Figure 49 shows that the error increases with time. The error is highest when fitting 
the four point curve for time points 112 and 118 mins. This is expected as the myoglobin will 
have degraded slightly over time by this point, and some shifts in the spectrum are expected. 
Considering the largest error in Figure 49 of 0.0087 at 572 nm, and a corresponding absorbance 
at this wavelength of 0.661, the error equates to 1.3% of the absorbance measurement. This small 
percentage error shows that the myoglobin assay correction described, maps out the CO-RM 
absorbance effectively. The myoglobin assay was deemed a suitable technique for measuring the 
CO-releasing from these complexes and the information obtained can now be fully analysed. 
Figure 50 below shows a plot of the measured Mb-CO concentration before any correction and 
after the full four point correction. 
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Figure 50. A plot of Mb-CO concentration vs. time for the myoglobin assay for 40 µM CO-RM 
37, showing raw and fully corrected data. Mb-CO concentration calculated from the absorbance 
at 540 nm. 
Figure 50 shows that without the correction, the data are unsuitable for analysis as the 
calculations give a large negative concentration of Mb-CO. With the correction, the initial 
absorbance of Mb-CO is just above zero which is consistent with the fact that the initial spectrum 
appears like the deoxy-Mb spectrum. It is important to note that CO-RM 37 does not release any 
CO in the initial 45 mins dark period. When the solution was irradiated from above with a 6 W 
TLC lamp emitting irradiation of wavelength 365 nm, CO was released from the CO-RM and the 
concentration of Mb-CO increased. The total Mb-CO concentration observed at the end of the 
assay was 51 µM, representing myoglobin saturation with CO. This suggests that 40 µM CO-RM 
37 is releasing more than 40 µM CO. If the CO-RM is releasing more than one CO per molecule 
of CO-RM, then this can make a potentially efficient CO-releasing molecule. This is because 
lower concentrations are required to administer a given concentration of CO. This assay shows 
that this CO-RM is a photo-CO-RM and not an ET-CO-RM with respect to myoglobin. The CO-
RM does not degrade in the presence of sodium dithionite which has been previously shown to 
induce CO-release from CO-RMs.97 This assay confirms that this complex is robust under 
aqueous and reducing conditions. 
CO-RM 37 is structurally similar to the [Mn(CO)4{S2CNMe(CH2CO2H)}] (7) prepared by Mann 
and co-workers.58 CO-RM 7 is thermally stable in buffer solution for long periods of time but 
when it is exposed to myoglobin, CO-release is then observed. The 2-phenylpyridine-based CO-
RM 37 does not release CO in solution with myoglobin or sodium dithionite until irradiated with 
light. This suggests that there is something significantly different about the bonding in the 
phenylpyridine complex that stops the myoglobin binding up CO. The covalent carbon–
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manganese bond may be stronger than that of a thioacetate type ligand. This may help keep the 
complex stable in the presence of myoglobin. This is an encouraging result as it gives control 
over when the CO is released. 
There are however some limitations when it comes to correcting the myoglobin assay and this 
includes the fact that only four points of correction are used to remove any interference. This 
means that it can be difficult to correct for the any slight changes that occur in between these 
points. The error analysis in this project shows that correction closely maps the calculated 
spectra. This may not always be the case and great care needs to be taken. If there are large un-
predictable changes in absorbances that need to be corrected for then this analysis could be 
unsuitable. 
Significant human input is required for the correction procedure. This includes analysing the UV 
spectra qualitatively to assess if the imperfections in the spectra are due to precipitation or from 
the formation of new species/reaction with myoglobin. It also requires observation of solutions 
being analysed to assess for visible signs of precipitation. If there is too much interference in the 
spectra then the myoglobin assay is unsuitable for analysis. In the analysis discussed in this 
section. The shift up due to CO-RM precipitation still results in a curve shaped very much like 
the deoxy-Mb curve demonstrating little if any initial interaction of the myoglobin with the added 
CO-RM. 
Also as shown in Figure 50, if the uncorrected curve was considered, then the change in Mb-CO 
concentration would exceed the concentration of Mb-CO in the solution and this needs correcting 
for considering that a negative concentration of Mb-CO does not make sense. It is also important 
to consider that because this change exceeds the concentration of Mb-CO present; it means that 
the rate of CO release would be altered. Calculating the half-life of CO-release requires data 
points up to half the concentration of CO-RM used and the rate would differ. The interference 
from CO-RM precipitation in the UV-spectra needs to be removed to allow accurate and 
comparable half-lives to be calculated. 
The myoglobin assay correction is necessary so that comparison within a series can be 
performed. One may want to consider that the precipitate may dissolve at different rates across a 
series, but a standard method of analysis needed to be established. This method was further 
developed from an established widely cited literature procedure.96  
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3.2.2 Two part non-linear myoglobin assay correction 
As mentioned in section 3.2.1, towards the end of the assay the smooth curve that represents the 
CO-RM absorbance/interference gets more complex. Rather than a smooth decrease with 
increasing wavelength, due to changes that occur on CO-release there is more of an S-shaped 
curve. This is difficult to fit with just one equation and results in increase error following four 
point correction. In this situation the four points can be fitted using two separate equations. The 
first equation fits a line to the first three points. The two segment linear equation in Sigmaplot 
software fits two linear lines to the points in one go with a fairly smooth transition between the 
intermediate point. This is performed for the first three isosbestic points. The correction between 
the 3rd and 4th isosbestic point can then be mapped out using a simple linear y = mx + c equation. 
Figure 51 shows the isosbestic points that need to be mapped out for correction for a typical set 
of CO-release curves (from CO-RM 77 discussed in section 7). 
 
Figure 51. Comparison of absorbance/precipitation of CO-RM 77 in a myoglobin assay with the 
mapped absorbance using non-linear regression so that 2 nm spaced data points can be generated 
for spectral correction. 
As time progresses it is clear that an S-shaped curve develops as this particular CO-RM is 
irradiated in solution. A quadratic type equation will typically map out the first few curves in this 
series but will not accurately model the later ones. Using the two segment linear equations to 
correct from 510 to 568 nm and the linear equation from 568 nm to 586 nm gives a closely 
modelled absorbance for each CO-RM/by-product interference.  
Figure 52 shows the errors from the corrected data in Figure 51. 
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Figure 52. The error in absorbance after a correction of a myoglobin assay using CO-RM 77 
The S shaped curves are modelled well as determined by the error above. The error here is lower 
compared to the errors shown in Figure 49; showing that using the two-part correction is 
efficient when the four points cannot be accurately modelled with a single equation. The 
correction at 510 nm removes the majority of the CO-RM interference/absorbance, and the two 
part correction removes the remaining differences. This correction procedure allows for 
interference in the UV-Vis spectra to be removed from this assay and produces accurate data with 
relatively small errors. 
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3.3 Discussion of CO-release from CO-RMs 37-41 
With all the correction procedures established in the myoglobin assay that is used in this work, all 
of the CO-RMs in this initial phenylpyridine series can be corrected and the data can be analysed. 
Figure 53 shows data from myoglobin assays using 40 µM CO-RMs 37-41 in each separate 
experiment. In these myoglobin assays a 6 W TLC lamp emitting light of wavelength 365 nm 
was used. Irradiation was initiated after 45 mins and was used for two minutes every five minute 
period to allow for a spectrum to be recorded. 
 
Figure 53. Myoglobin assays using 50 µM myoglobin with 40 µM of each CO-RM at 37 °C. 
Solutions irradiated from above after 45 mins with a 6 W TLC lamp emitting light of wavelength 
365 nm above the sample. Irradiation on for two mins every five minute period.  
The data in Figure 53 shows that the series of substituted phenylpyridine CO-RMs are photo-
activated CO-releasing molecules. During the dark period (45 mins) for CO-RMs 37-41, there is 
no CO-release observed. The CO-RMs are all stable in the presence of myoglobin and phosphate 
buffered saline. When the solutions were irradiated, conversion to carboxy-Mb is observed in all 
cases. The correction procedures used yielded spectra with well defined isosbestic points in all 
cases. The half-life (t½) has been calculated from these data and are shown in Figure 54. The 
half-life for CO-release from a CO-RM is calculated by assessing how many minutes from 
initiating irradiation it takes to release half the concentration of CO compared to the CO-RM 
concentration used. This is the standard method of reporting the half-life because a CO-RM may 
release multiple CO ligands. The kinetics shown in Figure 53 are a combination of several 
release rates and so the discussed half-life determination method is used. A t = 0 value was taken 
0
10
20
30
40
50
60
0 20 40 60 80 100 120
M
b
-C
O
 c
o
n
ce
n
tr
a
ti
o
n
 /
 µ
M
Time / Mins
H (37)
F (38)
Cl (39)
Br (40)
Ph (41)
2 mins on, 3 mins off 365 nm 
irradiation started here 
103 
as the start of irradiation as no significant CO-release was detected until this point by a thermal or 
enzyme-triggered mechanism.94  
 
Figure 54. Half-life values for CO-release from CO-RMs 37-41, t = 0 taken as the start of 
irradiation with a 6 W TLC lamp emitting light of wavelength 365 nm. Irradiation carried out for 
two mins per five mins. 
Under the same irradiation conditions, it is clear that varying the substituent at the para-position 
on the phenyl ring alters the half-life for CO-release. CO-RM 38 (F) and 40 (Br) release faster 
than the other CO-RMs with half-lives of 17 and 18 mins respectively. The introduction of an 
extra phenyl ring in to CO-RM 41 appears to have lowered the half life. It is likely that this extra 
apolar substituent has decreased aqueous solubility and reduced the amount of CO-RM available 
in solution for efficient irradiation. A similar amount of Mb-CO is generated with CO-RMs 37-
41 however it takes different amounts of time to achieve this depending on the substituent and 
this is important The increased amount of precipitation will also scatter more light reducing the 
amount of light that penetrates further into the solution.  
Molar extinction coefficient determination was also carried out on these complexes at 330 nm to 
see if altering the substituent changed the coefficient to some extent. A high molar absorption 
coefficient of the band associated with CO-release could lead to more efficient CO-release. Table 
9 shows the molar extinction coefficients for CO-RMs 37-41. 
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Table 9. Molar extinction coefficients (ε) for CO-RMs 37-41 in acetonitrile at 330 nm. 
Compound ε / mol−1 dm3 cm−1 (330 nm) R2
 
 
37 (H) 4054 ± 96 0.9997 
38 (F) 4522 ± 83 0.9998 
39 (Cl) 4534 ± 163 0.9993 
40 (Br) 4872 ± 25 1 
41 (Ph) 13166 ± 374 0.9996 
 
Substituting the para-position of the phenyl ring on the parent phenyl pyridine complex with a 
halogen increases the molar extinction coefficient by a maximum of 20% (40). This is not 
surprising considering that this substituent does not increase conjugation or significantly alter the 
electronic character of the system. Introduction of another phenyl ring (CO-RM 41) which is in 
conjugation with the original motif, increases the molar extinction coefficient over three fold 
compared to the parent complex (37). This is a significant change and if the solubility of this 
complex was not reduced by decreasing polarity, it is expected that there would be a significantly 
increased CO-release rate.  
The half-lives in this series of CO-RMs vary to some degree, however the CO-RMs are stable in 
aqueous solution ca. 45 mins. The CO-RMs do not release CO until irradiation is initiated. It is 
also important to note that the half lives reported are for the specific conditions used. If the 
sample was irradiated for longer in one period then the half-life for these complexes would be 
shorter. It is important to correlate irradiation time and power with the CO-release rates. 
 
3.3.1 Re-evaluation of CO-RMs 39 and 40 using an LED irradiation system. 
In contrast to the careful experimental conditions typically used in thermal reactions, there is less 
focus on how light is used as a reaction parameter. As shown in Figure 53, light is the most 
important parameter in this kinetic study when determining the CO-release rates. The 
wavelength, intensity, and distance of the source from the solution all significantly contribute to 
the kinetic data. This applies not only to a myoglobin assay, but to any reaction that requires 
significant contribution of light to make the reaction proceed. 
With this knowledge in mind, a cost effective LED system was developed to address the general 
issues associated with using a TLC lamp. When using a TLC hand-lamp the wavelength and 
intensity are fixed and the irradiation is emitted over a wide cone angle due to the lamp being 10 
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cm above the cuvette. A small LED with dimensions of only 4 mm × 4 mm allows development 
of a system that can clip directly on to a UV cuvette (Figure 55). 
 
Figure 55. The LED irradiation cap mounted on a UV-Vis cuvette 
The LED in Figure 55 is close to the sample meaning that a large proportion of the light passes 
through the sample, increasing efficiency. The LEDs can operate at a power consumption of up 
to 5 W, which is similar to that of a hand lamp. This is a high power consumption considering the 
size of the LED relative to a TLC lamp.  
A control unit was also developed, which can automatically control when the LED comes on and 
off. This helps to reduce error arising from manual control (Figure 56). 
 
Figure 56. The LED control unit developed at the University of York. 
The device in Figure 56  monitors and controls the LED power consumption. This means that the  
device can repeatedly deliver the same amount of light. This system was used in further CO-
release studies. 
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With the new LED system developed, CO-RMs 39 and 40 were re-tested in the myoglobin assay 
to compare the efficiency of the LED to the TLC lamp. Figure 57 shows myoglobin assays with 
40 µM CO-RM. 
 
Figure 57. CO-release from 40 µM CO-RM 39(left) and 40 (right) using 50–60 µM myoglobin. 
Irradiation with 365 nm TLC lamp and LED (400 nm, 2.4 W). On for 2m per 5m period. * 
indicates start of irradiation cycles. 0-35 mins omitted for clarity as it stays close to zero 
throughout this period. 
The myoglobin assays in Figure 57 demonstrate that the use of a 400 nm LED is more efficient 
than a TLC lamp. The LED was set to a power consumption of 2.4 W which is less than 50% of 
the output of a TLC lamp. With less power consumption than a TLC lamp, the CO-release rate 
from both CO-RM 39 and 40 is much faster when irradiation from an LED is used. With CO-RM 
39 the myoglobin is saturated 20 mins earlier when the LED is used. The half-life for CO-RM 39 
was reduced from 27 to 6 mins, and for CO-RM 40 is cut from 18 to 8 mins. This is a significant 
change and highlights the importance of the light source. 
These half-life values were determined using an LED emitting irradiation of wavleength 400 nm, 
with a power consumption of 2.4 W light. The light intensity could easily be increased further to 
shorten the half-life if required (this is shown with CO-RM 47 in section 4). This data clearly 
shows that the half-life of these CO-RMs is variable depending on what type of irradiation 
system is used. This provides an extra degree of control that some thermo- and enzyme-triggered-
CO-RMs cannot provide. 
 
µM
 
 
µM
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Figure 58. UV spectrum in MeCN at 1.125×10−4 mol dm−3 for CO-RM 40(Br) 
 
The UV-Vis spectrum in Figure 58 shows that CO-RM 40 has a weak absorbance at 400 nm. 
The 400 nm LED has a spectral width of ± 20 nm, with maximum intensity at 400 nm. This 
means that a large portion of the light from the LED is not being absorbed. Yet fast conversion 
from deoxy-Mb to carboxy-Mb is observed. CO-release is still faster than using the TLC lamp. 
The LED light is being absorbed at a wavelength with a lower absorption coefficient compared 
with 365 nm, emphasising how efficient the Mn(CO)4 motif is at releasing CO on photolysis. 
Even though some of the 400 nm light is not being absorbed, the use of 400 nm light is much 
more desirable since it is less likely to damage important biological molecules compared to 365 
nm light. 
It was then necessary to quantify how many molecules of CO are released from CO-RMs 39 and 
40. This was done by using a substoichiometric concentration of CO-RM relative to the 
concentration of myoglobin in an assay. The amount of CO-RM used was lower than the 
maximum possible amount of CO that could be released (four with an Mn(CO)4 system), so that 
myoglobin saturation was not possible. Figure 59 shows CO-release profiles from CO-RMs 39 
and 40 at only 10 µM in a myoglobin assay. 
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Figure 59. CO release from 10 µM CO-RMs 39 and 40 using 50-60 µM myoglobin in a 
myoglobin assay. Irradiation with LED (400 nm, 2.4 W). On for two mins per five min period. * 
indicates start of irradiation cycles. CO-release profiles carried out by Conrad Wagner  
 
The CO-release profiles in Figure 59 show that both CO-RMs release almost three molecules of 
CO per molecule of CO-RM. This is advantageous compared to ruthenium-based CO-RM-3 in 
the literature that only releases one CO,80 as a lower concentration of CO-RM is required to get 
the same amount of CO. The kinetic curves are much smoother with the automatically timed 
LED system. The TLC lamp studies were still essential in gaining initial information but moving 
forward, the LED system is much more suited to these kinetic studies. 
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3.4 Palladium-mediated cross-coupling on a CO-RM 
CO-RMs 39 and 40 contain a halide substitent, providing the opportunity to functionalise these 
CO-RMs and improve their properties. This has been previously carried out on a tricarbonyl iron 
pyrone complex using palladium chemistry.73 A palladium-mediated cross-coupling has been 
carried out directly on CO-RM 40 using phenyl boronic acid to give CO-RM 41 via a different 
route to what was previously used in this project, based on a modified literature procedure.98 This 
demonstrates that this CO-RM is directly functionisable. Scheme 13 shows the conditions 
developed by Buchwald and co-workers with some modifiations to carry out this reaction on 
potentially sensitive CO-RM 40. 
 
Ph
N
PhB(OH)2 (1.5 eq.)
Pd(OAc)2 (1 mol%)
Xphos (2 mol%)
K3PO4 (2 eq.)
Toluene
50 °C, 20 h
41, 67% Yield
Mn(CO)4
Br
N
Mn(CO)4
40
 
Scheme 13. Modified Suzuki–Buchwald conditions carried out on 40 to prepare CO-RM 41 via 
an alternative route. Conditions developed in collaboration with Joshua Bray.  
 
Despite the presence of base, phosphine ligand and palladium catalyst; it is possible to carry out a 
cross-coupling reaction directly on CO-RM 40. It is impressive that these conditions work at 50 
°C lower than for similar organic substrates reported in the literature (100 °C).98 Performing this 
reaction at higher temperature (70 °C) in an attempt to improve the yield, resulted in degradation 
of both the starting material and cross coupled product to their corresponding free ligands. The 
lower temperature is necessary to maintain stability of the cyclometalled species. The reactivity 
of the C–Br bond appears activated under the conditions in Scheme 13. With the manganese 
centre back-bonding into the pi* orbtial on the metal carbonyl, it is expected that the manganese 
atom is then electron deficicent. This results in withdrawal of electron density out of the ring and 
subsequently the C–Br bond. This type of cross-coupling reaction has not been previously 
performed on a manganese complex, such as CO-RM 40 before.  
The product from Scheme 13 was already previously prepared by reaction of ligand 35 with 
BnMn(CO)5 (42) and comparison of 1H and 13C NMR, IR and LIFDI-MS data with the original 
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reported synthesis confirms the presence of cross-coupled product. This reaction was carried out 
as an example to show that the cross-coupling conditions are effective. 
3.5 Conclusions on initial phenylpyridine CO-RM series 
This initial CO-RM series establishes that the phenylpyridine-Mn(CO)4 motif has the potential to 
progress into further CO-RM studies. Synthesis of CO-RMs 37-41 was carried out in two linear 
steps; which is a short route to some encouraging structural motifs. The CO-RMs were 
characterised using a variety of techniques demonstrating high purity, and there can be 
confidence in the assigned structures. Group theory analysis was also carried out to demonstrate 
that CO-RMs 37-41 had the correct number of CO stretches in their IR spectra: this is an useful 
technique when working with metal carbonyl complexes. It is essential that CO-RMs taken 
forward for further study can be made in high purity to avoid false positive or negative results. 
 
CO-release quantification using a myoglobin assay has shown that the CO-RMs 37-41 are robust 
photo-CO-RMs. They have controllable half-lives making the motif suitable for further 
development. The myoglobin assay procedure has been optimised for CO-release quantification 
with CO-RMs that precipitate at the required concentration and assays were shown to have a low 
percentage of error compared to the absorbances measured. This gives a degree of confidence 
and reliability to the Mb-CO concentrations obtained from these assays. Some expertise and 
careful judgment is required when fitting the curves to the four isobestic points during correction 
procedures. This procedure is not trivial, but yields high-quality final results. 
 
Unfortunately there is a degree of precipitation in aqueous medium with 40 µM CO-RMs 37-41. 
This is a serious issue that had to be addressed, and was carried out by further functionalisation 
shown in section 4. Even though CO-RMs 37-41 are not as drug-like as other molecules 
synthesised in this project, they were essential for the development of all the other CO-RMs. 
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4 Developement of water compatible CO-RMs 
4.1 Synthesis and characterisation of ester CO-RM 45 
With the knowledge that the initial phenylpyridine CO-RM series 37-41 releases CO efficiently 
under photochemical conditions, the next step in this project was to develop more polar CO-RMs. 
These need to be either water soluble or compatible (i.e. remains in solution on addition to 
aqueous solution in a small amount of DMSO). DMSO is commonly used in biological testing at 
low concentrations and there are many solubilising agents available in the pharmaceutical 
industry that can be used as a DMSO replacement.95  
The first step in the synthesis of a new series of CO-RMs was to prepare more polar substituted 
phenylpyridine ligands. A 2-(4-hydroxy-phenyl)pyridine 43 scaffold was prepared using a 
Suzuki–Miyaura reaction and the details are shown in Scheme 14. 
 
Scheme 14. The synthesis of 2-(4-hydroxy-phenyl)pyridine (43) 
The procedure developed by Liu and co-workers is efficient at coupling bromopyridine substrates 
with various boronic acids:92 Polar para-hydroxyphenylboronic acid is tolerated well in this 
reaction giving an 80% yield after only 30 minutes reaction. Ligand 43 was then used in a 
Williamson ether synthesis to extend the molecule further, and Scheme 15 shows the details for 
the synthesis.99 
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Scheme 15. The synthesis of methyl [4-(pyridin-2-yl)phenoxy]acetate 44. 
Zhang and co-workers showed that reaction of similar substrates in acetone gave poor yields 
using one equivalent of chloro-methylacetate and K2CO3.99 Slight adjustments to the procedure 
gave 44 in 92% Yield. The use of 1.2 eq. of chloromethyl acetate and 1.5 eq. of K2CO3 in acetone 
in a sealed thick-walled round-bottomed flask provided optimal conditions for this synthesis. 
Sealing the flask allowed the acetone to reach higher temperatures and the reaction then went to 
completion, as determined by TLC analysis. The low boiling point of both acetone and 
chloromethyl acetate makes the removal of unwanted starting material under reduced pressure 
straight forward. Only an extraction workup was required to obtain the pure product 44.  
Compound 44 was then treated with BnMn(CO)5 (42) in toluene in a similar fashion to the 
preparation of CO-RMs 37-41. Toluene was used as an alternative solvent in this reaction due to 
poor solubility of 44 in hexane. The reaction did not go to full completion and column 
chromatography was required to remove small amounts of remaining BnMn(CO)5 (42), and 
unreacted ligand 44. The new ester CO-RM 45 was isolated with a yield of 81%. 
The 1H NMR of CO-RM 45 shows similar changes on complexation (Figure 60).  
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Figure 60. The 400 MHz 1H NMR spectra in CDCl3 of ligand 44 (top) and CO-RM 45 (bottom) 
at 300 K. 
The NMR data in Figure 60 shows that on complexation, the loss of the para-substituted 
aromatic splitting is observed. The two doublets at 6.99 and 7.94 ppm (3J = 9.0 Hz) are not 
present in the spectra of CO-RM 45. The IR spectrum of CO-RM 45 shows four bands in a 
similar position as for CO-RMs 37-41. Crystals of 45 were obtained by diffusion of hexane into a 
solution of 45 in CH2Cl2 which were analysed by X-ray crystallography, and the solved X-ray 
structure is shown in Figure 61. 
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Figure 62. Left: CO-release profile for CO-RM 45 at 40 µM in PBS buffer pH 7.4. Irradiation 
with a 6 W 365 nm TLC hand lamp for 2 mins per 5 min period. Right: Full UV/vis spectra from 
510-586 nm after four point correction. 
The data in Figure 62 shows that CO-RM 45 releases CO in a similar fashion to the previous 
series of complexes. Unfortunately the ester group is not polar enough to solubilise CO-RM 45 in 
solution and some precipitation was observed as seen previously with CO-RMs 37-41. A half-life 
for CO-release of 29 mins was observed for this complex. This is similar to bi-phenylpyridine 
CO-RM 41. On the other hand, it is promising that this molecule still behaves like a photo-CO-
RM. Introduction of even more complex functionality does not affect the CO-RMs reactivity to 
aqueous buffer solution and myoglobin. 
 
4.2 Development and synthesis of acid-containing CO-RM 47 
The myoglobin assay for CO-RM 45 showed that a more polar moiety was required to make a 
water compatible CO-RM. The approach taken was to consider hydrolysing the methyl ester in 
CO-RM 45 to give carboxylic acid functionality. This functional group should be deprotonated in 
PBS buffer at pH 7.4 and the complex should be more water soluble. This was a promising 
strategy because only one reaction from CO-RM 45 could yield a structure with considerably 
different physical properties. 
Initial synthetic studies involved attempting hydrolysis of ligand 44 to develop a set of conditions 
that could then be used on ester-containing CO-RM 45. In order to circumvent possible problems 
during ester hydrolysis, a mild procedure developed by Karlsson and co-workers that can 
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hydrolyse esters at ambient temperature was utilised.100 Scheme 16 shows the conditions used to 
hydrolyse the methyl ester in ligand 44.  
 
Scheme 16. The ester hydrolysis of ligand 44 to form carboxylic acid ligand 46. 
The hydrolysis of ester ligand 44 in wet acetonitrile under the given conditions was efficient 
giving 46 in 67% yield. The same conditions were used to hydrolyse the ester in CO-RM 45, 
however the reaction was carried out under a nitrogen atmosphere initially followed by argon. 
This precaution was taken in case the product (47) was air sensitive. Scheme 17 shows the 
conditions used on CO-RM 45 to hydrolyse the ester. 
N
O
OMeO
Mn(CO)4
N
O
OHO
Mn(CO)4
Et3N (3 eq.)
LiBr (10 eq.)
CH3CN/H2O (98:2)
25oC. 2 h
Argon
47, 84% Yield45
 
Scheme 17. The hydrolysis of CO-RM 45 under mild conditions to give CO-RM 47 
The hydrolysis was successful giving CO-RM 47 in 84 % yield, up from 67% in the ligand test 
reaction. This synthetic route provided sufficient amounts of CO-RM for further studies. This 
approach to preparing complex 47 was taken as the complexation with benzyl pentacarbonyl 
manganese is typically efficient in hydrophobic solvents. Ligand 46 is significantly more polar 
than any other ligand previously prepared, and is poorly soluble in hexane or toluene. It was 
therefore deemed appropriate to hydrolyse the ester of CO-RM 45 instead of attempting to find 
alternative cyclo-metallation conditions. 
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The 1H NMR spectra in Figure 63 show the changes to CO-RM 45 on ester hydrolysis. 
 
Figure 63. 400 MHz 1H NMR spectra in d6-DMSO of ligand 46 (top) CO-RM 45(middle) and 
CO-RM 47 (bottom) at 300 K.  
The NMR data in Figure 63 shows that the singlet signal for the CH3 on the methyl ester at 3.8 
ppm is not present in either ligand 46 or CO-RM 47. This suggests that the ester has been 
successfully hydrolysed. There is also a broad singlet at 13.15 ppm in the 1H NMR spectrum of 
CO-RM 47, and this chemical shift is diagnostic of carboxylic acid functionality. The IR 
spectrum of CO-RM 47 still contains the four peaks diagnostic of the tetracarbonyl manganese 
unit. It is pleasing that the ‘Mn(CO)4’ moiety is stable under the reaction conditions used. The 
data obtained suggests synthesis of pure carboxylic acid CO-RM 47. 
  
 
46 
 
 
45 
 
 
47 
118 
4.3 CO-release investigations with acid-containing CO-RM 47. 
With the new acid-containing CO-RM 47 synthesised and characterised, it was then necessary to 
test its CO-release properties using a myoglobin assay. Initial studies were carried out before the 
development of the LED system and assays were carried out using 20, 40 and 60 µM CO-RM 47. 
The results from this assay are shown in Figure 64. 
 
Figure 64. The CO-release profile of CO-RM 47 at 20, 40 and 60 µM concentrations in the 
presence of 50 µM myoglobin. Irradiation (365 nm, 6 W) initiated after 45 mins with two mins 
on, three mins off cycles. 
The myoglobin assays in Figure 64 show that CO-RM 47 is an efficient CO-releasing molecule. 
CO is not released until irradiation is initiated, which results in saturation of myoglobin at all the 
above concentrations. The half-life for CO-RM 47 under these conditions was found to be faster 
than any CO-RM previously prepared in this project, and the values are shown in Figure 65. 
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Figure 65. The t½ values for CO-RM 47 at 20, 40 and 60 µM under 365 nm 6 W TLC lamp 
irradiation with two mins irradiation every five min period. 
CO-RM 47 releases more CO in the same amount of time on irradiation at higher concentrations 
but the observed half-life values do not significantly vary with different concentrations.  
CO-RM 47 does not precipitate in aqueous solution when added in 5 µl DMSO to 1 ml PBS 
buffer. This is a significant step forward in the development of this class of CO-RMs as it can be 
administered in solution without any precipitation or interference. This lack of precipitation is a 
potential reason for a shorter half-life with more CO-RM being in solution. Figure 66 shows all 
the UV spectra for the 40 µM assay shown in Figure 64. This data has only been corrected at 510 
nm. 
 
Figure 66. All UV-Vis absorption spectra for myoglobin assay using 40 µM CO-RM 47. Only 
510 nm correction applied. 
CO-RM 47 is soluble on administration to the myoglobin solution and there is no skewing of the 
UV spectra, and the solution remains clear. Four point corrections for this assay is not required.  
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A comparison of CO-release from CO-RM 47 using TLC lamp and LED irradiation was then 
performed. Substiochiometric assays were also carried out to determine the number of CO 
molecules released from CO-RM 47. Figure 67 shows the CO-release data from these 
experiments. 
 
Figure 67. CO release profile of CO-RM 47 at 10 and 40 µM concentrations. Irradiation (400 nm 
2.4 W) on for two mins per five min period. Irradiation started after 45 mins as indicated. 
The myoglobin assays in Figure 67 show that use of the LED significantly increases the rate of 
CO-release from CO-RM 47. The half-life is reduced from 16 to 5 mins when using the 400 nm 
LED system. This further highlights the increased efficiency of using an LED close to the 
sample. Use of 10 µM CO-RM 47 shows that three molecules of CO are released from each 
molecule of CO-RM. This is comparable with the data obtained using halogenated CO-RMs 39 
and 40. The substituent in the para-phenyl position is still not altering the number of CO 
molecules released. The initial rate of CO-release for the two 10 µM repeats is the same. There is 
a small amount of error in the total CO-release but this would be expected due to some degree of 
myoglobin degradation over the course of the experiment.  
The LED system in combination with CO-RM 47 releases CO rapidly, with a half-life of only 
five minutes (this equates to only two mins of irradiation). As discussed previously, different CO-
release rates can be required depending on the type of treatment required.7 Fast CO release rates 
in the stomach could result in over-vasodilatory action giving rise to lack of peristalsis.101 
Therefore further CO-release assays were carried out with CO-RM 47. These were designed to 
assess the control that could be achieved when initiating CO-release. The next myoglobin assay 
used only 0.5 W of power instead of 2.4 W using an LED emitting light of wavelength 400 nm.  
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Figure 68. Myoglobin assay with 10 µM CO-RM 47. Irradiation (400 nm, 0.5 W) for two mins 
per five min period after 10 mins in the dark. 
The CO-release t½ value for the experiment in Figure 68 using 0.5 W irradiation was determined 
to be 8 mins. This increased by four mins compared to experiments performed at the same 
concentration of CO-RM when using a power consumption of 2.4 W. The change in half-life is 
not linear and this is expected due to the fact that not all of the irradiation passing through the 
sample will be absorbed. This is an important experiment as it shows that the half-life of CO-RM 
47 can be controlled by varying the intensity of the irradiation. This variation in CO-release rate 
has not yet been demonstrated by any other photo-CO-RM in the literature.  
Having established that the CO-RM 47 does not release CO until irradiation is initiated, the next 
step was to establish if CO-release could be halted if irradiation was stopped mid-experiment. 
This would give an extra degree of control over the CO-release process if the compound was to 
be irradiated in vivo. If the amount of CO in vivo was monitored as irradiation was used, then the 
irradiation could be stopped in the event of excessive CO-release. Figure 69 shows the results 
from a myoglobin assay in which a stepwise irradiation procedure was used. 
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indicate two mins (400 nm
The myoglobin assay data in 
turning off the LED. This means that the resulting species produced after initial irradiation are 
stable in aqueous solution and in the presence of myoglobin. A photo
ability to switch off and back on again after initial irradiation has not yet been shown in the 
literature until publication of this research.
that the same amount of CO is released compared to previous experiments.
The CO-release behaviour of CO
it is an efficient photo-CO
were formed in solution on the irradiation of the CO
spectrometry. A 0.5 mg ml
using ESI-MS (+ve mode). The experiment was performed using CH
DMSO could not be used here due to incompatibility with ESI
was then irradiated with light of wavelength 400 nm for one minute in between each subsequent 
ESI-MS measurement. 
changed over the time of the irradiation experiment.
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data using 10 µM CO-RM 47 with stepwise irradiation. Blue rectangles 
, 2.4 W) irradiation.  
Figure 69 shows that CO-release from CO
-CO
59
 It is encouraging that if the irradiation is resumed 
-RM 47 has been well characterised, and it has been established 
-RM with thermal stability. The next step was to establish what species 
-RM. This was performed using ESI mass 
−1
 solution of CO-RM 47 in 50:50 (v/v) CH
-MS instrumentation. The solution 
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Figure 70. ESI-MS (+ve mode) profile for peaks detected on the 400 nm irradiation of CO-RM 
47 in 50:50 (v/v) CH3CN/H2O. 
On irradiation the molecular ion for CO-RM 47 at 395 m/z is depleted. Some species attributable 
to the peaks at 230 and 274 m/z accumulate. Scheme 18 shows a proposed degradation pathway 
based on the ESI-MS data in Figure 70.  
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Scheme 18. Proposed degradation pathway for CO-RM 47 in 50:50 (v/v) CH3CN:H2O on 
irradiation with light of wavelength 400 nm (2.4 W). 
On irradiation of CO-RM 47, an intermediate species with 409 m/z was detected (47a). This 
matches with the loss of CO from the molecule ion followed by coordination of an acetonitrile 
ligand from solution. This is expected as the vacant coordination site following CO loss would 
give a 16 electron complex, which would rapidly result in coordination of another ligand. Species 
47a is an intermediate and its intensity rises and then decreases close to zero. As the peak at 409 
m/z accumulates, peaks at 230 and 262 m/z were detected (47b and c). The peak at 262 m/z is also 
an intermediate, which is likely to be a tricarbonyl manganse(I) species (47c). This has resulted 
from cleavage of the manganacycle giving uncoordinated free ligand 47b at 230 m/z. Species 47c 
also depletes on further irradiation, and is likely to be responsible for further CO-release. 
Myoglobin assay studies indicate release of three molecules of CO released per molecule of CO-
RM 47. This means that the species at 262 m/z may be responsible for further CO-release.  
It is proposed that CO-RM 47 can also degrade by a secondary pathway. A peak at 274 m/z was 
detected with significant intensity (47e). This peak did not deplete following further irradiation 
just like free ligand 47b. It is proposed that 47e has an additional carboxylic acid group at the 
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ortho-phenyl position. It is likely that 47e results from a CO migration from the manganese 
centre over to the phenyl ring (47d).This can then be attacked by water to give a carboxylic acid-
containing species 47e at m/z 274. The mechanistic process that forms 47e consumes one CO 
ligand from the manganese centre, and this could be a significant contributor to why only three 
out of a possible four CO ligands are released in aqueous solution. Another potential reason is 
that increased back-bonding from the manganese to remaining CO ligands following initial CO-
release may increase the energy needed to release further CO ligands. With only one CO ligand 
remaining, is it likely that the M–CO bond is too strong to be broken using 400 nm light. 
In summary, CO-RM 47 has been shown to be an efficient photo-CO-RM with suitable water 
compatibility. Even though 47 has to be administered in DMSO, it does not precipitate on 
addition to aqueous solution. DMSO is not the ideal solvent to use for these studies but it is used 
at a low concentration and is typically used in biology for the administration of drug compounds 
in initial studies.59 CO-RM 47 has been shown to have a variable half-life of CO-release 
dependent on the intensity of irradiation. CO-release can be halted by simply turning the light off 
during an experiment. This CO-RM has a strong degree of control in terms of its CO-release, that 
many CO-RMs in the literature have not been shown to possess. 
 
4.4 Biological investigations with CO-RM 47 
With the CO-releasing properties of CO-RM 47 established, it was then necessary to take this 
CO-RM forward into biological studies. CO-RM 47 has been shown to release CO efficiently in 
0.01 M PBS buffer at pH 7.4, however further investigations into its CO-release in biological 
media were required. 
LB media (Lysogeny broth) is a biological medium commonly used for the growth of E. coli and 
S. aureus. It is a nutient rich medium containing all the nutrients these species need to grow. 
DMEM (Dulbecco’s modified eagle medium) in combination with foetal calf serum (FCS) is an 
even richer medium used for the growth of eukaryotic cell lines. This medium contains a 
complex mixture of defined amino acids, hormones, sugars and other nutrients. DMEM/FCS is 
also typically used for the growth of RAW 264.7 macrophage cells. 
With the knowledge that these media would be used in biological investigations with CO-RM 47, 
it seemed appropriate to test the CO-release behaviour of this CO-RM in these solutions. 
Myoglobin assays using 20 µM CO-RM 47 in PBS, LB medium and 90% (v/v) DMEM:FCS 
medium with 400 nm 2.4 W irradiation were carried out as performed previously. Figure 71 
shows the results from these CO-release investigations. 
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Figure 71. The use of 20 µM CO-RM 47 in a 50 µM myoglobin assay using different aqueous 
media (monitored by UV-Vis spectroscopic analysis). Arrow indicates start of irradiation (400 
nm, 2.4 W). LED on for two mins every five minute period. 
DMEM:FCS medium contains: various proteins, amino acids, hormones, sugars, and other 
nutrients. Despite this, CO-RM 47 is stable in this medium. The CO-RM can then be activated 
with light when required. Furthermore, the initial CO-release rates are almost identical in the 
different aqueous mixtures. CO-RM 47’s CO-release rate under the conditions tested is 
independent of all the additional species in solution. This demonstrates how robust this CO-RM 
47 is under thermal conditions.  
 
4.4.1 Eukaryotic cell studies with CO-RM 47 
If CO-RM 47 is to progress as a potential pharmaceutical agent, the viability of RAW 264.7 
macrophages cells along with CO-RM toxicity had to be assessed. RAW 264.7 cells are white 
blood cells and are associated with the detection of foreign bodies within an organism. This 
potentially makes them very sensitive to new drug compounds/foreign species, since these cells 
will contain many receptors capable of detecting foreign functionality. The sensitivity of these 
cells makes them a suitable starting point for initial viability tests. 
With the knowledge that CO-RM 47 is a thermally stable compound, the toxicity of the by-
products formed by irradiation in solution was assessed. This was performed by irradiating the 
CO-RM in DMSO before it was added to the cells. This allowed the toxicity of the combined by-
products, following irradiation to be assessed. 
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RAW 264.7 cells were grown in culture plates in 10% (v/v) DMEM:FCS medium until they were 
confluent. Fresh medium containing 10, 50 and 100 µM CO-RM was then added to the cells, 
which were then incubated overnight at 37 °C under a 5% CO2 atmosphere.  
The viability and cytotoxicity of the compound tested were assessed using two complementary 
assays. Alamar Blue and LDH assays required live cells and dead cells respectively to detect a 
response. Using two complementary assays means that information obtained via different 
mechanisms can be obtained, increasing the reliability of the results obtained. 
The Alamar blue assay uses a sterile 10% reazurin solution in culture medium.102 The reazurin 
can only be reduced to resorufin if the cells are alive. On reduction of reazurin (48) to resorufin 
(49) (Scheme 19), a distinct blue to red colour change is observed. This can be quantified using 
UV-Vis spectroscopic analysis. Wells with no compound added are counted as the live control, 
and cells with 1% Triton X-114 added are counted as a dead control. The percentage viability can 
then be scaled between the absorbance values for the dead and live control. 
 
 Scheme 19. The conversion of reazurin (48) to resorufin (49) which can only be carried out in 
live cells. Spectrometric change detected by UV-Vis spectroscopic analysis. 
The LDH assay measures the amount of lactate dehydrogenase released from cells up on death.103 
On cell death the membrane ruptures and cellular contents are released. LDH is a stable enzyme 
which converts lactate to pyruvate, and this conversion can be quantified by using the enzyme 
that is released from cells in to the medium upon death. The more cells that die means that more 
catalysis to produce pyruvate will take place due to increased LDH levels. The assay is scaled 
between a live and dead control in the same way as the Alamar blue assay. 
Ester CO-RM 45 and acid-containing CO-RM 47 were tested using an Alamar blue and LDH 
assay together to assess the viability of these CO-RMs. The photo-degradents were also tested by 
pre-irradiation as previously described. CO-RM F8 was also tested along side the other CO-RMs 
to ensure that the tests were comparable with previously published results.74 Figure 72 shows 
results from the Alamar blue assays performed. 
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Figure 72. Alamar blue assay data from CO-RMs 45, 47, and F8 using RAW 264.7 cells in 
24/96 well plates. Compounds tested at the above concentrations with and without irradiation 
(400 nm, 2.4 W) before addition to the cell culture. 
 
CO-RM 47 is > 90% viable with RAW 264.7 cells at all the tested concentrations. This includes 
when the CO-RM is directly added to the medium with the cells, and also when it has been 
irradiated for eight mins before it is added to the culture. This means that both the CO-RM and its 
biological and photo-degradents, are viable at the tested concentrations. These initial tests are 
encouraging and further bioligcal studies can be carried out using CO-RM 47. Ester CO-RM 45 
shows a slight reduction in viability and this highlights the importance of hydrolysing the ester 
from CO-RM 45 to make a more water compatible CO-RM 47. The viability of CO-RM F8 
closely matches the previously published results validating the method.71-72, 74 
Figure 73 shows the complimentary LDH assay results for the same tests carried out in Figure 
72. 
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Figure 73. LDH for CO-RMs 45, 47 and CO-RM F8 with RAW 264.7 cells. Compounds tested 
at the above concentrations with and without irradiation (400 nm, 2.4 W) before addition to the 
cell culture. 
The LDH assay data in Figure 73 is in agreement with the Alamar blue assay data results in 
Figure 72. The percentage LDH release with CO-RM 47 does not go above the cell only control. 
It is expected that there will be a small amount of LDH release without compound, as some cells 
will die over the experiment period. This is because a plastic plate is not a natural environment 
for the cells. It is important to note that these assays may not perfectly mirror each other, since 
they assess the cells via a different method. Additionally, cell viability and cytotoxicity are not 
the same thing, and there can be some difference between the tests. While there is viability with 
ester CO-RM 45 as determined by the Alamar blue assay, there is no significant LDH production 
on the administration of this compound. This suggests some biological pathways are interupted 
with out killing the cells. Literature CO-RM F8 also does not show any LDH production in these 
studies matching with literature studies carried out. 
These studies show that CO-RM 47 is a viable molecule with respect to chemically sensitive 
RAW 264.7 cell. This biological work represents a significant step towards the development of a 
new photo-CO-RM. 
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4.4.2 NO suppression using CO-RM 47 with RAW 264.7 macrophages. 
It is known that CO can suppress the production of nitric oxide (NO) in cells.70 It is also known 
that NO can exhibit an inflammatory response,29 and if NO is suppressed then an anti-
inflammatory response can be observed. NO2− (nitrite) is a stable degradation product of NO and 
so it can be used to quantify the amount of NO produced by cells. This means that by using 
certain controls, it is possible to observe if the CO released by CO-RMs is causing a suppression 
of NO production in RAW 264.7 cells. 
The concentration of nitrite can be quantified using a Greiss assay.104 To assess if the CO-RMs 
synthesised can stop the production of nitrite, RAW 264.7 cells need to be stimulated to produce 
NO. This can be done using LPS, which is found on the surface of bacteria. Macrophages such as 
RAW 264.7 can detect LPS, and this can trigger the production of NO. IFN-γ is a cytokine that, 
together with LPS, can trigger a potent anti-inflammatory response.105 Part of this response 
involves the production of high concentrations of NO. 
LPS and IFN-γ were used together to stimulate the production of a high concentrations of NO 
from RAW 264.7 cells. A CO-RM can be added to see if there is a reduction in NO production. 
This would then suggest that the CO-RMs are producing CO and that this CO is suppressing the 
NO production. 
Greiss assay experiments were carried out using CO-RM 47 at a concentration of 50 µM. This 
concentration was chosen because it was well within viable limits as determined by Alamar blue 
and LDH assays. Two separate 96 well plates were prepared with RAW 264.7 cells. One plate 
was irradiated for eight minutes with an LED (3.6 W, 400 nm) and the other was not. This was to 
assess if the light was causing any unusual effects. The results of the initial study are shown in 
Figure 74. 
         
Figure 74. Greiss assay data:
murine macrophages after incubation with 50 
is irradiated for eight mins (3.6 W, 400 nm).
The Greiss assay data in 
light of wavelength 400 nm. There is a reduction in nitrite production on irradiation in the 
absence of CO-RM. This could be due to damage to the cells due to the light. Macrophages will 
not experience such intense light compared to skin cells and perhaps this could explain their 
sensitivity.  
However, in the presence of 50 
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significantly stronger inflammatory response than just LPS in isolation. CO
a strong inflammatory response which is particularly encouraging. Initial results were carried out 
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stimulation were too low for accurate Greiss assay quantification. This i
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4.4.3 Investigations with CO
RAW 264.7 macrophage cell studies have established that CO
respect to a sensitive eukaryotic cell line. It has also been est
possesses some anti-inflammatory properties. As discussed in section 
towards bacteria under the correct conditions and the next step in this research was to assess the 
effect of CO-RM 47 on bacteria. 
Initial investigations were carried out using 
µM. Special LED system attachments were developed so that bacteria could be irradiated in 
sterile conditions under repeatable conditions. 
Figure 75. LED system developed for irradiation 
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Figure 76. E. coli W3110 growth with varying concentration of CO-RM 47 at 37 °C with 200 
rpm rotation in 15 ml Falcon™ tubes. 
E. coli are not affected by the presence of CO-RM 47 under all the tested concentrations. The 
bacteria grow at the same rate with the compound present. This means that the compound is not 
toxic to E. coli (however there is no irradiation present). It is known from myoglobin assay 
studies that the CO-RM does not degrade in LB media until irradiation is initiated, so unless E. 
coli can breakdown this CO-RM, it is not expected that there will be much thermal CO-release 
occurring in these particular experiments. 
In order to evaluate the effects of rotation speed, it was decided that future experiments should be 
carried out with 100 rpm rotation on the orbital shaker. This is because at 200 rpm rotation, the 
solutions would be well oxygenated. This would not reflect an in vivo situation because the 
majority of oxygen would be tightly bound in haem-containing proteins such as myoglobin and 
haemoglobin. The bacteria in this situation would have to compete for the oxygen to allow 
efficient growth, and so shaking at 100 rpm to reduce the oxygen to more realistic levels seems 
appropriate. 
With the knowledge that CO-RM 47 is stable in LB media, it seemed logical to deliberately 
degrade it before adding it to the bacteria in the way that was done in the RAW 264.7 cell 
studies. CO-RM 47 was therefore irradiated for eight minutes (400 nm, 2.4 W) in LB media prior 
to addition of the bacteria. Figure 77 shows the results of this initial irradiation study. 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 2 4 6 8
O
D
6
0
0
Time / Hours
Control
10 µM
50 µM
100 µM
134 
 
Figure 77. Pre-irradiation study with 100 µM CO-RM 47. Eight mins irradiation (400 nm, 2.4 
W) of CO-RM 47 in LB media before addition to the E. coli culture. Growth was then carried out 
for eight hours at 37 °C. 
The by-products formed after eight minutes irradiation are also not toxic towards E. coli under 
the given conditions. Direct irradiation of E. coli in the presence of CO-RM 47 was then carried 
out. Figure 78 shows the growth curve from this initial direct irradiation study. Note: This study 
was carried out separately from the curve in Figure 77 
 
Figure 78. Five mins direct irradiation (400 nm, 2.4 W) of E. coli W3110 in the presence of 100 
µM CO-RM 47. Irradiation carried out at three hours into the experiment for 5 mins total. 
Figure 78 shows that at 100 µM CO-RM 47 in LB media (with 0.5% DMSO) appears to increase 
the growth of E. coli compared to control. However, with five mins irradiation the growth is 
reduced to the OD of the bacteria-only control. This suggests that there is a reduction in growth 
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of E. coli on irradiation. This increase in growth was expected to be due to DMSO and not the 
CO-RM, and so a growth curve with DMSO under these conditions was performed (Figure 79). 
 
Figure 79. Growth of E. coli W3110 with and without DMSO at 37 °C in LB media, with 
rotation in Falcon™ tubes at 100 rpm on an orbital shaker.  
The curve in Figure 79 confirms that DMSO is responsible for increased growth at 100 rpm. It is 
known that E. coli can use DMSO as an electron source via the use of membrane protein DMSO 
reductase.106 This extra electron source in the presence of DMSO may increase growth rates. 
With the knowledge that CO-RM 47 causes a slight decrease in growth rates on irradiation in the 
presence of DMSO, controls were required to assess if the irradiation was responsible for this 
decrease. Figure 80 shows the details of this irradiation-only control. 
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Figure 80. Growth curve with 32 mins direct irradiation (400 nm, 2.4 W) of E. coli W3110 at 37 
°C in LB media with 100 rpm rotation. 
With 32 mins direct irradiation of E. coli there is no change in the growth of the bacteria. This 
strongly suggests that the decrease observed in Figure 78 was due to the action of CO-RM 47. 
This control was carried out for 32 mins to allow further irradiation in future experiments. 
The decrease observed with five minutes of irradiation is not very encouraging, as the OD does 
not decrease below the value observed without DMSO. This is why the duration of irradiation 
was increased in further experiments. Figure 81 shows a repeat of the experiment in Figure 78 
but with 32 mins total irradiation instead of five.  
 
Figure 81. Growth curve with 32 mins direct irradiation (400 nm 2.4 W) of E. coli W3110 with 
100 µM CO-RM 47. Irradiation carried out between three and four hours into the experiment. 
With an increased irradiation time, there is an improved reduction in the OD reduction of E. coli 
on irradiation in the presence of CO-RM 47. Following eight hours growth, the OD is reduced by 
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35% to below the OD of the control without any DMSO. This represents a significant 
improvement in the action of CO-RM 47 on E. coli.  
With a significant decrease in the growth of E. coli observed, the next step was to modify the 
conditions to assess if they could be optimised. Two modifications were made and the first was to 
switch from Falcon™ tubes to eight ml Bijou tubes. The length of a bijou tube is shorter and so 
the light path length to all the bacteria will be shorter. Figure 82 shows the set-up that was used 
for new bacterial irradiation conditions. 
 
Figure 82. Irradiation set-up with new eight ml Bijou tubes. 
The second modification involved increasing the irradiation duration to 68 mins delivered over 
two hours (irradiation on for four mins and off for one minute to prevent over heating of the LED 
and to maintain 37 °C growth temperature in the medium). Figure 83 shows the results with the 
two disscussed modifications. 
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Figure 83. Growth curve with 68 mins direct irradiation (400 nm, 2.4 W) of E. coli W3110 with 
100 µM CO-RM 47 in LB media. Irradiation was carried out between three and five hours.  
Despite the increase in irradiation time, there was no improvement in the toxicity of CO-RM 47 
towards E. coli. This could be because the increased irradiation is degrading some of the by-
products that may participate in antibacterial action. It also could be variation between 
experiments and that the increase in irradiation is not actually releasing further CO. 
It was postulated that with irradiation commencing at three hours, the OD of the bacteria has 
increased enough to significantly interfere with penetration of light through the culture medium. 
This could reduce the rate of CO-release. A further experiment was designed so that irradiation 
was started two hours earlier allowing less growth from the initial starting OD value of 0.05. 
Figure 84 shows the results from this irradiation study. 
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Figure 84. Growth curve with 68 mins direct irradiation (400 nm, 2.4 W) of E. coli W3110 with 
100 µM CO-RM 47 in LB media. Irradiation carried out between one and three hours. 
Starting irradiation two hours earlier has a dramatic effect on the action of CO-RM 47. Irradiation 
on its own without the CO-RM causes a lag in the growth of E. coli. The lower OD appears to 
improve the action of the CO-RM. On irradiation of the CO-RM at one hour there is no growth of 
E. coli above the starting OD over an eight hour period. This suggests either strong inhibition of 
growth or antibacterial activity. To distinguish between the two, three further repeats of this 
experiment were carried out but with an additional plating study. This involved taking aliquots 
from cultures at zero and four hours. This represents before and after irradiation. The aliquots 
were diluted so that individual colonies could be counted after incubation on agar plates. Table 
10 shows the numbers obtained from this plating study. 
  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 2 4 6 8
O
D
6
0
0
Time / h
0.5% DMSO
100 µM CO-RM 47 
0.5% DMSO + irrad
100 µM CO-RM 47 + 
irrad
140 
Table 10. Colony counts from E. coli W3110 cultures, before and after 68 mins irradiation (0 and 
4 h) (400 nm, 2.4 W). Incubation in LB media with 100 µM CO-RM 47. 
Repeat  Time/ h Dilution  Colony count 
1 0 500 229 
1 4 No dilution 33 
1 4 500 0 
2 0 500 283 
2 4 No dilution 46 
2 4 50 0 
2 4 500 0 
3 0 500 235 
3 4 No dilution 180 
3 4 500 0 
 
The plating study was carried out with three further repeats which all show the similar curves as 
shown in Figure 84. The dilution study shows that the reduction in growth is a strong 
antibacterial effect and not a bacteriostatic. This antibacterial effect is in the order of 99-99.9%, 
and this is particularly encouraging. It is interesting that simply moving the irradiation to after 
one hour initial growth turns this CO-RM into a potent antibacterial agent. This result was 
obtained with bacteria that were 13-14 days old from when they were initially grown from stocks. 
It was therefore necessary to examine how effective CO-RM 47 would be on younger E. coli. 
Figure 85 shows the results from the use with E. coli that were six days old. 
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Figure 85. Growth of E. coli W3110 in LB media with 100 µM CO-RM 47. Irradiation (400 nm, 
2.4 W) started at one hour for 68 mins total. E. coli was from a six day old plate used for 
experiment. 
CO-RM 47 is still effective at stopping the growth of E. coli that is six days old for several hours, 
but re-growth occurs in the 7th hour of the experiment. This should still represent a large 
percentage of killing, as E. coli is capable of doubling in population every 30 mins as shown by 
earlier experiments.  
It has been established that under the correct conditions, CO-RM 47 shows potent antibacterial 
activity against E. coli in combination with irradiation of wavelength 400 nm. It was then 
necessary to carry out a control experiment to test if the photo-products of irradiation were toxic 
to E. coli. A pre-irradiation experiment was performed to match the irradiation times used in 
previous experiments. The results from this control  experiment are shown in Figure 86. 
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Figure 86. Growth curve of E. coli W3110 in LB media with 100 µM CO-RM 47. Media with 
100 µM CO-RM 47 was irradiated for 68 mins (400 nm, 2.4 W) before addition of E. coli. The 
culture was then allowed to grow with no further irradiation. 
Presence of the by-products from 68 mins irradiation does not affect the growth of E. coli very 
much. The media was not flushed with air before the bacteria was added, and this is suggests that 
all the photo-products are not toxic. This includes some remaining extra cellular CO that was not 
expelled from the medium after irradiation. The data suggests that fresh CO-RM is required to 
get the antibacterial effect.  
In summary, CO-RM 47 has been shown under certain conditions to be an effective antibacterial 
agent against E. coli. The controls also suggest that CO is likely to be responsible for the effect 
observed as pre-irradiation experiments fail to show the same antibacterial effect. One of the 
draw backs with this experimental procedure is that a significant amount of irradiation is required 
to get a potent antibacterial effect. 
 In comparison with histidine photo-CO-RM 21, the CO-release rate of CO-RM 47 is 
significantly faster.78 This means that CO-RM 21 may struggle to show any antibacterial activity 
due to such a slow CO-release rate. A short half-life is likely to be required for this treatment, 
which may explain why ruthenium CO-RM-3 (t½ = 1 minute) has also been shown to be effective 
against E. coli.107 
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4.4.4 Investigations with CO-RM 47 on S. aureus 8325-4 
Staphylococcus aureus is another strain of bacteria which is responsible for a number of severe 
infections, particularly in hospitals. Older patients and those with a reduced immune system are 
particularly vulnerable to infection. There are also many strains which are becoming resistant to a 
wide range of antibiotics and alternative treatments for these strains are urgently required.108 As 
shown with ruthenium dimer CO-RM-2, it is possible to use a CO-RM to induce a detrimental 
effect on S. aureus. Having shown that under the correct conditions, CO-RM 47 can be 
antibacterial towards E. coli, it seemed logical to expand its scope to further strains of bacteria. 
The next strain to be tested was S. aureus. 
Initial investigations with CO-RM 47 and S. aureus established the viability under thermal 
conditions. Initial growth curves were also used to establish if DMSO was affecting the growth 
rate. Figure 87 shows the first growth carried out with CO-RM 47 on S. aureus. 
 
Figure 87. Growth of S. aureus 8325-4 in LB media with 100 rpm rotation with 100 µM CO-RM 
47 at 37 °C. 0.5% DMSO used as a control. 
Initial investigations show that S. aureus cannot use DMSO beneficially like E. coli can. The 
results also show that there is a decrease in the growth of S. aureus without the need for 
irradiation. This suggests that there might be a small amount of CO released from CO-RM 47 
thermally over the long-term. The reduction is not very significant and there is not a potent 
antibacterial effect here. 
Following on from the experiment in Figure 87, it was appropriate to proceed with irradiation of 
CO-RM 47 with S. aureus. These studies were carried out prior to knowledge about irradiating at 
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one hour after inoculation. This next study was carried out with 68 mins of irradiation after three 
hours of initial growth (Figure 88). 
 
Figure 88. Growth of S. aureus in LB media with 100 rpm rotation with 100 µM CO-RM 47 at 
37 °C. 0.5% DMSO used as a control. Irradiation (400 nm, 2.4 W) started at three hours for a 
total of 68 mins (4 mins on, 1 min off cycles). 
The data in Figure 88 shows that with irradiation, there is a significant reduction in the growth of 
S. aureus. It has been reported in the literature that S. aureus can be particularly sensitive to 400 
nm irradiation.109-110 Therefore a further control with light only was required to assess the 
difference between irradiation, both with and without CO-RM.  
Figure 89 shows this additional experiment.  
 
Figure 89. Growth curve with S. aureus 8325-4 in LB medium at 37 °C with 100 rpm rotation. 
68 mins irradiation (400 nm, 2.4 W) started after three hours (LED on for four mins per five min 
period). 
The control experiment in Figure 89 shows that irradiation and CO-RM 47 together give a more 
potent effect that irradiation on its own.  
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After it was realised in studies with E. coli that irradiation after one hour initial growth improves 
the effectiveness of the treatment; the same strategy was then employed in studies with S. aureus. 
Figure 90 is a repeat of the study in Figure 88 with irradiation starting after one hour initial 
growth instead of three. 
 
Figure 90. Growth of S. aureus in LB media with 100 rpm rotation with 100 µM CO-RM 47 at 
37 °C. 0.5% DMSO used as a control. Irradiation (400 nm) started at three hours for a total of 68 
mins (four mins on, one min off). Starting OD lower than carried out in previous experiments. 
It is important to note that the curves in Figure 90 were carried out with a lower starting OD than 
previously carried out. This results in CO-RM 47 having a potent effect on S. aureus without 
irradiation. This is unusual considering the stability of CO-RM 47 in this medium. At the lower 
OD (fewer bacteria), there could be a higher CO-RM/target ratio, which could explain why this 
effect with no irradiation is observed. Without irradiation there is still slow growth throughout 
the experiment suggesting it is not killing a large percentage of bacteria.  
When irradiation is used the OD is static throughout the whole experiment both with and without 
CO-RM 47. However a plating viability study was carried out with S. aureus to verify if a 
difference between the two could be observed. Table 11 shows the colony numbers from aliquots 
taken at one and three hours, representing before and after irradiation respectively. 
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Table 11. Plating study with S. aureus, aliquots taken at one hour and three hours from the 
cultures used in Figure 90. Study with 100 µM CO-RM 47 in LB media. Dilutions are noted in 
bold 
1 h CO-RM 3 h CO-RM (irrad)  1 h DMSO 3 h DMSO (irrad) 
500x 500x 500x 500x 
530 0 565 13 
5000x 5000x 5000x 5000x 
78 0 71 0 
 
As previously shown in the literature, irradiation of wavelength 400 nm has a potent effect on S. 
aureus, and this is also shown in the case with DMSO only.109-110 With 400 nm irradiation only, 
there is a 97% killing rate under the given irradiation conditions. This shows how sensitive S. 
aureus is to the irradiation used. With 100 µM CO-RM 47 this killing rate is increased to over 
99%. The difference is very slight, but the 13 remaining bacteria detected in that aliquot could 
turn in to 1000’s after treatment. Using a lower starting OD and irradiating earlier in these 
experiment results in a more potent effect.  
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4.5 Conclusions on CO-RM 47 and its properties 
CO-RM 47 has been prepared in 50% overall yield in four linear steps, and complicated 
purification was not required. CO-RM 47 has also been fully characterised using a wide variety 
of techniques demonstrating high purity. This is essential when carrying out biological tests on 
potentially sensitive cells. False results at this stage could have large implications in further 
studies. 
CO-RM 47 has been shown to release three molecules of CO per molecule of CO-RM. This is 
beneficial as less CO-RM will be required to get a desired concentration of CO released. The 
tetracarbonyl phenylpyridine manganese(I) motif does not exhibit different modes of CO-release 
in myoglobin assays when it is structurally modified in the para-phenyl position. This is 
encouraging when considering the aims of this project. CO-RM 47 has been shown to be viable 
with RAW 264.7 cells and to have varying detrimental effects on both E. coli and S. aureus at 
concentrations that do not kill RAW 264.7 cells. Ester CO-RM 45 was mildly toxic to RAW 
264.7 macrophage cells, highlighting the importance of hydrolysing the ester to give CO-RM 47.  
CO-RM 47 has been shown to suppress the effect of inflammatory stimulation and it is likely that 
CO released from CO-RM 47 is responsible for this. This CO-RM has great potential and further 
studies in the future to get this CO-RM closer to clinical trials would be desirable. Irradiation of 
wavelength 400 nm is out of the harmful UV region of the spectrum. People experience 400 nm 
irradiation on their skin when simply outside in the sun. At low bacterial densities, there is a 
possibility that the irradiation might not even be required (Figure 90). The results in this section 
justify further biological studies using CO-RM 47 
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5 Development of Functionisable CO-RMs 
5.1 Synthesis and characterisation of alkyne tagged CO-RMs 
CO-RM 47 has been developed from an initial tetracarbonyl phenylpyridine manganese(I) 
structure to improve its solubility and subsequently CO-release rates. However, this CO-RM has 
no intentional means of protein targeting. There is a possibility to use the acid functionality on 
CO-RM 47 in esterification and amide formation reactions to introduce functionality capable of 
protein binding. It was however decided that using a Huisgen [3+2] cycloaddition approach that 
has been previously used on (tpm)Mn(CO)3 developed by Schatzschneider and co-workers would 
be a more suitable initial approach.61 Functionalisation on 4-hydroxyphenylpyridine (43) was 
used to develop a new target CO-RM. A second derivative with an extra CH2 group between the 
phenyl group and the oxygen was also prepared amid concerns of potential phenolic ether 
hydrolysis. Figure 91 shows the structure of the designed target CO-RMs.  
 
Figure 91. The structure of target alkyne CO-RMs 62 and 63. 
The target structures contain terminal alkyne functionality, which has the potential to be used in 
cycloaddition chemistry. This could introduce variation in functionality to generate an analogue 
library. As mentioned, CO-RM 63 has an additional methylene group that could help reduce 
steric and electronic interference from the attached groups with the tetracarbonyl manganese. 
This chemistry can be used in the following way to generate new structures (Scheme 20).111 
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Scheme 20. Potential Huisgen [3+2] cycloaddition conditions to introduce desired R group on 
CO-RM 62. The same conditions could also be used on CO-RM 63. 
By activating the alkyne functionality on CO-RM 62 with copper(II) sulfate pentahydrate, the 
azide and alkyne can then undergo a cycloaddition reaction to give a 1,4-triazole ring with the 
desired R group attached. It is possible that 1,5-triazole regio-isomers of the desired product 
could be formed in this reaction where the azide adds in the cycloaddition rotated by 180 degrees, 
but a literature procedure was found that exclusively gave only the 1,4-isomer, and this was 
important when trying to design an efficient synthesis.111 
The synthesis of CO-RM 62 started from phenol compound 43, but for the synthesis of CO-RM 
63 an additional alcohol-containing ligand was required. Scheme 21 shows the synthesis of 
extended alcohol 50. 
 
Scheme 21. Suzuki–Miyaura coupling conditions used to prepare ligand 50 
Similar conditions were used to prepare phenolic ligand 43, however a longer reaction was 
required to get full conversion. This is likely to be due to the alcohol functionality not being in 
conjugation with the ring system in this case, Pleasingly, two hours reaction time gave ligand 50 
in a respectable 83% yield. 
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With the two alcohol-containing ligands 43 and 50 synthesised, the next step was to introduce 
alkyne functionality into the system. Similar conditions used by Schatzschneider and co-workers 
on their tpm ligand system were adopted here, as this had been shown to work successfully.61 
The Williamson ether synthesis conditions used to make the propargyl ligand 52 is shown in 
Scheme 22 . The same conditions were also used to make shorter ligand 51. 
 
Scheme 22. The synthesis of compound 52 using a William ether synthesis. 
By converting alcohol 50 to its corresponding sodium salt, the oxygen atom is then activated, 
allowing nucleophilic attack on propargyl bromide to give the target alkyne 52. Alkyne 52 was 
isolated with a yield of 66%, which is comparable with the yields obtained on the tpm ligands by 
Schatzschneider and co-workers.112 The shorter ligand 51 was also synthesised using these 
conditions and was isolated with a yield of 75%. This is a slight improvement on the extended 
ligand. Both of these reactions yielded sufficient quantities of alkyne ligand to continue with the 
next synthesis.  
The next step in the synthesis of CO-RMs 62 and 63 was intended to be the final step in the 
synthesis and involved reacting the synthesised alkyne ligands with BnMn(CO)5 to introduce the 
tetracarbonyl manganese(I) system. Scheme 23 shows the conditions used in an attempt to 
synthesise CO-RM 63. 
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Scheme 23. Attempted conditions used to cyclometallate ligand 52. 
After initial heating at 75 °C, rather than turning the yellow/light brown colour typically observed 
with previous cyclo-metallation reactions; this reaction turned dark brown/black and significant 
amounts of precipitation occurred. The desired product was not isolated from attempted cyclo-
metallation of either ligand 51 or 52. It was postulated that the alkyne functionality was reacting 
with the tetracarbonyl manganese unit, resulting in precipitation of manganese(IV) species which 
are typically are dark brown in colour. Analysis of literature research carried out by Nicholson 
and co-workers provided a potential explanation for what was occurring in this reaction (Scheme 
24).113 
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Scheme 24. Reaction of an ortho-Mn(CO)4 aryl ketone with alkynes to produce indenols, 
indenones, and hexadienyl manganese tricarbonyl species.  
When ortho-Mn(CO)4 aryl ketones (53) are heated with a wide variety of alkynes, these react to 
produce indenols (54), indenones (55), and a structurally interesting hexadienyl manganese(0) 
tricarbonyl species (56). Generation of 56 arises from triple insertion of the alkyne species. It was 
suspected that some kind of insertion process was occurring with the phenylpyridine system, 
which involved alkyne ligand 52 reacting with a molecule of CO-RM 63 once it has been formed.  
The research by Nicholson and co-workers explored a wide variety of alkynes in their reactions, 
and this was very useful in solving the synthetic problem of synthesising CO-RM 63. Many 
functional groups on either side of the alkyne used in these reactions were tolerated, with the 
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exception of two SiMe3 substituents. Reflux of 53 in benzene with the TMS alkyne for 64 hours 
yielded only 9% of indenol 54. The TMS group is likely associated with blocking the reaction of 
the alkyne with 53. This information was then employed in stopping the terminal alkyne in ligand 
52 reacting. It was decided that since only one side of the alkyne in ligand 52 could be 
functionalised, that a bulky TIPS group could be used to try and reduce the alkyne reactivity. 
Scheme 25 shows the synthesis of TIPS protected alkyne 58 using a modified literature 
procedure.114 
1) LDA (1 eq.) –78 °C, THF
2) TIPS-Cl (1 eq.)
–78 °C - Ambient temp.
16 h, THF
N
O
N
O
58, 73% Yield
TIPS
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Scheme 25. Synthesis of TIPS protected alkyne ligand 58 
Lithiation of the terminal alkyne in 52, followed by trapping with TIPS chloride gave 58 in a 
respectable 73% yield. The corresponding shorter TIPS alkyne 57 was also synthesised using the 
same method and was isolated with a yield of 76%. 
With protected TIPS alkyne ligands 57 and 58 prepared, the next step was to attempt a cyclo-
metallation reaction to see if the introduction of TIPS group would allow cyclometallation to 
occur. Scheme 26 shows the conditions used to form TIPS protected complex 60. 
N
O
Mn(CO)4
N
O
BnMn(CO)5 (1 eq.)
Hexane, 16 h, reflux.
60, 98% Yield
TIPS TIPS
58
 
Scheme 26. Reaction of TIPS protected ligand 58 with BnMn(CO)5 to give complex 60. 
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Pleasingly, introduction of TIPS functionality on the alkyne eliminates any significant side 
reactions, and pure product was isolated with a 98% yield following a simple filtration. The 
success of this reaction highlights the importance of reporting unsuccessful reactions in the 
literature. While Nicholson and co-workers were deliberately trying to react alkynes with 
manganese complexes, the reporting of their ‘less successful’ reaction was useful in this research. 
Without this knowledge the synthesis of complex 60  may have not been achievable in the same 
time-frame. The corresponding shorter TIPS complex 59 was also prepared in 97% yield.  
An additional communication was published by Wang and co-workers.115 This paper helps to 
further explain what was occurring in the unprotected cyclometallisation reactions. The research 
shows how heating tetracarbonyl phenylpyridine manganese(I) complexes in the presence of 
terminal alkynes yields alkenyl products (Scheme 27). 
 
Scheme 27. Literature synthesis of alkenyl phenylpyridines using a manganese catalyst system. 
In this reaction MnBr(CO)5 (20) with the amine base, produces tetracarbonyl phenylpyridine 
manganese(I) complex 37 via a different route. This complex then reacts with alkynes to form the 
alkenyl phenylpyridine 61. This is another potential pathway that could have occurred when 
attempting to cyclometallate the unprotected alkynes with BnMn(CO)5 (42).  
With the TIPS protected complex synthesised, the final step in the synthesis of CO-RMs 62 and 
63 was a TIPS deprotection. This was done using TBAF·3H2O at ambient temperature. Scheme 
28 shows the conditions used to isolate target complex 63.  
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Scheme 28. The synthesis of CO-RM 59 from its corresponding TIPS protected complex 56. 
A CH3CN/CH2Cl2 mixture was used to enable full dissolution of the apolar TIPS protected 
complex. The complex was unfortunately only synthesised in 51% yield, and it was discovered 
that the TBAF reagent converted a significant amount of TIPS complex 60 to its corresponding 
free ligand 52. However a sufficient quantity of CO-RM 63 was isolated, which could then be 
used for further studies. The corresponding alkyne complex 62 was also prepared using the same 
method with 1 eq. of TBAF·3H2O in 52% yield. 
Complexes 62 and 63 have been successfully prepared and isolated for use in further studies 
including synthesis, CO-release, and biology (see section 5.2). 
 
5.2 CO-release studies with alkyne CO-RMs 62 and 63 
The CO-release rates of CO-RMs 62 and 63 was quantified using myoglobin assays. These were 
performed with each CO-RM at 10 and 40 µM concentrations. Irradiation of wavelength 400 nm 
was used as before, so that half-life values for CO-release could be compared with previously 
synthesised CO-RMs. Figure 92 shows the CO-release profiles for CO-RMs 62 and 63 at 10 and 
40 µM. 
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Figure 92. The CO-release profiles of CO-RM 62 (left) and 63 (right) at 10 and 40 µM with 45-
50 µM myoglobin in PBS buffer pH 7.4. Irradiation (400 nm, 2.4 W) on for two minutes per five 
minute period. CO-RM 62 40 µM curve and CO-RM 63 10 µM curve shifted left to match 
starting irradiation times for comparison at different concentrations. CO-release not observed in 
any case until irradiation was initiated. 
The CO-release profiles for CO-RM 62 and 63 show that despite changing the functionality on 
the phenyl ring quite significantly, it does not affect the mode of CO-release. Both 62 and 63 do 
not release CO until the irradiation is initiated. At 40 µM, both CO-RMs saturate the myoglobin, 
and at 10 µM both CO-RMs are releasing three molecules of CO per molecule of CO-RM. This 
matches the number of CO molecules released from CO-RM 47. It appears that despite the 
change in functionality in the para-phenyl position, that the Mn(CO)4 moeity is acting as an 
isolated CO-releasing unit. Figure 93 shows the half-life values calculated from the data in 
Figure 92. 
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Figure 93. Half-life values for CO-release from CO-RM 62 and 63 at 10 and 40 µM. 
The half-lives of CO-RMs 62 and 63 are comparable to CO-RM 47 (5 mins). This further 
emphasises how changing functionality is not altering the CO-release properties of the 
‘Mn(CO)4’ unit. CO-RM 63 at a concentration of 10 µM appears to have a fast half-life of three 
minutes. This could be due to complete solubility at this concentration. It is unfortunate that there 
is a small amount of precipitation with CO-RMs 62 and 63 at a concentration of 40 µM, but this 
was corrected as previously using four point correction. 
 
5.2.1 Biological studies with CO-RM 62 and 63 on RAW 264.7 cells 
Even though CO-RMs 62 and 63 show a small amount of precipitation, it was still important to 
test their viability against RAW 264.7 cells. In the pharmaceutical industry there are many drugs 
that are not directly soluble in water including many steroids and solubilising agents which can 
be used in formulation with such compounds.95 This could be done with the CO-RMs in this 
project. It is also important to note that there was significantly less precipitation with these 
functionalised compounds compared to the initial CO-RM series (37-41) discussed previously in 
section 3. 
CO-RMs 62 and 63 were therefore tested with RAW 264.7 cells in both Alamar blue and LDH 
assays using the same conditions that were used with CO-RM 47 (Figure 94). 
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Figure 94. Alamar blue assay (left) and LDH assay (right) for CO-RMs 62 & 63 using RAW 
264.7 cells in a 24/96 well plate with DMEM + 10% FCS medium. Compounds tested at the 
above concentrations with and without irradiation (400 nm, 2.4 W, 8 mins) before addition to the 
cell culture. 
Unfortunately CO-RM 62 shows cytotoxicity at 50 and 100 µM concentrations. Both the Alamar 
blue and LDH assay shows complementary data with CO-RM 62 inducing significant amounts of 
LDH being released. Perculiarly, when CO-RM 62 is irradiated for eight minutes prior to 
addition to the cells, the toxicity is almost completly alleviated. The photo by-products generated 
do not affect cell viability or induce LDH release. This CO-RM is likely to produce free ligand 
(51) and (CH3CN)3Mn(CO)3 (47c) just like CO-RM 47 does and it has already been shown that 
47c is viable in pre-irradiation experiments. It is possible that there is something about the 
geometry of CO-RM 62 that targets an important enzyme resulting in the observed cytotoxicity 
and viability reductions.  
CO-RM 63 with an additional methylene linker, unlike CO-RM 62 is viable with and without 
irradiation. CO-RM 62 and 63 are similar in structure and this methylene group is important with 
respect to macrophage cell viability and cytotoxicity. It was proposed that the phenolic propargyl 
group in CO-RM 62 could be hydrolysed to produce a phenol containing species (64), causing a 
significant degree of toxicity. The presence of the Mn(CO)4 group withdrawing electron density 
out of the aromatic rings, could increase the rate of hydrolysis compared to the free ligand. 
With the above propositions in mind, a new phenolic CO-RM 64 was prepared from ligand 43 to 
test the above hypotheses. Scheme 29 shows the synthesis of phenol-containing CO-RM 64. 
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Scheme 29. The synthesis of CO-RM 64 
This CO-RM was particularly difficult to synthesise due to insolubility of ligand 43 in suitable 
cyclometallation solvents. The CO-RM was prepared in 32% yield, giving sufficient material to 
carry out biological investigations. 
CO-RM 64 was tested in both Alamar blue and LDH assays (Figure 95). 
 
Figure 95. Cell viability tests using CO-RM 64 on RAW 264.7 murine macrophages after 
overnight incubation. Left: Alamar blue assay with straight addition (blue) and pre-irradiation 
(red), right: LDH assay. Both assays are referenced to a 1% triton X-114 control. CO-RM 64 
wass pre-irradiated for eight mins (2.4 W, 400 nm) before addition to RAW 264.7 cell culture. 
Phenol-containing CO-RM 64 shows potent reductions in cell viability and significant 
cytotoxicity at even 50 µM, with 0% viability at 100 µM. There is also a slight improvement in 
cell viability when the CO-RM is irradiated before addition to culture. This matches with the 
unusual behaviour of propargyl-containing CO-RM 62, and suggests that phenolic CO-RM 64 is 
produced on administration of CO-RM 62. The presence of a CH2 linker between the main 
functionality in CO-RM 63 could prevent ether bond hydrolysis as no significant cell death 
observed with CO-RM 63. 
0
20
40
60
80
100
120
Control 10 µM 50 µM 100 µM
%
 C
e
ll
 v
ia
b
il
it
y
64 64, pre-irradiated
0
20
40
60
80
100
120
Triton 0 10 µM 50 µM100 µM
%
 C
y
to
to
x
ic
it
y
64
Mn(CO)4
N
OH
159 
5.3 Cycloaddition chemistry for the functionalisation of CO-RM 63 
CO-RM 63 has been shown to be an efficient CO-releaser and is viable with RAW 264.7 cells. 
CO-RM 62 shows signs of toxicity potentially due to propargyl hydrolysis. This may not be an 
issue once cycloaddition chemistry has introduced a triazole ring, but with the data available it 
was deemed less risky to take CO-RM 63, rather than CO-RM 62 forward for further synthetic 
studies. 
 
5.3.1 The synthesis and characterisation of extended CO-RM 65 
The next stage was to demonstrate that CO-RM 63 could be used as a substrate in [3+2] 
cycloaddition chemistry. The first reaction carried out was used to improve the solubility of CO-
RM 63 to produce a CO-RM similar to acid-containing CO-RM 47. The conditions used to 
functionalise CO-RM 63 to produce triazole containing CO-RM 65 are shown in Scheme 30.111 
 
Scheme 30. Huisgen [3+2] cycloaddition conditions to synthesise CO-RM 65. 
Initial attempts at this reaction using lower concentrations of CuSO4·5H2O (0.1 eq.) and sodium 
ascorbate (0.2 eq.) resulted in an incomplete reaction. It was then difficult to purify the 
compound by column chromatography due to the free acid functionality which caused streaking 
on TLC plates. With an increased catalyst loading and sodium ascorbate concentration (0.3 eq. of 
each), complete reaction and purification was achieved with an acid work up to get the polar CO-
RM in to the organic layer. The compound was prepared in an excellent 98% yield. Figure 96 
shows the 1H NMR spectrum of CO-RM 65 in DMSO, which shows evidence for key structural 
features. It is also important to note that reactions carried out on a 45 mg scale (based on CO-RM 
63), only worked in 8 ml medium size sample vials. The original reaction that was scaled up to 
160 
45 mg in a small 2 ml sample vial did not go to completion. This is possibly due to deactivation 
of catalyst by oxygen and stirring issues. 
 
Figure 96. 700 MHz 1H NMR spectrum of CO-RM 65 in DMSO-d6 at 300 K. 
The 1H NMR spectrum of CO-RM 65 shows clear evidence for the presence of pure target 
compound. There is a singlet at 8.99 ppm corresponding to the triazole proton in the 
cycloaddition product. Importantly the integration of this proton matches correctly with the 
integration of all the protons within phenylpyridine structure strongly suggesting that each 
molecule of alkyne-containing CO-RM  63 has reacted to produce one molecule of triazole-
containing species. The two broad peaks at 8.1 ppm correspond to the new phenyl protons k+k′ 
and L+L′ and these show strong correlation in a 1H COSY NMR experiment. These peaks are 
unusually broad compared to the phenyl-pyridine proton signals suggesting there are some 
unusual secondary effects. It is possible that there is some restricted rotation about the phenyl-
triazole bond on the NMR time scale. The data obtained suggests the presence of pure CO-RM 
65. 
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5.3.2 CO-release and biological studies with CO
CO-RM 65 was tested in three myoglobin assays to verify if further structural modification 
affects the CO-release from the Mn(CO)
cycloaddition chemistry conditions, but it still has some drug like features suc
ring and the carboxylic acid, and could have some interesting properties. One myoglobin assay at 
40 µM and two assays with 10 
stepwise irradiation to see if structural modificatio
demonstrated with CO-
Figure 97. Myoglobin assays in PBS buffer pH 7.4 for CO
10 µM assay. Right: 10 
every five mins or blue rectangles
in time. 
CO-RM 65 can be classified a photo
conditions. It is stable in the 
wavelength 400 nm. It is capable of saturating 50 
65. CO-RM 65 also releases three molecules of CO just like all previous CO
phenylpyridine-containing series. This CO
concentrations used in 
methods can be used to improve the properties of a CO
improved. 
CO-RM 65 was also tested in viability studies with RAW 264.7 cells to see how the further 
structural modification would affect cell viability (
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-RM 65 
4 motif. CO-RM 65 was initially synthesised to develop 
µM CO-RM were carried out. The second 10 
n still allows ‘on and off’ switching as 
RM 47. These myoglobin assays are shown in Figure
-RM 65. Left:
µM assay with step wise irradiation.* marks start of two min
 mark two mins irradiation (400 nm, 2.4 W) at the given point
-activated CO-RM under the given myoglobin assay 
dark and releases CO efficiently when irradiated with light of 
µM of myoglobin when using 40 
-RM does not precipitate in aqueous solution at the 
Figure 97. This [3+2] cycloaddition chemistry example shows how the
-RM, and in this case the solubility is 
Figure 98). 
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Figure 98. Alamar blue assay for CO-RM 65 with RAW 264.7 murine macrophages. Left: direct 
addition at the given concentration. Right: Irradiation (2.4 W, 400 nm, 8 mins) performed in 
DMSO before addition to the cells.  
There is a reduction in cell viability at higher concentrations of CO-RM 65 which is then 
eradicated if the CO-RM is irradiated in DMSO before addition to the cell culture. Unfortunately 
a degree of colour was formed on the irradiation of this CO-RM in DMSO. This does not 
interfere with the Alamar blue assay as all the medium is replaced following incubation with the 
cells. However, with the LDH assay the CO-RM remains in the medium and this colour makes 
this CO-RM unsuitable for testing in the LDH assay. 
In summary, further mechanistic studies would need to be carried out in future to find out the true 
cause of this reduction in cell viability. CO-RM 65 contains a CH2 linker between the phenyl 
pyridine and the rest of the structure so phenolic CO-RM 64 would not be produced on 
hydrolysis of the linker. This suggests that the original molecule or one of its biological by-
products is responsible for the toxicity observed. It is important to note that at 50 µM CO-RM 65 
is viable, and can release three molecules of CO per molecule of CO-RM. This means that up to 
150 µM CO can be produced on the irradiation of 50 µM CO-RM 65. Much lower concentrations 
of CO released from CO-RMs in the literature have been shown to give beneficial biological 
effects. There is still future promise for CO-RM 65 and it should be taken forward for further 
biological studies. 
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5.4 Functionalisation of CO-RM 63 with a biotin marker 
As shown in section 5.3.1, CO-RM 63 can successfully be used as a substrate in cycloaddition 
chemistry. It seemed logical to try this chemistry with more biologically relevant structures. The 
more complex biological target chosen for studies was a d-biotin conjugate. Biotin is found in 
both eukaryotic and prokaryotic biological systems and is associated with a wide range of 
biological functions.116 It can bind strongly with avidin/streptavidin (KD ≈ 10−15 M), and will not 
dissociate from the binding site without avidin denaturation.117 The binding is so strong that 
radioactive biotin (containing 14C) is required to detect the minute amount of free biotin in 
solution. 
The strong binding of biotin to avidin makes it an excellent model for making a targeted CO-RM. 
A conjugate with biotin can be synthesised, and this can then be assessed for binding to avidin as 
a target. It has been shown by Walker and co-workers that under certain conditions E. coli will 
take up large peptide-biotin conjugates through their biotin transporter which they would not 
usually take up without the biotin linker.116 This is a potentially method for forcing bacteria to 
take up pharmaceutical agents, including CO-RMs; although there might be difficulties with 
getting sufficient uptake. This is because E. coli can synthesise its own biotin and in some cases 
requires nanomolar concentrations to survive.118  
The following target biotin-CO-RM conjugate 71 was proposed (Figure 99). 
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Figure 99. Target structure for a biotin-CO-RM conjugate 71 
Target structure 71 contains CO-RM 63 (blue) which is then to be conjugated with a biotin 
(green) azide structure containing a three carbon linker. The linker (red) acts as a spacer to 
prevent the CO-RM structure from interfering with biotin-avidin binding. The biotin azide (70) 
and CO-RM 62 can be linked using cycloaddition chemistry in the same way that was used to 
prepare CO-RM 65. The synthesis of CO-RM 71 is discussed below.  
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With the synthesis of CO-RM 62 already completed, all that remained was to synthesise the 
biotin azide linker (70) and this was done by methods shown in Scheme 31. 
 
Scheme 31.Synthesis of biotin-containing azide 70  
Conversion of 3-chloropropylamine hydrochloride (66) to 3-azidopropylamine (67) by 
nucleophilic attack with NaN3 was performed in aqueous solution using a literature procedure.119 
The azide product was obtained in 87% yield in comparison with 99% yield reported in the 
literature. This synthesis of 67 was repeated several times and it is suspected that 87% is a more 
realistic yield as this compound was particularly volatile. The reaction gave sufficient quantities 
of 67 for further synthesis. It is important to be aware of the safety precautions associated with 
handling small azide compounds such as 66. This compound has a very high nitrogen content and 
is therefore potentially explosive. Due to this, plastic spatulas, clear-seal glassware, and a blast 
shield were all used in the synthesis of 66 to prevent any explosion occurring. 
To form an amide bond between 67 and 68, the carboxylic acid functionality on biotin required 
activation to allow further reactions to be carried out under mild conditions. Biotin (68) was 
activated by the formation of an N-hydroxysuccinimide ester. This was achieved using DCC as a 
coupling agent to give NHS-biotin (69) in a respectable 91% yield. 
With an N-hydroxysuccinimide ester (69) prepared, the coupling of biotin and 3-
azidoaminepropane could be carried out under mild conditions with only triethylamine in DMF at 
ambient temperature. There was no requirement for an additional coupling agent in this reaction, 
and this made purification by silica gel chromatography trivial. The required biotin azide (70) 
was successfully synthesised with a yield of 76%. 
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The final step in the synthesis of biotin conjugate CO-RM 71 was to perform the [3+2] 
cycloaddition reaction with CO-RM 63 and biotin azide 70 using the following conditions 
(Scheme 32). 
 
Scheme 32. Initial attempted [3+2] cycloaddition additions for the synthesis of CO-RM 71 
Initial reactions started using lower concentrations of CuSO4·5H2O and sodium ascorbate (0.1 
and 0.2 eq.), which resulted in an incomplete reaction as was the case with CO-RM 65. Silica gel 
column chromatography could easily remove any unreacted alkyne CO-RM 63. One spot was 
shown by TLC analysis of the column fractions, but 1H NMR spectroscopic analysis indicated 
that the biotin and ‘CO-RM’ sections of the molecule did not match in integration. The biotin 
azide starting material was co-eluting with the product. This means that azide (70) needed to be 
consumed in this reaction or purification would prove extremely difficult. Further reactions with 
increased catalyst concentration (0.3 eq. and 1 eq.) did not result in complete reaction as 
determined by 1H NMR spectroscopic analysis. A reaction time of 48 hours also did not result in 
a compete reaction with 1 eq. CuSO4·5H2O. 
These initial reaction attempts were carried out in large sample vials (12 ml) under air (Figure 
100) and it was postulated that the air may be slowly deactivating the catalyst. Leaving the 
reaction for longer (48 h) also did not result in complete reaction. 
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Even with the possibility that air was deactivating the catalyst, it was decided that the conditions 
would be modified further. This was done so that the reaction could still work without the need to 
deoxygenate the solvent, making the reaction easier to perform. 
 
Figure 100. Sample vials used for small scale [3 + 2] cycloaddition reactions to synthesise CO-
RMs 65 and 71. 
The reaction proceeded significantly in the large sample vials but never to completion. On 
switching to the medium size vial with 1 eq. of CuSO4·5H2O and 2 eq. sodium ascorbate, the 
reaction goes to completion within 24 hours. Pure product (95 % as determined by 1H NMR 
spectroscopic analysis) was obtained with only a work up extraction. Under the same conditions 
in a medium vial there is a clear difference in the conversion to product and the reaction was 
repeated to give the same results. It is proposed that in the medium sized vial the smaller head 
space means that over the course of the experiment, there is not enough oxygen within the vial to 
completely deactivate the catalyst. This means that the reaction proceeds to completion under 
these conditions. There may also be some differences in the stirring, affecting how starting 
materials and products come in and out of solution, and it is evident from the image in Figure 
100 how the vortexes formed on solution stirring could vary in vials of different size.  Figure 101 
shows the 1H NMR spectrum of the product obtained from both reaction repeats using 1 eq. of 
CO-RM 63 and 1 eq. of biotin azide 70. 
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Figure 101. 400 MHz 1H NMR spectrum of two batches of biotin conjugate CO-RM 71 in 
MeOD-d4 at 300 K. Note: Batch 2 contains some residual ethyl acetate from workup . 
The 1H NMR spectra in Figure 101 above show that both batches are >90% pure without 
significant amounts of starting material left in the reaction. All the proton resonances with the 
exception of the amine signals are observed in the NMR spectrum above. Presumably the amine 
signals will not be observed in methanol due to exchange. There are however some small 
amounts of unknown impurities and EtOAc present, especially in the second batch of material. 
This was not desirable despite the promising reaction conversion without any further purification 
following workup. CO-RM 71 was obtained in 72% yield using this method. 
It was proposed that reaction with 1 eq. of alkyne and azide, any small weighing errors could 
result in small amounts of remaining starting material that do not react. Therefore two further 
reactions were attempted using 0.5 eq. of biotin azide 70 and 1 eq. of alkyne CO-RM 63. With 
these conditions all of the biotin azide should be completely consumed in the reaction and the 
remaining 0.5 eq. of alkyne CO-RM 63 can be easily removed by column chromatography due a 
significant difference in polarity. These new conditions including 48 hours reaction time to 
ensure complete azide consumption. Scheme 33 shows the conditions used to prepare biotin-
containing CO-RM 71. 
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Scheme 33. The synthesis of CO-RM 71 using modified optimised conditions 
Using the modified conditions in Scheme 33 followed by silica gel column chromatography, pure 
batches of CO-RM 71 were obtained with a 50% yield. The yield is somewhat reduced compared 
to previous conditions and some product is likely lost during further purification. This new 
method results in very pure material which is much more suited to detailed characterisation 
studies. Batches 1 and 2 are still >90% pure as shown by 1H NMR spectroscopy. Figure 102 
shows the 1H NMR spectrum of the material obtained from these new conditions (batch 3). 
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Figure 102. 400 MHz 1H NMR spectrum of CO-RM 71 in MeOD-d4 at 300 K. Spectrum has 
been expanded for clarity, with the structure below.  
The 1H NMR spectrum in Figure 102 shows that batch 3 is >98% pure compared to >95% 
achieved  with the previous batches. The use of a substoichiometric concentration of azide 70 
meant that all of it reacted prior to column chromatography, so co-elution was no longer an issue. 
The relative integration between the ‘CO-RM’ and biotin sections in this batch match closely. In 
the 1H NMR spectrum of 71, the triazole proton signal is also detected at 8.05 ppm and its 
integration matches with the rest of the resonances from the molecule. Further NMR studies 
including: 1H{1H}, 1H COSY, 13C DEPT-135, HSQC and HMBC, were used to fully characterise 
CO-RM 71. It was possible to map out the entire structure of the molecule using these 
techniques. ESI mass spectrometry and IR spectroscopy data also supports the proposed structure 
of CO-RM 71. Four batches of this CO-RM 71 were made and the elemental analysis for each 
batch was out particularly on the nitrogen. The large molecular weight and series of fused rings 
of this compound could result in incomplete combustion during the elemental analysis procedure 
altering the CHN ratio. However, the 1H NMR spectrum of CO-RM 71 batch 3 does not show 
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any significant impurities. Further binding studies (discussed in section 5.4.2) suggest that batch 
3 is sufficiently pure. 
5.5 CO-release and biological studies with biotin conjugate CO-RM 71 
It has been established in section 5.3 that biotin CO-RM 71 has been successfully synthesised. 
The next step was to assess if this molecule could release CO. CO-RM 71 was utilised in 
myoglobin assays at 10 and 40 µM concentrations. Figure 103 shows the CO-release profiles for 
CO-RM 71 in PBS pH 7.4 using conditions typically used previously. 
 
Figure 103. 10 (left) and 40 µM (right) CO-RM 71 used in myoglobin assays. * marks the start 
of two mins irradiation (2.4 W, 400 nm) every five mins. 
Despite the complexity of CO-RM 71, it still acts as a photo-CO-RM. There is no CO-release 
from this structure to myoglobin in the dark, and fast CO-release is observed on irradiation at 400 
nm. CO-RM 71 releases 2.5 molecules of CO per molecule of CO-RM, which is slightly lower 
than the previous CO-RMs prepared. This type of reduction was expected as a similar decrease 
was observed with the (tpm)Mn(CO)3 peptide conjugates prepared by Ulrich and co-workers.61 
CO-RM 71 unfortunately precipitates slightly at concentration of 40 µM in PBS buffer, and some 
four point correction was required to correct for this. This lack of solubility is likely to be related 
to the large molecular weight in combination with the apolar section of the CO-RM. However, it 
was found that reducing the concentration to 30 µM resulted in no precipitation and the CO-RM 
remains in solution at this concentration. CO-RM 71 can release up to 75 µM of CO at this 
concentration, which is enough to consider using it in further studies. 
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5.5.1 RAW 264.7 cell studies with biotin-containing CO-RM 71 
CO-RM 71 was then tested in viability studies with RAW 264.7 studies using an Alamar blue 
assay. It was found that CO-RM 71 photo-products absorb a small amount of light in the visible 
region and was therefore deemed unsuitable for testing in LDH assays. However the Alamar blue 
assay can still provide a significant amount of information as the cells must be alive to detect a 
response. Figure 104 shows the results obtained from this Alamar blue assay. 
 
Figure 104 .Alamar blue assay using varying concentrations of CO-RM 71 with RAW 264.7 
murine macrophages. Left: direction addition in DMSO. Right: Eight mins (400 nm, 2.4 W) 
irradiation in DMSO before addition to cells. 
CO-RM 71 has been shown to be completely viable with RAW 264.7 cells at various 
concentrations. It was decided that this CO-RM should not be tested above its known solubility 
limit as the large molecular weight would likely result in considerable precipitation at a 
concentration of 100 µM. 
As with many of the previous CO-RMs prepared in this project, CO-RM 71 is still viable 
following eight minutes irradiation in DMSO prior to addition to the cells. The photo by-products 
of this compound are also viable. Excluding the CO-RMs prepared in this project, there are no 
photo-CO-RMs in the literature to date that make an in situ i-CO-RM by pre-irradiation. It is 
essential to assess whether the products of irradiation are viable. If these products are toxic to 
cells, then irradiation would result in the death of many cells in further studies and this is 
undesirable. 
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5.5.2 Binding studies using CO-RM 71 and avidin: an example of targeting. 
It has been shown that with varying degrees of functionalisation, that the parent phenylpyridine 
complex maintains its stability, and is a photo-CO-RM in the presence of myoglobin in aqueous 
solution. The next step with CO-RM 71 was to investigate if it can bind to a target. The selected 
target is avidin to which biotin binds strongly, with a high dissociation constant.117, 120 It is 
important to assess if the linker and CO-RM fragment conjugated to biotin affects the binding to 
avidin. The three carbon linker should provide sufficient distance between the CO-RM and the 
biotin unit to prevent any significant interference. 
 
5.5.2.1 HABA/avidin assay with CO-RM 71 
The ability of biotin to bind to avidin was assessed using two methods, and the first of these was 
a HABA/avidin assay. Figure 105 shows how the HABA avidin assay can be used to quantify 
the concentration of biotin within a sample.121 
  
Figure 105. The HABA avidin assay method for biotin quantification (Image by Thermo 
scientific, Copyright 2014) 
Hydroxyazobenzoic acid (72) is an orange dye that absorbs strongly at 500 nm. It can bind 
strongly to avidin but binds weaker than biotin. The biotin can displace HABA out of a HABA-
avidin complex, resulting in a lower molar extinction coefficient of the dye. This is due to a 
change in local environment, resulting in a change in absorbance. This change in absorbance is 
linearly dependent on the amount of HABA dye displacement, and consequently the amount of 
biotin in solution. The HABA/avidin assay can be used to quantify the amount of biotin within a 
sample and this can help assess if CO-RM 71 binds to avidin in solution. 
173 
Four solutions were prepared containing 30 µM of a defined compound. The solutions of each 
compound were based on their molecular weight  and were prepared in 0.5% (v/v) DMSO/0.01 M 
PBS pH 7.4. If there is a pure compound in the solution at 30 µM which contains a biotin moeity, 
then it will quickly displace 30 µM of HABA from avidin, giving an assay read out of 30 µM. If 
there are any impurities that do not bind, or significant amounts of free biotin are present, then 
the assay read out concentration will deviate from the calculated concentration. This is because 
the initial weight of compound used was based on the molecular weight of the compound. All of 
the solutions in 0.5% DMSO had their UV spectrum with no HABA/avidin measured as a control 
and these values were subtracted in concentration determination calculations. 
Assay read-out values for CO-RM 71 and various controls used in the HABA/avidin assay are 
shown in Table 12.  
Table 12. HABA avidin assay data for various compounds in 0.5% DMSO:0.01M PBS buffer 
pH 7.4. Assay shows intended solution concentration and the read out determined from the assay. 
Compound added Added conc.  Assay conc. 
CO-RM 71    30 µM  30.6 µM  
Free biotin (68)  30 µM  24.9 µM 
CO-RM 65 (control)   30 µM  0 µM  
DMSO (0.5%) 0.5% (v/v)  0 µM 
 
When a 30 µM solution of CO-RM 71 is added to a HABA/avidin solution, the shift in 
absorbance at 500 nm gives a concentration read out of 30.6 µM, which is close to the intended 
concentration. This suggests high purity and also suggests that the compound is displacing 
equimolar concentrations of HABA. Free biotin (68) was also tested at 30 µM and the assay gave 
a read out of 24.9 µM. This is close to the intended concentration; it may be slightly lower due to 
commercial d-biotin not always being 100% active/pure. It is possible that the purification of all 
the biotin reagents throughout synthesis of CO-RM 71 has actually enriched the biotin activity. 
This control shows that CO-RM 71 is binding in this assay in a similar fashion to free biotin. 
Acid-containing CO-RM 65 was also tested in the HABA/assay as an extra control. This CO-RM 
has many structural features found within biotin CO-RM 71. It contains the phenylpyridine 
Mn(CO)4 unit and the triazole functionality from the cycloaddition reaction. It was important to 
test CO-RM 65 in this assay to assess if a similar structure without biotin could not displace 
HABA from the avidin protein, giving a false read out. CO-RM 65 did not reduce the absorbance 
at 500 nm showing that it does not displace HABA from avidin. It is the biotin section of CO-RM 
71 that is responsible for binding to avidin. 
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All these data together show that CO-RM 71 is binding with avidin efficiently with a binding 
constant higher than HABA. This data in conjugation with all the NMR characterisation shows 
that a pure compound with strong avidin binding has been prepared. 
5.4.2.2 Isothermal Titration Calorimetry (ITC) studies with CO-RM 71  
The disadvantage of the HABA/avidin assay is that it does not give detailed information relating 
to the binding strength of CO-RM 71. This is why isothermal titration calorimetry (ITC) was 
used as an additional technique. 
ITC experiments involve titrating a biotin ligand (or a biotin containing species) into a solution of 
avidin. Both solutions are regulated to 25 °C and the ITC apparatus then detects temperature 
changes due to any interactions taking place. The instrument calculates energy changes by 
maintaining a temperature of 25 °C, and the amount of energy that the instrument has to add or or 
take out due to thermodynamic processes is recorded. 
The avidin containing cell has a volume of 1.4 ml and the ligand syringe has a volume of 0.28 ml. 
This means that if the concentration of ligand is 10-fold higher than the protein, then there will be 
a 2:1 ratio of ligand to protein at the end of the titration experiment. The 0.28 ml of ligand can be 
added over 20 injections so a saturation point can be observed when a 1:1 molar ratio has been 
achieved. Once the avidin binding site is saturated, no more binding occur and so the energy 
released from binding will cease. 
Biotin (or CO-RM 71) at a concentration of 20 µM was titrated in to 2 µM avidin monomer (4 
identical binding sites in the tetramer protein) to give a 2:1 ligand:binding site ratio as discussed. 
Both CO-RM 71 and free biotin were tested in this assay. The ITC titration curves for free biotin 
are shown in Figure 106. 
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Figure 106. ITC titration curves for the addition of free biotin (68) into avidin in PBS buffer pH 
7.49. End of the titration results in a 2:1 ligand/protein binding site ratio. 
This initial ITC titration shows free biotin binding with avidin showing clear 1:1 binding with the 
avidin monomer binding site. The energy released from the binding drops off dramatically once a 
1:1 ligand to binding site ratio has been achieved, suggesting a high binding constant which is 
already expected for free biotin. The energy released on biotin/avidin binding has been calculated 
to be 22 kcal mol−1, which matches closely to the literature value obtained by Stjurkuusk and 
Wadsö.120 This control experiment shows that the ITC experiment is correctly calibrated and that 
CO-RM 71 can be reliably tested. Figure 107 shows the same experiment, but carried out with 
CO-RM 71 instead of free biotin. 
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Figure 107. ITC titration curves for the addition of CO-RM 71 into avidin in PBS buffer pH 
7.49. End of the titration results in a 2:1 ligand/protein binding site ratio.  
The ITC data for CO-RM 71 is similar to free biotin but with a few differences. The enthalpy 
change from CO-RM 71-avidin binding has been found to be 10 kcal mol−1, which is 12 kcal 
mol−1 less than free biotin. This means that the CO-RM 71 does not bind as strongly as free biotin 
but there is still a significant enthalpy change. The binding energy does not always reflect the 
dissociation constant which is related to both the on and off rates. 
Even though the binding energy is lower compared to free biotin, there is still a steep drop in 
energy release when one equivalent of CO-RM 71 has been titrated in to avidin. The gradient of 
the curve is large for both free biotin and CO-RM 71, suggesting they have similar dissociation 
constants. The curves from this ITC data are so steep that the binding constants for both 
complexes are out of range of the technique, demonstrating that the CO-RM 71 binds strongly to 
avidin, just like free biotin. A 14C-containing biotin conjugate would be required to accurately 
compare dissociation constants.117 
With the knowledge that CO-RM 71 was binding strongly to avidin, it was then employed in a 
myoglobin assay in the presence of avidin to show that the CO-RM can release CO while bound 
to avidin. The avidin binding site was in excess of CO-RM 71 (2:1 ratio) so that all of the CO-
RM would be bound to avidin (Figure 108). 
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Figure 108. Left: Myoglobin assay with 10 µM CO-RM with 20 µM avidin binding site. 
Irradiation (400 nm, 2.4 W) started after 10 mins. Irradiation on for two mins per five minute 
period. Right: UV-Vis spectra corresponding to the myoglobin assay in the left graph. 
The myoglobin assay data in Figure 108 shows that biotin-containing CO-RM 71 can effectively 
release CO when irradiated while bound to avidin. Only small amounts of four point correction 
were required to reduce the error to acceptable values as discussed in section 3. These data show 
how a CO-RM was tagged to a protein, and despite all this functionalisation and conjugation, the 
‘Mn(CO)4’ CO-release motif still acts in isolation as a photo-CO-RM in the presence of 
myoglobin. 
  
0
5
10
15
20
25
0 10 20 30 40 50 60
M
b
-C
O
 c
o
n
ce
n
tr
a
ti
o
n
 /
 µ
m
Time / Minutes
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
500 550 600
A
λ / nm
Irradiation 
started 
178 
5.6 Conclusions on alkyne-containing functionalised CO-RMs 
CO-RMs 62 and 63 were successfully synthesised despite some initial problems with alkyne 
reactivity. This reactivity was controlled using a triisopropylsilyl (TIPS) protecting group and 
inspiration for this came from ‘unsuccessful’ reactions from other researchers work, highlighting 
the importance of reporting unsuccessful results. 
CO-RM 62 was found to be toxic towards RAW 264.7 cells, but fortunately CO-RM 63 was 
prepared alongside this as a reserve, and this CO-RM is viable with RAW 264.7 cells. This 
shows that considering what functionality is typically associated with toxicity, can be beneficial 
when synthesising a series of potential drug compounds. 
CO-RM 63 was used in [3+2] cycloaddition chemistry to develop a CO-RM (71) that was 
conjugated to biotin. ITC binding studies are encouraging and suggest strong binding between 
CO-RM 71 and avidin. This is one of the first examples where a CO-RM has been designed to 
bind to a specific target, and has then been show to do just that. There are solubility issues with 
CO-RM 71, but it is still soluble at 30 µM and is capable of releasing 75 µM CO at this 
concentration. It is also possible that once this CO-RM is bound to its avidin target, that the 
protein could improve solubility. Sequential administration could be used to allow accumulation 
of the CO-RM, although future testing would be required. Initial success with the conjugation of 
biotin into CO-RM 71 opens up many possibilities to synthesis a library of CO-RMs containing a 
variety of selective tags. 
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6 A CO-RM based on natural L-tryptophan. 
In chapters 3-5, several new series of CO-RMs have been developed which are capable of 
releasing efficiently on irradiation with light of wavelength 400 nm. This is starting to push out 
of the harmful irradiation region and this wavelength could certainly be considered for treatment 
with CO-RMs on skin and a short distance into skin tissue. However if photo-CO-RMs are to be 
considered for treatment of ailments deeper within tissue then a higher wavelength of light would 
be required to prevent mass absorption of all the light by macromolecules etc. Blue light is 
absorbed a lot more by tissue compared to red light and one can imagine the potential advantages 
of having a CO-RM which can be activated by light externally without the need to use fibre optic 
probes.122 The absorption of light by tissue and other molecules highlights one of the main 
disadvantages of photo-CO-RMs. One of the main aims of this project it to begin solving this 
issue.  
 
 6.1 Synthesis and characterisation of CO-RM L-75 
Initially, the idea to use tryptophan as a ligand in a CO-RM was based around the inherent 
fluorescent properties of the indole ring on the amino acid side chain. This indole ring could 
allow for excitation by light for potential use in cellular imaging studies. It was also desirable to 
introduce a natural ligand in to a CO-RM because of its non-toxic properties. It has already been 
shown that CO-RM 47 releases free ligand on irradiation, and knowing that the free ligand 
released is not cytotoxic could reduce the chances of producing a viable CO-RM. 
With the above in mind, the initial intention was to react L-tryptophan (73) with BnMn(CO)5 (42) 
to produce similar cyclometallated manganese(I) species. Scheme 34 shows the initial intended 
synthesis of a tryptophan containing CO-RM. 
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Scheme 34. Initial attempted synthesis of target CO-RM structure 74. 
The intention was to produce a tetracarbonyl manganese(I) species (74) but with a six-membered 
manganacycle, contrasting with the five-membered rings previously prepared. Unfortunately 
reaction of BnMn(CO)5  with L-tryptophan did not result in conversion to a new species other 
than what appeared to be thermal degradation of some BnMn(CO)5. L-Tryptophan (73) is a polar 
molecule (water soluble) and it was proposed that reaction in this solvent would not occur simply 
due to solubility issues. This reaction was then attempted in methanol in which L-tryptophan is 
more soluble. Scheme 35 shows the conditions used to synthesise new CO-RM 75. 
 
Scheme 35. The synthesis of a new L-tryptophan-containing manganese(I) CO-RM 75  
The conditions were modified based on previous knowledge that removing some unreacted polar 
species from a compound can be difficult. With this in a mind a slight excess of BnMn(CO)5 (42) 
was used so that the L-tryptophan (73) could completely react. The small remaining quantity of 
BnMn(CO)5 starting material could be removed using a specialised hexane/MeCN work up. 
These two organic solvents are not miscible, and it is unlikely that any tryptophan-containing 
complex would be soluble in the hexane layer, and so would remain in the MeCN phase allowing 
facile isolation. A bright yellow powder was obtained at the end of the reaction. 
Interestingly, the intended six-membered manganacycle 74 was not the product of the reaction. 
Significant consumption of BnMn(CO)5 was observed by TLC analysis suggesting some reaction 
was occurring. The 1H NMR spectrum of the isolated material indicated that all of the indole 
protons were still present. There was little if any shifting of the indole proton signals, suggesting 
that C–H activation of the indole 2-position had not occurred (Figure 110).  
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The 1H NMR spectra of L-tryptophan and CO-RM L-75 are shown in Figure 109. 
 
Figure 109. 400 MHz 1H NMR spectrum of L-tryptophan (bottom) and CO-RM L-75 (top) in 
DMSO-d
 6 at 300 K. Note: Assignments for CO-RM L-75 are shown in the spectra in Figure A24 
in Appendix 1 
In the 1H NMR spectrum of L-tryptophan, there is a very broad signal underneath the indole 
proton signals between 6.5-8,5 ppm, which is likely to be due to the amine protons. It is clear that 
some exchange on the NMR time scale is occurring in solution. 
Even though there is some broadening in the peaks in the spectrum of CO-RM L-75, it is still 
possible to make out the indole proton peaks from the tryptophan part of the structure. With 
referencing to the DMSO solvent peak there is clearly no shift of these indole protons, including 
the indole N–H proton compared the peaks from L-tryptophan (Figure 109). 
There is also a new singlet at 5.63 ppm which is likely to be due to the amine resonance. There is 
some exchange in this spectrum and some exchange will be expected. This amine is likely to 
have arisen from shifting of the broad signal under the indole proton signals in the L-tryptophan 
1H NMR spectrum, which is now no longer present. On coordination of the amine to the 
manganese centre, the signal has sharpened and has shifted to lower field (5.63 ppm), which is 
expected due to the electron withdrawing nature of the manganese(I) carbonyl centre. Addition of 
D2O to the NMR sample confirms that the NH2 signal at 5.63 ppm is exchanging as its intensity 
with respect to the indole protons was decreased by 50%.  
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The water peak at 3.25 ppm is broad, but is not a completely smooth Gaussian peak, and it is 
proposed that the alkyl C–H proton signals are overlapping with the water peak. Alkyl protons H, 
I, and J are not in direct bonding with the manganese centre and are not expected to shift. Figure 
109 shows that these alkyl protons H, I and J are under the water signal in the 1H NMR spectrum 
of L-tryptophan. 
There is a key signal at 2.10 ppm in the 1H NMR spectrum of CO-RM L-75 that integrates for 
close to three protons. It is proposed that this singlet arises from the methyl group of a 
coordinated acetonitrile ligand. The integration is likely to be slightly less than three due to some 
exchange in solution. There is also a signal at a chemical shift of 1.6/1.2 ppm in both the solution 
and solid state 13C NMR respectively for CO-RM L-75. This is diagnostic of a coordinated 
acetonitrile ligand. The 13C solid state NMR spectra also shows key resonances at 220 ppm with 
corresponding spinning side bands typical of a metal carbonyl environment. 
The IR spectrum of the new species also provided key information on what had occurred during 
in the reaction (Figure 110). 
 
Figure 110. The solution IR spectrum of L-tryptophan-containing CO-RM L-75 (red) and           
L-tryptophan (black) and BnMn(CO)5 (blue) 
The IR spectrum of tryptophan-containing CO-RM L-75 contains no peak at 2107 cm–1 
indicating no remaining BnMn(CO)5 starting material. CO-RM L-75 still has three sharp metal 
carbonyl signals in its IR spectrum. The spectrum indicates a species was present with pseudo C3v 
symmetry. A new metal carbonyl species has been formed in this reaction, but typically reaction 
with BnMn(CO)5 produces an Mn(CO)4 species, so it appears that further CO loss has occurred 
in the synthesis of CO-RM L-75. There is also a shift in the frequency of the carboxylic acid 
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C=O stretch in L-75 when compared to frequency of the same functional group in L-tryptophan. 
This peak shifts to lower energy from 1644 to 1604 cm–1. This suggests interaction of the 
carboxylic acid functionality with the metal centre rather than the indole ring. An alternative five-
membered manganacycle could be formed between the acid and amine within the L-tryptophan 
structure. 
With all the data obtained for this complex, it was proposed that the likely structure is the one 
shown in Figure 111. 
 
Figure 111. Proposed structure of new L-tryptophan containing CO-RM L-75. 
The IR spectrum suggests the presence of a tripodal Mn(CO)3 structure with interaction of the 
amine and acid from the L-tryptophan shown in Figure 111. This complex is isostructural with 
the Mohr histidine complex 21 when analysing the coordination around the manganese(I) centre. 
The Mohr histidine complex 21 was prepared according to literature procedure and its IR 
spectrum was analysed alongside the tryptophan complex prepared in this work. Figure 112 
shows the IR spectra of 21,73 and L-75. 
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Figure 112. Solution IR spectra of tryptophan (red), CO-RM 75 (green) and Mohr histidine 
complex 21 (blue).78 
The IR spectrum of the Mohr histidine complex (21) is similar to the spectrum of CO-RM L-75. 
This suggests the presence of a similar Mn(CO)3 unit with a primary amine coordinated to the 
metal centre. With the C=O stretch of the acid functionality in both complexes having a similar 
frequency, it is likely that they have the same coordination mode, with the acid deprotonated and 
covalently bonded to the manganese centre. These data support the proposed structure in Figure 
111. 
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6.1.1 Further structural investigations on CO-RM 75 and its isomers 
With the presence of a stereocenter within CO-RM 75, it is imperative that this structural feature 
is investigated and characterised. None of the techniques used in the previous section discussed 
distinguish between the L and D enantiomers of this complex. This needs to be analysed as some 
racemisation may occur during synthesis. CO-RM 75 was also prepared in the same way with 
both D- and DL-tryptophan to prepare an enantiomer and racemate complex of 75. L-75, DL-75 
and D-75 were then analysed by circular dichroism and optical rotation ([α]D20). 
The optical rotation recorded for D-75 was [α]D20 +248.2 (c=1, DMSO), and for L-75 was [α]D20 
–286.5 (c=1, DMSO). The magnitude these two values are consistent with the starting 
enantiopurities of purchased D- and L-tryptophan respectively. The DL-racemate gave an [α]D20 
of −7.30 which is close to zero in comparison to the intensity obtained for the D- and L-75 
batches.  
Circular dichroism spectra of CO-RM L-75, D-75 and DL-75 were recorded to get information 
about how each isomer interacts with light between wavelengths 280-550 nm (Figure 113). 
 
Figure 113. CD spectra of D-75 (red), L-75(green) and DL-75(blue) in DMSO (c = 6×10−4 mol 
dm−3). Each spectrum is an average of four runs. 
The CD spectra complement the data obtained from the [α]D20 experiments. The L-75 CD mirrors 
the D-75 isomer CD spectrum taking into account the enantiopurities of tryptophan starting 
materials. Pleasingly the DL-75 CD spectrum is flat showing no indication of enantioenrichment.  
Both the optical rotation experiments suggest that the L-tryptophan remains as the L-isomer in its 
corresponding manganese complex. There is no conversion from one isomer to the other during 
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synthesis. This is promising from a pharmacological point of view as fewer species to deal with 
in a pharmaceutical mixture is certainly an advantage. 
To add an extra degree confidence to the data already obtained, some DFT calculations were 
performed by Dr. Jason Lynam on various potential isomers of CO-RM 75 to calculate the 
relative energies of possible structures. Figure 114 shows the proposed potential structures for 
CO-RM 75 along with their calculated energies relative to isomer A1. Solvation in MeOH was 
also included in further calculations. The reaction was performed in methanol and so performing 
calculations in this solvent is relevant.  
 
 
 
Figure 114. Isomeric structures (A, B and C) and DFT calculated structures considered as 
products resulting from the reaction of L-tryptophan with BnMn(CO)5. Energies are Gibbs Free 
Energies in the gas phase (black) and with solvent correction for MeOH (red). Energies are 
relative to Isomer A1 determined at the (RI-)PBE0/def2-TZVPP level. Calculated by Dr. Jason 
Lynam. 
The DFT calculations show thermodynamically how potential structures differ from each other 
and if all were to exist, this data gives information about the relative quantities of each isomer in 
solution. The C isomers are over 100 kJ mol−1 higher in energy relative to the A isomer when 
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solvated with methanol. This is a large energy difference making the formation of isomer C at 75 
°C particularly unlikely. The B isomers are closer in energy compared to the C isomers but 1H 
NMR and IR spectra rule out the presence of κ2-binding from the carboxylic acid and interaction 
from the amine functionality. The initial proposed structure (Scheme 34/Structure 74) was not 
run in these calculations as experimental evidence strongly suggests that this structure was not 
formed; The 1H NMR spectrum of the material shows that the indole ring has clearly not been 
cyclometallated as all the protons on the indole ring are still intact. 
All the data suggests either of A isomers but unfortunately it is not possible to distinguish 
between the two. CO-RM 75 is proposed to be either isomer A1 or A2 but could be a mixture of 
the two which are inter-converting. Considering the broadening of the 1H NMR spectra compared 
to L-tryptophan it is certainly possible that some inter-conversion between isomer A1 and A2 is 
taking place. There can be a degree in confidence in the characterisation of CO-RM L-75 and the 
material prepared can be taken forward for further studies. 
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6.2 CO-release and mechanistic studies with CO-RM L-75 
With CO-RM L-75 sufficiently characterised it was then necessary to assess how it releases CO 
in aqueous medium. A myoglobin assay was used again to assess this CO-release at both 10 and 
40 µM concentrations. Figure 115 shows these assays with irradiation at 400 nm. 
More myoglobin assays have been carried out to assess the CO release from CO-RM L-75. The 
first assay carried out uses a 400 nm LED at 2.4 W to release the CO.  
 
Figure 115. Myoglobin assay CO release profiles in PBS pH 7.4 at 37 °C for CO-RM L-75. Left: 
10 µM assay producing 20 µM Mb-CO. Right : 40 µM assay saturating myoglobin. CO-release 
initiated at ten mins with two mins of irradiation (2.4 W, 400 nm) every five mins. 
One of the initial promising properties of CO-RM L-75 is that it remains completely soluble after 
addition in DMSO to aqueous medium.  
The CO releasing properties of CO-RM L-75 are similar to that of many of the phenylpyridine 
derivatives. The photo-activated CO-release from L-75 is faster than anything previously 
prepared in this project. With 400 nm light, the half-life of CO-release for L-75 is reached within 
2.5 mins at 10 µM and within 3.5 minutes at 40 µM. Within both these time periods, only two 
mins of irradiation has been delivered. This is quick CO-release compared to many of the CO-
RMs previously prepared. 
This CO-RM can be photo-activated to induce CO-release and is stable in the presence of 
myoglobin. A further myoglobin assay was  carried out with 40 µM CO-RM L-75, showing that 
it is fairly stable for at least 45 minutes with myoglobin in the dark with minimal CO-release 
(Figure 116). 
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Figure 116. A 50µM myoglobin assay with no irradiation using 40 µM CO-RM L-75 in PBS 
buffer pH 7.4. 
There is slow CO-release in the dark but this is less than 4 µM of CO over this period. This is 
only a small fraction percentage of the total CO that could be released on irradiation (up to 80 
µM at this concentration). Complex L-75 is still acting very much like a photo-CO-RM. This 
small amount of release may come from increased reactivity due to the potentially exchangeable 
acetonitrile ligand. This small amount of either thermal or ET-triggered CO-release may prove 
useful in further studies. 
CO-RM L-75 only releases two molecules of CO per molecule where as previous CO-RMs 
release three. The phenylpyridine-based CO-RMs prepared so far are releasing one fewer CO per 
molecule than the number of CO ligands in the molecule. This is expected as the manganese 
centre will back-bond more strongly as each CO is released, and when there is only one CO 
ligand bound to the manganese, it will be so strongly bound that it will not be photolytically 
released.123 A UV-Vis spectrum of CO-RM L-75 was recorded and this suggests that it could 
release CO using irradiation of lower energy than 400 nm light (Figure 117). 
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Figure 117. UV-Vis spectrum of CO-RM L-75 in MeCN at 1.5×10−4 mol dm−3. 
There is a small band in the UV spectrum of CO-RM L-75 with a λmax at 360 nm. This is a 
possible reason why the CO-RM releases CO quickly when irradiated with 400 nm light. This 
small band tails off past 450 nm. In more myoglobin assays, new LEDs were used that emit 
irradiation of wavelength 465 nm ± 20 nm. This blue light is at the high end of the visible 
spectrum. This LED was used in a myoglobin assay to see if this lower energy light could still 
release CO from CO-RM L-75. These data are shown in Figure 118. 
 
Figure 118. Myoglobin assay CO release profiles in PBS pH 7.4 at 37 °C for CO-RM L-75. Left: 
10 µM assay producing 14 µM Mb-CO. Right: 40 µM assay saturating 50 µM myoglobin. CO 
release was initiated at 10 mins with two mins of irradiation (2.4 W, 465 nm) every five mins. 
CO-RM L-75 can release CO when irradiation of wavelength 465 nm is used. The CO-release 
rate is slower compared to using irradiation of wavelength 400 nm. This is expected as the molar 
extinction coefficient is lower at 465 nm decreasing the chance of photon absorption. CO-RM L-
75 at a concentration of 40 µM can convert all the myoglobin to Mb-CO. This is particularly 
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efficient considering that the CO-RM has a weak absorbance at the irradiation wavelength. 
Unfortunately there are 0.5 eq. fewer CO molecules released with light of wavelength 465 nm. 
A UV-Vis spectroscopy study was also carried out to assess if the smaller absorption band is 
associated with photo-initiated CO release (Figure 119). A solution of CO-RM L-75 was 
prepared in DMSO and an initial UV spectrum was recorded. 
 
Figure 119. Decay of the M–CO UV absorption band from L-75 over time when photo-irradiated 
(400 nm, 2.4W) in DMSO (the time in brackets refer to the irradiation time between UV-vis 
measurements).  
On irradiation of this smaller UV band in DMSO, there is a significant decrease in intensity as 
the total irradiation time increases. This suggests that the absorption band is associated with 
photo-activated CO-release from CO-RM L-75. 
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6.2.1 ReactIR™ studies with CO-RM 75 
ReactIR™ studies were also carried out with CO-RM 75 to follow the loss of the metal carbonyl 
C=O stretches by real time IR spectroscopy. This was done in both methanol and a DMSO/PBS 
mixture. A solution of CO-RM DL-75 was added into a solution of methanol and was followed 
over time (Figure 120). 
  
Figure 120. Decay of metal carbonyl C=O stretches from 1 mM DL-75 measured by in situ 
ReactIR™. Continuous irradiation performed (2.4 W, 400 nm). Left: methanol, right: 10% 
DMSO/ 0.01M PBS pH 7.4. 
Unusually all of the metal carbonyl signals are depleted in these ReactIR™ experiments. This may 
appear contradictory to the myoglobin assays which suggests that all the CO is not released from 
the CO-RM. It is not possible to measure the IR spectrum in real time in 0.5% (v/v) DMSO/H2O 
due to needing such high concentrations of CO-RM (3 mM) to get a good signal/noise ratio. This 
means that in the myoglobin assay mixture, all the CO is likely not released. It is possible that on 
irradiation, a large number of different species are produced, broadening the IR bands and 
therefore lowering their intensity below the lower limit of detection. These studies still confirm 
that the metal carbonyl stretches significantly decrease on, and not until irradiation occurs 
(Figure 121). 
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Figure 121. Decay/stability studies by observation of metal carbonyl C=O stretch at 1935 cm−1 
from DL-75 measured by in situ ReactIR™. Left: methanol with no irradiation, right: methanol 
with continuous irradiation (400 nm, 2.4 W) after five mins initial darkness. 
ReactIR™ data in Figure 121 shows that CO-RM DL-75 is not degraded significantly in the dark. 
These data shows that the intensity of the metal carbonyl C=O stretch at 1935 cm−1 does not 
decrease over a one hour period. With 400 nm irradiation a smooth kinetic curve is obtained with 
a half-life of only two minutes, and this matches closely with the t½ observed from the myoglobin 
assay in Figure 115.  
 
6.2.2 ESI-MS degradation studies with CO-RM DL-75 
With the kinetics of CO-release from CO-RM L-75 characterised, it was then necessary to carry 
out the same +ve mode ESI-MS degradation study that was done with CO-RM 47. It would be 
important to have an idea of what species would be formed on irradiation of this compound. Two 
ESI-MS degradation studies with different capillary exit voltages were carried out. The two 
experiments were carried out using a skimmer voltage of 42 V and a capillary exit voltage of 43 
and 80V respectively. By changing the capillary exit voltage it was possible to optimise the 
sensitivity and detection of particular CO-RM 75 fragments. A 0.5 mg ml−1 solution of CO-RM 
DL-75 in 50:50 CH3CN/H2O was irradiated for one minute (465 nm, 2.4 W) in between ESI-MS 
measurements. Figure 122 and Figure 123 shows the relevant ESI-MS ions detected in this 
study at the two different capillary exit voltages. 
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Figure 122. ESI-MS degradation study for CO-RM DL-75 in 50:50 (v/v) CH3CN/H2O. Capillary 
exit voltage = 43 V. Skimmer voltage = 42 V. (465 nm, 2.4 W irradiation used) 
 
Figure 123. ESI-MS degradation study for CO-RM DL-75 in 50:50 (v/v) CH3CN/H2O. Capillary 
exit voltage = 80 V. Skimmer voltage = 42 V. (465 nm, 2.4 W irradiation used). 
Both ESI-MS studies show the reduction of the molecular ion at m/z 384 and increase of a signal 
at m/z 205, which corresponds to free L-tryptophan. This matches with the data obtained for acid 
CO-RM 47. However, there are clearly some differences in the mechanism of degradation with 
tryptophan CO-RM 75. The peak at m/z 262 which corresponds to [(CH3CN)3Mn(CO)3]+ (47c) is 
detected in these experiments, but only using the reduced capillary exit voltage. In the profiles 
shown in Figure 122 and Figure 123; this peak at m/z 262 does not increase and diminish in 
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intensity like an intermediate as was observed with CO-RM 47. In the degradation of CO-RM 75 
a small amount of 47c was detected initially which then depletes over time with irradiation. This 
suggests that [(CH3CN)3Mn(CO)3]+ (47c) does not play such an important role in the degradation 
pathway for CO-RM 75. It is possible that in this situation that the peak at m/z 262 is from small 
amounts of thermal degradation and decreases in intensity due to further irradiation. This is not 
the case with acid CO-RM 47 as the ion at 262 m/z (47c) in that case is not present before 
irradiation. The peak for 47c in this case grows in and depletes over the course of the experiment.  
Scheme 36 shows the other peaks detected in the ESI-MS degradation study of CO-RM DL-75 
and shows what they may correspond to. 
 
Scheme 36. Proposed degradation of CO-RM DL-75 during 465 nm irradiation in 50:50 (v/v) 
CH3CN/H2O.  
It is proposed that after initial solvation of CO-RM 75, there will be some ligand exchange of the 
CH3CN for H2O. This was not detected by ESI-MS, but the loss of the CH3CN is observed by 
with m/z 343 (75a). Irradiation of this species will also result in further CO loss followed by 
additional ligand coordination. Both double and triple CO-loss products are detected at m/z 287 
and 259 respectively (75b and 75c). Significant amounts of free tryptophan were formed but it is 
not clear at which point in the degradation pathway this is formed. It could be formed at several 
different stages by competing pathways. It is difficult to assess whether some of the species in 
Scheme 36 are formed in the ESI-MS instrument or whether they are formed in solution. 
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However, Brian Mann and co-workers have proposed similar CO-dissociation/solvent 
coordination degradation pathways for their [Mn(CO)4{S2CNMe(CH2CO2H)}] (7) and it is 
certainly possible that some of the species in Scheme 36 are present in solution.58 There can be a 
degree of confidence in the formation of free tryptophan ligand from CO-RM 75. 
 
6.3 Eukaryotic biological studies with CO-RM L-75 on RAW 264.7 cells 
With detailed mechanistic studies on the CO-release and degradation of CO-RM L-75 in hand, it 
was then necessary to carry out cell viability and cytotoxicity studies on RAW 264.7 murine 
macrophages. This compound was tested using Alamar blue and LDH assays as done previously 
and these results are shown in Figure 124. 
  
Figure 124. Alamar blue assay (left) and LDH assay (right) with RAW 264.7 cells in 10% (v/v) 
HI-FCS/DMEM medium. Addition of 10-100 µM CO-RM L-75 by direct addition and pre-
irradiation (8 mins, 2.4 W, 465 nm) in DMSO. 
The data in Figure 124 shows that CO-RM L-75 is viable with RAW 264.7 cells both before and 
after eight minutes irradiation of wavelength 465 nm, which has been shown to efficiently induce 
CO-release from CO-RM L-75. This CO-RM shows similar viability to acid-containing CO-RM 
47, as well as literature CO-RMs F3, F8, and [Mn(CO)4{S2CNMe(CH2CO2H)}] (7).58, 71-72, 74 The 
CO-RM appears to exhibit some cytoprotective action as the RAW 264.7 cells release less LDH 
in the presence of CO-RM L-75 compared to without.  
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6.3.1 NO suppression using CO-RM L-75 with RAW 264.7 macrophages 
CO-RM 47 has previously been tested and shown to induce an anti-inflammatory response with 
RAW 264.7 macrophages that were strongly stimulated with LPS and IFN-γ. This study was also 
carried out with CO-RM L-75. With the knowledge that 400 nm light appeared to affect the cells 
without CO-RM, 465 nm light was used in these experiments with the anticipation that this 
would not affect the cells as much with it being well in to the visible region of the spectrum. 
Figure 125 shows the Greiss assay data for tests with CO-RM L-75 using four mins irradiation. 
 
Figure 125. Greiss assay data - determination of nitrite levels in supernatant from RAW 264.7 
murine macrophages after incubation with 50 µM CO-RM L-75. Identical plates set up except 
one is irradiated for 4 mins (3.6 W, 465 nm). 
Interestingly, in the absence of CO-RM L-75 with only four mins 465 nm light, there is no 
change in the amount of NO2− production from the macrophages. With CO-RM L-75 present, 
there is a clear reduction in NO2− production. This reduction is present without the need for 
irradiation. There is a 35% reduction in nitrite levels in the presence of 50 µM CO-RM L-75 
which is a significant drop considering the intensity of the inflammatory response. This decrease 
is 14% higher than the reduction observed with acid-containing CO-RM 47. This experiment was 
carried out at a completely viable concentration of CO-RM L-75 and an LDH assay was also 
carried out alongside the Greiss assay in Figure 125 as an extra control. The assay detected less 
LDH in the wells with CO-RM L-75, LPS and IFN-γ than they did in the wells with only cells. 
This suggests that the reduction in nitrite production arises from the anti-inflammatory action of 
CO-RM L-75 and not direct toxicity issues. It was postulated that the anti-inflammatory action of 
CO-RM L-75 in the absence of light comes from the small amount of thermal or enzyme-
triggered CO-release detected in the myoglobin assay before any irradiation. This suggests that 
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only a small amount of CO is required to suppress the potent inflammatory response induced by 
LPS and IFN-γ. This could also explain why four minutes irradiation, which should release 
significant amounts of CO, does not further reduce the NO2− production.  
It is unfortunate that irradiation of CO-RM L-75 does not enhance the effects observed with 
RAW 264.7 cells considering it was designed to be a photo-CO-RM. However there are still 
great advantages to designing CO-RMs to be photo-activated, even if they might not be irradiated 
in treatment. The main reason is that if the CO-RM does not release significantly to myoglobin 
then it is likely to be fairly stable towards many CO binding proteins. In reality, one would not 
want all the CO from this CO-RM to be sequestered by myoglobin in vivo as this would not 
induce any significant beneficial biological effect. Releasing CO to other important targets is 
more desirable and designing the CO-RM not to donate CO to myoglobin has its advantages. The 
irradiation of CO-RM L-75 does not enhance the CO-RMs properties in these studies but it may 
still have its uses in bacterial studies where more CO might be required to get a beneficial effect. 
 
 6.4 Studies on E. coli W3110 with CO-RM L-75 
CO-RM L-75 has been shown to efficiently release CO and is viable with RAW 264.7 cells. The 
next stage in this research is to take this promising tryptophan-based CO-RM forward into 
bacterial studies. CO-RM L-75 has been shown to be viable up to a concentration of 100 µM 
with RAW 264.7 cells, and so bacterial viability/toxicity assays were not carried out above this 
concentration. If CO-RM L-75 was found to inhibit bacterial growth at 100 µM, then there is a 
chance it could do so without killing sensitive macrophages.  
Initial studies with E. coli involved taking a similar approach to that which was carried out with 
CO-RM 47. E. coli W3110 were grown in LB media and then irradiated after one hour at 400 nm 
for a total of 68 minutes. This study was done with bacteria that had been grown on a LB agar 
plate and were stored at 4 °C for six days before use. Figure 126 shows the results from an initial 
growth/irradiation study. 
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Figure 126. The growth curve for six day old E. coli W3110 in LB media at 37 °C with 100 µM 
L-75. Irradiation (400 nm, 2.4 W, 68 mins) performed between one and three hours. 
CO-RM L-75 is not as effective on six day old E. coli as acid CO-RM 47. CO-RM 47 was 
capable of keeping the OD600 from increasing for seven hours before re-growth under these 
conditions. With CO-RM L-75 the E. coli grew back only one hour after irradiation ceases. There 
is still promise from this study as CO-RM and irradiation together caused a more detrimental 
effect than each of these variables in isolation. This experiment was repeated with E. coli from 
the same plate but when they were 7-8 days old (Figure 127). 
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Figure 127. The growth curve for 7-8 day old E. coli W3110 in LB media at 37 °C with 100 µM 
L-75. Irradiation (400 nm, 2.4 W, 68 mins) performed between one and three hours. Data is an 
average of experiments from 7-8 day old bacteria used in repeat experiments. 
With the bacteria being stored at 4 °C for a further 1-2 days, the effectiveness of CO-RM L-75 on 
E. coli has increased by a significant amount. The bacteria take an extra hour to grow back 
compared to the study carried out with six day old E. coli (Figure 126). This is not as effective as 
CO-RM 47 at this irradiation wavelength. A final set of irradiation repeats were carried out using 
E. coli that were 13-14 days old (Figure 128). 
 
Figure 128. The growth curve for 13-14 day old E. coli W3110 in LB media at 37 °C with 100 
µM L-75. Irradiation (400 nm, 2.4 W, 68 mins) performed between one and three hours. Data is 
an average of experiments from 13 and 14 day old bacteria used in identical repeat experiments. 
With the E. coli at 13-14 days old there is a dramatic change in the effectiveness of CO-RM L-75 
with 68 mins irradiation. These data are comparable to the data obtained with CO-RM 47 on E. 
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coli of the same age. Irradiation or CO-RM only is not causing a significant detrimental effect. 
There is a clear difference in the bacteria as their age increases and this will be discussed further.  
A plating viability study was carried out on E. coli three times to assess how many bacteria were 
capable of forming colonies after irradiation treatment on E. coli that are 13-14 days old. The 
growth curves for these plating studies match what was observed in Figure 128 and the data from 
the plating studies is shown in Table 13. 
Table 13. Colony counts from E. coli W3110 cultures corresponding to Figure 128, representing 
before and after irradiation (0 h and 4 h) (400 nm, 2.4 W, 68 minutes). Incubation in LB media 
with 100 µM CO-RM L-75. Stock plate with E. coli was 13-14 days old. 
Repeat  Time taken / h Dilution  Colony count 
1 0 500x 282 
1 4 500x 0 
2 0 500x 330 
2 4 0x 80 
2 4 500x 0 
3 0 500x 258 
3 4 0x 330 
3 4 500x 4 
 
The plating study shows that on average over 99% of the E. coli are killed under conditions 
tested. There is a small amount of variation with slightly less killing in repeat three, but this is 
really promising work showing that CO-RM L-75 can exhibit anti bacterial activity on E. coli. 
This is one of first examples of a photo-CO-RM showing a potent anti-bacterial effect in E. coli. 
Figure 129 shows an example of plates before and after irradiation which gave the data in Table 
13. 
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Figure 129. Left: colony counts of E. coli W3110 in the presence of 100 µM CO-RM L-75 at t = 
0 h (50x dilution) in LB media. Right: effect of L-75 at t = 4 h incubation after 68 mins 
irradiation (400 nm, 2.4 W). 
Recently, Schatzschneider and co-workers have also carried out studies on E. coli with 
[(tpa)Mn(CO)3]+Br− , and a mild effect is seen with this CO-RM and irradiation of wavelength 
365 nm.124 This irradiation wavelength is too low for effective tissue penetration and is likely to 
be damaging to eukaryotic cells. The effect observed with CO-RM L-75 in these studies is much 
more potent compared to the literature CO-RM [(tpa)Mn(CO)3]+Br−, and uses irradiation closer to 
the visible region of the electromagnetic spectrum.124 
 
6.4.1 E. coli W3110 aging study 
There is a significant change in the effectiveness of CO-RM L-75 on E. coli  relating to age, and 
further investigations into the potential source of this was required. In all experiments carried out 
at different ages so far, the E. coli all eventually grow to the same OD600 after eight hours, 
suggesting that they are not just significantly weakened by being older. There is however greater 
susceptibility to CO-RM L-75 in the presence of light. 
The age of the E. coli was drastically affecting the ability of CO-RM L-75 to kill them. A study 
was carried out to assess if this was to do with there being less bacteria alive on the plate, or if it 
was to do with the increased OD at 1 h in the fresh cultures due to fast initial growth. A plating 
study was performed to assess how the viable colony numbers on a plate changed over one 
month. The bacteria were put in to a solution of LB media with 100 µM CO-RM L-75 and were 
plated out as previously. This was done with fresh, 9, 18, and 27 day old E. coli (Table 14).  
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Table 14. Plate counting for E. coli W3110 at varying age. Samples prepared in LB media to an 
OD600 of 0.2 with 100 µM CO-RM L-75 and was immediately diluted and plated. 
Days old Dilution  Colony count 
27 500x 40 
18 500x 282 
9 5000x 234 
1 5000x 397 
 
The study shows that over a period of one month, a significant proportion of the E. coli had died. 
After 18 days approx. 90% had died, and this explains the extended the lag phase observed with 
older cultures. Even though the culture was prepared each time so that it had the same starting 
OD there is a clear difference in the number of living bacteria. This could contribute to age 
dependent ability of the CO-RMs to kill E. coli. When the E. coli is fresh there is no lag phase 
and the OD increases quickly, giving a higher OD at the time of irradiation compared to older 
cultures. This increased turbidity could contribute to the decreased effectiveness of the CO-RMs, 
as the light gets scattered rather than passing all the way through the solution and inducing CO-
release. 
A study with CO-RM L-75 was carried out with fresh E. coli that had just grown up on the plate. 
The OD was started ten times lower than carried out to see if turbidity was infact a significant 
issue in these experiments. The E. coli grew after one hour to the same OD as observed in the 
older experiments due to the bacteria being fresh out of 37 °C overnight growth. Results from the 
experiment are shown in Figure 130. 
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Figure 130. Growth of fresh E. coli W3110 with 100 µM CO-RM L-75 in LB media. Starting 
cultures made from stock with an OD = 0.2 and diluted by 100 for the experiment. Irradiation 
(400 nm, 2.4 W, 68 mins) was carried out between one and three hours. 
The OD600 at the point of irradiation is the same in Figure 130 as in experiments with older 
cultures, suggesting similar numbers of bacteria at this point in the experiment. The E. coli grows 
less with CO-RM L-75 and irradiation but do not die at a 99% rate as was the case with the older 
E. coli. This is suggesting that over time something significant is happening to the E. coli’s 
biology that causes it to be much more susceptible to CO release. Even though it is known that 
the majority of E. coli die after a few weeks, the ones that are still alive are capable of growing 
efficiently as shown by the control curves in all these experiments.  
The aging effect observed could possibly be related to the oxidises that E. coli uses such as bd 
and bo oxidases.47 The ratio of these essential CO-binding proteins could change over the aging 
process. If CO can inactivate one of these essential enzymes more easily, and it is in major excess 
at the time, it is postulated that this could explain the aging effect observed.  
Despite this aging effect, there is a potent effect observed with CO-RM L-75 on irradiation of 14 
day old E. coli. Further studies were required to discover the source of this antibacterial effect. 
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6.4.2 Further controls to suggest CO is the cause of antibacterial activity 
Current experiments demonstrate both CO-RM L-75 and irradiation have to be present together 
to see the desired effect. CO-RM L-75 is not toxic to E. coli without irradiation, suggesting that 
this molecule and its by-products are not toxic either. The photo-products of CO-RM L-75 were 
also tested for toxicity, as this might not be produced in the dark. 
In the literature, using the by-products of a CO-RM to suggest the action of CO is widely carried 
out. This is known as an i-CO-RM (inactive CO-RM).22 Many tests involve using ‘proposed’ 
fragments as an i-CO-RM. This presents many disadvantages as adding an intermediate at a 
certain concentration may not reflect the concentration profile in the real experiment. The 
proposed intermediates might not even be present, and so it is difficult to draw a strong 
conclusion in relation to CO action from this kind of i-CO-RM control experiment.   
An alternative method to assess the toxicity of CO-RMs by-products is to make an in situ i-CO-
RM. This involves either leaving a CO-RM in solution for a known time period if it degrades 
thermally, or irradiating it in solution for the same period of time that would be used in main 
experiments. The advantage of doing this is that the products produced in this situation should 
closely mirror those of the main experiment with bacteria. After degradation has been carried out, 
the bacteria can be added to this solution after, and growth curves can be carried out. This 
experiment gives a realistic profile of the products that will be in solution. Even though it is not 
known exactly what all the degradation products are, these experiments are likely to match the 
concentrations of products from the bacteria experiments. Figure 131 shows results from this 
pre-irradiation experiment with CO-RM L-75. 
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Figure 131. Growth curve of E. coli W3110 in LB media with 100 µM CO-RM L-75. Media 
with 100 µM CO-RM was irradiated for 68 mins (400 nm, 2.4 W) before addition of E. coli to 
culture. The culture was then allowed to grow with no further irradiation. 
With 100 µM irradiated CO-RM L-75, the presence of the photo-products from the 68 mins 
irradiation does not affect the growth of E. coli significantly. The media was not flushed with air 
before the bacteria were added. This suggests that the photo-products were not toxic at the 
concentrations generated by 68 mins irradiation at 400 nm. It also suggests that what causes the 
toxic effect when the E. coli are directly irradiated with the CO-RM has to be inside or on the 
surface of the cell. 
The next control experiment carried out was similar to that shown in Figure 131 but involves 
irradiating the bacteria directly after the ‘pre-irradiation’ of the CO-RM. This will assess the 
toxicity of the photo-products in the presence of light. It could be possible that light sensitises the 
bacteria then making some of the by-products toxic. Considering the myoglobin assay data for 
this CO-RM, it is expected that all the CO will have been released within the 68 minutes 
irradiation. The results from the ‘CO-RM pre-irradiation + direct bacterial irradiation’ study are 
shown in Figure 132. 
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Figure 132. Growth curve with E. coli W3110 in LB media with 100 µM CO-RM L-75 was 
irradiated without E. coli for 68 mins. E. coli was then added to culture and was directly for 68 
mins (400 nm, 2.4 W) after one hour initial growth.  
The photo-products of CO-RM L-75 with irradiation causes some reduction in growth compared 
to the DMSO control, but this is not as effective as irradiating directly with freshly dissolved CO-
RM L-75. This suggests the initial starting molecule and irradiation are required to get the strong 
antibacterial effect. This experiment has been repeated twice and also shows the same effect. 
These controls were done using E. coli with a similar age used in the direct irradiation 
experiments (Figure 128). 
All the controls carried out strongly suggest that the CO is causing the toxic effect, but only when 
the CO is released directly from CO-RM L-75. Such detailed controls/mechanistic investigations 
have not been previously carried out on a photo-CO-RM. It is hoped that these detailed control 
experiments will be adopted by other researchers when investigating the antibacterial action their 
photo-CO-RMs. 
The final control that has been carried out involves establishing if one of the photo-degradents 
was toxic under irradiation conditions. It is known from mass spectrometry studies in section 
6.6.2 that irradiation of CO-RM L-75 liberates free L-tryptophan. It was necessary to investigate 
if the presence of L-tryptophan and irradiation at the same concentrations caused any effect. An 
irradiation experiment was carried out using 100 µM L-tryptophan administered in 0.5% DMSO 
just like the CO-RM. The results of this precautionary control are shown in Figure 133. 
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Figure 133. Growth of E. coli W3110 with 100 µM L-tryptophan in the presence and absence of 
light. Irradiation after 1 h initial growth for a total of 68 mins (400 nm, 2.4 W).  
L-tryptophan (73) with irradiation does not alter the growth rate of E. coli. Both irradiated 
cultures with and without tryptophan grow in the same fashion, showing that it is the irradiation 
causing the slight inhibition and not L-tryptophan. This result was expected as L-tryptophan does 
not absorb where the 400 nm LED emits, so no photo-degradation was expected. 
To summarise, CO-RM L-75 has been well characterised in terms of CO-release and has been 
shown to exhibit a strong effect against E. coli, which are more sensitive to treatment with 
increasing age. Both CO-RM 47 and L-75 appear to be more effective on dormant E. coli, which 
could present its own advantages. Many current antibiotics target actively growing bacteria by 
the inhibition of cell wall synthesis.125 Dormant bacteria may not be targeted due to the lack of 
cell wall synthesis using previous antibiotics. CO-RMs tested in this project are more potent 
against older bacteria and this could prove very useful if this CO-RM was used in tandem with a 
current antibiotic to ensure complete bacterial death. Further studies would be necessary to 
confirm this. 
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6.4.3 Further E. coli studies with CO-RM L-75 and 465 nm irradiation. 
Detailed studies have been carried out with CO-RM L-75 showing its antibacterial ability against 
E. coli in conjugation with irradiation of wavelength 400 nm. It has been shown by myoglobin 
assay studies in section 6.2 that this CO-RM releases CO with irradiation of wavelength 465 nm; 
and so investigations into the effect of CO-RM L-75 with 465 nm irradiation were carried out. 
These are the first studies of a CO-RM activated by visible light being tested on E. coli. 
The first test that was carried out using irradiation of wavelength 465 nm, and was essentially a 
repeat of studies with irradiation of wavelength 400 nm. E. coli of a similar age (14 days) were 
used so that data could be directly compared (Figure 134). 
 
Figure 134. Growth curve with14 day old E. coli W3110 and 100 µM CO-RM L-75 from a 
starting OD of 0.159 diluted by 10. Irradiation (465 nm 2.4 W, 68 mins) started after one hour 
initial growth. Irradiation stopped after 3 hours. LED on for 4 mins per 5 min cycle 
CO-RM L-75 with irradiation of wavelength 465 nm is not as effective against E. coli under the 
same conditions used with 400 nm irradiation. Re-growth is observed after irradiation stops and 
is comparable to the effect seen in younger E. coli with 400 nm treatment (Figure 126). This is 
expected as irradiation of wavelength 465 nm was shown to release CO more slowly in 
myoglobin assays. Also 0.5 eq. less total CO is released with 465 nm irradiation compared to at 
400 nm. This may explain why it is not as effective. 
A repeat of the experiment shown in Figure 134 was carried out in the same way but with a 10-
fold lower starting OD. This experiment was designed to assess if turbidity has much of an effect 
under these conditions (Figure 135). 
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Figure 135. Growth curve with 14 day old E. coli W3110, and 100 µM CO-RM L-75 from a 
starting OD of 0.15 diluted by 100. Irradiation (465 nm, 2.4 W, 68 mins) started after one hour 
initial growth. 
CO-RM L-75 with irradiation of wavelength 465 nm has a more potent effect when the initial 
starting OD of E. coli is lower. The lower OD will allow for improved light penetration through 
the liquid medium; meaning that more CO-RM will absorb irradiation over the same time period. 
Irradiation at wavelength 465 nm also has a fairly detrimental effect on E. coli without CO-RM. 
However, with 100 µM CO-RM L-75 there is a much more potent effect with no growth 
observed over an eight hour period. A plating study was also carried out along side this study to 
assess the viability of E. coli with and without CO-RM L-75 on exposure to irradiation of 
wavelength 465 nm (Table 15). 
Table 15. E. coli W3110 plating viability study data obtained alongside results from Figure 135. 
Aliquots taken before and after 465 nm irradiation (one and three hours respectively). Plating 
dilutions are shown in bold. 
1 h (Before 
irradiation) 
3 h Irradiated 1 h (before irrad 
DMSO only) 
3 h irrad (DMSO 
only) 
50x 50x 50x 50x 
300 14 259 206 
500x 500x 500x 500x 
35 3 42 33 
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The data in Table 15 shows that under the given conditions, there is a 95% antibacterial effect on 
E. coli with 465 nm irradiation and 100 µM CO-RM L-75. The DMSO control only shows a 20% 
killing rate presumably due to irradiation. This suggests that both CO-RM and irradiation 
together are required to get a potent antibacterial effect. This is the first example of a visible-
light-induced CO-RM showing a detrimental effect on E. coli. 
Tryptophan-based CO-RM L-75 has potential for the treatment of E. coli as determined by all the 
growth curves/viability studies performed. There are some issues with turbidity reducing the 
effectiveness of the CO-RM and more studies with increased irradiation power could be carried 
out in the future to solve this issue. This highlights the requirement for CO-RMs which release 
CO with irradiation of lower energy; however CO-RM L-75 is certainly a step in the right 
direction and still has potential to be used in further studies. Despite the turbidity issues this CO-
RM could potentially be used for surface treatment due to the lack of turbidity issues in this 
situation although more studies would need to be carried out for this. 
Finally, in our publication of CO-RM L-75, it is referred to as TryptoCO-RM.126 
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6.5 Investigations with CO-RM L-75 on S. aureus 8325-4 
CO-RM L-75 has been employed in further studies to assess its action on S. aureus. 
CO-RM L-75 has shown potent antibacterial activity on E. coli W3110 with both 400 and 465 
nm irradiation. The next step in this research was to extend the scope of CO-RM L-75 and test it 
on more strains of bacteria. The first of these is S. aureus 8325-4 which is a wild type strain. 
Initial studies with S. aureus were based on similar studies carried out on E. coli. S. aureus was 
grown in LB medium in the presence and absence of CO-RM L-75. Irradiation of wavelength 
400 nm was also used so that a comparison to E. coli studies could be made. Figure 136 shows 
the initial growth curve carried out with S. aureus in the presence of CO-RM L-75. 
 
Figure 136. Growth of one day old S. aureus with 100 µM CO-RM L-75 in LB medium at 37 °C 
with 100 rpm shaking in 8 ml bijou tubes. Irradiation (400 nm, 2.4 W, 68 mins) started after one 
hour initial growth. 
Initial studies with one day old S. aureus with CO-RM L-75 show that it prevents the growth of 
S. aureus without the need for irradiation. This is unusual considering that these bacteria were 
fresh. Older bacteria were required to get this kind of effect when using acid CO-RM 47. It is 
possible that S. aureus is much more sensitive to CO from CO-RMs than E. coli. It was shown 
that CO-RM L-75 can release very small amounts of CO thermally (Figure 116), and this could 
be the source of this inhibitory effect. A plating study was carried along side this initial study to 
assess the affect of CO-RM L-75 and 400 nm irradiation together (Table 16). 
  
0
0.15
0.3
0.45
0 2 4 6 8
O
D
6
0
0
Time / h
0.5% DMSO
0.5% DMSO + irrad
100 µM L-75
100 µM L-75 + irrad
213 
 
Table 16. Plating study for S. aureus 8325-4 before and after irradiation (400 nm, 2.4 W, 68 
minutes) in the presence of 100 µM CO-RM L-75 
Days old Time taken / h Dilution Colony count 
1 1 50x 634 
1 3 50x 32 
 
CO-RM L-75 with 400 nm irradiation kills 95% of S. aureus under the tested conditions. This is 
a encouraging result considering that the bacteria tested were only one day old. With 400 nm 
irradiation there is much less of an aging effect here, in contrast to the E. coli studies.  
It was important to establish whether the effect observed without irradiation was bacteriostatic or 
bactericidal. A repeat of the growth curve in Figure 136 was performed and a plating study was 
carried out by taking aliquots from the non-irradiated culture with CO-RM L-75 (Table 17). 
Table 17. S. aureus plating study taken from non-irradiated samples with 100 µM CO-RM L-75. 
Days old Time taken / h Dilution  Colony count 
4 0 50x 870 
4 4 50x 783 
4 7 50x 820 
 
The ‘thermal’ effect on S. aureus with relatively fresh bacteria is infact bacteriostatic. The CO-
RM is preventing S. aureus from growing over a seven hour period without killing them.  
Investigations into the source of this bacteriostatic effect were performed. Initial studies centred 
on establishing if the effect was coming from a small amount of photo-activated CO-release by 
ambient light; or from very slow thermal release as determined by a myoglobin assay. Growth 
curves with S. aureus were therefore set up with CO-RM L-75 in ambient light and in the 
complete dark (bijou tubes were wrapped in foil). This study was repeated and results with errors 
are shown in Figure 137. 
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Figure 137. Growth of S. aureus 8325-4 in LB media at 37 °C with 100 µM CO-RM L-75 in 
ambient light, and the dark. 0.5% DMSO in ambient light used as a control. No irradiation was 
used. 
The ‘thermal’ effectiveness of CO-RM L-75 on S. aureus is not changed by being grown in the 
dark. Great care was taken to keep the sample in the dark as much as possible. This was not 
possible when taking aliquots for analysis but this is only for a small amount of time compared to 
the duration of the experiment. Given the precautions taken, it is difficult to rationalise the 
amount of CO-release on the basis of stray light. There is some slow thermal CO-release, or the 
bacteria are initiating degradation either inside or on the surface of the cell.  
The next step in this investigation was to pre-irradiate CO-RM L-75 in LB medium to generate 
its corresponding i-CO-RM. CO-RM L-75 was pre-irradiated for 68 mins and the S. aureus were 
then cultured as performed previously (Figure 138). 
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Figure 138. Growth curve with S. aureus 8325-4 in LB media with 100 µM CO-RM L-75. CO-
RM L-75 was pre-irradiated in LB media (2.4 W, 400 nm, 68 mins) in the absence of the 
bacteria. S. aureus was subsequently added to the i-CO-RM/LB media solution and cultured for 
six hours at 37°C. 
The experiment in Figure 138 was carried out with three independent repeats on separate days, 
which explains why there is some variation between repeat measurements. It is difficult to obtain 
exactly the same starting OD when starting a new experiment. Each batch of bacteria are slightly 
different so it can be difficult to directly compare these experiments. However taking the 
variation between experiments into account, it is clear that fresh CO-RM is required to get the 
bacteriostatic effect. When the CO-RM has been irradiated without bacteria, the bacteria grow 
only marginally slower than the controls without CO-RM. This mechanistic study suggests that 
CO-release from the CO-RM is responsible for the inhibition of growth observed. 
 
6.5.1 Further Irradiation (400 nm) studies with S. aureus and CO-RM L-75 
It has been shown that CO-RM L-75 can exhibit a 95% bactericidal effect with irradiation on S. 
aureus, and a bacteriostatic effect without irradiation. These data was obtained using bacteria that 
were fresh. Previous studies show improved results on older E. coli with CO-RM L-75 and this 
strategy was also taken with S. aureus.  
S. aureus was grown with and without CO-RM L-75 at a concentration of 100 µM using bacteria 
stored at 4 °C for 8 days. This batch of bacteria was older than previously used batches and was 
designed to see if there was an improved effect. Irradiation was also used in this study (Figure 
139 and Table 18). 
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Figure 139. Growth of eight day old S. aureus 8325-4 with 100 µM CO-RM L-75 in LB medium 
at 37 °C with 100 rpm shaking in 8 ml bijou tubes. Irradiation (400 nm, 2.4 W, 68 mins) started 
after one hour initial growth. 
Table 18. Plating study with eight day old S. aureus corresponding to aliquots taken at one and 
three hours from the cultures used in Figure 139. Aliquots taken from both irradiated and non-
irradiated cultures with 100 µM CO-RM L-75. Dilution factors shown in bold 
1 h (Before 
irradiation) 
3 h Irradiated 1 h ‘Thermal’ 3 h ‘Thermal’ 
50x 50x 50x 50x 
>2000 5 >2000 >2000  
500x 500x 500x 500x 
458 0 490 533 
 
The experiments with eight day old S. aureus show that they are much more susceptible to CO-
RM L-75 in the presence of irradiation; but the bacteriostatic effect without irradiation does not 
improve. With irradiation in this case there is a greater than 99% toxicity with the use of 
irradiation compared to the previous 95% observed.  
With the knowledge that CO-RM L-75 was acting efficiently on S. aureus, a repeat of the above 
experiment was performed using 50 µM CO-RM L-75 (Figure 140 and Table 19). 
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Figure 140. Growth of nine day old S. aureus 8325-4 with 50 µM CO-RM L-75 in LB medium 
at 37 °C with 100 rpm shaking in 8 ml bijou tubes. Irradiation (400 nm, 2.4 W, 68 mins) started 
after one hour initial growth. 
Table 19. Plating study with nine day old S. aureus corresponding to aliquots taken at 1 and 3h 
from the cultures used in experiments from Figure 140. Aliquots taken from both irradiated and 
non irradiated cultures with 50 µM CO-RM L-75. Dilution factors shown in bold  
1 h (CO-RM, before) 3 h CO-RM Irrad 1 h Thermal 3 h Thermal 
50x 50x 50x 50x 
>2000 63 >2000 >2000  
500x 500x 500x 500x 
403 3 337 531 
 
On the older cultures of S. aureus, CO-RM L-75 is still effective with 400 nm irradiation with a 
>95% killing observed under the given conditions. This is not as effective as it is with CO-RM L-
75 at a concentration of 100 µM. The bacteriostatic effect is starting to drop away at lower 
concentrations with a fair degree of growth over the two hours of the experiment without 
irradiation. The growth is still slower compared to the 0.5% DMSO control. It is promising that 
this CO-RM can have a detrimental effect on S. aureus at a concentration that is viable with 
RAW 264.7 cells. 
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6.5.2 Visible-light irradiation studies with CO-RM L-75 on S. aureus 8325-4 
Tryptophan-based CO-RM L-75 has an antibacterial effect when irradiated at 400 nm with S. 
aureus, but as demonstrated on E. coli CO-RM L-75 can be effective when irradiated with light 
of wavelength 465 nm. This justified further irradiation studies on S. aureus using irradiation of 
wavelength 465 nm.  
Initial studies using irradiation of wavelength 465 nm were based on the previous conditions that 
used 400 nm irradiation but using different LEDs (Figure 141 and Table 20). 
 
Figure 141. Growth of one day old S. aureus 8325-4 with 100 µM CO-RM L-75 in LB medium 
at 37 °C with 100 rpm shaking in 8 ml bijou tubes. Irradiation (465 nm, 2.4 W, 68 mins) started 
after one hour initial growth. Missing points due to aliquots taken for plating studies. 
Table 20. Plating study with one day old S. aureus corresponding to aliquots taken at one and 
three hours from the cultures used in experiments from Figure 141. Aliquots taken from both 
irradiated cultures with 100 µM CO-RM L-75 and irradiated DMSO only controls. Dilution 
factors shown in bold 
1 h CO-RM  
(Before) 
3 h CO-RM Irrad 1 h (before, DMSO) 3 h Irrad 
(DMSO) 
500x 500x 500x 500x 
255 17 479 787 
 
The initial study using CO-RM L-75 with 465 nm irradiation exhibits a 90-95% killing rate on S. 
aureus when analysing the colony numbers before and after irradiation. The DMSO control 
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shows significant growth over the same period, demonstrating that both CO-RM and light are 
required together.  
The unusual feature about these results is that unlike the previous results, the colony numbers 
before irradiation do not match between the DMSO and CO-RM control. There are more colonies 
in the DMSO control after one hour incubation compared to the CO-RM culture. This suggests 
that some colonies have died in the first hour in the presence of CO-RM without irradiation. This 
suggests that there is some degree of antibacterial action of CO-RM L-75 on S. aureus without 
the need for irradiation. Is it evident that there is some degree of variability between experiments 
and every set of cells used in each repeat will vary in some way. However, all repeats at 100 µM 
are showing at least a bacteriostatic effect when assessed by plating study.  
The above experiment (Figure 141 and Table 20) with irradiation at wavelength 465 nm was 
then repeated again using a 10-fold lower starting OD. This experiment was designed to assess 
how turbidity affects irradiation studies; and to assess if the number of bacteria per unit volume at 
the same concentration of CO-RM altered the effectiveness of the treatment (Figure 142 and 
Table 21) 
 
Figure 142. Growth of one day old S. aureus 8325-4 with 100 µM CO-RM L-75 in LB medium 
at 37 °C with 100 rpm shaking in 8 ml bijou tubes. Irradiation (465 nm, 2.4W, 68 mins) started 
after one hour initial growth. Missing points due to aliquots taken for plating studies. Starting OD 
10-fold lower than the experiment in Figure 141. 
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Table 21. Plating study with one day old S. aureus corresponding to aliquots taken at 1 and 3h 
from the cultures used in experiments from Figure 142. Aliquots taken from both irradiated 
cultures with 100 µM CO-RM L-75 and irradiated (465 nm) DMSO only controls. Dilution 
factors given in bold. 
1 h CO-RM 
(Before) 
3 h CO-RM 
Irrad 
1 h (before, 
DMSO) 
3 h Irrad 
(DMSO) 
50x 50x 50x 50x 
71 3 384 507 
 
With a starting OD 10-fold lower, there is an even bigger mismatch between the one hour colony 
counts with 100 µM CO-RM L-75 and DMSO only. This strongly suggests that having fewer 
bacteria in the same volume of medium increases the bactericidal effect of CO-RM L-75 without 
irradiation. If there are 384 colonies before irradiation in DMSO, then this could actually be 
taken as the starting number rather than the 71 colonies with CO-RM. This would mean that 
lowering the OD also increases the effectiveness of CO-RM L-75 with 465 nm irradiation. This 
would be expected due to less light scattering and increased light absorption by the CO-RM.  
 
6.6 Leghaemoglobin mechanistic studies: a CO scavenger rescue agent 
The pre-irradiation studies carried out in section 6.5 suggest that CO released from CO-RM L-75 
is responsible for the effects observed on S. aureus.  To support this claim it was necessary to 
carry out some more detailed studies.  
Leghaemoglobin (LegHb) is an oxygen and CO binding protein found within many leguminous 
plants within their root nodules.127 LegHb has a fast CO binding rate of 13.5 µM−1 s−1 compared 
with only 0.51 µM−1 s−1 for myoglobin. LegHb and Mb have similar CO dissociation rates (0.012 
s−1 and 0.019 s−1), and this makes LegHb a potentially useful mechanistic tool for CO-RM 
studies.128 LegHb can be added to bacterial cultures and used as a ‘CO sponge’ to quickly 
sequester CO that is released from the CO-RM. It will bind the CO faster than myoglobin can 
making it potentially more efficient for this application. If the use of this protein can reverse the 
action of a CO-RM on bacteria, then this would strongly support the action of CO rather than any 
metallic fragments. 
With the above information in mind, David Richardson at the University of East Anglia kindly 
provided an E. coli BL21 sample containing a plasmid with multiple copies of the LegHb 
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genome sequence. This sample was prepared as reported previously.129 The modified strain was 
cultured in auto induction medium at 37 °C to a high OD to obtain sufficient quantities of 
protein. The crude protein extract containing LegHb was obtained by sonication of cultured cells 
to break the cell wall and membrane. LegHb was purified by using an anionic exchange column 
eluting with a NaCl gradient. An SDS page gel was run to confirm protein purity and this is 
shown in Figure 143. 
 
 
Figure 143. Left: SDS Page gel of LegHb. Right: Pure LegHb sample in Tris Buffer. 
With pure LegHb protein obtained, it could be used in further bacterial studies as a CO 
scavenger. S. aureus appears to be much more sensitive to CO from CO-RM L-75 compared to 
E. coli. To investigate this, a substoichiometric concentration of LegHb was added to cultures 
relative to the CO-RM concentration (100 µM). LegHb at concentration of 22 µM was added to 
LB media in a solution of 10 mM tris buffer pH 7.8 (protein storage buffer). Control experiments 
without LegHb had the same volume of tris buffer added to ensure everything was at the same 
concentration. The OD was measured at 650 nm in these experiments to reduce interference from 
the LegHb absorbance. Figure 145 and Table 22 show the first growth curve and plating study 
carried out with LegHb. 
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Figure 144. Growth curve with 10 day old  S. aureus growth curve in LB medium at 37 °C with 
100 µM CO-RM L-75 and 22 µM LegHb CO scavenger. 
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Table 22. Plating study results matching with Figure 144 comparing treatment of nine day old S. 
aureus with 100 µM CO-RM L-75 after six hours of growth. Dilution factors shown in bold 
6 h CO-RM 6 h CO-RM + LegHb 
500x 500x 
6 855 
5000x 500x 
0 136 
 
 
Figure 145. Images of 500× dilution plates which gave the data in Figure 144. 
This experiment shows that LegHb protects S. aureus from the action of CO-RM L-75. 
Treatment with LegHb results in many more colonies surviving six hours CO-RM treatment. 
Figure 145 shows that despite the slight increase in absorbance due to LegHb, the absorbance 
continues to increase by nearly two-fold over the six hour period. Without LegHb the OD of the 
culture immediately drops below its starting value and continues to decrease. LegHb does not 
completely mitigate the effects of CO-RM L-75, but reduces its potency, suggesting it is binding 
free CO that is released from CO-RM L-75.  
A substoichiometric amount of LegHb is able to rescue S. aureus and this suggests that only a 
small amount of CO is associated with the antibacterial effect observed. This would match with 
the slow amount of CO-release from CO-RM L-75 detected in the myoglobin assay without 
irradiation.  
It is postulated that that CO-RM L-75 may be degraded inside the bacteria releasing CO to its 
target. This would be difficult to prove with bacteria having natural manganese uptake 
mechanisms130-131. CO released inside the cell may diffuse outside of the cell and be bound up 
tightly by the LegHb. This could then prevent this molecule of CO from diffusing back inside 
another cell and binding to a target. Regardless of the mechanism of CO-release from CO-RM L-
75, there can be confidence that S. aureus is more sensitive to CO than E. coli. 
     6 h CO-RM                       6 h CO-RM + LegHb 
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When nine day old S. aureus is used in these experiments, they appear more sensitive to CO-RM 
L-75 at this age without light, with a large proportion of S. aureus dying when LegHb is not 
present. There appears to be a similar age based effect with S. aureus just like with E. coli. 
A repeat of the experiment in Figure 144 was performed to help confirm the observed results and 
the data is shown in Figure 146 and Table 23. 
 
Figure 146. A growth curve with 10 day old S. aureus in LB medium at 37 °C with 100 µM CO-
RM L-75 and 22 µM LegHb CO scavenger. Additional LegHb only control added. 
Table 23. Plating study results matching with Figure 146 comparing treatment of 10 day old S. 
aureus with 100 µM CO-RM L-75 after six hours growth. Repeat experiment of Figure 144.  
6 h CO-RM 6 h CO-RM + LegHb 
500x 500x 
0 673 
5000x 500x 
0 71 
 
The repeat experiment demonstrates that LegHb is rescuing S. aureus from the effects of CO-
RM. The bacteria which were one day older show similar rates of rescue with LegHb with similar 
levels of antibacterial action without LegHb are observed. The extra control with LegHb was also 
carried out to rule out any interference LegHb itself.  
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This repeat experiment further contributes to the suggested mechanism of action. It would be 
difficult to use LegHb in photo-activated studies because LegHb significantly absorbs where the 
400 and 465 nm LEDs emit and the decreased light penetration could give false positive results. 
This experiment was repeated a final time with fresher S. aureus (five days old). This experiment 
was performed to confirm the age dependent action of CO-RM L-75 (Figure 147 + Table 24) 
 
Figure 147. Five day old S. aureus growth curve in LB medium at 37 °C with 100 µM CO-RM 
L-75 and 22 µM LegHb CO scavenger. Additional LegHb only control added. Second repeat 
experiment. 
Table 24. Plating study results matching with Figure 147 comparing treatment of five day old S. 
aureus with 100 µM CO-RM L-75 after six hours of growth. Second repeat experiment. 
6 h CO-RM 6 h CO-RM + LegHb 
500x 500x 
477 762 
5000x 5000x 
57 155 
 
The second repeat of these LegHb investigations shows an age dependent antibacterial action of 
CO-RM L-75 on S. aureus. With five day old bacteria there is less of an anti bacterial effect. 
However this experimental repeat still demonstrates the ability of LegHb to rescue the S. aureus 
from the action of CO-RM L-75. 
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6.6.1 Dual repeat studies with CO-RM L-75 on S. aureus using LegHb 
Despite three repeat experiments showing that LegHb can reduce the potency of CO-RM L-75, 
further experiments were carried out. Previous results were carried out on separate days with 
different batches of bacteria and only one plate was used for each dilution study. This was done 
because there were concerns regarding the time it takes to obtain bacterial aliquots and perform 
plating studies. The bacteria are grown in a 37 °C room and must be removed for samples to be 
taken. Keeping the time at lower temperature to a minimum is essential. Studies with more 
simultaneous repeats were required to allow for some more statistical analysis. LegHb 
incubations were repeated using two vials for each type of measurement with a plate for each 
vial. Considering that the DMSO and LegHb only controls do the same thing previously, these 
were omitted from these experiments so as to keep the time samples were out of the 37 °C room 
to a minimum. The detailed growth curve and colony counting study is shown in Figure 148 and 
Table 25.   
 
Figure 148. Seven day old S. aureus 8325-4 growth curve with 100 µM CO-RM L-75 and 22 
µM LegHb at 37 °C. Curves are an average of two side by side repeats. 
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Table 25. Plating study values for aliquots taken from seven day old S. aureus cultures used in 
Figure 148. Repeat one and two: aliquots taken from separate vials and spread out in the same 
fashion. Dilution factors indicated in bold. 
Repeat 1 
0 h CO-RM  4 h CO-RM 0 h CO-RM + LegHb 4 h CO-RM + LegHb 
500x 500x 500x 500x 
234 1 202 307 
5000x 5000x 5000x 5000x 
26 0 31 54 
Repeat 2 
500x 500x 500x 500x 
221 4 196 284 
5000x 5000x 5000x 5000x 
13 0 22 29 
 
With the plating study in Figure 148 aliquots were taken at four hours, instead of six hours, to 
assess if the antibacterial effect of CO-RM L-75 had occurred earlier than previously observed. 
The variation in numbers between the two repeats is small and there is antibacterial action from 
the CO-RM after four hours which can be significantly reduced with the presence of LegHb. In 
this experiment the S. aureus increases in numbers over the four hours when CO binding agent 
LegHb is present.  
To summarise, CO-RM L-75 has been shown to exhibit a variety of effects against S. aureus 
8325-4, both with and without light. The CO-RM has a significant effect without irradiation 
suggesting S. aureus is sensitive to low concentrations of CO. The effects of the CO-RM are 
enhanced by irradiation of wavelength 400 and 465 nm, and with increasing age. Pre-irradiation 
studies and studies with Leg-Hb which scavenges CO from the solution suggest that CO is 
released from CO-RM L-75. It also suggests that the antibacterial effects of CO-RM L-75 are not 
due to metal fragments. To date, these studies in keeping with the studies performed with E. coli, 
represent some of the most detailed mechanistic studies carried out on these bacteria in the 
literature. 
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6.7 Investigations with CO-RM L-75 on Neisseria gonnorhoeae MS11 
Tryptophan-based CO-RM L-75 has shown some very promising antibacterial activity on both E. 
coli and S. aureus. N. gonorrhoeae is a sexually transmitted disease which if left untreated can 
cause serious health problems.132-134 In the first-world this has typically not been a top health 
concern due to being easily treatable with a course of antibiotics. However recently, new strains 
of N. gonnorhoeae have been discovered which are resisting many commonly used antibiotics.132-
134
 There have been human N. gonorrhoeae infections in Japan where all current treatments have 
proved ineffective and many peoples’ health is at serious risk.132-134 The persistence of these N. 
gonorrhoeae strains increases the chance of these strains spreading rapidly and causing serious 
problems. There is an urgent requirement for new effective treatments of N. gonorrhoeae, and 
CO-RM L-75 could potentially be a new treatment. This warrants detailed testing of CO-RM L-
75 on N. gonorrhoeae. 
Initial investigations with N. gonorrhoeae MS11 drew upon the previous knowledge obtained 
from tests on E. coli and S. aureus. A growth curve was carried out using BHI medium with a 
yeast autolysate supplement (YAL) in the presence and absence of CO-RM L-75 at a 
concentration of 100 µM. BHI + YAL was found to be a suitable medium for N. gonorrhoeae, 
with significant growth over the period of the experiment. It is undesirable to use a medium in 
which the bacteria were particularly weakened, and this is why a YAL supplement was used. N. 
gonorrhoeae throughout these investigations were cultured from stocks on Columbia agar plates 
with 5% horse blood for 48 hours. Bacteria were used within two days after this initial growth 
and were stored at 37 °C under 5% CO2 prior to use. Aging studies were not performed here due 
to their sensitivity. Cells cannot be stored for as long as other strains of bacteria without 
significantly weakening them. Figure 149 shows the initial growth experiment carried out with 
CO-RM L-75 on N. gonorrhoeae. 
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Figure 149. Growth curve with N. gonorrhoeae MS11 in BHI + YAL growth medium with 100 
µM CO-RM L-75. Irradiation was used as indicated after one hour initial growth (400 nm, 2.4 W, 
68 mins) 
As shown in Figure 149, N. gonorrhoeae is capable of growing successfully in this medium with 
a four-fold increase in OD600 over the eight hour growth period. Irradiating N. gonorrhoeae at 
400 nm for 68 mins without CO-RM L-75 results in a large reduction in growth, but there is 
evidence for re-growth towards the 8th hour of the experiment. With CO-RM L-75 at a 
concentration of 100 µM, the same significant drop in OD600 occurs but there is no re-growth 
later in the experiment. The same applies to both irradiated and non-irradiated cultures with CO-
RM L-75. This suggests that CO-RM L-75 is having a similar action on N.gonnorhoeae as it is 
on S. aureus and E. coli. The OD600 of cultures with CO-RM L-75 at a concentration of 100 µM 
do not increase above the starting OD throughout the course of experiment without irradiation. 
This suggests another thermal or enzyme-triggered mechanism of CO-RM activation. 
As carried out with previous strains of bacteria, plating studies were carried out to assess the 
percentage cytotoxicity of CO-RM L-75 on N. gonorrhoeae (Figure 150). This study was done 
with and without irradiation. 
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Figure 150. N. gonorrhoeae MS11 growth curve in BHI + YAL medium with 100 µM CO-RM 
L-75. Carried out in the presence and absence of irradiation (400 nm, 2.4 W, 68 mins) which was 
started at one hour. Aliquots taken at one and three hours representing before and after irradiation 
for a plating study. Trend lines not included due to the low OD used and single repeats in this 
experiment 
Table 26. Plating study corresponding to Figure 150. Both samples contain 100 µM CO-RM L-
75. Left pair: irradiation between 1-3h), right pair: no irradiation. Dilutions indicated in bold 
1 h (CO-RM) 3 h (CO-RM irrad) 1 h CO-RM 3 h CO-RM 
500x 500x 500x 500x 
260 71 230 127 
5000x 5000x 5000x 5000x 
35 7 29 17 
 
CO-RM L-75 at a concentration of 100 µM in BHI + YAL shows a detrimental effect to N. 
gonorrhoeae both with and without irradiation. There is a 45% reduction in numbers without 
irradiation confirming that N. gonorrhoeae is also sensitive to CO released from a CO-RM as 
seen against S. aureus. With irradiation there is an increase in cytotoxicity giving a 73% 
reduction in numbers. However considering the large amount of CO that should be released from 
CO-RM L-75 on irradiation, this is not having a significant effect on the bacteria. The BHI + 
YAL medium is a rich medium and contains many species that absorb at the point of irradiation. 
In this medium it is proposed that a significant proportion of irradiation is being absorbed and is 
not being used to activate the CO-RM. It is promising that CO-RM L-75 shows a mild 
antibacterial effect without irradiation but an alternative growth medium was required for 
remaining experiments in this work.  
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RPMI medium has been previously been used within the Moir research group to grow Neisseria 
meningitidis. N. meningitidis is closely related to N. gonorrhoeae and RPMI medium was used as 
an alternative medium for further experiments. Initial studies showed that RPMI medium on its 
own was not sufficient to allow for efficient growth of N. gonorrhoeae. Using YAL together with 
RPMI created a new medium which N. gonorrhoeae could grow efficiently in.  
Initial experiments were carried out using CO-RM L-75 without irradiation to assess the 
antibacterial effect observed without irradiation in this new medium. A short growth curve and 
complimentary plating study was carried out (Figure 151 and Table 27) 
 
Figure 151. Growth curve with N. gonorrhoeae at 37 °C in RPMI + YAL medium. Use of 0.5% 
DMSO with or without 100 µM CO-RM L-75. Aliquots removed at zero and four hours during 
the experiment Lines not included due to fewer data points. Data points missing due to aliquots 
taken for plating study.  
Table 27. N. gonorrhoeae plating study corresponding to the aliquots taken from Figure 151 at 
zero and four hours. Dilutions indicated in bold 
 0 h CO-RM 4 h CO-RM 0 h DMSO 4 h DMSO 
500x 500x 500x 500x 
438 0 534 717 
5000x 5000x 5000x 5000x 
55 0 75 80 
 
In RPMI + YAL medium there is a potent antibacterial effect without the need for irradiation. 
438 colonies were present at the start of the experiment at 500× dilution, with none present at the 
same dilution after 4 hours incubation. Without CO-RM L-75 the bacteria survive and increase in 
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numbers over the same period of time. This suggests that moving to this new medium is not 
weakening the bacteria. However, CO-RM L-75 does appear to be much more potent in this new 
medium. It is postulated that the protein rich BHI medium, which contains a large number of 
undefined contents, could cause degradation of the CO-RM reducing its effectiveness. A repeat 
of this experiment was carried out at a higher starting OD to assess how toxic this CO-RM 
actually is (Figure 152 and Table 28). 
 
Figure 152. Repeat growth curve with N. gonorrhoeae MS11 at 37 °C in RPMI + YAL medium. 
Use of 0.5% DMSO with or without 100 µM CO-RM L-75. Aliquots removed at zero and four 
hours during the experiment. Higher starting OD was used for this experiment. Lines not 
included due to fewer data points. Data points missing due to aliquots taken for plating study. 
Table 28. N. gonorrhoeae MS11 plating study corresponding to the aliquots taken from Figure 
152 at zero and four hours. Dilutions indicated in bold.  
0 h CO-RM 4 h CO-RM 0 h DMSO 4 h DMSO 
500x 500x 500x 500x 
>2000 0 >2000 >2000 
5000x 5000x 5000x 5000x 
365 0 459 1264 
 
The data in Figure 152 shows that there is a significant increase in bacterial growth when a 
higher starting OD is used. The OD of the culture with CO-RM L-75 present drops well below 
the starting OD, but with 0.5% DMSO the bacteria grow significantly in numbers over the 
experiment. The plating study shows that the cytotoxicity of CO-RM L-75 in this medium is even 
more potent than initially thought. There is >99.9% bactericidal effect in the presence of the CO-
RM L-75. This is the first time a CO-RM has been used to show detrimental effects on N. 
gonorrhoeae MS11.  
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6.7.1 N. gonorrhoeae MS11 studies using LegHb as a rescue agent. 
With CO-RM L-75 showing a potent antibacterial effect against N. gonorrhoeae. It was then 
necessary to carry out further mechanistic investigations to see if CO release from CO-RM L-75 
was killing N. gonorrhoeae. This involved using LegHb as a rescue agent as was performed 
previously with S. aureus. The first experiment using LegHb in experiments with N. gonorrhoeae 
is shown in Figure 153 and Table 29. 
 
Figure 153. N. gonorrhoeae MS11 growth curve in RPMI + YAL medium with 100 µM CO-RM 
L-75 and 22 µM LegHb. 
Table 29. Plating study corresponding to aliquots taken at zero and four hours from the cultures 
represented in Figure 153. Dilutions indicated in bold. 
0 h CO-RM  4 h CO-RM 0 h CO-RM + LegHb 4 h CO-RM + LegHb 
5000x 5000x 5000x 5000x 
163 4 181 32 
50000x 50000x 50000x 50000x 
13 1 17 1 
 
The bactericidal effect observed in RPMI medium is lower than previously observed but is still > 
97% toxic to N. gonorrhoeae. The growth curve shows that N. gonorrhoeae is rescued by the 
presence of LegHb. This suggests a similar mechanism of action (i.e CO) of CO-RM L-75 on S. 
aureus. The LegHb control grows by the same amount as the DMSO-only control. 
The experiment in Figure 153 was repeated but excluding the LegHb only control, so that double 
repeats could be carried out (Figure 154 and Table 30). N. gonorrhoeae is a temperature 
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sensitive bacteria and keeping it at its optimum growth temperature of 37 °C for as much time as 
possible is essential to try and reflect in vivo conditions.  
 
Figure 154. N. gonorrhoeae growth curve in RPMI + YAL medium with 100 µM CO-RM L-75 
and 22 µM LegHb. Cultures with CO-RM L-75 and LegHb are an average of two side by side 
repeats. 
Table 30. Plating study data corresponding to aliquots taken at zero and four hours from cultures 
represented in Figure 154. Dilutions indicated in bold 
Repeat 1 
0 h CO-RM  4 h CO-RM 0 h CO-RM + LegHb 4 h CO-RM + LegHb 
500x 500x 500x 500x 
>1000 0 >1000 106 
5000x 5000x 5000x 5000x 
157 0 141 9 
Repeat 2 
500x 500x 500x 500x 
>1000 0 >1000 110 
5000x 5000x 5000x 5000x 
118 0 123 8 
 
These repeat studies show that N. gonorrhoeae can be rescued by the use of substoichiometric 
amounts of LegHb relative to the amount of CO-RM L-75. There is an antibacterial effect above 
99% in these repeats which is reduced to only 90% by the use of LegHb. The degree of rescue in 
these experiments is less than that observed in the experiments with S. aureus. However, there is 
a significant enough change here to be confident that there is a similar mechanism of action on N. 
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gonorrhoeae as there is with S. aureus. Both S. aureus and N. gonorrhoeae are both very 
sensitive to CO.  
 
6.8 Spectral investigations with CO-RM L-75, LegHb and Mb  
With LegHb acting as a potential ‘CO sponge’ in the presence CO-RM L-75 in bacterial cultures, 
further UV-Vis spectroscopic studies were carried out with CO-RM L-75 and LegHb to 
investigate how the CO is transferred to the LegHb.  
Initial studies explored whether LegHb could bind CO gas without the need for sodium 
dithionite. Then CO-RM L-75 was tested as the CO source (Figure 155).
  
Figure 155. Left: UV spectrum of 22 µM LegHb and the changes upon binding CO gas. Right: 
UV-Vis spectra of 22 µM LegHb with 100 µM CO-RM L-75 taken every five mins. Sample was 
kept in the dark once the experiment was started. 
The UV-Vis data in Figure 155 shows that a similar set of spectral changes occur on binding CO 
from gas and from CO-RM L-75. It also shows that CO-RM L-75 is capable of releasing CO 
without the need for a sodium dithionite. There is potential for the bacteria to produce a reducing 
environment as they use up all the oxygen in the culture, but with the presence of CO-RM L-75 
the majority of the cells are not actively growing.  This is therefore unlikely to be the case. The 
fact that it takes 55 minutes to saturate only 22 µM LegHb using 100 µM CO-RM L-75, suggests 
that the CO-RM is slowly releasing its CO as shown in the myoglobin assay (Figure 116). The 
LegHb is not just sequestering the CO straight from the CO-RM, it is appears to be binding the 
CO as it is gradually released thermally into solution. 
0
0.05
0.1
0.15
0.2
500 550 600
A
λ /nm
LegHb no dithionite
LegHb + CO
0
0.05
0.1
0.15
0.2
0.25
0.3
500 550 600
A
λ / nm
236 
 
It is proposed that this small amount of CO is responsible for the antibacterial effects observed in 
the N. gonorrhoeae experiments. 
The same experiment with CO gas was also carried out to assess if myoglobin would bind CO in 
the same way without sodium dithionite. It was found that no spectral change was observed on 
bubbling with CO gas. Myoglobin does not bind CO strongly/fast enough to displace the bound 
oxygen without the use of sodium dithionite.  
With the above taking in to consideration, a final N. gonorrhoeae experiment was carried out 
using CO-RM L-75. Myoglobin was employed as a second potential rescue agent although it was 
expected that it would not bind up the CO in solution. Figure 156 and Table 31 shows the 
growth curves and corresponding plating study carried out alongside this.  
 
Figure 156. N. gonorrhoeae growth curve with CO-RM L-75 and 18 µM myoglobin in RPMI + 
YAL medium at 37 °C with 100 rpm rotation. 
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Table 31. Plating study data corresponding to aliquots taken at zero and four hours from cultures 
represented in Figure 156. Dilutions factors are shown in bold. 
Repeat 1 
0 h CO-RM  4 h CO-RM 0 h CO-RM + Mb 4 h CO-RM + Mb 
500x 500x 500x 500x 
>1000 39 >1000 65 
5000x 5000x 5000x 5000x 
173 8 174 5 
Repeat 2 
500x 500x 500x 500x 
>1000 36 >1000 46 
5000x 5000x 5000x 5000x 
188 6 187 4 
 
The myoglobin experiments above suggest that myoglobin is not binding any CO released from 
solution both with and without bacteria. The variation between repeats is small and there is not a 
large degree of rescue with myoglobin. 
The studies in this section show that LegHb is a new mechanistic tool for gaining insight in to 
how CO-RMs exhibit detrimental effects against bacteria. LegHb has not been previously used in 
this manner and has been useful in the bacterial studies presented in this study. 
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6.9 Concluding remarks on CO-RM L-75 and its properties  
In summary, CO-RM L-75 has been shown to have a potent antibacterial effect against N. 
gonorrhoeae. The most potent effect was observed in RPMI + YAL medium without the need for 
irradiation with a killing rate over 99%. CO-RM L-75 is similar to the previous phenylpyridine 
CO-RMs prepared in this project; but differs by an exchangeable acetonitrile ligand and an N^O 
mode of coordination as opposed to C^N. It is proposed that this exchangeable ligand site allows 
for slow thermal CO release which is believed to cause the thermal or enzyme-triggered action on 
S. aureus and N. gonorrhoeae. It may be possible that an enzyme within each strain of bacteria 
can facilitate CO release inside the cell at a much faster rate. This CO could then immediately 
bind a target within the cell. CO-RM L-75 has proven to be a promising new potential 
pharmaceutical molecule with many possible applications.  
CO-RM L-75 was designed to be a photo-CO-RM, however it possesses some antibacterial 
activity without the need for irradiation. Designing a CO-RM to be a photo-CO-RM with respect 
to aqueous solution and proteins such as myoglobin and LegHb can be advantageous. In vivo, one 
would not want to administer a CO-RM for it to be immediately be bound up by myoglobin as 
this is not the desired target. CO-RM L-75 does not rapidly release its CO to myoglobin; which 
means it can be administered into the body and will not immediately degrade due to the presence 
of myoglobin. Subsequent irradiation allows for rapid CO-release, and could be metabolised 
inside bacterial cells which kills them due to CO then binding to important respiration enzymes.  
There is variation in the degree of antibacterial effects being observed throughout different 
repeats and experiments. There are also unusual aging effects observed with E. coli and S. 
aureus. The cells at older ages still grow rapidly and it is difficult to draw conclusions to what the 
aging effect means in the broader context of a potential in vivo study. Bacteria in vivo are under 
many forms of stress from human immune responses and other factors. The key conclusion from 
all of the research in this section is that under certain conditions, the CO-RMs synthesised in the 
project exhibit a potent effect on three infectious strains of bacteria, and the only way to find out 
if they will work in vivo, is to test them as such. 
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7 Visible-light-induced CO-release using a dye CO-RM. 
7.1 Synthesis and characterisation of a dye Mn(CO4) CO-RM. 
To widen the potential applications of photo-CO-RMs, creating new analogues and discovering 
structural features which increase the wavelength of light required for CO-release is desirable as 
shown with previous CO-RMs. CO-release at higher wavelength allows for deeper tissue 
penetration by light122, increasing the type of potential conditions that could be treated using 
photo-activated CO-RMs. Irradiation at lower wavelengths is quickly absorbed by 
macromolecules which could prevent efficient CO-release. This would limit the use of these CO-
RMs to skin/wound treatment if photolysis was required to get an effect. 
To discover a new motif with structural features that would increase the wavelength of CO-
release, A literature search was performed to find a lead molecule. Initial literature searches were 
carried out in dyes pigments journal. There was particular interesting in using dyes to create a 
new CO-RM, as these molecules are designed to absorb well into the visible region of the 
spectrum. They are often designed to have a very high molar absorption coefficient with 
extended conjugation systems with ‘push-pull’ electronic systems. 
Research by Wang and co-workers reported a series of structurally interesting azodyes.135 
Scheme 37 reports the synthesis of a dye selected for use in further synthetic studies. 
 
Scheme 37. The synthesis of benzothiazole containing azo-dye 76, stars indicate future target 
atoms for functionalisation 
Azo dye 76 was selected for further studies because of the interesting spectral properties it has. 
76 has a λmax at 512 nm with a reported molar extinction coefficient of 52000 mol−1 dm3 cm−1. 
This is a high wavelength and molar extinction coefficient considering the size of the molecule 
and the amount of conjugation. The ‘push-pull’ conjugated system within this molecule is likely 
to be responsible for its interesting optical properties. The strong mesomeric effect from the N,N-
 diethyl group in tandem with the elect
transfer across the molecule. Ligand 
makes it an excellent candidate ligand for photo
Dye 76 was used in many reaction
previously been introduced onto phenylpyridine ligands. The initial intention with this molecule 
was to install the Mn(CO)
dye. The idea was that this 
lower wavelength photo
Initial attempts to cyclometallate 
as seen by TLC and column chromatography (
 
Figure 157. Left: TLC of crude reaction mixture when synthesizing CO
from the purification of the crude reaction mixture.
It is proposed that the azo dye starting material was decomposing, and swapping its substituents 
to create different azo dyes giving rise to the array of colours observed on the TLC plate/column. 
Optimisation proved unsuccessful in preventing degradation. Reactions were attempted using 
lower temperatures (40 and 75 
°C little conversion to any new products was observed, and at 75 °C no
following column chromatography.
BnMn(CO)5 to react with the dye substrate in the desired fashion, but this simultaneously causes 
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. 
Figure 159. 400 MHz 1H NMR spectrum of CO-RM 77 in CD2Cl2 at 300 K 
On cyclometallation of dye 76, a typical resonance pattern is seen around the phenyl ring. The 
signal for Ha only contains a long range 4J W-coupling to Hb as expected. Hb is a doublet of 
doublets due to W coupling with Ha and a shorter range 3J coupling with Hc. Hc only has a 
matching coupling constant back to Hb. A 1H-1H COSY experiment confirms these discussed 
couplings and assignments. The COSY experiments also show coupling between protons Hd+e 
and Hf +g. These data suggests the proposed structure for CO-RM 77. 
A solution IR spectrum of CO-RM 77 was obtained in CH2Cl2 to confirm the presence of the 
metal carbonyl ligands within the structure (Figure 160). 
He+f Hd+g 
Hb 
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Figure 160. Left: IR spectrum of CO-RM 40 for comparison. Right: IR spectrum of azodye CO-
RM 77 
The main difference between the two IR spectra is that the spectrum for CO-RM 77 appears to 
have three peaks instead of four. The IR spectrum of bromo-phenylpyridine CO-RM 40 was 
shown for comparison to demonstrate that the frequency, shape and spacing of the peaks similar. 
It is proposed that the change in structure has resulted in the middle two M−CO peaks from CO-
RM 77 significantly overlapping. This is why there are three apparent peaks are observed instead 
of four. This could certainly be expected with the nitrogen that coordinates to the manganese 
being in a different chemical environment. The peak at 1990 cm−1 in the spectra of CO-RM 77 is 
not symmetrical which suggests two overlapping peaks. LIFDI and ESI mass spectrometry 
measurements both show a molecular ion peak corresponding to the target Mn(CO)4 complex as 
opposed to a tricarbonyl species. With the data in hand there can be a strong degree of confidence 
that the target CO-RM 77 has been successfully synthesised.  
CO-RM 77 was unfortunately only isolated with a yield of 5%, which can be linked to the 
significant amount of thermal degradation shown by TLC and column chromatography. Despite 
the poor yield, this CO-RM could possess some unique properties, and this warrants further 
investigations  
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7.2 Spectral, CO-release and mechanistic studies with dye CO-RM 77 
With sufficiently pure CO-RM 77 to hand, the next step was to characterise its relevant 
properties. CO-RM 77 was designed to increase the wavelength of irradiation required to initiate 
CO-release, and so spectral properties were the first to be investigated. Initial experiments 
involved UV-Vis spectral analysis (Figure 161). 
 
Figure 161. UV-Vis spectra of azo dye 76 and its corresponding Mn(CO)4 complex 77 in 
CH2Cl2. 
As mentioned previously, the dye ligand 76 has a λmax at 512 nm and is a vibrant red colour. 
Complexation of dye 76 to produce a tetracarbonyl manganese(I) dye species (77) significantly 
shifts the λmax of CO-RM 77 up by 60 nm giving a dark purple colour. The λmax of the free ligand 
is already relatively high considering the size of the molecule and the amount of conjugation. So 
the shift observed on complexation is an improvement to the optical properties of this system. 
Using UV-Vis spectroscopy, the molar extinction coefficient of both the dye and CO-RM 77 
were determined for comparison and for purity information (Figure 162). Trend lines were 
forced through zero and concentrations were based on the molecular weight of the compound. 
Any significant error in the measurements would result in a line which does not pass through zero 
without a reduction in R2. 
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Figure 162. Molar extinction coefficient determination in CH2Cl2 for dye 76 (left) and CO-RM 
77 (right). 
With a literature ε512 for dye 76 of 52000 mol−1 dm3 cm−1, this matches fairly closely with the 
value obtained from this experiment of 49100 ± 881 mol−1 dm3 cm−1, adding a degree of 
reliability to the result. There will be some error within measurements carried out in both cases 
but the R2 value obtained here is very close to one when forced through zero matching the 
concentration measurements. CO-RM 77 has a ε576 of 26300 ± 830 mol−1 dm3 cm−1. This is lower 
than the value obtained for the free dye 76, but considering the shift to higher wavelength this is 
still a high molar extinction coefficient.  
There is also a new band present in the UV-Vis spectrum of CO-RM 77 with a λmax at 422 nm. 
This band has a ε422 of 8204 ± 264 mol−1 dm3 cm−1 which higher than for any other CO-RM 
prepared in this project at this wavelength.  
With the UV-Vis profile of CO-RM 77 characterised, it was then necessary to see if the UV 
spectrum would change on irradiation at various wavelengths. To obtain information about which 
bands might be associated with any spectral changes seen, blue (465 nm), green (525 nm) and 
amber (590 nm) LEDs were used to irradiate CO-RM 77 in CH2Cl2 (Figure 163).  
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Figure 163. Left: Spectral changes of CO-RM 77 on irradiation (465 nm, 2.4 W) in CH2Cl2, each 
interval represents two minutes of irradiation. Experiment also carried out in the same fashion 
using 525 and 590 nm irradiation. Right: Normalised absorbance for CO-RM 77 at 565 nm as it 
is being irradiated at the given wavelengths.  
On the irradiation of CO-RM 77 with irradiation of wavelength 465 nm, there are clear and 
defined spectral changes. The peak from the pi-system at 576 nm decreases in intensity and shifts 
back over to 520 nm, close to the λmax of free ligand. This suggests that free ligand might be 
released just like many of the other CO-RMs in this project. No spectral change was observed in 
the dark for 25 minutes, and irradiation and the given wavelengths is responsible for the spectral 
changes observed. 
The most important feature about the results in Figure 163 is that CO-RM 77 shows the same 
spectral changes when irradiated with light of wavelength 525 and 590 nm. The changes are 
significantly slower than with irradiation of wavelength 465 nm, but this is significant increase in 
the wavelength that has been used to release CO from a CO-RM previously. This is the highest 
wavelength of irradiation that has ever been used to show a change in the spectral profile of a 
CO-RM. However it is clear from these results that the absorption band at 576 nm is not 
associated with CO-release/spectral change. If it was then it is likely that the CO-release would 
be fast due to the large molar extinction coefficient and this wavelength. The M−CO absorption 
band at 420 nm is likely to be responsible for CO-release in all these cases. This band is 
estimated to tail off to close to 600 nm. Despite the pi-system in this CO-RM not being associated 
with CO-release; using a dye to make a CO-RM has created a system with an M−CO absorption 
band higher in wavelength than anything previously prepared this project.  
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The spectral studies in Figure 163 suggest that free ligand is produced on irradiation of the CO-
RM. To confirm this, an ESI-MS degradation study was performed as previously (Figure 164). 
 
Figure 164. ESI-MS degradation study of CO-RM 77 in CH2Cl2 using irradiation (465 nm, 2.4 
W).Irradiation was stopped while running each ESI-MS measurement. 
When a solution of CO-RM 77 is irradiated at 465 nm, the intensity of the molecular ion at 477 
m/z decreases, and increasing peaks matching the mass of free ligand 76 is observed at 311 m/z. 
This suggests a similar type of degradation process as observed with previous CO-RMs. This 
data also confirms why the λmax of the irradiated species shifts down back towards the λmax of the 
free ligand. Compiling the ESI-MS degradation data obtained in this project, it is likely that most 
bidentate tetracarbonyl manganese(I) complexes release free ligand during their photo-
degradation process. 
  
7.2.1 CO-release from dye CO-RM 77 initiated by visible-light 
It has been shown that CO-RM 77 undergoes a significant spectral change on irradiation with 465 
nm light producing free ligand. The next step was to assess how CO-RM 77 behaves in aqueous 
solution with myoglobin as carried out with other CO-RMs previously. There were however 
significant initial concerns with using this CO-RM in the myoglobin assay. This was due to the 
large absorbance from the CO-RM during same region of the spectrum as myoglobin. To tackle 
this problem the myoglobin assays were carried out with low concentrations of CO-RM to reduce 
the absorbance from the CO-RM in comparison to the myoglobin. Two myoglobin assays were 
carried out using 5 and 10 µM CO-RM 77 (Figure 165). 
0.E+00
5.E+04
1.E+05
2.E+05
2.E+05
3.E+05
3.E+05
4.E+05
4.E+05
5.E+05
5.E+05
0 100 200 300 400 500 600 700 800 900
Io
n
 C
o
u
n
t
Total Irradiation time / s
m/z = 311
m/z = 477
248 
 
 
Figure 165. Myoglobin assays in PBS buffer pH 7.4 for CO-RM 77. Left: 5 µM CO-RM assay, 
Right: 10 µM CO-RM assay.* marks start of irradiation (465 nm, 2.4 W, two mins every five 
mins) 
With reduction in the used concentration of CO-RM 77 in the myoglobin assays, it was possible 
to correct for the CO-RM absorption profile throughout the experiment. The myoglobin assay 
correct procedures in section 3 shows the corrected CO-RM absorption profiles and the mapped 
absorbances for subtraction. The errors after correction are just as low as described in that 
section.  
CO-RM 77 shows a small amount of CO-release before irradiation just like CO-RM L-75. This 
might be useful when treating sensitive bacteria such as S. aureus and N. gonorrhoeae. This 
thermal or enzyme-triggered release is very slow in comparison with the CO-release observed on 
irradiation at 465 nm. Irradiating CO-RM 77 with light of wavelength 465 nm releases CO 
effectively at both 5 and 10 µM, with half-life values of 13 and five mins respectively. This is 
relatively quick considering that 465 nm irradiation is being used here, and this must relate to the 
shifted M–CO absorption band at 420 nm. 
CO-RM 77 is releasing two molecules of CO per molecule of CO-RM which is less than other 
tetracarbonyl CO-RMs previously prepared. However this is still more than some CO-RMs in the 
literature such as ruthenium-based CO-RM 3. 
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7.3 Concluding remarks on azodye-containing CO-RM 77  
In summary, a promising dye CO-RM structure (77) has been prepared and characterised in terms 
of its spectral and CO-release properties. The preparation of this CO-RM significantly increased 
our knowledge about how to increase the wavelength of CO-release. Further investigations into 
how this structure increases the wavelength of CO release could be useful. The CO-RM releases 
CO efficiently when irradiated with light of wavelength 465 nm, and it is likely that it will release 
CO using higher wavelengths (considering the spectral changes observed on irradiation with light 
of wavelength 525 and 590 nm). Further myoglobin assay studies would be required to assess this  
CO-RM 77 has some really interesting properties, but the yield for the synthesis is poor and 
requires further optimisation. The current synthesis presents problems when biological and 
chemical tests are required, as the yield cannot meet the required amount of compound required. 
The expected reason for the low yield is due to the azo dye structure decomposing due to the heat 
required for the cyclometallisation reaction as observed by TLC and column chromatography. A 
potential alternative structure and synthesis is discussed in section 8.  
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8 Overall conclusions 
8.1 Initial phenylpyridine complex series 
This project has taken an initial tetracarbonyl (2-phenylpyridine-κ2N,C8)manganese(I) structure 
and developed it in several different ways to improve various properties. A relatively simple 
complex has been functionalised with a variety of functional groups including: halogens, 
carboxylic acids, alkynes, and biotin.  
Initial investigations were focused on establishing if the tetracarbonyl (2-phenylpyridine-
κ
2N,C2)manganese(I) structure would be a suitable starting point in terms of creating a photo-
CO-RM that could be functionalised without significantly changing its properties. By creating a 
series of substituted phenylpyridine complexes, it was established via a myoglobin assay that the 
phenylpyridineMn(CO)4 moeity was indeed a suitable candidate for further CO-RM synthesis. 
Despite changing substituents at the para-position on the phenyl ring, the stability of all the CO-
RMs in an initial series (R = H, F, Cl, Br, Ph) was not affected. All five CO-RMs in this initial 
series (37-41) were stable in aqueous medium in the presence of myoglobin, but released CO 
efficiently on irradiation at 365 nm with a UV hand lamp. It would be undesirable if adding 
functionality on to the parent structure significantly changed how the CO-RM released CO.  
All the CO-RMs in this series precipitated at concentrations that would be required to release 
significant amounts of CO in a biological setting. This is undesirable and it was concluded that 
further functionalisation was required to make a compound that could potentially progress into 
clinical trials. These initial target are simply not water compatible enough compared to 
ruthenium-based CO-RM-3 and [Mn(CO)4{S2CNMe(CH2CO2H)}] (7) detailed in the literature.58, 
136
 This meant that further structural modifications were required to improve the properties of the 
CO-RMs.  
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8.2 Improving the solubility of phenylpyridine based CO-RMs 
The solubility problem with the initial series of CO-RMs was solved by the introduction of 
carboxylic acid functionality on a small chain in the para-position of the phenyl ring. This group 
is ionised at physiological pH meaning it is deprotonated in most biological environments. This 
extra charge improved the solubility of CO-RM 47. This CO-RM can be prepared in high yield 
and on scale that provides enough material for a significant number of biological studies (Figure 
166). 
 
Figure 166. The structure of water compatible CO-RM 47 
Introduction of the carboxylic acid functionality meant that when the CO-RM was added to 
aqueous solution it did not precipitate. This was a significant step from having analogues which 
were more proof of principle, to something which may actually progress forward as a potential 
pharmaceutical agent. CO-RM 45 releases three molecules of CO per molecule of CO-RM which 
is comparable to [Mn(CO)4{S2CNMe(CH2CO2H)}] (7) prepared by Mann and co-workers.58 It is 
also important to note that with the lack of precipitation, this CO-RM has a half-life shorter than 
the initial CO-RM series. With more CO-RM in solution and no turbidity to scatter irradiation, 
the rate of CO-release from this complex is much more efficient.  
Many of the CO-RMs reported in the literature do not release CO in the dark, and then release 
CO on irradiation.61-62, 78, 137 However, many papers do not report enough details on how 
irradiation experiments are carried out. It was demonstrated with CO-RM 47 that its half-life 
significantly decreases on switching from a 365 nm TLC hand lamp to a 400 nm LED system. In 
all the irradiation studies using LEDs in this project, the LEDs have been at a set distance, and 
defined power consumption. The LED irradiation system developed at the University of York has 
demonstrated that photo-CO-RMs can have their half-life varied by changing the intensity of the 
irradiation. This provides advantage over thermo- and enzyme-triggered CO-RMs; as the CO-
release from these complexes is somewhat fixed by the thermodynamics of the interactions 
between their targets. With photo-CO-RMs both the irradiation and concentration can be used to 
control how CO is released within a system; because the irradiation intensity can be varied. CO-
RM 47 could be used as fast releaser like ruthenium CO-RM-3 using high intensity irradiation,136 
or could be used a slow steady CO-releaser such as CO-RM A1 by using low intensity irradiation 
power.138 
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8.2.1 Antibacterial action of CO-RM 47 
CO-RM 47 has been shown to possess potent antibacterial properties against E. coli W3110 with 
irradiation of wavelength 400 nm. CO-RM 47 is also viable at the same concentration with RAW 
264.7 cells meaning that it has the potential to be used in further in vivo studies. CO-RM 47 kills 
99% of E. coli which were stored at 4 °C for 14 days. This could be advantageous as these 
bacteria are likely to be more dormant compared to bacteria taken straight out of a 37 °C culture 
room. Dormant bacteria which avoid antibiotic treatment can be a serious problem following a 
course of antibiotics. This CO-RM has the potential to treat against these kinds of problematic 
bacteria. 
It is important to discuss that a potent antibacterial effect has been found under the conditions 
tested, but this will of course not reflect the conditions in vivo. There are many factors to take 
into consideration. For example if this CO-RM was to be used to treat a skin infection with 400 
nm irradiation. The CO-RM may not be effective due to poor light penetration, but it could be 
enhanced by working together with the immune system. CO-RMs can boost the immune system 
and reduce inflammation, among numerous other beneficial biological changes. It may be 
possible that a CO-RM will not have a direct antibacterial effect, but could enhance the ability of 
the immune system to deal with the infection. The only real way to know if this CO-RM can 
actually be an effective treatment is to start in vivo studies. It is important to emphasise that CO-
RM 47 could be viable with 20 different cell strains in a 96 well plate, but toxic in vivo, wasting 
considerable money and time on initial studies. There is also an urgent requirement for more 
antibacterial agents, and taking this in to account there is enough data on CO-RM 47 to take it to 
further studies.139 
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8.3 Development of biologically compatible CO-RMs 
CO-RM 47 releases a molecule of its corresponding free ligand on irradiation, and this could be 
of concern when developing new analogues. This creates a metabolite which could be toxic 
following irradiation. Luckily this is not the case with the CO-RM 47 but when designing new 
analogues this is certainly something to bear in mind. Taking this into consideration, a new CO-
RM containing unprotected L-tryptophan was developed (Figure 167). 
 
Figure 167. The isomers of CO-RM L-75. 
By using L-tryptophan as ligand, it was anticipated that free L-tryptophan would be released on 
irradiation. This turned out to be the case and was confirmed by ESI-MS studies. L-tryptophan 
(73) is a natural biological molecule required by most organisms, and the release of a benign 
metabolite is certainly desirable in terms of reducing toxicity and potential side effects. While the 
free ligands from other CO-RMs have been shown to be non toxic, it is unknown what side 
effects they may have. With the release of L-tryptophan from CO-RM L-76, there can be a strong 
degree of confidence that the release of L-tryptophan is unlikely to cause any significant side 
effects. 
In the structure of CO-RM L-75, L-tryptophan is bound to a manganese(I) centre via a bidentate 
N^O coordination mode. This differs from the C^N binding mode of the phenylpyridine complex. 
There are also only three CO ligands in this system with a potentially exchangeable acetonitrile 
ligand. These differences result in a shift of the UV absorption bands associated with CO-release 
to higher wavelength in comparison with the phenylpyridine derivatives. This results in efficient 
CO-release from CO-RM L-75 when irradiated at 465 nm, which cannot be achieved with CO-
RM 47. Irradiation of wavelength 465 nm will penetrate deeper in tissue (0.5 mm) and this means 
that CO-RM L-75 could still be used to treat conditions within the skin.122 It is also important to 
consider that this CO-RM does not need irradiation to have a detrimental effect on S. aureus and 
N. Gonorrhoeae and has the potential to be used deep within tissue. 
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8.3.1 CO-RM L-75 exhibits antibacterial activity against three species 
CO-RM L-75 has also been to shown to possess a potent anti-bacterial effect on E. coli under the 
same conditions as CO-RM 75. This CO-RM can also exhibit a detrimental effect on E. coli at 
465 nm which is the first example where a CO-RM has been used in conjunction with visible 
light to kill bacteria. 
Acid-containing CO-RM 47 failed to show any significant effect on S. aureus compared to the 
effect of the irradiation, where as CO-RM L-75 has been shown to have a potent effect, both with 
and without irradiation. It is postulated that the acetonitrile coordination site allows for small 
amounts of thermal CO-release while still maintaining stability in the presence of proteins such 
as myoglobin. It is clear from these studies that S. aureus is much more susceptible to CO than E. 
coli. This means that using CO-RMs as a means of treating S. aureus is a promising research 
direction.  
CO-RM L-75 also shows the same type of anti bacterial activity against N. gonorrhoeae MS11 in 
RPMI + YAL medium. There is antibacterial activity in order of 99% without the need for 
irradiation. N. gonorrhoeae is also very sensitive to CO just like S. aureus, and this is good news 
from a research prospective. It is likely to be sensitive due to only containing one cytochrome c 
oxidase enzyme making it very vulnerable to inactivation by CO.45-46 Control experiments show 
that N. gonorrhoeae grows efficiently in this medium with DMSO, showing that it is not 
weakened in this medium. 
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8.3.2 LegHb as a CO scavenger for mechanistic studies 
A strong CO binding protein LegHb can significantly reduce the antibacterial effects of CO-RM 
L-75 when used in substoichiometric concentrations relative the amount of CO-RM. CO-RM L-
75 at a concentration of 100 µM is capable of releasing 200 µM CO; and only 22 µM LegHb is 
capable of reducing the antibacterial effect significantly. This suggests that only a small amount 
of CO is released in these experiments contributing to the suggestion that N. gonorrhoeae is 
sensitive to CO.  
CO-RM L-75 is also viable with RAW 264.7 macrophages and shows evidence of an anti-
inflammatory action in the presence of LPS and IFN-γ. This means that the CO-RM could be 
used for more than just antibacterial purposes. 
There are significant results showing that CO-RM L-75 is a promising potential therapeutic 
molecule, and this CO-RM should be taken in to further studies. This should include further 
mechanistic studies in to the source of antibacterial action without irradiation, and possible in 
vivo studies. 
 
8.4 Modifying CO-RMs using [3+2] Huisgen cycloaddition chemistry 
Previously prepared CO-RMs have been shown to possess excellent CO-releasing properties and 
in vitro biological activity. However, these CO-RMs have no means of targeting a specific 
location within a biological system making them potentially inefficient. It would be desirable if 
functionality could be a attached to a CO-RM, allowing it to accumulate in a particular organ. 
This means very low concentrations could be administered which would potentially reduce 
toxicity. The CO-RM could then accumulate in the desired organ where an infection was present.  
In this project, the phenyl pyridine manganese(I) lead complex has been functionalised with a 
terminal alkyne group allowing to be used as a substrate in azide-alkyne [3+2] cycloaddition 
chemistry (Scheme 39). 
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Scheme 39. Functionisable CO-RM 63 employed in [3+2] cycloaddition chemistry to introduce 
further functionality.  
Para-azidobenzoic acid was used as a substrate to functionalise CO-RM 63 to generate acid CO-
RM 65. This CO-RM is an extended analogue very similar to acid CO-RM 47 with its carboxylic 
acid functionality. While CO-RM 65 was initially synthesised to develop methodology, it 
releases CO efficiently and does not precipitate in aqueous solution. It is also viable with RAW 
264.7 cells up to a concentration of 50 µM. This analogue has the potential to be taken forward 
for further study and the extended structure may possess some interesting biological activity. 
Following success with para-azidobenzoic acid, CO-RM 63 was functionalised with an azide 
linked biotin compound (70) to generate a CO-RM with significant functionality and complexity 
(71). CO-RM 71 releases CO-efficiently, is viable with RAW 264.7 cells at its soluble 
concentrations ( up to 30 µM), and binds strongly with avidin. This makes it one of the first CO-
RMs designed to bind to a desired target. It has also been shown to release-CO while bound to its 
avidin target. This shows how this CO-RM system could be used to develop analogues which 
could localise in a particular biological location.  
The inspiration to use click chemistry to functionalise CO-RMs came from a paper by 
Schatzschneider and co-workers.61 In this work a manganese(I) CO-RM wass tagged with various 
peptides to create complex conjugates. While it has been shown that these peptide-CO-RM 
conjugates release-CO, it has not been shown that these conjugates can then be used for 
localisation. In this work biotin CO-RM 71 has been shown to release CO efficiently on 
irradiation and has been shown to bind strongly to its desired target. 
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8.5 Increasing the wavelength of light required to initiate CO-release 
Longer wavelengths of light penetrate further in tissue and the aim of this work was to prepare a 
new analogue which would absorb higher in the visible spectrum than previously obtained. This 
was achieved by preparing a CO-RM based on an azodye (Figure 168). 
 
Figure 168. Structure of an azodye-Mn(CO)4 complex synthesised in this project. 
While the pi-pi* transition that gives the compound an intense purple colour is not associated with 
CO-release, the CO-release from this complex can be initiated at a wavelength much higher than 
anything previously prepared. CO-RM S1 shows efficient CO release at 470 nm, which is one of 
the highest wavelengths of irriadiation used photo-CO-RM currently the literature.137 CO-RM 77 
shows efficient CO-release at 465 nm in a myoglobin assay. CO-RM 77 also shows the same 
spectral change in aqueous solution when irradiated 465, 525 and 590 nm light. The rates are 
different but the same type of change is observed, suggesting that this CO-RM also releases CO 
at these wavelengths. This is one of the most promising CO-RMs prepared to date, although yield 
of CO-RM 77 is poor and requires optimisation.  
The structural features in CO-RM 77 provide information about what kind of motif is required to 
increase the wavelength of light required to initiate CO-release. Development of further 
analogues based on this structure could yield CO-RMs which could release CO with red light. 
Red light penetrates deep into tissue significantly increasing the range of treatments that photo-
CO-RMs could be used for.  
To close discussions, this project has developed several new interesting pharmaceutical 
molecules, which have the potential to make it in to pre-clinical trials. The majority of the aims in 
this project have been achieved and further study with these CO-RMs has been justified. 
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9 Future work 
9.1 Initial phenylpyridine series 
It has been shown that bromo-CO-RM 40 can be functionalised with Suzuki-Buchwald 
chemistry. The substrate used may not be as biologically relevant as some of the work carried out 
later on this project, but the conditions work giving pure product in good yield (67%). There is 
potential for more biologically interesting molecules to be tagged on to initial CO-RM 40. The 
initial functionalisation reaction was carried out in toluene, and some modifications might be 
required to introduce more polar substrates.  
 
9.2 Future derivation of CO-RM 47 
CO-RM 47 has improved solubility and CO-releasing properties compared to the initial CO-RM 
series. As discussed previously the structure is promising and should go into initial in vivo 
studies. However it has no current means of localisation. Future work could focus on the 
development of a coupling system directly on to CO-RM using amide synthesis (Scheme 40). 
 
Scheme 40. Potential to use CO-RM 47 in further analogue (78) synthesis. 
Amide synthesis is well documented and there are a huge variety of coupling agents that could be 
used to carry out this reaction efficiently.140 This chemistry could allow endless functionality to 
be attached on to this molecule just like with the alkyne derivatives. This would allow for peptide 
targeting. Peptides which are known to bind strongly with target proteins could be used in the 
synthesised proposed in Scheme 40. This means that localisation of a peptide in a particular 
organ or type of tissue could be achieved. However great care must be taken in choosing peptides 
which do not illicit a potent immune response as this could cause serious inflammation. One 
could imagine using short sequences such as Thr-Phe-Ser-Asp-Leu which has already been 
conjugated to CO-RM 29 as shown in the literature.61 
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9.3 Future work with alkyne CO-RM 63 
Alkyne CO-RM 63 has been used in two reactions to create molecules tagged with desired 
substrates. This chemistry could be extended to tag in a wide variety of substrates including 
peptides as proposed for CO-RM 79. This could be achieved in a similar way to the way it was 
done to synthesis biotin CO-RM 71. A proposed synthesis could be as shown in Scheme 41  
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Scheme 41. Proposed synthesis for conjugating peptides with CO-RM 63 
Using this synthesis method, a library of peptide conjugates could be created. One may ask why 
would it be advantageous to have two different methods of making CO-RM conjugates? Well it 
may be possible that certain peptides are not compatible with one synthetic procedure but are 
with others. It may also be possible that the different structural motifs described with the same 
peptide may bind differently to their target. Having a several different synthetic routes to similar 
complexes would certainly be desirable. 
 
9.4 Future studies with Tryptophan based CO-RM L-75 
CO-RM L-75 is one of the most promising CO-RMs prepared in this project with exciting 
properties against three strains of bacteria, and viability with RAW 264.7 macrophages. For 
mechanistic purposes CO-RM L-75 is not fluorescent enough at the correct wavelength to be 
used in cell microscopy studies. This kind of studies could give large amounts of information 
including whether the CO-RM gets in to prokaryotic and eukaryotic cells, and where it is 
localised. This would required the development of second generation tryptophan CO-RMs. 
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Synthetic work by Fairlamb and co-workers uses palladium chemistry to prepare functionalised 
tryptophan derivatives (Scheme 42)141. 
 
Scheme 42. C–H activation chemistry used to functionalise protected L-tryptophan 
Using a palladium acetate catalyst system, it is possible to synthesise analogues of tryptophan 
substituted on the ortho-position of the indole. Several different boronic acids were used in this 
study to prepare a library of substituted tryptophan compounds. These analogues have a shifted 
λem of fluorescence to lower energy compared to unfunctionalised tryptophan. These derivates 
could be used to prepare a whole series of new CO-RMs based on CO-RM L-75, which could be 
fluorescent enough at the appropriate wavelength of excitation for confocal microscopy studies. 
Scheme 43 shows the proposed synthesis of these potential new analogues. 
 
Scheme 43. Proposed synthesis for new a new generation of Tryptophan based CO-RMs. 
The new CO-RMs in Scheme 43 could enable a wide variety of visual mechanistic studies to be 
undertaken to allow more to be understood about how these CO-RMs cause the potent 
antibacterial effects that they exhibit. Some detailed localisation studies could also be carried out 
in RAW 264.7 cells. This could be done by fluorescence studies using the proposed CO-RMs 
detailed in Scheme 43. It could also be performed using Raman imaging techniques carried out 
by Schatzschneider and co-workers.142 This may give more insight into why CO-RM L-75 has 
anti-inflammatory properties.  
As well as the mechanistic studies, CO-RM L-75 on its own is still a promising potential 
pharmaceutical molecule and further studies need to be carried out to get this molecule closer to 
clinical trials. CO-RM L-75 has not yet been tested for its vasodilatory properties where as CO-
RM S1, CO-RM F3, and ruthenium CO-RM-3 has been. Tests to see if CO-RM L-75 can relax 
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aortic rings like these other CO-RMs is important in terms of establishing what kind of 
applications CO-RM L-75 may have. As well as these initial studies in vivo viability tests need to 
be carried out, and if these are successful then discovering what conditions CO-RM L-75 could 
treat could truly commence. 
9.5 Future studies with dye related CO-RMs 
With dye CO-RM 77 exhibiting some very interesting and useful properties, further research into 
this azodyeMn(CO)4 motif is a high priority. The push-pull electronic pi-system within CO-RM 
77 is likely responsible for the interesting shift up of the M–CO absorption band. Performing 
DFT calculations on free ligand 76 and CO-RM 77 to find out how the electrons are distributed 
in this system could provide some useful information in terms of designing new analogues which 
release CO at an even higher wavelength could be obtained. One may also want to consider 
making a similar analogue of CO-RM 77 with fewer CO ligands in an attempt to reduce energy 
required to promote an electron from the t2g to the eg orbitals on the metal. This could lead to 
longer wavelength CO release at the sacrifice of releasing fewer CO molecules per CO-RM. 
The current synthesis of CO-RM 77 is poor due to thermal degradation during the synthesis. 
Future work could involve developing a new CO-RM with the azo dye functionality in pi-
conjugation with the main structure. This removes the need to heat the azo-dye in the synthesis, 
potentially preventing any degradation. A potential synthesis route is proposed in Scheme 44. 
 
Scheme 44. The proposed synthesis of a second generation dye CO-RM 82 inspired by azodye 
76 
Target molecule CO-RM 82 has a similar end structure to the dye used to make CO-RM 77. The 
benzothiazole unit has been replaced with CO-RM 81 which could be easily made using its 
corresponding commercially available ligand (80). This synthesis could create a new CO-RM 
262 
 
with high wavelength release and more interesting spectral properties. If the manganese unit in 
CO-RM 81 can survive the diazotisation conditions, the yields for this synthesis could be much 
higher compared to CO-RM 77. CO-RMs 47 and 65 are exposed to acidic work up conditions 
during their synthesis and both are isolated in high yield, suggesting that the manganese unit 
should be sufficiently stable to withstand the acidic conditions needed to carry out diazotisation.
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10 Experimental Section 
10.1 Chemistry general experimental details 
All reactions were carried out under a nitrogen atmosphere unless otherwise stated. Chemical 
reagents were purchased from Sigma Aldrich, Alfa Aesar or Frontier Scientific and used as 
received.  All dry solvents were obtained from a Pure Solv MD-7 solvent machine and were 
stored in ampoules under nitrogen until required. Ethers from this machine were deoxygenated by 
sonication with nitrogen bubbling for at least 30 mins. 
All TLC analysis was carried out using Merck 5554 silica plates and spots were visualised using 
UV light at 254 and 365 nm. Column chromatography was carried out using silica gel 60 
purchased from Sigma Aldrich. 
Solution 1H and 13C NMR analysis was carried out on Jeol ESC400/ESX400 and Bruker 
AV500/AV700 spectrometers. All chemical shifts in 1H NMR spectra are reported in ppm (δ) and 
are referenced to the residual NMR solvent (CDCl3: 7.26 ppm, DMSO-d6: 2.50 ppm, MeOD-d4: 
3.31 ppm, CD2Cl2: 5.32 ppm). The spectra were processed in MNova software. All chemical 
shifts in 13C NMR spectra are reported in ppm (δ) and are referenced to the NMR solvent. 
(CDCl3: 77.36 ppm, DMSO-d6: 39.52 ppm, MeOD-d4: 49.00 ppm, CD2Cl2: 53.49 ppm). For the 
13C NMR of some of the tetracarbonyl manganese(I) complexes, the metal carbonyl peaks were 
not observed due to long relaxation time in the solvent used. IR spectroscopy confirms the 
presence of these metal carbonyls. 
Mass spectrometry was carried out using a Bruker microTOF instrument. All data were acquired 
in positive ion mode using ESI or LIFDI ionisation. High resolution ESI spectrometry data is 
reported with less than 5 ppm error unless otherwise stated. All LIFDI data reported is within 120 
ppm error. 
ESI-MS degradation studies of CO-RMs 47, 75 and 77 were performed in 50:50 (v/v) 
CH3CN/H2O or CH2Cl2 at a concentration of 0.5 mg ml−1. The solution was passed through 
cotton wool each time a sample was required, a 100 µl aliquot was taken and diluted by 10-fold. 
In the experiments 4 µl injections of the diluted solution were used for all measurements. After 
obtaining an initial spectrum the sample was irradiated for one minute and a spectrum was taken 
between each irradiation. Varying capillary exit and skimmer voltages are used to optimise the 
experiment depending on the CO-RM used. This variation can reduce the amount of molecular 
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ion fragmentation making it easier to detect products of irradiation. Irradiation was carried out 
using either a 400 or 465 nm LED (2.4 W power).  
 
Melting points of all complexes and ligands were obtained on a Perkin Elmer DSC 7 machine. 
Experiments were run using a ramp rate of 10 °C min−1 to above the required melting 
temperature. The melting point was taken as the onset of the observed endothermic peak. The 
machine was calibrated using an indium standard. 
IR spectroscopy was carried out on a Thermo-Nicolet Avatar-370 FT-IR spectrometer. Spectra 
were taken in either solid state (KBr disc), or in solution. 
UV-Visible spectroscopy for the myoglobin assay and molar absorption coefficient determination 
was carried out on a JASCO V-560 spectrometer using PMMA cuvettes of pathlength 10 mm A 
baseline in the required solvent was carried out prior to starting an assay. Photo-initiated carbon 
monoxide release was carried out using a 5 W 400 nm LED directly above the solution. 
[α] measurements were carried out on a JASCO DIP-370 digital polarimeter using a 
concentration of 10 g L−1 using a cell of path length 100 mm. DMSO was used as solvent and 
was used for a background measurement. 
CD measurements were carried out using a JASCO J-810 polarimeter using a concentration of 
6×10−4 mol dm−3
 
using a quartz cell of path length 1 mm. DMSO was used as solvent for all 
measurements including backgrounds. 4 scans were taken between 280 and 550 nm for each 
sample.  
Fluorescence emission measurements for CO-RM L-75 were carried out on a Shimadzu RF-
5301PC Spectrofluorophotometer in 95:5 (v/v) H2O/DMSO using two-fold dilutions starting from 
c = 1.3×10−6 mol dm−3 using a quartz cell of path length 10 mm. 
The decomposition of CO-RMs in solution were followed using a Mettler Toledo React IR™ 
iC10 IR spectrometer with a silicon probe. IR spectra are taken in real-time every 60 seconds and 
complex irradiation was performed using either a 365 nm 4 W TLC lamp, a 400 nm 5W LED or 
465 nm 5 W LED set to power consumption level of 2.4W. 
Elemental analysis was carried using an Exeter Analytical CE-440 Elemental Analyser. 
Elemental analysis was not performed on all compounds. In some cases this was due to limited 
amounts of final compound (such as dye 77). In other cases some intermediate compounds in a 
synthetic route were not analysed, however the important final compound in a series was 
analysed and purity was demonstrated. Compounds not analysed using this technique show good 
purity by 1H NMR and were successfully used to prepare further compounds.  
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10.1.1 Further general details on measurements 
10.1.1.1 1H NMR details 
1H NMR chemical shift data are reported to two decimal places. 1H NMR coupling constant data 
are reported to one decimal place with rounding to the nearest 0.5 Hz in cases where there is 
small error in the coupling constant. Coupling between peaks in these cases have been confirmed 
to show coupling by 1H COSY correlation NMR experiments. 
10.1.1.2 Myoglobin assay error analysis 
Following four point correction in the myoglobin assay detailed in sections 3.2 and 10.3, the error 
in the myoglobin assay is calculated at 2 nm intervals from 510 nm to 586 nm. The errors are 
calculated from the difference of the myoglobin assay spectra are compared to their calculated 
spectra. The calculated UV-Vis spectra are based on percentage combinations of reference deoxy 
and carboxy-Mb taken prior to starting an assay. The percentage combinations of the reference 
spectra depends on the conversion of deoxy-Mb to carboxy-Mb during an experiment. Increased 
conversion to carboxy-Mb requires a larger contribution in the calculations from the carboxy-Mb 
reference spectrum. These reference spectra are always recorded again when a new assay is 
performed to account for variations in the UV-Vis spectra over time. The error can be expressed 
at a particular wavelength by calculating the ratio between the calculated error and the 
absorbance of the measurement at this wavelength. All myoglobin assays in this work does not 
have an error at a particular wavelength above 4% representing a close match between the 
reference and experimental data. 
10.1.1.3 Details on RAW 264.7 cell assays 
Errors in both the Alamar Blue and LDH assays detailed in section 10.5.1 are calculated from the 
triplicate measurements carried out for each variable. The standard deviation for each variable is 
calculated and expressed as a percentage ± from the mean average value. It is expressed as a 
percentage because the viability and LDH released are also expressed in this way, so values with 
appropriate error bars can be represented graphically. 
 
10.1.1.4 Details on bacterial cell assays 
Where possible, errors are calculated from the triplicate measurements carried out for each 
variable. Errors are represented as ± standard deviation from the mean average value. It was 
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impractical to carry out three triplicate measurements on the same day due to the sensitivity of 
the bacteria. Due to variation in bacteria between batches this was not always possible in these 
cases. Therefore three repeat experiments were carried out on separate days and these could then 
be used in triplicate analysis in most cases. Due to how bacteria can vary between batches, this 
was not always possible in these cases each repeat experiment was analysed separately and 
conclusions were drawn from the three repeats as a whole. 
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10.2 New irradiation system 
A new method of carrying out photochemical reactions and assays has been developed at the 
chemistry department at the University of York. An LED has been mounted on a special plastic 
cap that fits over the top of a PMMA cuvette (Figure 169). 
 
Figure 169. An LED mounted on a special plastic cap fitted in to a PMMA cuvette. 
This LED is connected to the control unit shown in Figure 170 and the functions are shown in 
Table 32. 
 
Figure 170. Control unit for the irradiation system 
  
       1                    2       3               4                 5                6 
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Table 32. Functions of different switches on the irradiation system shown in Figure 170. 
Number Name/Brief function 
1 Current Monitor - Measures power that the LED is drawing in milliamps 
2 Dimmer Switch - Turn to increase or decrease power 
3 Start/Hold button, Up = hold (time will not count), Down = Start/Reset 
counter 
4 Mode inverter- Can be used to change off/on modes 
5 Timer display : Left two digits = Mins, Right two digits = Seconds 
6 Timer controls – can be used to change how long the LEDs come on and 
off for 
 
This irradiation system allows light intensity to be varied. It also allows for automated on and off 
cycles to be programmed into the system making it possible to automate experiments. This 
system ensures that consistent irradiation of a well defined wavelength is produced for the 
desired experiments. 
10.3 Experimental procedure for the myoglobin assay 
Lyophilised equine heart myoglobin (11 mg, purchased from Sigma Aldrich), was dissolved in 
10 ml of 0.01 M PBS buffer solution (pH 7.4) to give an absorbance of approx.0.7 at 550 nm. 
This mass of myoglobin will give a solution with an approximate myoglobin concentration of 50 
µm depending on the myoglobin batch. Sonication for five minutes will usually give full 
myoglobin dissolution. The solution was filtered through cotton wool to ensure optical clarity. 1 
ml of myoglobin solution was added to a PMMA 1 ml UV cuvette and approx. 1 mg of sodium 
dithionite was added. The solution was mixed with a micropipette twice. The UV spectrum of the 
deoxy-Mb solution was then obtained. CO gas was bubbled through the 1 ml of solution for 15 
seconds. The Mb-CO UV spectrum was then obtained. These were used as reference spectra for 
determining the Mb-CO concentrations at intermediate mixtures of deoxy/carboxy-Mb. 
A new 1 ml cuvette containing 1 ml of myoglobin stock solution was then prepared and 
incubated at 37 °C ready for the assay. 1 mg of CO-RM was dissolved in 100 µl of DMSO. Using 
the CO-RM stock solution, 100 µl of a second stock solution was prepared. The second stock 
solution is 200 times the concentration required in actual assay (e.g 8 mM for a 40 µM assay). 
Sodium dithionite (approx. 1 mg) was added to the new 1 ml myoglobin cuvette and the solution 
was mixed twice.  
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Immediately after this, 5 µl of the secondary CO-RM stock solution was added to the new deoxy-
Mb solution giving final CO-RM concentrations of 10, 20, 40 and 50 µM as required. The 
solution was mixed again twice and the solution was layered with light mineral oil (500 µl) to 
prevent CO escape. The assay was then started immediately. UV spectra were acquired every five 
minutes and irradiation was used when required but not when the spectrometer was scanning. 
The sample was irradiated from above at 400 or 465 nm for typically for two or three minutes 
every five minute period. The assay was not carried out for longer than 2.5 hours due to potential 
myoglobin degradation. 
10.3.1 Standard data treatment for the myoglobin assay 
Deoxy-Mb contains an absorption maximum at 560 nm. As CO is released from the administered 
CO-RM, the absorption maximum at 560 nm decreases and two new peaks at 540 nm and 578 
nm arise in the spectra. These new peaks come from Mb-CO. The total concentration of 
myoglobin in the stock solution prepared is calculated from the maximum absorption peak at 540 
nm in the saturated Mb-CO solution. Equation 1 shows how this is calculated.143 
Mb-CO = (OD/	ε) 	× 	1000 
Equation 1. Calculating the total myoglobin concentration for an assay stock solution. ε = 
extinction co-efficient of Mb-CO= 15.4 mM cm−1, OD540 = Absorbance of saturated Mb-CO 
solution at 540nm. 
The calculation of Mb-CO concentrations throughout the assay are also calculated from the 
OD540. A second coefficient (ε2) is required for these experiments as there are two species 
absorbing in solution, deoxy-Mb and Mb-CO. This coefficient takes in to account the change in 
absorbance at 540nm (∆OD540). This calculation also requires a second wavelength. This is used 
as a reference point to increase the accuracy of the calculations. The UV-Visible spectra of 
deoxy-Mb and Mb-CO share four isosbestic points (ODiso) at 510, 550, 570, and 585 nm. The 
isosbestic point at 510 nm was used as the reference point to calculate the coefficient ε2. This was 
done using Equation 2. 
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 =
ΔOD −	ΔOD × 1000
Mb⎻CO
 
Equation 2. Calculating the second Mb-CO extinction coefficient(ε2).∆ODiso510 = Change in 
absorbance at the 510 nm isosbestic point, ∆OD540 = change in absorbance at 540 nm. Mb-COmax 
= maximum concentration of myoglobin. ε2 = new extinction coefficient. 
Using the new extinction coefficient, the concentration of myoglobin in an unknown sample can 
be calculated. This is done using Equation 3. 
Mb-CO =
(ΔOD −	ΔOD)
ε
	× 	1000 
Equation 3. Calculating the unknown Mb-CO concentration in a sample. ∆OD540 = change in 
absorbance at 540 nm, ∆ODiso510 = Change in absorbance at the 510 nm isosbestic point, ε2 = new 
absorption coefficient. 
10.3.2 Myoglobin assay correction using non-linear regression. 
The data treatment for myoglobin assay data detailed in section 9.3.1 is only sufficient for CO-
RMs that do not absorb in the 500-600 nm region of the UV-vis spectrum, and also for CO-RMs 
which precipitate to any extent causing turbidity. The majority of the absorbance due to turbidity 
can be accounted for by the correction at 510 nm; however it does not account for the difference 
in light scattering across the 500-600 nm region. A procedure developed by Fairlamb and co-
workers was developed to account for this turbidity/CO-RM absorbance.94 This procedure can 
also be used to account for other minor differences between the reference spectra and the spectra 
measured during the assay. 
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10.4 Chemical synthesis 
10.4.1 Synthetic procedures for small phenyl pyridine ligands 
General procedure 1 - synthesis of 2-(4-bromophenyl)pyridine (34)  
 
This synthesis is based on a modified literature procedure93, 144 
In a nitrogen atmosphere glove box, to an oven dried Schlenk tube equipped with a magnetic 
stirrer bar was added Pd(PPh3)4 (0.02 eq., 0.033 mmol, 38.3 mg). The Schlenk tube was removed 
from the glove box and was attached to a Schlenk line. Under a high flow of nitrogen was added 
4-bromobenzene boronic acid (1.5 eq., 1.66 mmol, 502 mg), followed by 2-bromopyridine (1 eq., 
2.5 mmol, 158 µl/260 mg). 1.9 M Na2CO3 (aq) (6 ml) and THF (9 ml) was then added via syringe. 
The reaction was heated to 60 °C for 64 h. The reaction was allowed to cool and deionised water 
(40 ml) was added. The product was extracted with dichloromethane (3 × 40 ml), dried with 
MgSO4 and filtered. The solvent was removed under reduced pressure to yield crude product. 
The crude product was purified using silica gel column chromatography using 90:10 PET 
ether/ethyl acetate as eluent. The solvent was removed under reduced pressure to give a 
crystalline, slightly off white solid (231 mg, 59% Yield). 
MP (DSC): 64 °C ; 1H NMR (400 MHz, CDCl3) δ 8.69 (dd, J = 4.8, 1.0 Hz, 1H), 7.88 (d, J = 8.3 
Hz, 2H), 7.76 (apr.td, 1H), 7.70 (dd, J = 8.0, 1.0 Hz, 1H), 7.60 (d, J = 8.3 Hz, 2H), 7.28–7.23 (m, 
1H (under ref. Peak)); 13C NMR (100 MHz, CDCl3) δ 156.6, 150.1, 138.5, 137.2, 132.2, 128.8, 
123.8, 122.8, 120.7; Elemental Analysis (CHN) C : 56.15% H: 3.49% N: 5.77% (calc.: C: 
56.44% H: 3.34 %N: 5.98%); ESI-MS m/z = 233.9917 [M+H]+ (calc. for C11NH9Br = 233.9913); 
IR (Pressed KBr disc) : 1581, 1556, 1458, 1426, 1389, 1147, 1095, 1066, 1001, 833, 772, 625, 
539, 453 cm−1. 
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Synthesis of 2-(4-Fluorophenyl)pyridine (32) 
 
This synthesis is based on a modified literature procedure93, 144 
32 was synthesised using general procedure 1 (see synthesis of 34) using ABcat (0.007 eq., 11.6 
µMoles, 12.2 mg), 4-fluorobenzene boronic acid (1.5 eq., 2.5 mmol, 502 mg). The product was 
isolated as a slightly off white solid (226 mg, 79% Yield).  
MP(DSC): 42 °C ;1H NMR (400MHz, CDCl3) δ 8.67 (ddd, J = 4.8 Hz, 1.7 Hz, 1.0 Hz, 1H), 7.98 
(dd, J = 9.0 Hz, 5.4 Hz, 2H), 7.74 (apr. td, 1H) , 7.67 (dt, J = 8.0 Hz, 1.0 Hz, 1H), 7.22 (ddd, J = 
8.3, 4.8, 1.0 Hz, 1H), 7.15 (apr. t, J = 9.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 165.0, 162.6, 
156.7, 150.0, 137.1, 135.9, 135.8, 129.0, 128.9, 122.3, 121.1, 116.0, 115.9; Elemental Analysis 
(CHN) C: 76.79% H: 4.71% N: 7.95%(Calculated : C: 76.29% H: 4.66% N: 8.09%) ESI-MS m/z 
= 174.0717 [M+H]+ (calc. for C11NH9F = 174.0713).  
Synthesis of 2-(4-chlorophenyl)pyridine (33) 
 
This synthesis is based on a modified literature procedure93, 144 
33 was synthesised using general procedure 1, but using 4-chlorobenzene boronic acid (1.5 eq., 
2.5 mmol, 378 mg) and 2.0 M K2CO3(aq) (6 ml). The product was isolated as a crystalline, slightly 
off white solid (261 mg, 83% Yield). 
MP(DSC): 51°C ; 1H NMR (400 MHz, CDCl3) δ 8.69 (dd, J = 4.6, 0.7 Hz, 1H), 7.94 (d, J = 8.5 
Hz, 2H), 7.76 (apr. td, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 8.5 Hz, 2H), 7.27−7.22 (m, 1H 
(under ref. peak)); 13C NMR (100 MHz, CDCl3) δ 156.6, 150.1, 138.1, 137.2, 135.4, 129.3, 
273 
 
128.5, 122.8, 120.7;  Elemental Analysis (CHN) C: 69.19% H: 4.30% N: 7.18%(calc.: C: 69.67% 
H: 4.25% N: 7.39%) ESI-MS m/z = 190.0422 [M+H]+ (calc. for C11NH9Cl = 190.0418); IR 
(Pressed KBr disc): 1585, 1565, 1491, 1462, 1433, 1397, 1153, 1087, 1009, 985, 847, 829, 773, 
734, 702, 676, 633, 613, 541, 491, 452 cm−1. 
Synthesis of 2-(4-biphenyl)pyridine (35) 93, 144 
 
35 was synthesised using general procedure 1 (1.66 mmol, 2-bromopyridine) but using biphenyl 
boronic acid (1.2 eq., 1.99 mmol, 331 mg). The product was isolated as a white solid (226 mg, 
59% Yield). 
MP(DSC):
 
144 °C;
 
1H NMR (400 MHz, CDCl3) δ 8.72 (dt, J = 4.7, 1.1 Hz, 1H), 8.09 (d, J = 8.5 
Hz, 2H), 7.81–7.75 (m, 2H), 7.72 (d, J = 8.5 Hz, 2H), 7.67 (d, J = 8.0 Hz, 2H), 7.47 (t, J = 8.0 
Hz, 2H), 7.37 (apr. t, J = 7.3 Hz, 1H), 7.26–7.22 (m, 1H (under ref. peak)); 13C NMR (100 MHz, 
CDCl3) δ 157.4, 150.1, 142.1, 141.0, 138.7, 137.1 129.2, 127.9, 127.8, 127.6, 127.5, 122.5, 
120.9; Elemental Analysis (CHN): C: 87.84% H: 5.75% N: 5.92% (calc. C: 88.28% H: 5.67% N: 
6.06%) ESI-MS m/z = 232.1122 [M+H]+ (calc. for C17NH14= 232.1120); IR (Pressed KBr disc): 
1603, 1595, 1584, 1570, 1556, 1487, 1464, 1448, 1430, 1400, 1296, 1181, 1149, 1058, 1035, 
1003, 983, 906, 847, 786, 752, 711, 687, 644, 625, 608, 452 cm−1. 
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10.4.2 Synthesis of short phenyl pyridine complexes and (Bn)Mn(CO)5 
Synthesis of Benzyl pentacarbonyl manganese(I)(42)
 
145
 
 
To an oven-dried Shlenk tube equipped with a magnetic stirrer under nitrogen was added 
mercury (3 cm3). Sodium metal (4 eq, 1.07 mmol, 246 mg) was added in small pieces with high 
stirring to allow dissolution. In a separate Schlenk tube under nitrogen was added Mn2(CO)10 (1 
eq., 2.68 mmol, 1.04 g), followed by anhydrous, deoxygenated THF (40 ml). The THF solution 
was then transferred by cannula on to the sodium amalgam and was stirred for 3 hours. In a 
separate Schlenk tube equipped with a magnetic stirrer under nitrogen was added benzyl chloride 
(2 eq., 5.36 mmol, 617 µl / 678 mg). The Schlenk tube containing benzyl chloride was placed in a 
bath of ice and water and was put under vacuum with stirring for 60 seconds. At ambient 
temperature, the THF solution of NaMn(CO)5 was transferred by cannula into the benzyl 
chloride. The mixture was stirred at ambient temperature (20 °C) for 20 h. The solution was then 
filtered through a bed of Celite™ and was washed with diethyl ether (5 × 20 ml). The contents 
were then loaded on to silica gel and this was added on to a pad of silica (5 cm). The pad was 
washed with petroleum ether (3 × 40 ml). The solvent was removed to yield product 
contaminated with benzyl chloride. Benzyl chloride was removed at 35 °C under vacuum. The 
product must be broken up periodically with a spatula and put back under vacuum. A slightly 
yellow crystalline product was obtained. (1.179 g, 76% yield). 
MP (DSC): 40 °C; 1H NMR (400 MHz, CDCl3); δ 7.18 (m, 4H), 6.97(m, 1H), 2.41 (s, 2H). IR 
(solution THF): 2107, 2047, 2009, 1987 cm-1; ESI-MS m/z: 286.9748 [M+H]+ (Calculated for 
MnO5C12H8: 286.9747). 
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General procedure 2 Synthesis of Tetracarbonyl (2-(phenyl κ,C2pyridine-κ,N)manganese(I) 
(37)146-147 
 
To an oven dried Schlenk tube equipped with a magnetic flea under nitrogen was added 2-
phenylpyridine (1 eq., 1 mmol, 143 µl/ 155 mg), BnMn(CO)5 (1 eq., 1 mmol, 286 mg) followed 
by dry deoxygenated hexane (16 ml). The mixture was heated with stirring for 6 h. The reaction 
mixture was allowed to cool to ambient temperature. The hexane solution was filtered through a 
pipette packed with cotton wool and removal of solvent under reduced pressure yielded a pure 
yellow crystalline solid (284 mg, 88% Yield). 
MP(DSC) : 114 °C; 1H NMR (400 MHz, CDCl3) δ 8.72 (d, J = 5.5 Hz, 1H), 7.97 (d, J = 7.5 Hz, 
1H), 7.87 (d, J = 8.1 Hz, 1H), 7.81–7.74 (m, 2H), 7.28 (td, J = 7.5, 1.0 Hz, 1H), 7.17 (td J = 7.5, 
1.5 Hz, 1H), 7.11 (ddd, J =7.5, 5.5, 1.5 Hz, 1H): 13C NMR (100 MHz, CDCl3) δ 174.9, 166.4, 
153.9, 146.2, 141.7, 137.9, 130.3 124.2, 124.0, 122.4, 119.3. Elemental Analysis (CHN): C: 
56.65% H: 2.98% N: 4.06% (calc.: C: 56.10% H: 2.51% N: 4.36% LIFDI-MS m/z = 321.0202 
[M]+ (calc. for MnC15H8NO4 = 320.9834). IR (Solution: THF) : 2071, 1986, 1972, 1928, 1600, 
1576, 1477 cm −1. 
Synthesis of Tetracarbonyl (2-(4-fluorophenyl)κ,C2-pyridine-κ,N)Manganese(I) (38) 
 
Using the details from general procedure 2, BnMn(CO)5 (1 eq., 0.5 mmol, 143 mg), 2-(4-fluoro-
phen-4-yl)pyridine (1 eq., 0.5 mmol, 86.5 mg) and hexane (8 ml) were used to prepare complex 
38. After 6 h, the reaction mixture was allowed to cool to ambient temperature. CH2Cl2 (10 ml) 
was added to dissolve the yellow precipitate. The mixture was filtered through cotton wool and 
solvent was removed under reduced pressure to yield product containing 20% starting material 
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(32). The impure product was reacted with more BnMn(CO)5 (0.2 eq.) at 75 °C in hexane for six 
hours. Addition of dichloromethane and filtration as previously mentioned yielded a pure yellow 
solid (74 mg, 43% Yield). 
MP(DSC): 163 °C; 1H NMR (400 MHz, CDCl3) δ 8.69 (dt, J = 5.6, 1.2 Hz 1H), 7.87−7.78 (m, 
2H), 7.75 (dd, J = 8.5, 5.1 Hz, 1H), 7.68 (dd, J = 8.5, 2.5 Hz, 1H), 7.06-7.15 (m, 1H), 6.84 (td, J 
= 8.5, 2.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 179.6, 165.7, 165.3, 162.7, 154.2, 142.4, 
138.3, 127.5, 127.3, 125.7, 125.6, 122.5, 119.5, 111.8, 111.6 ; Elemental Analysis (CHN) C: 
52.94% H: 2.21% N: 3.98% (Calculated: C: 53.12% H: 2.08% N: 4.13%)  ESI-MS m/z = 
339.9827 [M+H]+ (calc. for MnC15H8FNO4= 339.9812). IR (Solution: THF): 2075, 1993, 1977, 
1936, 1605, 1587, 1571, 1558, 1480, 1464, 1431, 1315, 1262, 1192 cm−1. 
Synthesis of Tetracarbonyl (2-(4-chlorophenyl)κ,C2pyridine-κ,N)manganese(I) (39) 
N
+
Mn(CO)5
1 eq.1 eq.
Mn(CO)4
N
Hexane
75 °C, 6 h, Under N2
Cl Cl
39, 83% Yield
 
Using the details from general procedure 2, BnMn(CO)5 (1 eq., 0.25 mmol, 72 mg), 2-(4-chloro-
phenyl)pyridine (1 eq., 0.25 mmol, 50 mg) and hexane (4 ml) were used to prepare complex 39. 
At the end of the reaction, the reaction mixture was allowed to cool to ambient temperature. 
Dichloromethane (5 ml) was added to the mixture to dissolve the yellow precipitate. The solution 
was filtered through cotton wool packed in a pipette. Removal of solvent under reduced pressure 
gave pure product (82 mg, 83% Yield). 
MP (DSC): 161 °C; 1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 4.3 Hz, 1H), 7.93 (s, 1H), 7.85-
7.78 (m, 2H), 7.68(d, J = 8.0 Hz, 1H), 7.15 (d, J = 6.5 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 
178.2, 165.7, 154.2, 144.7, 140.7, 138.4, 136.8, 125.1, 124.6, 122.9, 119.7. Elemental Analysis 
(CHN) C: 50.53% H: 2.11% N: 3.72% (calc.: C: 50.66% H: 1.98% N: 3.94%)  LIFDI-MS m/z = 
354.9831 [M]+ (calc. for MnC15H7ClNO4= 354.9444). IR (Solution: THF): 2077, 1993, 1978, 
1936, 1605, 1567, 1543, 1478, 1424 cm−1. 
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Synthesis of Tetracarbonyl (2-(4-bromophenyl)κ,C2pyridine-κ,N)manganeseI (40) 
 
Using the details from general procedure 2, BnMn(CO)5 (1 eq, 0.75 mmol, 215 mg), 2-(4-bromo-
phenyl)pyridine (1 eq., 0.75 mmol, 176 mg) and hexane (12 ml) were used to prepare complex 
40. At the end of the reaction, the Schlenk tube was stored at −18 °C overnight. The product had 
precipitated out of solution and the hexane solution was removed with a pipette. The 
yellow/brown solid product was then dried under reduced pressure. (217 mg, 72% Yield). 
MP (DSC): 208 °C; 1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 5.6 Hz, 1H), 8.09 (d, J = 1.9 Hz, 
1H), 7.88-7.78 (m, 2H), 7.61 (d, J = 8.5 Hz, 1H), 7.31 (dd, J = 8.5, 2.0 Hz, 1H), 7.15 (d, J = 6.7, 
2.1 Hz, 1H); 13C NMR (126 MHz CDCl3) δ 219.5, 214.0, 213.2, 178.6, 165.6, 154.0, 144.8, 
143.3, 138.1, 127.2, 126.1, 125.1, 122.8, 119.5. Elemental Analysis (CHN) C: 44.97% H: 1.75% 
N: 3.39% (calc.: C: 45.03% H: 1.76% N: 3.50%); ESI-MS m/z = 399.9017 [M+H]+ (calc. for 
MnC15H8BrNO4= 399.9012). IR (Solution : THF ) : 2075, 1992, 1977, 1936, 1259 cm −1. 
Synthesis of Tetracarbonyl (2-(biphenyl)κ,C2pyridine-κ,N)manganeseI (41) 
 
 
Using the details from general procedure 2, BnMn(CO)5 (1 eq., 0.5 mmol, 143 mg), 2-
(biphenyl)pyridine (1 eq., 0.5 mmol, 116 mg) and hexane (8 ml) were used to prepare 41. At the 
end of the reaction, the reaction mixture was allowed to cool to ambient temperature. CH2Cl2 (10 
ml) was added to the mixture to dissolve the yellow precipitate. The solution was filtered through 
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cotton wool packed in a pipette. Removal of solvent under reduced pressure gave pure product as 
an off white solid (144 mg, 72% Yield). 
MP(DSC): 138 °C; 1H NMR (400 MHz, CDCl3) δ 8.74 (d, J = 6.0, 1.7, 1.0 Hz, 1H), 8.21 (d, J = 
1.8 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.83-7.77 (m, 1H), 7.77-7.70 (m, 
2H), 7.48 (t, J = 7.6 Hz, 2H), 7.42 (dd, J = 8.0, 1.8 Hz, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.13 (ddd, J 
= 7.5, 6.0, 1.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 175.6, 166.4, 154.2, 154.6, 142.8, 141.7, 
140.2, 138.2, 129.1, 127.8, 127.7, 124.6, 123.6, 122.6, 119.7; Elemental Analysis (CHN) C: 
63.61 % H: 3.44 % N: 3.39 % (calc.: C: 63.49% H: 3.04% N: 3.53%); LIFDI-MS m/z = 397.0349 
[M]+ (calc. for MnC21H12NO4= 397.0147). IR (Solution: THF): 2073, 1989, 1974, 1932, 1602, 
1582, 1562, 1477, 1475 cm−1. 
Alternative synthesis of complex 41 via a palladium-mediated cross-coupling reaction 
Ph
N
PhB(OH)2 (1.5 eq.)
Pd(OAc)2 (1 mol%)
Xphos (2 mol%)
K3PO4 2 eq.
Toluene
50 °C, 20 h
41, 67% Yield
Mn(CO)4
Br
N
Mn(CO)4
 
This synthesis is based on a modified literature procedure.98 
To a dry Schlenk tube equipped with a magnetic stirrer bar was added complex 40 (1 eq., 125 
µMol, 50 mg), phenyl boronic acid (1.5 eq., 187.5 µMol, 23 mg) and K3PO4 (2 eq., 250 µMol, 34 
mg). The Schlenk tube was evacuated and backfilled with N2 three times. To a second Schlenk 
tube under N2 was added Pd(OAc)2 (5 mg) and Xphos (21.2 mg). Dry, degassed THF (1 ml) was 
added to the second Schlenk tube to prepare a red stock solution of catalyst/ligand, stirring is 
required for at least one minute to ensure dissolution. Dry degassed toluene (1 ml) was added to 
the Schlenk tube and the contents were stirred for 5 minutes at ambient temperature. Catalyst 
stock solution (60 µl) giving Pd(OAc)2 (1 mol%, 0.3 mg) and Xphos (2 mol%, 1.2 mg) was 
added via syringe to the  reaction Schlenk tube. The reaction mixture was then heated to 50 °C 
with vigorous stirring in the dark for 20 h. The reaction was quenched by cooling to ambient 
temperature. This was then filtered through a pipette packed with Celite™ and subsequently 
filtered through a silica plug in a pipette eluting with toluene collecting small fractions. Solvent 
was then removed under reduced pressure to give crude product. The crude mixture was purified 
by silica gel column chromatography. It was loaded on to silica using CH2Cl2, and then was 
charged on to a column packed with 5% EtOAc: petroleum ether. The product was eluted by 
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switching to 10% and finally 15% (v/v) EtOAc:Pet ether. Removal of column solvent under 
reduced pressure gave product 41 as an off white solid (32 mg, 67% yield). 
10.4.3 Synthesis of polar phenylpyridine ligands 
Synthesis of 2(4-hydroxyphenyl)pyridine (43) . General procedure 3 
N
OH
OH
B(OH)2
N
Br
1 eq. 1.5 eq.
Pd(OAc)2 (0.5 mol%)
K3PO4 (2 eq.)
Ethylene glycol
30 min. 80 °C
Under Air
43, 80% Yield
 
This compound was synthesised using a modified literature procedure.92 
To a 250 ml round bottomed flask equipped with a magnetic stirrer was added Pd(OAc)2 (0.005 
eq., 50 µMol, 11.2 mg), 4-hydroxybenzeneboronic acid (1.5 eq., 15 mmol, 505 mg), potassium 
tri-phosphate (2 eq., 20 mmol, 4.24 g), 2-bromopyridine (1 eq., 10 mmol, 950 µl/1.58 g), and 
ethylene glycol (60 ml). The reaction was heated to 80 °C for 30 minutes and was allowed to cool 
to room temperature. Water (75 ml) and saturated brine (75 ml) were added and the aqueous 
layer was extracted with dichloromethane (4 × 100 ml). The organic layers were combined and 
dried with MgSO4 and filtered. Solvent was removed under reduced pressure to yield the crude 
product. The crude product was purified by silica gel column chromatography (40:60 v/v PET 
ether/ethyl acetate followed by 50:50 (v/v) petroleum ether/ethyl acetate). The solvent was 
removed to isolate the title compound as a white solid (1.37 g, 80% yield). 
M.P. (DSC): 164 °C; 1H NMR (400 MHz, CDCl3) δ 8.62 (ddd, J = 5.0, 1.8, 1.0 Hz, 1H), 7.79–
7.71 (m, 3H), 7.65 (d, J = 8.0 Hz, 1H), 7.21 (dd, J = 7.4, 5.0 Hz, 1H), 6.80 (d, J = 8.5 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ 158.2, 157.9, 149.2, 137.7, 130.8, 128.9, 121.9, 121.1, 116.2; 
Elemental Analysis (CHN) C: 76.85% H: 5.31% N: 8.04% (calc.: C: 76.17% H: 5.30% N: 
8.18%);  ESI-MS m/z = 172.0755 [MH]+ (calc. for C11H10NO= 172.0762); IR (KBr disc): 3367–
2120, 1603, 1560, 1523, 1470, 1425, 1381, 1273, 1245, 1183, 1153, 1097, 998, 966, 839, 778, 
744, 714, 646, 623, 580, 552, 492, 473 cm−1. Note: OH peak was not observed in the 1H NMR 
spectrum, but is clearly observed in the IR spectrum. 
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Synthesis of methyl [4-(pyridin-2-yl)phenoxy]acetate (44). 
 
This synthesis was based on a modified literature procedure99. 
To a thick walled round bottomed flask equipped with a magnetic stirrer was added 2-(4-
hydroxy-phenyl)pyridine (1 eq., 5.84 mmol, 1.00 g), potassium carbonate (1.5 eq., 8.76 mmol, 
1.21 g) and chloro-methylacetate (1.2 eq., 7.01 mmol, 760 mg/615 µl). Acetone (50 ml) was 
added and the flask was sealed with a screw lid. The mixture was the heated to 80 °C for 20 h. 
The reaction mixture was allowed to cool to room temperature and deionised water was added 
(60 ml). The aqueous layer was extracted with dichloromethane (3 × 60 ml) and the organic layer 
was dried with MgSO4 and filtered. Removal of solvent under reduced pressure yielded pure 
product as an off white solid (1.30 g, 92% yield). 
M.P.(DSC): 95 °C ; 1H NMR (400 MHz, CDCl3) δ 8.64 (ddd, J = 4.8, 1.7 Hz, 1.0 Hz, 1H), 7.94 
(d, J = 9.0 Hz, 2H), 7.71 (dd, J = 8.0, 1.7 Hz, 1H), 7.65 (apr. dt, 1H), 7.17 (ddd, J = 7.2, 4.8, 1.0 
Hz, 1H), 6.99 (d, J = 9.0 Hz, 2H), 4.69 (s, 2H), 3.81 (s, 3H);13C NMR (100 MHz, CDCl3) δ 
169.6, 158.9, 157.2, 149.9, 137.1, 133.5, 128.6, 122.0, 120.2, 115.1, 65.7, 52.7;  ESI-MS m/z = 
244.0971 [M+H]+ (calc. for C14H14NO3 = 244.0974); IR (Pressed KBr disc): 1757, 1601, 1587, 
1561, 1512, 1467, 1435, 1396, 1314, 1307, 1275, 1212, 1177, 1157, 1114, 1080, 1029, 1005, 
982, 913, 840, 825, 781, 743, 715, 702, 639, 603, 551, 490 cm−1. 
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Synthesis of 2-(4-hydroxymethyl-phenyl)pyridine (50) 
N
B(OH)2
N
Br
1 eq. 1.5 eq.
Pd(OAc)2 (0.5 mol%)
K3PO4 (2 eq.)
Ethylene glycol
2 h, 80 °C
Under Air
50,83% Yield
HO
HO
 
Using general procedure 3, Pd(OAc)2 (0.005 eq., 50 µMol, 11.2 mg), (4-
hydroxymethyl)phenylboronic acid (1.5 eq., 15 mmol, 2.28 g), K3PO4 (2 eq., 20 mmol, 4.24 g), 
2-bromopyridine (1 eq., 10 mmol, 950 µl/1.58 g), and ethylene glycol (60 ml) were used to 
synthesise the title compound. The product was isolated as a clear colourless oil (1.5 g, 83% 
yield).  
1H NMR (400 MHz, CDCl3) δ 8.65–8.55 (ddd, J = 4.8, 1.5, 1.0 Hz, 1H), 7.83 (d, J = 8.0 Hz, 2H), 
7.69 (apr. td, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.18 (ddd, J = 7.3, 4.8, 1.0 
Hz, 1H), 4.64 (s, 2H), 4.14 (s, 1H); 13C NMR(100 MHz, CDCl3) δ 157.5, 149.7, 142.5, 138.3, 
137.2, 127.4 127.2, 122.4, 121.1, 64.6; ESI-MS: m/z = 186.0918 [MH]+ (Calc. for C12H12NO = 
186.0913). 
10.4.4 Synthesis of polar phenylpyridine complexes 
Synthesis of tetracarbonyl (2-(4-hydroxy-phenyl)κ,C8-pyridine-κ,N) manganese(I) (64) 
N
OH
+
Mn(CO)5
1.1 eq.
1 eq.
Mn(CO)4
N
OH
Toluene
80 °C, 24 h
64, 32% Yield
 
Using the details from general procedure 2, BnMn(CO)5 (1.1 eq., 2.57 mmol, 735 mg), 2-(4-
hydroxy-phenyl)pyridine (1 eq., 2.34 mmol, 400 mg) and toluene (30 ml) were used to prepare 
the title complex 64. At the end of the reaction, the solvent was removed under reduced pressure. 
The crude mixture was loaded on to silica using dichloromethane. The compound was purified by 
silica gel column chromatography (30:70 (v/v) diethyl ether/PET ether). Removal of solvent 
under reduced pressure yielded product as an off white solid (250 mg, 32% yield). 
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M.P. (DSC): 127 °C (crystalline change) 171 °C (melt); 1H NMR (400 MHz, CDCl3) δ 8.64 (d, J 
= 5.6 Hz, 1H), 7.74 (d, J = 4.2 Hz, 2H), 7.69 (d, J = 8.4 Hz, 1H), 7.42 (d, J = 2.5 Hz, 1H), 7.03 
(m, 1H), 6.66 (dd, J = 8.4, 2.5 Hz, 1H) , 4.98 (s, 1H); 13C NMR (100 MHz CDCl3) δ 178.4 
,166.3, 157.2, 154.0, 139.6, 138.0, 127.5, 125.8, 121.6, 118.9, 111.9; Elemental Analysis (CHN) 
C: 53.38% H: 2.46% N: 3.99% (calc.: C: 53.28% H: 2.68% N: 4.14%);  ESI-MS m/z = 337.9871 
[M+H]+ (calc. for MnC15H9NO5= 337.9856); IR (Solution: THF): 3264, 2072, 1988, 1971, 1929, 
1604, 1580, 1556, 1481, 1467, 1432, 1268, 1221, 1162 cm−1. 
Synthesis of tetracarbonyl (methyl [4-(pyridin-2-yl-κ,N)phen-κ,C2-oxy]acetate) 
manganese(I) (45) 
 
Using the details from general procedure 2, (Bn)Mn(CO)5 (1 eq., 1.82 mmol, 521 mg), methyl [4-
(pyridin-2-yl)phenoxy]acetate (1 eq., 1.82 mmol, 472 mg) and toluene (29 ml) were used to 
prepare the title complex 45. After 21 h heating, the reaction mixture was allowed to cool to 
room temperature. The solvent was removed under reduced pressure and crude solid was loaded 
on to silica using dichloromethane. The crude mixture was purified using silica gel column 
chromatography (80:20 (v/v) PET ether/ethyl acetate). Removal of solvent under reduced 
pressure gave pure product (600 mg, 81% yield). 
M.P. (DSC): 144 °C; 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 5.6 Hz, 1H), 7.75 (d, J = 3.6 Hz, 
2H), 7.90 (d, J = 8.5 Hz, 1H), 7.52 (d, J = 2.5 Hz, 1H), 7.04 (m, 1H), 6.71 (dd, J = 8.5, 2.5 Hz, 
1H), 4.75 (s, 2H), 3.84 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 175.1, 169.5, 165.9, 158.8, 153.8, 
140.2, 137.8, 126.1, 125.2, 121.6, 118.9, 110.8, 65.3, 52.4; Elemental Analysis (CHN) C: 52.80% 
H: 2.99% N: 3.20% (calc.: C: 53.10% H: 2.48% N: 3.44%); ESI-MS m/z = 410.0061, [M+H] + 
(calc. for MnC18H13NO7 = 410.0067); IR (THF): 2073, 1990, 1973, 1931, 1767, 1743, 1604, 
1581, 1554, 1467, 1428 cm−1. 
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Synthesis of methyl [4-(pyridin-2-yl)phenoxy]acetic acid (46) 
 
To a round bottomed flask equipped with a magnetic stirrer was added methyl [4-(pyridin-2-
yl)phenoxy]acetate (1 eq., 1 mmol, 243 mg), and lithium bromide (10 eq., 10 mmol, 868 mg). 
Triethylamine (3 eq., 3 mmol, 303 mg/418 µl), deionised water (100 µl) and acetonitrile (5 ml) 
were then added. The reaction was stirred at 25 °C for 1.5 h. Deionised water (15 ml) was added 
to the reaction and the mixture was acidified with 2 M HCl
 
to pH 3. The aqueous layer was 
extracted with ethylacetate (3 × 30 ml). The remaining aqueous extract was neutralised with 
NaOH to pH 5 and was extracted with ethyl acetate a further three times. The organic extract was 
dried with MgSO4 and filtered. The solvent was removed under reduced pressure to yield pure 
product as a white powder (156 mg, 67% yield). 
MP (DSC): 166 °C; 1H NMR (400 MHz, DMSO-d6) δ: 8.62 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.03 
(d, J = 8.9 Hz, 2H), 7.89 (apr. dt, 1H), 7.84 (td, J = 7.3, 1.8 Hz, 1H), 7.29 (ddd, J = 7.3, 4.8, 1.3 
Hz, 1H), 7.02 (d, J = 8.9 Hz, 2H), 4.75 (s, 2H); 13C NMR (101 MHz, DMSO-d6) δ: 170.2, 158.7, 
155.7, 149.4, 137.2, 131.7, 127.9, 121.9, 119.5, 114.7, 64.5; Elemental Analysis (CHN) C: 67.32 
% H: 4.80 % N: 6.26 % (calc.: C: 68.11 % H: 4.84 % N:6.11 %); ESI-MS m/z =  [M+H]+ (calc. 
for C13H12NO3 = 230.0812); IR (KBr Disc): 3432, 1728, 1601, 1563, 1516, 1471, 1432, 1277, 
1234, 1181, 1073, 998, 927, 845, 778, 755, 741, 686, 645, 605, 519, 500, 436 cm−1. 
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Synthesis of tetracarbonyl (methyl [4-(pyridin-2-yl-κ,N)phen-κ,C2-oxy]acetic acid) 
manganese(I) (47) 
N
O
OMeO
Mn(CO)4
N
O
OHO
Mn(CO)4
Et3N (3 eq.)
LiBr(10 eq.)
CH3CN/H2O (98:2)
25 oC. 2 h
Argon
47, 84% Yield
 
To a round bottomed flask equipped with a magnetic stirrer was added (methyl [4-(pyridin-2-yl-
κ,N)phen-κ,C2-oxy]acetate)Manganese(I) (1 eq., 0.733 mmol, 300 mg), and lithium bromide (10 
eq., 7.33 mmol, 636 mg). The flask was purged with argon using a balloon. Triethylamine (3 eq., 
2.19 mmol, 223 mg/307 µl), deionised water (140 µl) and acetonitrile (7 ml) were then added. 
The acetonitrile was degassed by sonication with argon bubbling from a balloon for 15 minutes 
prior to addition. The reaction was stirred at 25 °C for 2 h. Deionised water (15 ml) was added to 
the reaction and the mixture was acidified with 2 M HCl
 
to pH 2-3. The aqueous layer was 
extracted with dichloromethane (3 × 30 ml). The organic extract was washed with water (20 ml) 
and was dried with MgSO4 and filtered. The solvent was removed under reduced pressure to 
yield pure product as a yellow solid (246 mg, 84% yield). 
M.P. (DSC): 153 °C (broad); 1H NMR (400 MHz, DMSO-d6) δ 13.15 (broad s, 1H) 8.72 (d, J = 
5.6 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 8.00 (m, 2H), 7.35 (d, J = 2.5 Hz, 1H), 7.31 (ddd, J = 7.0, 
5.6, 1.2 Hz, 1H) 6.75 (dd, J = 8.5, 2.5 Hz, 1H), 4.78 (s, 2H); 13C NMR (100 MHz, d6-DMSO) δ 
221.0, 215.4, 214.4, 175.8, 171.1, 165.7, 159.8, 155.1, 140.6, 139.8, 126.9, 126.6, 123.6, 120.3, 
111.1, 65.3; Elemental Analysis (CHN) C: 51.65% H: 2.71% N: 3.49% (calc.: C: 51.67% H: 
2.56% N: 3.54%);  ESI-MS m/z = 395.9916, [M+H]+ (calc. for MnC17H11NO7 = 395.9911); IR 
(THF): 2071, 1989, 1972, 1931, 1766, 1731, 1604, 1581, 1554, 1469, 1428, 1314, 1284 cm−1. 
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10.4.5 Synthesis of alkyne linked ligands 
Synthesis of 2-[4-(prop-2-ynyloxy)phenyl]pyridine (51) - general procedure 4. 
 
This compound was prepared using a modified literature procedure.61 
To a suspension of sodium hydride (1 eq., 7 mmol, 178 mg) in THF (40 ml), was  added a 
solution of 2-(4-hydroxyphenyl)pyridine (1 eq., 7 mmol, 1.21 g) in THF (40 ml) in a Schlenk 
tube via cannula transfer over 10 mins. The resulting solution was refluxed for 1.5 h. The 
solution was allowed to cool and propargyl bromide (1 eq., 7 mmol, 833 mg) was then added. 
The solution was refluxed for a further 40 h. The reaction mixture was then allowed to cool to 
room temperature, and water (40 ml) was added. The aqueous phase was then extracted with 
CH2Cl2 (3 × 50 ml). The organic layers were combined, then washed with saturated sodium 
carbonate (2 × 50 ml), water (2 × 50 ml), were then dried with MgSO4 and filtered. The solvent 
was evaporated to yield the crude product. The crude was dissolved in dichloromethane and was 
loaded on to silica. The crude mixture was purified by silica gel column chromatography using 
30:70 (v/v) Et2O:petroleum ether increasing to 40:60. Removal of solvent yielded pure product as 
an off-white solid (1.1 g, 75% yield). 
M.P. (DSC): 81 °C; 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 4.8 Hz, 1H), 7.96 (d, J = 8.8 Hz, 
2H), 7.72 (apr. td, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.17 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 7.07 (d, J = 
8.8 Hz, 2H), 4.75 (d, J = 2.5 Hz, 2H), 2.54 (t, J = 2.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
158.7, 157.3 ,149.9, 137.0, 133.3, 128.5, 121.9, 120.2, 115.4, 78.7, 76.0, 56.2; ESI-MS: m/z = 
210.0920 [MH]+ (calc. for C14H12NO = 210.0193); Elemental Analysis (CHN) C: 80.02% H: 
5.26% N: 6.58% (calc.: C: 80.36% H: 5.30% N: 6.69%); IR (THF):3232, 2128, 2118, 1608, 
1588, 1564, 1514, 1467, 1436, 1377, 1307, 1275, 1242, 1223, 1176, 1154, 1112 cm−1. 
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Synthesis of 2-(4-[(prop-2-ynyloxy)methyl]phenyl)pyridine (52) 
 
Using general procedure 4, 2-(4-hydroxymethyl-phenyl)pyridine (1 eq., 6 mmol, 1.11 g), sodium 
hydride (1 eq., 6 mmol, 143 mg) and propargyl bromide (1 eq., 6 mmol, 714 mg) were used to 
synthesise the title compound. Pure product was obtained as an orange oil (892 mg, 66% yield).  
1H NMR (400 MHz, CDCl3) δ 8.68 (dt, J = 4.8, 1.3 Hz, 1H), 7.98 (d, J = 8.2 Hz, 2H), 7.75–7.67 
(m, 2H), 7.46 (d, J = 8.3 Hz, 2H), 7.20 (ddd, J = 5.8, 4.9, 2.6 Hz, 1H), 4.66 (s, 2H), 4.19 (d, J = 
2.3 Hz, 2H), 2.49 (t, J = 2.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 157.3, 149.8, 139.2, 138.3, 
137.0, 128.7, 127.2, 122.4, 120.8, 79.9, 75.1, 71.4, 57.4; ESI-MS: m/z = 224.1066 [MH]+ (Calc. 
for C15H14NO = 224.1070); IR (CH2Cl2): 1607, 1589, 1564, 1515, 1467, 1435, 1375, 1220, 1177 
cm−1. 
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Synthesis of 2-[4-(3-triisopropylsilyl-prop-2-ynyloxy)phenyl]pyridine (57) - general 
procedure 5. 
 
This compound was synthesised using a modified literature procedure.114 
 
2-[4-(prop-2-ynyloxy)phenyl]pyridine (1 eq., 1 mmol, 209 mg) was dissolved in dry THF (10 
ml). The mixture was cooled to −78 °C and LDA (1 eq., 1 mmol) was added over five mins via 
syringe. The reaction mixture was allowed to warm to 0 °C for five mins. The mixture was 
cooled back to −78 °C and TIPS chloride (1 eq., 1 mmol, 192 mg/214 µl) was added. The 
mixture was allowed to warm to ambient temperature and was stirred overnight. Saturated 
NH4Cl(aq)(10 ml) was added and the mixture was extracted with Et2O (2 × 20 ml). The organic 
layer was then washed with water (10 ml) and saturated brine (10 ml) and was dried with MgSO4 
and filtered. Removal of solvent under reduced pressure yielded crude product. The crude 
product was loaded on to silica using dichloromethane. The product was purified by silica gel 
column chromatography. The column was started using petroleum ether to remove apolar 
impurities. The product was eluted with 8% Et2O: petroleum ether (v/v). Removal of solvent 
under reduced pressure yielded the product as a clear orange oil (279 mg, 76% yield). 
1H NMR (400 MHz, CDCl3) δ 8.65 (ddd, J = 4.8, 1.6, 1.0 Hz, 1H), 7.94 (d, J = 8.8 Hz, 2H), 
7.78–7.59 (m, 2H), 7.16 (ddd, J = 7.0, 4.8, 1.4 Hz, 1H), 7.10 (d, J = 8.8 Hz, 2H), 4.78 (s, 2H), 
1.04 (s, 21H); 13C NMR (100 MHz, CDCl3) δ 158.9, 157.3, 149.8, 137.0, 132.8, 128.3, 121.8, 
120.2, 115.6, 102.1, 89.7, 57.1, 18.8, 11.4; ESI-MS: m/z = 366.2238 [MH]+ (calc. for 
C23H32SiNO = 366.2248) 
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Synthesis of 2-(4-[(3-triisopropylsilyl-prop-2-ynyl-oxy)methyl]phenyl)pyridine (58). 
 
 
Using general procedure 5, 2-(4-[(prop-2-ynyloxy)methyl]phenyl)pyridine (1 eq., 1.91 mmol, 
426 mg), LDA (1 eq., 1.91 mmol) and TIPS chloride (1 eq., 1.91 mmol, 368 mg/ 408 µl) in THF 
(15 ml) were used to synthesise the title compound 58. The compound was purified using silica 
gel column chromatography starting with petroleum ether moving to 20% Et2O: petroleum ether 
(v/v). The compound was isolated as a clear orange oil (499 mg, 73% Yield).  
1H NMR (400 MHz, CDCl3) δ 8.69 (dt, J = 5.0, 1.3 Hz, 1H), 7.99 (d, J = 8.1 Hz, 2H), 7.78–7.68 
(m, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.23 (ddd, J = 6.6, 5.0, 2.2 Hz, 1H), 4.70 (s, 2H), 4.24 (s, 2H), 
1.10 (s, 21H); 13C NMR (100 MHz, CDCl3) δ 157.5, 150.0, 139.2, 138.7, 137.1, 128.9, 127.3, 
122.4, 120.8, 103.5, 88.4, 70.9, 58.1, 18.9, 11.5; ESI-MS: m/z = 380.2394 [MH]+ (Calc. for 
C24H34NOSi = 380.2404); Elemental Analysis (CHN) C: 75.36% H: 8.72% N: 3.68% (calc.: C: 
75.94% H: 8.76% N: 3.69%); IR (solution: CH2Cl2): 2170, 1587, 1468, 1436, 1349, 1264, 1078 
cm−1. 
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10.4.6 Synthesis of alkyne linked complexes 
Synthesis of tetracarbonyl 2-[4-(3-triisopropylsilyl-prop-2-ynyloxy)phenyl]κ,C2-pyridine-
κ,N) manganese(I)(59) - general procedure 6 
 
 
2-[4-(3-triisopropylsilyl-prop-2-ynyloxy)phenyl]pyridine (1 eq., 2.285 mmol, 833 mg) and 
BnMn(CO)5 (1 eq., 2.285 mmol, 654 mg) were dried under vacuum in a Schlenk tube for 15 
minutes. Hexane (30 ml) was then added via cannula transfer from an ampoule. The reaction 
mixture was refluxed with stirring for 16 h. The solution was allowed to cool to room 
temperature and was filtered through a pipette packed with Celite™. The solvent was removed 
under reduced pressure to yield the product as an off-yellow solid (1.17 g, 97% yield). The 
compound did not require further purification after the reaction but if it was required this could 
be done using silica gel column chromatography. 
M.P. (DSC): 95 °C; 1H NMR (400 MHz, CDCl3) δ 8.65 (dt, J = 5.5, 1.3 Hz, 1H), 7.77–7.72 (m, 
2H), 7.71 (d, J = 8.6 Hz, 1H), 7.60 (d, J = 2.5 Hz, 1H), 7.03 (td, J = 5.5, 3.1 Hz, 1H), 6.79 (dd, J 
= 8.6, 2.5 Hz, 1H), 4.84 (s, 2H), 1.05 (s, 21H); 13C NMR (100 MHz, CDCl3) δ 177.9, 166.4, 
159.3, 154.0, 139.9, 137.9, 126.3, 125.4, 121.6, 119.0, 112.0, 102.3, 89.3, 56.8, 18.9, 11.4; ESI-
MS: m/z = 532.1345 [MH]+ (calc. for C27H31MnNO5Si = 532.1347); Elemental Analysis (CHN) 
C: 60.58% H: 5.77% N: 2.56% (calc.: C: 61.01% H: 5.69% N: 2.64%); IR (Solution: THF): 
2073, 1989, 1973, 1931, 1604, 1580, 1553, 1468, 1431, 1317, 1281, 1211, 1198, 1165 cm−1. 
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Synthesis of tetracarbonyl 2-(4-[(3-triisopropylsilyl-prop-2-ynyl-oxy)methyl]phenyl) κ,C2-
pyridine-κ,N) manganese(I) (60) 
 
 
Using general procedure 6, 2-(4-[(3-triisopropylsilyl-prop-2-ynyl-oxy)methyl]phenyl)pyridine (1 
eq., 3.24 mmol, 147 mg) and BnMn(CO)5 (1 eq., 3.24 mmol, 111 mg) were used with hexane (30 
ml) to synthesise the title complex as an off yellow solid (1.7 g, 98% Yield). 
M.P. (DSC): 82°C; 1H NMR (400 MHz, CDCl3) δ 8.74–8.69 (m, 1H), 7.92 (d, J = 1.6 Hz, 1H), 
7.88 (d, J = 8.2 Hz, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.20(dd, J = 8.1, 1.7 
Hz, 1H), 7.15–7.07 (m, 1H), 4.70 (s, 2H), 4.30 (s, 2H), 1.11 (s, 21H); 13C NMR (100 MHz, 
DMSO-d6) δ 220.0, 214.5, 213.4, 172.5, 164.7, 154.4, 145.9 , 140.9, 139.1, 139.0, 124.5, 124.0, 
123.7, 120.0, 104.3, 86.8, 70.5, 57.3, 18.4, 10.6; ESI-MS: m/z = 546.1494 [MH]+ (calc. for 
C28H33MnNO5Si = 546.1503); Elemental Analysis (CHN) C: 61.48% H: 5.91% N: 2.51% (calc.: 
C: 61.64% H: 5.91% N: 2.57%); IR (solution: CH2Cl2): 2170, 2075, 1991, 1977, 1932, 1605, 
1477, 1268, 1076 cm−1.
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Synthesis of tetracarbonyl 2-[4-(prop-2-ynyloxy)phenyl] κ,C2-pyridine-κ,N) manganese(I) 
(62) - general procedure 7 
 
Tetracarbonyl 2-[4-(3-triisopropylsilyl-prop-2-ynyloxy)phenyl]κ,C2-pyridine-κ,N) manganese(I) 
(1 eq., 0.525 mmol, 279 mg) was dissolved in a mixture of MeCN (5 ml) and CH2Cl2 (1 ml). 
TBAF·3H2O (1 eq., 0.525 mol, 165 mg) was added to the reaction mixture with stirring. After 15 
minutes, H2O (20 ml) was added the aqueous layer was extracted with CH2Cl2 (3×20 ml). The 
organic extract was dried with MgSO4 and was filtered. Removal of solvent under reduced 
pressure yielded crude product. The crude product was loaded on to silica using CH2Cl2. The 
crude mixture was purified by silica gel column chromatography. The column was packed using 
petroleum ether and the product was eluted with 10% ethyl acetate/petroleum ether. Removal of 
solvent under reduced pressure yielded pure product as an off white solid (103 mg, 52% Yield). 
M.P. (DSC): 125 °C (decomposition); 1H NMR (400 MHz, CDCl3) δ 8.66 (d, J = 5.7 Hz, 1H), 
7.79–7.68 (m, 3H), 7.59 (d, J = 2.5 Hz, 1H), 7.09–6.98 (m, 1H), 6.78 (dd, J = 8.5, 2.5 Hz, 1H), 
4.80 (d, J = 2.3 Hz, 2H), 2.57 (d, J = 2.3 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) δ 178.1, 
166.2, 159.0, 154.0, 140.2, 138.0, 126.7, 125.4, 121.8, 119.0, 111.2, 78.9, 75.9, 56.0; LIFDI-MS: 
m/z = 374.9863 [M]+ (Calc. for C18H10NO5Mn = 374.9939); Elemental Analysis (CHN) C: 
56.80% H: 2.83% N: 3.47% (calc.: C: 57.62% H: 2.69% N: 3.73%); IR (solution: THF):3242, 
2117, 2073, 1989, 1973, 1931, 1645, 1603, 1579, 1552, 1476, 1431, 1213 cm−1. 
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Synthesis of tetracarbonyl 2-(4-[(prop-2-ynyloxy)methyl]phenyl) κ,C2-pyridine-κ,N) 
manganese(I) (63) 
 
Using general procedure 7, tetracarbonyl 2-(4-[(3-triisopropylsilyl-prop-2-ynyl-
oxy)methyl]phenyl) κ,C2-pyridine-κ,N) manganese(I) (1 eq., 3.037 mmol, 1.657 g), MeCN (30 
ml), CH2Cl2 (6 ml) and TBAF.3H2O (1.2 eq, 3.644 mol, 1.15 g) were used to synthesise the title 
complex over 2 h. The crude mixture was purified using silica gel column chromatography 
starting with 10% Et2O:petroleum ether moving to 20%. Removal of solvent under reduced 
pressure yielded pure product as an off white solid (606 mg, 51% yield).  
M.P (DSC).107 °C(decomposition);1H NMR (400 MHz, DMSO-d6) δ 8.72 (d, J = 5.5 Hz, 1H), 
8.28–8.13 (m, 1H), 8.03–7.95 (m, 2H), 7.74 (d, J = 1.6 Hz, 1H), 7.33 (ddd, J = 7.2, 5.5, 1.3 Hz, 
1H), 7.09 (dd, J = 8.0, 1.7 Hz, 1H), 4.53 (s, 2H), 4.21 (d, J = 2.4 Hz, 2H), 3.48 (t, J = 2.4 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 175.4, 166.4, 154.2, 146.1, 141.4, 139.3, 138.2, 124.34, 
124.32, 122.7, 119.7, 80.1, 75.0, 72.3, 57.8; ESI-MS: m/z = 390.0184 [MH]+ (calc. for 
C19H13MnNO5 = 390.0169); Elemental Analysis (CHN) C: 58.58% H: 3.23% N: 3.48% (calc.: C: 
58.62% H: 3.11% N: 3.60%); IR (Solution: CH2Cl2):3237, 2120, 2076, 1991, 1976, 1933, 1605, 
1587, 1479, 1273, 1257, 1081 cm−1. 
  
293 
 
10.4.7 Synthesis of a biotin azide conjugate (70) 
Synthesis of 3-azido-1-propylamine (67)112, 148 
 
To a stirred solution of 3-chloropropylamine hydrochloride (1 eq., 4.31 mmol, 560 mg), 
dissolved in water (5 ml) was added NaN3 (2.78 eq., 12.0 mmol, 840 mg), and the mixture heated 
to 80 °C. After 16 h, KOH pellets (1 eq.) were added to basify the solution, followed by 
extraction with diethyl ether (3 × 5 ml). The organic phase was dried with MgSO4 and filtered. 
Removal of solvent under reduced pressure to gave pure product as a colourless oil (312 mg, 
72% yield). Note: This molecule is volatile, and low pressure and temperature on a rotator 
evaporator is essential.  
1H NMR (400 MHz, CDCl3) δ 3.33 (td, J = 6.8, 2.0 Hz, 1H), 2.76 (td, J = 6.8, 2.0 Hz, 1H), 1.68 
(qnd, J = 6.8, 2.0 Hz, 1H), 1.39 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 49.4, 39.5, 32.6; ESI-MS: 
m/z = 101.0822 [MH]+ (Calc. for N4C3H9 = 101.0822). 
Safety in the Handling of Sodium Azide and other Azides 
 
Sodium azide is toxic and can be absorbed through the skin. It decomposes explosively upon 
heating to above 275 °C. Sodium azide reacts vigorously with CS2, bromine, nitric acid, dimethyl 
sulfate, and a series of heavy metals, including copper and lead. In reaction with water or 
Brønsted acids the highly toxic and explosive hydrogen azide is released. It has been reported 
that sodium azide and polymer-bound azide reagents form explosive di- and triazidomethane with 
CH2Cl2 and CHCl3, respectively. Heavy-metal azides that are highly explosive under pressure or 
shock are formed when solutions of NaN3 or HN3 vapours come into contact with heavy metals 
or their salts. Heavy-metal azides can accumulate under certain circumstances, for example, in 
metal pipelines and on the metal components of diverse equipment (rotary evaporators, freeze 
drying equipment, cooling traps, water baths, waste pipes), and thus lead to violent explosions. 
Some organic and other covalent azides are classified as toxic and highly explosive, and 
appropriate safety measures must be taken at all times. Plastic spatulas, clear seal glassware, 
and blast shields are highly important to ensure safe working conditions. 
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Synthesis of Biotin-NHS (69)119 
HN NH
S
H H
O
OH
O
HN NH
S
H H
O
O
O
N
O
O
DCC (1.3 eq.)
NHS (1 eq. )
DMF ambient temp., 16 h.
69, 91% Yield
 
d-Biotin (1 eq., 2.05 mmol, 0.5 g ) and N-hydroxysuccinimide (1 eq., 2.05 mmol, 236 mg) were 
dissolved in hot DMF (15 ml) in a 50 ml round-bottom flask with stirring. N,N-
dicyclohexylcarbodiimide (1.3 eq., 2.66 mmol, 0.55 g) was added, and the solution was stirred 
overnight at ambient temperature (20 °C), during which time a white precipitate formed. The 
reaction mixture was filtered, and the filtrate was evaporated and triturated with ether. The white 
precipitate obtained by trituration with Et2O was filtered and washed with ether to give a white 
powder. (627 mg, 91% Yield). 
1H NMR (400 MHz, DMSO-d6) δ 6.40 (s, 1H), 6.34 (s, 1H), 4.26 (dd, J = 7.5, 5.2 Hz, 1H), 4.10 
(ddd, J = 7.5, 4.4, 1.7 Hz, 1H), 3.11–3.02 (m, 1H), 2.83–2.72 (m, 5H), 2.63 (t, J = 7.5 Hz, 2H), 
2.54 (d, J = 12.4 Hz, 1H), 1.73–1.29 (m, 6H); 13C NMR (101 MHz, DMSO-d6) δ 170.8, 169.0, 
163.0, 61.0, 59.2, 55.3, 33.4, 30.0, 27.8, 27.6, 25.5, 24.3. ESI-MS: m/z = 342.1122 [MH]+ (Calc. 
for C14H20N3O5S = 342.1118); Note: There are some small unknown impurities in this material. 
These do not affect the next step in any significant fashion. Pure material has been obtained in 
subsequent steps by using this material. 
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Synthesis of a biotin-azide-conjugate (70) 
 
This experimental procedure is based on a modified literature procedure.119 
Et3N (1 eq., 0.879 mmol, 187 µL) was added to a solution of 3-aminopropylazide (1.4 eq., 1.23 
mmol, 123.2 mg) in DMF (13 ml), followed by the addition of biotin-NHS (1 eq., 70 mg, 0.20 
mmol) in DMF (9 ml). The resulting solution was stirred at room temperature for 24 h. The 
solvent was evaporated under reduced pressure. The crude residue was purified by flash 
chromatography (acetone/MeOH, 10:1) to give the desired biotin-azide-conjugate (220 mg, 0.674 
mmol, 76 %) as an off white solid. 
1H NMR (400 MHz, MeOD-d4) δ 4.49 (dd, J = 7.9, 4.5 Hz, 1H), 4.30 (dd, J = 7.9, 4.5 Hz, 1H), 
3.36 (t, J = 6.9 Hz, 2H), 3.25 (t, J = 6.9 Hz, 2H), 3.23–3.18 (m, 1H), 2.93 (dd, J = 12.8, 5.0 Hz, 
1H), 2.71 (d, J = 12.8 Hz, 1H), 2.21 (t, J = 7.5 Hz, 2H), 1.92–1.54 (m, 6H), 1.51–1.37 (m, 2H); 
13C NMR (101 MHz, MeOD-d4) δ 176.2 ,166.1, 63.4, 61.6, 57.1, 50.2, 41.0, 37.7, 36.8, 29.80, 
29.74, 29.5, 26.9; ESI-MS: m/z = 349.1411 [MNa]+ (Calc. for SO2N6C13H22Na = 349.1417). 
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10.4.8 Synthesis of CO-RMs via [3+2] cycloaddition chemistry 
Synthesis of tetracarbonyl (2-[4-(([1-(4-carboxyphenyl)-1H-1,2,3-triazol-4-
yl]methoxy)methyl)phenyl-κ,C2]pyridine-κ,N) manganese(I) (65). 
 
 
This synthesis was carried out using a modified literature procedure.111 
To an 8 ml screw sample vial equipped with a microwave stirrer bar was added 62 (1 eq., 0.116 
mmol, 45 mg) followed by tBuOH (1.5 ml). The mixture was stirred for five minutes at ambient 
temperature. 4-azidobenzoic acid (1 eq., 0.115 mmol, 19 mg) was added to the reaction mixture 
followed by water (1.35 ml). CuSO4·5H2O (0.3 eq., 115 µl, 0.0348 mmol) was added to the 
mixture from a 0.3 M aqueous solution followed by sodium ascorbate (0.3 eq., 35 µl, 0.0348 
mmol) from a 0.5 M aqueous solution. The vial was sealed with parafilm™ and the mixture was 
stirred in the dark for 40 h at ambient temperature. After 40 h, consumption of 63 was observed 
by TLC analysis. Water (10 ml) was added followed by 1 M HCl (until pH 1). The acidified 
aqueous layer was extracted with ethyl acetate (3 × 15 ml) and was dried with MgSO4 and 
filtered. Removal of solvent under reduced pressure gave pure product as an off white solid (62 
mg, 98% yield). 
M.P. (DSC): 159 °C(decomposition);1H NMR (700 MHz, DMSO-d6) δ: 13.24 (s, 1H), 8.99 (s, 
1H), 8.75 (d, J = 5.3 Hz, 1H), 8.23 (d, J = 8.1 Hz, 1H), 8.17–8.06 (m, 4H), 8.05–7.98 (m, 2H), 
7.81 (s, 1H), 7.36 (t, J = 6.3 Hz, 1H), 7.19 (d, J = 7.9 Hz, 1H), 4.76 (s, 2H), 4.66 (s, 2H); 13C 
NMR (176 MHz, DMSO-d6) δ: 220.2, 214.6, 213.4, 172.4, 166.4, 164.7, 154.4, 145.7, 145.4, 
139.8, 139.5, 139.1, 131.1, 130.6, 124.5, 123.8, 123.7, 122.5, 120.0, 119.8, 71.7, 63.0; ESI-MS: 
m/z = 553.0582 [MH]+ (Calc. for C26H18MnN4O7 = 553.0550); Elemental Analysis (CHN) C: 
56.56 % H:3.32% N:9.62 % (calc.: C: 56.53% H: 3.10% N: 10.14%); IR (Solution: CH2Cl2): 
2075, 1991, 1976, 1932, 1733, 1699, 1695, 1607, 1586, 1093, 1042 cm−1. 
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Synthesis of Biotin conjugate-CO-RM (71) 
O
N
Mn(CO)4
N
N
N
HN NH
S
H H
O
NH
O
CO-RM 63 (1 eq.)
CuSO4·5H2O (1 eq.)
Sodium ascorbate (2 eq.)
tBuOH/H2O 1:1
Ambient temp., 24 h
Under Air
HN NH
S
H H
O
NH
N3
O
1 eq. 70
71, 72 or 50% Yield
 
This synthesis is based on a significantly modified literature procedure.111 
To an 8 ml screw cap sample vial was added azide 70 (1 eq., 0.077 mmol, 25.1 mg), followed by 
CO-RM 63 (1 eq. 0.077 mmol, 30 mg). tBuOH (1.25 ml) was then added and the mixture was 
stirred with a magnetic flea to aid dissolution (complete dissolution will not occur). Water (840 
µl) was then added followed by the addition of CuSO4·5H2O as a 0.3 M solution (1 eq., 0.077 
mmol, 256 µl, 19.2 mg) and sodium ascorbate as a 1 M solution (2 eq., 0.154 mmol, 154 µl, 30.5 
mg). The vial was closed and sealed with para-film™ and was stirred for 24 h at ambient 
temperature. TLC analysis at the end of this period showed the consumption of CO-RM 62 . The 
reaction mixture was diluted with EtOAc (5 ml) and was transferred to a separating funnel 
containing water (10 ml). The mixture was extracted with ethyl acetate (4 × 5 ml). The organic 
layer was dried with MgSO4 and filtered. Removal of solvent under reduced pressure yielded 
pure product as an off white solid (40 mg, 0.056 mmol, 72% Yield). 
M.P. (DSC): 75 °C (decomposition); 1H NMR (400 MHz, MeOD-d4) δ 8.77 (ddd, J = 5.6, 1.5, 
0.7 Hz, 1H), 8.09 (apr. dt, J = 8.3, 1.2 Hz, 1H), 8.04 (s, 1H), 7.96-7.89 (m, 2H), 7.88 (d, J = 1.6 
Hz, 1H), 7.26 (ddd, J = 7.2, 5.6, 1.3 Hz, 1H), 7.19 (dd, J = 8.0, 1.5 Hz, 1H), 4.72 (s, J = 1.9 Hz, 
2H), 4.64 (s, J = 1.6 Hz, 2H), 4.51–4.40 (m, 3H), 4.28 (dd, J = 7.9, 4.5 Hz, 1H), 3.25–3.16 (m, 
3H), 2.90 (dd, J = 12.7, 4.9 Hz, 1H), 2.68 (d, J = 12.7 Hz, 1H), 2.20 (t, J = 7.0 Hz, 2H), 2.11 (p, J 
= 7.0 Hz, 2H), 1.80-1.53 (m, 4H), 1.44 (m, 2H); 13C NMR (700 MHz, MeOD-d4) δ 221.6, 215.7, 
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215.0 176.3, 174.8,167.0, 155.4, 147.4, 145.8, 141.5, 140.8, 139.8, 125.5, 125.4, 125.2, 124.2, 
120.8, 73.7, 64.2, 63.3, 61.6, 57.1, 49.2 (peak observed by 13C DEPT-135 under solvent peak), 
41.1, 37.3, 36.7, 31.1, 29.8, 29.4, 26.8; ESI-MS: m/z = 716.1677 [MH]+ (calc. for MnSO7N7 
C32H35 = 716.1694); Elemental Analysis (CHN) C: 52.56 % H: 4.78% N: 12.42 % (calc.: C: 
53.71% H: 4.79% N: 13.70%); IR (Solution: MeOH): 2075, 1992, 1977, 1936, 1681, 1653, 1605, 
1588, 1567, 1333, 1313, 1269, 1231 cm−1. Note: This reaction can also be performed using 0.5 
eq., biotin azide 70 (0.00385 mmol, 12.6 mg) with everything else on the same scale using a 
reaction time of 48 h to give purer material. After work up as detailed previously, CO-RM 71 can 
be purified by silica gel column chromatography starting with 5% (v/v) MeOH/CH2Cl2 moving to 
10% (v/v) MeOH/CH2Cl2. Removal of solvent under reduced pressure yielded pure product as 
yellow solid (14 mg, 0.00195 mmol 50% yield).  
10.4.9 Synthesis of Amino acid containing Manganese Complexes 
Synthesis of Tricarbonyl Acetonitrile (L-2-Amino-3-(1H-indol-3-yl)propanoic acid) 
ManganeseI (L-75) 
 
An oven dried (130 °C) Schlenk tube equipped with a magnetic stirrer was evacuated and refilled 
with nitrogen three times. L-tryptophan (1 eq, 2.5 mmol, 511 mg), and BnMn(CO)5 (1.02 eq, 
2.55 mmol, 730 mg) were added to the Schlenk tube under a high flow of nitrogen. The two 
solids were then dried under vacuum for 30 mins. Under a high nitrogen flow, dry, deoxygenated 
methanol (50 ml) was added by cannula transfer. The mixture was heated to 75 °C with slow 
stirring due to the initial insolubility of tryptophan. The tube was then sealed with a hot 
condensing finger (to ensure the finger was dry before introduction to the flask) and was heated 
to 75 °C under a flow of nitrogen. Once reflux was achieved, the flask was sealed at the tap and 
heated at 75 °C for 48 h. Occasional periods of vigorous stirring for one minute were required to 
ensure all the tryptophan solid would dissolve and react. The mixture was allowed to cool to 
room temperature. The methanol was removed under reduced pressure in the Schlenk tube to 
leave a crude residue as a yellow solid. Dry CH3CN (20 ml) was then added via syringe followed 
by dry hexane (40 ml). The solution was stirred for two minutes and the upper hexane layer was 
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removed by syringe. Two more portions of hexane (40 ml) were added to the Schlenk tube and 
were removed as described. Removal of CH3CN under reduced pressure yielded a yellow solid. 
(820 mg, 82% Yield). 
MP(DSC): 202 °C (decomposition) ; 1H NMR (400 MHz, d6-DMSO) δ 10.97 (broad s, 1H), 7.60 
(broad s, 1H), 7.38 (broad, s, 1H), 7.24 (broad s, 1H), 7.12 (broad s, 1H), 7.02 (broad s, 1H), 5.63 
(broad s ,NH2 but exchange processes reduce integration, D2O shake supports this), 2.10 (broad s 
,3H). 13C NMR (100 MHz, d6-DMSO): 136.7, 128.1, 125.2, 121.4, 119.0 (broad s), 118.5, 111.9 
(broad s), 1.6. Solid state 13C NMR Direct excitation: (100 MHz) δ 220.2, 186.3, 137.1, 128.1, 
120.3, 111.6, 1.3. Solid state 13C NMR Cross polarisation: (100 MHz) δ 185.1, 136.7, 128.2, 
109.0, 1.2. Elemental Analysis(CHN): C: 49.94% H: 3.64% N: 9.37% (Calculated containing 0.3 
eq. of MeOH observed in 1H NMR: C: 49.55% H: 3.79% N: 9.93%); ESI-MS m/z = 343.0118, 
[M+H−MeCN]+(calc. for MnC14H12N2O5 = 343.0121), m/z = 384.0385, [M+H]+ (calc. for 
MnC16H15N3O5 = 343.0387) IR (Solution: THF): 3281 (broad), 2028, 1922, 1897, 1599, 1454, 
1180 cm−1 IR: (KBr disc): 3412, 3319, 3261, 2035, 1927, 1900, 1564, 1413 cm-1 IR: (Solution: 
MeOH): 2037, 1933, 1921, 1607 cm−1. IR (Solution: CH2Cl2): 3680, 3465, 3343, 2253, 2032, 
1929, 1906, 1606, 1418 cm−1. [α]D20: L isomer = –286.5 (c=1, DMSO), D isomer = [α]D20 +248.2 
(c=1, DMSO); UV/Vis (acetonitrile): λmax (ε) = 272 (7505), 360 nm (1443 mol−1 dm3 cm−1). 
Note: The D isomer used for CD measurements and [α]D was made in same way but using D-
tryptophan purchased from Sigma Aldrich. The DL racemate complex was made from a bought 
DL-tryptophan racemate. The [α]D measurements taken above match the starting enantiopurities 
of the bought starting materials. 
Details from EPSRC National Solid-state NMR Service at Durham for Complex L-75 
The complex gives much broader lines than free tryptophan. Two spectra were recorded, a CP 
experiment with interrupted decoupling and a DE experiment. This should only give signals from 
quaternary (and methyl) carbons. There is a signal at 185 ppm from the acid group, up from 
176/178 ppm in the free tryptophan ligand. The other three quaternaries are at 109, 128 and 137 
ppm. The CO signal is just visible but it is clearer in the direct excitation spectrum. In the DE 
experiment, there is the signal at 1 ppm due to the co-ordinated acetonitrile. There is an extensive 
manifold of spinning sidebands, centred at 220 ppm, from the CO carbons. It is not possible to 
resolve individual CO lines it is not possible to tell whether these groups are all the same but IR 
spectroscopy confirms the presence of three carbonyls. In principle, the carbon will be coupled to 
the manganese which would result in a multiplet or more likely just broadening of the signal. The 
extensive sideband manifold, and the fact that the centreband has a lower intensity than the first 
high-frequency sideband, is typical of an M-C≡O environment. 
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Synthesis of the Mohr Histidine complex78 (21) 
 
This complex was prepared exactly as reported in the literature. 50:50 MeCN-d3/D2O shifts the 
resonance of the residual solvents. The 1H NMR was referenced to the peak at 7.99 ppm which 
appears in the literature data as the water peak shifts significantly due to a mixed solvent 
combination. Referencing this peak to 7.99 ppm matches all the other peaks with the literature 
NMR spectrum. 
MP(DSC): decomp. above 250°C; 1H NMR (400 MHz, d3-MeCN/D2O) δ 7.99 (broad s, 1H), 
6.99 (broad s, 1H), 3.78 (broad, s, 1H), 3.00 (broad s, 2H), ESI-MS m/z = 293.9911, [M+H]+ 
(calc. for MnC9H9N3O5 = 293.9917), m/z = 315.9733, [M+Na]+ (calc. for MnC9H8N3O5Na = 
315.9733). IR (Solution: CH3OH): 2031, 1925, 1917, 1613 cm−1. 
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10.4.10 Synthesis of an azo dye based Manganese(I) complex 
Synthesis of 4-[(E)-1,3-benzothiazol-2-yldiazenyl]-N,N-diethylaniline (76) 
 
Note: 2-aminobenzathiazole was distilled using Kugelrohr apparatus prior to use (93 °C /1 Torr). 
This synthesis is based on a modified literature procedure with an alternative workup.135 
To acetic acid (6 ml) was added 2-aminobenzathiazole (1 eq., 1 mmol, 150 mg) and concentrated 
sulfuric acid (2 ml). NaNO2 (1.02 eq., 1 mmol, 70 mg) in water (3 ml) was then added to the 
sulfuric acid solution and stirred for 2 hours at 0 °C during which an orange colour develops. 
N,N-diethylaniline (1 eq., 1 mmol, 149 mg/81 µl) was then added in methanol (10 ml) to the 
diazonium salt solution and the solution goes a dark blue. The solution was stirred and was 
allowed to warm up to ambient temp. (25 °C) and then was stirred for a further 16 h. Ethyl 
acetate (50 ml) and water (50 ml) was added to the aqueous layer in a separating funnel. 2M 
NaOH(aq) was then added until a significant amount of the bright red product goes in to the 
organic ethyl acetate layer. The aqueous layer was then extracted with more ethyl acetate (2 × 50 
ml). The organic layer was washed with brine (50 ml) and was dried with MgSO4 and 
subsequently filtered. The solvent was removed under reduced pressure to yield crude product as 
a dark powder. The product was purified by silica gel column chromatography by dry loading 
onto silica with CH2Cl2 and eluting with Ethyl acetate using a gradient from 15:85 to 40:60 (v/v) 
EtOAc: PET ether. Removal of solvent under reduced pressure yielded pure product as a dark 
crystalline solid (170 mg, 55% Yield). 
Note: The large volumes of extraction solvent were used to enable visualisation of the layers in 
the separation due to strong absorption from the product. 
1H NMR (400 MHz, CDCl3) δ 8.06 (dd, J = 8.0, 0.5 Hz, 1H), 7.96 (d, J = 9.3 Hz, 2H), 7.82 (dd, J 
= 8.0, 0.5 Hz, 1H), 7.45 (apr. t, J = 8.0 Hz, 1H), 7.36 (apr. t, J = 8.0 Hz, 1H), 6.71 (d, J = 9.3 Hz, 
2H), 3.46 (q, J = 7.1 Hz, 4H), 1.23 (t, J = 7.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 177.9, 
153.1, 152.6, 142.8, 134.3, 128.2(broad), 126.4, 126.2, 124.1, 122.3, 111.7, 45.3, 13.0. ESI-MS: 
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m/z = 311.1310 [MH]+ (Calc. for C17H19N4S = 311.1325); Elemental Analysis (CHN) C: 65.60% 
H: 5.79% N: 17.94% (calc.: C: 65.78 % H: 5.84 % N: 18.05%); 
Synthesis of dye-containing CO-RM (77) 
 
Azodye 76 (1 eq., 0.5 mmol, 155 mg) and BnMn(CO)5 (1 eq., 0.5 mmol, 143 mg) were added to 
a dry Schlenk tube under a flow of nitrogen. The reagents were dried under vacuum for 15 mins. 
Toluene (8 ml) was added via syringe. The mixture was heated to 95 °C, and on reaching 
temperature the Schlenk tube was sealed. The mixture was heated for a further 2.5 h. On cooling 
to room temperature the solvent was removed under reduced pressure to yield crude product. The 
crude mixture was purified by silica gel column chromatography by loading the crude mixture on 
to a minimum amount of silica with CH2Cl2. The product was eluted from the column using a 
gradient from 15:85 to 35:65 (v/v) Et2O/petroleum ether (all with 0.5% Et3N). The product was 
isolated as a purple solid (12 mg, 5% yield). 
1H NMR (400 MHz, CD2Cl2) δ 8.03 (d, J = 9.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 
Hz, 1H), 7.47 (d, J = 2.5 Hz, 1H), 7.41 (apr.t, J = 7.5 Hz, 1H), 7.30 (apr.t, J = 7.5 Hz, 1H), 6.74 
(dd, J = 9.0, 2.5 Hz, 1H), 3.62 (q, J = 7.0 Hz, 4H), 1.34 (t, J = 7.0 Hz, 6H); 13C NMR (101 MHz, 
CD2Cl2) δ 195.2, 175.7, 156.1, 151.8, 150.5, 137.0, 134.4, 126.1, 125.0, 122.8, 122.0, 121.4, 
112.5, 45.7, 12.8.; ESI-MS: m/z = 477.0401 [MH]+ (calc. for C21H18N4O4SMn = 477.0424); IR 
(Solution: CH2Cl2): 2076, 1990, 1942, 1603, 1581, 1386, 1338, 1297, 1210 cm−1. 
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10.5 Biological general experimental details 
10.5.1 Eukaryotic Cell Viability Assay details 
Culturing RAW 264.7 cells from a liquid nitrogen stock. 
Work with RAW 264.7 cells with was carried out in a category II laminar flow hood apart from 
when incubating the cells. 
TOX 7 and TOX 8 kits were purchased from Sigma Aldrich and were used as directed below for 
Alamar blue and LDH Assays. 
 A 1 ml stock containing RAW 264.7 Cells using a 10% DMSO/ Media mixture was partially 
thawed and was added to 10 ml of fresh DMEM media containing 10% heat inactivated FCS, 2 
mM L-glutamine, 100 units ml−1 penicillin and 0.1 mg ml−1 streptomycin . The cells were pelleted 
by centrifuging at 1200 rpm for 5 minutes. The pellet was re-suspended in 10 ml of complete 
medium. This was then transferred to a T-25 flask and was incubated at 37 °C under a 5% CO2 
atmosphere until confluent. 
Passaging the cells 
The media in the flask was disposed of and the cells were washed with 10 ml of 1x PBS pH 7.2. 
10 ml of fresh media was added and the cells were re-suspended in the media using a plastic cell 
scraper. It is important to be gentle at this stage. 2 ml of the cell suspension was added to a new 
T-25 cell flask and 8 ml of fresh media was added and the cells were incubated as before. The 
remaining 8 ml of cell suspension could be used for cell studies. Cells were not used in studies 
further than 10 passages to prevent false results due to mutation/contamination. 
Culturing cells in a 24 well plate 
The cells from the 8 ml suspension described previously were counted using a haemocytometer 
and approximately 5 ×105 cells were added to each well. The total volume of media in each well 
was 1 ml. The cells were incubated at 37 °C overnight and were 80-90% confluent the next day. 
Addition of CO-RM to cell culture in a 24 well plate. 
The media from overnight culture was replaced with 1 ml of fresh medium. The compound of 
interest was dissolved in DMSO at a concentration 200 times the final required value. 5 µl of this 
solution was then added to each well to provide the correct concentration. The cells were 
incubated overnight. 
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Culturing cells in a 96 well plate 
The cells from the 8 ml suspension described previously were counted using a haemocytometer 
and approximately 5 ×104 cells were added to each well. The total volume of media in each well 
was 200 µl. The cells were incubated at 37 °C overnight and were 80-90% confluent the next 
day. 
Addition of CO-RM to cell culture in a 96 well plate. 
The compound of interest was dissolved in DMSO at a concentrated 200 times the required 
value. 5 µl of this solution was then added to 1 ml of media in a 2 ml Eppendorf. This was shaken 
and 200 µ of the CO-RM /media solution was added to each well. The old media was removed 
from each well before addition. The cells were incubated overnight with the CO-RM solution. 
Alamar blue assay in a 24 well plate. 
After incubation with the CO-RM, the media from each well was removed and was replaced with 
1 ml of a 10% Alamar blue (Sigma Aldrich)/90% complete media mixture. The cells were then 
incubated for 4 hours at 37 °C. 200 µl of the media was then transferred to a flat bottomed 96 
well plate and was read on a plate reader at 570 nm with a background subtraction at 630 nm. 
Results were expressed as a percentage scaled between the difference in absorbance of a 1% 
Triton-X-114 control (dead cells) and a live control with no compound. 
Alamar blue assay in a 96 well plate. 
After incubation with the CO-RM, the media from each well was removed and was replaced with 
220 µl of a 10% Alamar blue (Sigma Aldrich) / 90% complete media mixture. The cells were 
then incubated for 6 hours at 37 °C. 200 µl of the media was then transferred to a flat bottomed 
96 well plate and bubbles were popped with a needle. The plate was read on a plate reader at 570 
nm with a background subtraction at 630 nm. Results were expressed as a percentage scaled 
between the difference in absorbance of a 1% triton-X-114 control (dead cells) and a live control 
with no compound. 
LDH assay in a 24 well plate 
After incubation with the CO-RM. 50 µl of supernatant was removed from each well and was 
added to a flat bottomed 96 well plate. 100 µl of LDH reaction mixture (Sigma Aldrich) was then 
added to each well across the plate using a multi-channel pipette (this is essential to ensure 
comparable absorbances). The plate was protected from light and after 30 minutes 15 µl of 1M 
HCl was added to each well with a multi-channel pipette. Any bubbles were popped with a 
needle and the plate was read on a plate reader at 490 nm with a background subtraction at 630 
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nm. Results were expressed as a percentage scaled between the difference in absorbance of a 1% 
triton-X-114 control (dead cells) and a live control with no compound. Blank media was also ran 
in this assay and the absorbance from this was subtracted from all wells. 
LDH assay in a 96 well plate 
After incubation with the CO-RM. The plate with the cells was centrifuged at 500 rpm for 5 
minutes. 50 µl of supernatant was removed from each well and was added to a flat bottomed 96 
well plate. 100 µl of LDH reaction mixture (Sigma Aldrich) was then added to each well across 
the plate using a multi-channel pipette (this is desirable to ensure comparable absorbances).All 
bubbles were popped swith a needle and the plate was read over time at 490 nm (subtraction at 
630 nm) until the absorbance of the 1% triton control reached at least 1.6. This will stop the 
reaction from going too far and enable the detection of low concentrations LDH. The results were 
expressed as a percentage scaled between the difference in absorbance of a 1% Triton-X-114 
control (dead cells) and a live control with no compound. Blank media was also used in this assay 
and the absorbance from this was subtracted from all wells.  
10.5.2 Nitric Oxide quantification: Greiss Assay Details 
A Greiss reagent system was purchased from Promega™ and was used as directed. 
50 µl of medium after overnight incubation with 50 µM CO-RMs 47 and L-75 both in the 
presence and absence of LPS (100 ng ml−1) and IFN-γ (25 U ml−1) was taken and analysed in the 
Greiss assay as directed by the kit instructions.  
10.5.3 Prokaryotic Cell Experiment Details 
10.5.3.1 E.coli W3110 cells: experimental details 
All culture work was carried out under sterile conditions working close to a gas burner flame. 
Plating out cells 
50:50 glycerol/LB media stocks of E.coli W3110 were streaked with a loop on to LB agar plates 
and grown at 37 °C overnight. The plates were then stored at 4 °C and samples were used within 
one month. 
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Liquid medium culture for growth curves 
Bacteria were transferred from the plates grown previously to LB media to give a stock solution 
of E. coli with an OD600 10 times that of the required starting OD for the experiments. 2.7 ml of 
media was added to 8 ml plastic bijou tubes. DMSO (15 µl) was then added for the controls. The 
CO-RM was also added to the tubes in the same volume of DMSO at 200 times the required 
concentration (i.e 20 mM dilutes to 100 µM). 300 µl of E. coli stock solution was then added to 
the 2.7 ml CO-RM/media solutions to give a 3 ml culture volume. The cultures were then grown 
at 37 °C rotating at 100 rpm on an orbital shaker and OD measurements were typically taken 
every hour.  
OD measurements were taken at 600 nm on a Jenway 6305 spectrophotometer. Measurements 
were taken with 300 µl aliquots in Eppendorf UVette® disposable cuvettes. The cuvettes were 
elevated by 3 mm in the sample holder to ensure the beam passed through the liquid correctly. 
Samples were shaken gently in the cuvettes immediately before measuring to ensure a 
homogeneous cell distribution. If the OD600 was expected to go over 0.8, all the samples at that 
time point were diluted by two to keep the OD/bacterial relationship linear. 
Procedure for irradiation of culture under sterile conditions 
The white sterile attachment shown in Figure 171 was stored in ethanol and was wiped dry and 
immediately placed close to the Bunsen burner flame.  
A 300 µl aliquot was taken from the sample and the lid was then replaced with the dry sterile 
attachment. The LED cap was then attached and the vials were wrapped in foil and were 
incubated with 100 rpm rotation.  
The irradiation was then started with each LED typically drawing a current of 200 mA and 
therefore a power of 2.4 W. Irradiation was delivered in 4 mins on, 1 min off cycles to prevent 
the LED from overheating. Irradiation in these experiments was typically carried out for a total of 
68 mins (17 full cycles). 34 minutes of this irradiation was done between 1 and 2 h. Another 34 
mins was delivered between 2 and 3 h. This was to allow for hourly OD measurements to be 
taken. After irradiation was complete the sterile attachment was replaced with a new bijou tube 
lid and aliquots for OD measurements were then taken out as normal for the rest of the 
experiment. 
  
 Figure 171. Left: full setup with
window. Right: 400 nm LED mounted in Falcon tube cap.
Procedure for the assessment of 
300 µl aliquots were taken at 0 h and 4 h during a new experiment. These time points represent 
before and after irradiation in the presence of 100 
then diluted by 50×, 500
agar plates and were incubated at 37 °C overnight.
of the bacteria refers to the time the bacteria were stored on an LB agar plate in a 4°C room under 
ambient light before use.
10.5.3.2 Procedure alterations for work with 
S. aureus was also treated with CO
viability studies with dilution were incubated overnight plus a further 24 h due to slower colony 
growth. All colonies that will actually grow on plain LB agar plates can be seen after the 40h
incubation. Lower dilutions are
E. coli to get sensible colony numbers per plate.
Some initial studies were also carried out with CO
was added to the medium at 40 °C before settin
stored in the dark at 4 °C prior to use. DMSO control plates were also made and stored in the 
same way.  
10.5.3.3 Procedure alterations for work with 
N. gonorrhoeae was stored in 50% MH medi
agar plates with 5% defibrinated horse blood. The horse blood was added to warm melted 
Columbia agar (50 °C) to keep the cells intact before setting. Stocks of 
plated out and grown at 37 °C u
work with. Plates were used within four days of plating out stocks.
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E. coli cell viability.
µM CO-RM and DMSO. These aliquots were 
×, 5000× and 50000×. 50 µl of each dilution was then
 Bacterial colonies were then counted. 
 
S. aureus 8325-4 
-RMs in the same way as E. coli W3110. However plates from 
 typically required in plating studies at the same OD compared to 
 
-RM 9a within set LB agar plates. The CO
g to reduce degradation. The plates were then 
N. gonorrhoeae MS11
um/glycerol stocks and was grown on Columbia 
nder 5% CO2 for 40 h to give sufficient numbers of bacteria to 
 
 
 
 spread on to LB 
The age 
-48h 
-RM 
 
N. gonorrhoeae were 
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N. gonorrhoeae was either grown in RPMI medium or BHI medium with a yeast autolysate 
supplement. The supplement powder was dissolved in 15 ml sterile water and 1.5 ml liquid 
supplement was added to 50 ml of medium. RPMI medium already contains 20 mM Na2CO3 as a 
CO2 source, where as 10 mM Na2CO3 is added to BHI medium via a 1M stock solution.  
DMSO and CO-RM was added to the culture as done previously. After incubation the culture 
was diluted out and grown on plates for viability studies. Plates were grown for 40-48 h to ensure 
that all colonies could be seen by eye. 
In most experiments only two sets of dilutions were chosen to reduce the time at non optimal 
growth conditions. These were chosen based on the starting OD to give sensible numbers of 
colonies to count. 
10.5.4 LegHb expression, extraction and purification 
A Leghaemoglobin DNA sequence from a soya bean plant was expressed in E. coli BL21 using a 
high copy number plasmid with an ampicillin resistance gene. From a −80 °C stock in 50/50 LB 
media/glycerol, E. coli was grown up overnight at 37 °C on an LB agar plate with 100 µg ml−1 
ampicillin (added to liquid agar at 50 °C before setting). A single colony was transferred to 5 ml 
of LB media with 100 µg ml−1 ampicillin in a Sterilin™ tube. This was grown at 37°C on an 
orbital shaker with 225 rpm rotation for 6 hours.  
The 5 ml culture was then transferred to 635 ml of auto induction medium in a 2 L baffled 
conical flask, which consists of the following: 
1. ZY media (590 ml) 
2. 20× NPS (31 ml) 
3. 50×52 (12.5 ml) 
4. 1M MgSO4 (630 µl) 
5. 100 mg ml−1 ampicillin (630 µl) 
6. 1000× metals (630 µl) 
 Stocks of each of these reagents are made up of the following: 
1. 5.99 g tryptone, 2.95 g yeast extract, 590 ml H2O. 
2. 33 g NH4SO4, 68g K2HPO4, 500 ml H2O. 
3. 25 g glycerol, 2.5 g glucose, 10 g α-lactose, 100 ml H2O. 
4. 12.04 g MgSO4 in 100 ml. 
5. 200 mg ampicillin sodium salt, 2ml H2O. 
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6. 50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2, 10 mM ZnSO4, 2 mM CoCl2, 2 mM CuCl2, 2 
mM NiCl2, 2 mM Na2MoO4, 2 mM Na2SeO3, 2 mM H3BO3 in 60 mM HCl. 
 
The culture in auto induction medium was grown at 37 °C overnight with shaking at 120 rpm. 
The culture which was now thick and dark in colour, was centrifuged at 5000 rpm for 15 mins at 
4 °C. The medium was discarded from the red pellet of cells which was subsequently 
resuspended in 35 ml 50mM Tris Buffer pH 9. The suspension of cells was then sonicated in a 50 
ml Falcon™ tube on ice using a standard probe with sonication for 10s/10s on/off cycles for a 
total sonication time of 3 minutes. 
Cell debris was then removed by two centrifugation cycles at 11000 rpm for 15 minutes (4 °C). 
Liquid was transferred to a new Falcon™ after the first centrifugation to remove most of the 
debris. 
The Protein was purified on a 1.5 cm diameter anionic exchange column using DEAE sepharose 
CL6B. The protein was loaded on to the column and was washed with 50mM Tris pH 9 until the 
red band indicative of the protein was running very close to the bottom of the column. The 
protein was then fully eluted using a gradient starting with 30 mM NaCl and 20 mM K2HPO4 
moving to 500mM NaCl. 5 ml eluent fractions were taken and the protein typically eluted in 
fractions 5–12. 
Purity of the protein was checked using an in-house 15% polyacrylamide SDS page gel using a 
set current of 400 mA. 
Upon confirming sufficient purity, the protein solution was concentrated 10 fold using a Vivaspin 
20 MWCO (PES) 5,000 Falcon ™ tube. The resultant protein solution was desalted by diluting 
10 fold with 10 mM Tris pH 7.4 and concentrating the new solution with the Vivaspin tube 10 
fold. This dilution with Tris buffer was performed once more to dilute any salt in the solution by 
a total 100 fold. 
The protein was divided in to aliquots and was stored at −20 °C and was used within two months 
of preparation. 
The concentration of the protein was determined by UV/visible spectroscopy using a literature 
molar extinction coefficient for Ferrous-Lb of 13000 mol−1 dm3 cm−1 (555 nm).127 
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10.6 General X-ray Diffraction details and data 
10.6.1 Details of general procedure from X-ray diffraction service 
Diffraction data wascollected at 110 K on an Oxford Diffraction SuperNova diffractometer with 
Mo-Ka radiation (l = 0.71073 Å) using a EOS CCD camera. The crystal was cooled with an 
Oxford Instruments Cryojet. Diffractometer control, data collection, initial unit cell 
determination, frame integration and unit-cell refinement was carried out with “Crysalis”. Face-
indexed absorption corrections were applied using spherical harmonics, implemented in SCALE3 
ABSPACK scaling algorithm. OLEX2 was used for overall structure solution, refinement and 
publication data. Within OLEX2, the algorithm used for structure solution was Superflip, 
refinement by full-matrix least-squares used theSHELXL-97. All non-hydrogen atoms were 
refined anisotropically. Hydrogen atoms were placed using a “riding model” and included in the 
refinement at calculated positions. 
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10.6.1.1 X-ray Crystal Structure Data and Images 
 
 
Figure 172. X-ray crystal structure of complex 39. Atoms displayed as ellipsoids at 50% 
probability. Hydrogen atoms omitted for clarity. Crystallised from CH2Cl2/Hexane. Selected 
bond lengths (Å) and angles(°):Mn(1)-C(1) = 1.8530(16) , Mn(1)-N(1) = 2.0569(13), Mn(1)-C(2) 
= 1.7999(13), Mn(1)-C(3) = 1.8318(17), Mn(1)-C(4) = 1.8624(16), Mn(1)-C(5) = 2.0412(16); 
C(5)-Mn(1)-C(3) = 175.23(7), C(1)-Mn(1)-N(1) = 90.21(6), C(3)-Mn(1)-C(2) = 90.94(7), C(2)-
Mn(1)-N(1) = 173.07(6), C(3)-Mn(1)-N(1) =95.98(6) , C(4)-Mn(1)-N(1) =88.22(6), N(1)-Mn(1)-
C(5) = 79.54(6) 
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Table 33. Crystal data and structure refinement for complex 39 
Identification code ijsf1224 
Empirical formula C15H7NO4ClMn 
Formula weight 355.61 
Temperature/K 110.00(10) 
Crystal system monoclinic 
Space group P21/c 
a/Å 10.1290(4) 
b/Å 10.2171(2) 
c/Å 13.7629(3) 
α/° 90.00 
β/° 101.871(3) 
γ/° 90.00 
Volume/Å3 1393.86(6) 
Z 4 
ρcalcmg/mm3 1.695 
m/mm-1 1.155 
F(000) 712.0 
Crystal size/mm3 0.2648 × 0.1908 × 0.03 
2Θ range for data collection 5.72 to 64.18° 
Index ranges -14 ≤ h ≤ 9, -14 ≤ k ≤ 14, -20 ≤ l ≤ 19 
Reflections collected 8831 
Independent reflections 4427[R(int) = 0.0235] 
Data/restraints/parameters 4427/0/199 
Goodness-of-fit on F2 1.052 
Final R indexes [I>=2σ (I)] R1 = 0.0338, wR2 = 0.0767 
Final R indexes [all data] R1 = 0.0452, wR2 = 0.0842 
Largest diff. peak/hole / e Å-3 0.48/-0.34 
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Figure 173. X-ray crystal structure of complex 40. Atoms displayed as ellipsoids at 50% 
probability. Hydrogen atoms omitted for clarity. Crystallised from CH2Cl2/Hexane. Selected 
bond lengths (Å) and angles(°):Mn(1)-C(11) = 2.0477(17) , Mn(1)-N(1) = 2.0638(14), Mn(1)-
C(15) = 1.8007(18), Mn(1)-C(12) = 1.8642(19), Mn(1)-C(13) = 1.8401(19), Mn(1)-C(14) = 
1.8544(19); C(14)-Mn(1)-C(12) = 168.51(8), C(13)-Mn(1)-C(12) = 95.58(8), C(11)-Mn(1)-C(15) 
= 93.25(7), (13)-Mn(1)-N(1) =96.04(7), C(15)-Mn(1)-N(1) = 172.80(7), C(14)-Mn(1)-N(1) 
=90.03(7) , C(12)-Mn(1)-N(1) =88.03(7), N(1)-Mn(1)-C(11) = 79.55(6) 
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Table 34. Crystal data and structure refinement for complex 40 
Identification code ijsf1123 
Empirical formula C15H7NO4MnBr 
Formula weight 400.07 
Temperature/K 110.00(10) 
Crystal system monoclinic 
Space group P21/c 
a/Å 10.2503(2) 
b/Å 10.2194(2) 
c/Å 13.8964(2) 
α/° 90.00 
β/° 100.7783(16) 
γ/° 90.00 
Volume/Å3 1430.00(5) 
Z 4 
ρcalcmg/mm3 1.858 
m/mm-1 3.733 
F(000) 784.0 
Crystal size/mm3 0.2326 × 0.2016 × 0.1628 
2Θ range for data collection 5.68 to 64° 
Index ranges -13 ≤ h ≤ 14, -7 ≤ k ≤ 14, -12 ≤ l ≤ 20 
Reflections collected 7682 
Independent reflections 4528[R(int) = 0.0211] 
Data/restraints/parameters 4528/0/199 
Goodness-of-fit on F2 1.056 
Final R indexes [I>=2σ (I)] R1 = 0.0303, wR2 = 0.0658 
Final R indexes [all data] R1 = 0.0407, wR2 = 0.0701 
Largest diff. peak/hole / e Å-3 0.53/-0.48 
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Figure 174. X-ray crystal structure of BnMn(CO)5 (42). Atoms displayed as ellipsoids at 50% 
probability. Hydrogen atoms omitted for clarity. Crystals obtained by sublimation. Selected bond 
lengths (Å) and angles(°):Mn(1)-C(1) = 2.2071(13) , Mn(1)-C(8) = 1.8483(14), Mn(1)-C(9) = 
1.8501(14), Mn(1)-C(10) = 1.8720(14), Mn(1)-C(11) = 1.8514(14), Mn(1)-C(12) = 1.8292(15); 
C(1)-Mn(1)-C(12) = 177.78(6), C(1)-Mn(1)-C(11) = 84.58(6), C(1)-Mn(1)-C(10) = 88.93(5), 
C(1)-Mn(1)-C(9) =84.52(7),   C(10)-Mn(1)-C(8) = 173.01(7),  C(11)-Mn(1)-C(9) =169.06(6) , 
C(8)-Mn(1)-C(11) =89.15(6), Mn(1)-C(8)-O(1) = 178.16(13). 
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Table 35. Crystal data and structure refinement for complex 42 
Identification code ijsf1229a 
Empirical formula C12H7O5Mn 
Formula weight 286.12 
Temperature/K 109.95(10) 
Crystal system monoclinic 
Space group P21/n 
a/Å 6.9018(3) 
b/Å 6.5722(3) 
c/Å 27.1897(13) 
α/° 90.00 
β/° 96.969(4) 
γ/° 90.00 
Volume/Å3 1224.21(9) 
Z 4 
ρcalcmg/mm3 1.552 
m/mm-1 1.086 
F(000) 576.0 
Crystal size/mm3 0.1428 × 0.1377 × 0.0636 
2Θ range for data collection 5.96 to 60.04° 
Index ranges -9 ≤ h ≤ 9, -9 ≤ k ≤ 9, -38 ≤ l ≤ 36 
Reflections collected 10916 
Independent reflections 3583[R(int) = 0.0278] 
Data/restraints/parameters 3583/0/163 
Goodness-of-fit on F2 1.076 
Final R indexes [I>=2σ (I)] R1 = 0.0297, wR2 = 0.0691 
Final R indexes [all data] R1 = 0.0342, wR2 = 0.0717 
Largest diff. peak/hole / e Å-3 0.37/-0.36 
 
  
 Figure 175. X-ray crystal structure of complex 
probability. Hydrogen atoms omitted for clarity. Crystallised from CH
bond lengths (Å) and angles(°):Mn(1)
= 1.8053(16), Mn(1)-C(3) = 1.8389(16
C(5)-Mn(1)-C(3) = 174.25(6), C(3)
Mn(1)-N(1) = 173.20(6),  C(3)
Mn(1)-C(5) = 79.41(5).
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64. Atoms displayed as ellipsoids at 50% 
2Cl
-C(1) = 1.8459(17) , Mn(1)-N(1) = 2.0678(12),
), Mn(1)-C(4) = 1.8565(19), Mn(1)
-Mn(1)-C(2) = 91.73(7), C(1)-Mn(1)
-Mn(1)-N(1) =96.89(7) , C(4)-Mn(1)-N(1) =
 
 
 
2/Hexane. Selected 
 Mn(1)-C(2) 
-C(5) = 2.0431(14); 
-N(1) = 90.73(6), C(2)-
 90.09(6), N(1)-
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Table 36. Crystal data and structure refinement for 64 
Identification code ijsf1223 
Empirical formula C15H8MnNO5 
Formula weight 337.16 
Temperature/K 110.00(10) 
Crystal system monoclinic 
Space group P21/c 
a/Å 8.6436(3) 
b/Å 6.9498(3) 
c/Å 22.1788(8) 
α/° 90.00 
β/° 91.922(3) 
γ/° 90.00 
Volume/Å3 1331.54(9) 
Z 4 
ρcalcmg/mm3 1.682 
m/mm-1 1.015 
F(000) 680.0 
Crystal size/mm3 0.2531 × 0.2374 × 0.0543 
2Θ range for data collection 5.88 to 60.06° 
Index ranges -9 ≤ h ≤ 12, -9 ≤ k ≤ 9, -31 ≤ l ≤ 21 
Reflections collected 7330 
Independent reflections 3892[R(int) = 0.0206] 
Data/restraints/parameters 3892/0/203 
Goodness-of-fit on F2 1.053 
Final R indexes [I>=2σ (I)] R1 = 0.0321, wR2 = 0.0748 
Final R indexes [all data] R1 = 0.0372, wR2 = 0.0776 
Largest diff. peak/hole / e Å-3 0.43/-0.33 
 
  
 Figure 176. X-ray crystal structure of complex 
probability. Hydrogen atoms omitted for clarity. Crystallised from CH
bond lengths (Å) and angles(°):Mn(1)
= 1.8660(14), Mn(1)-C(3) = 1.8263(14), Mn(1)
N(1)-Mn(1)-C(1) = 172.00(5), N(1)
Mn(1)-C(4) =90.38(5),   N(1)
Mn(1)-C(3) =92.67(6). 
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45. Atoms displayed as ellipsoids at 50% 
2Cl
-N(1) = 2.0672(11) , Mn(1)-C(1) = 1.8148(14), Mn(1)
-C(4) = 1.8527(14), Mn(1)
-Mn(1)-C(2) = 88.23(5), N(1)-Mn(1)
-Mn(1)-C(5) = 80.08(5), C(2)-Mn(1)-C(4) =169.52(6) , C(1)
 
 
2/Hexane. Selected 
-C(2) 
-C(5) = 2.0528(13); 
-C(3) = 95.30(5),   N(1)-
-
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Table 37. Crystal data and structure refinement for 45 
Identification code ijsf1124 
Empirical formula C18H12NO7Mn 
Formula weight 409.23 
Temperature/K 110.00(10) 
Crystal system triclinic 
Space group P-1 
a/Å 7.0000(4) 
b/Å 11.2458(6) 
c/Å 12.1356(8) 
α/° 67.181(6) 
β/° 83.042(5) 
γ/° 86.381(4) 
Volume/Å3 873.93(9) 
Z 2 
ρcalcmg/mm3 1.555 
m/mm-1 0.797 
F(000) 416.0 
Crystal size/mm3 0.2161 × 0.1857 × 0.0987 
2Θ range for data collection 5.86 to 64.52° 
Index ranges -9 ≤ h ≤ 9, -15 ≤ k ≤ 16, -18 ≤ l ≤ 17 
Reflections collected 9348 
Independent reflections 5500[R(int) = 0.0247] 
Data/restraints/parameters 5500/0/245 
Goodness-of-fit on F2 1.062 
Final R indexes [I>=2σ (I)] R1 = 0.0322, wR2 = 0.0796 
Final R indexes [all data] R1 = 0.0371, wR2 = 0.0831 
Largest diff. peak/hole / e Å-3 0.48/-0.42 
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Appendix 1 
1H NMR spectra of prepared compounds 
 
Figure A1. 400 MHz 1H NMR spectra of phenylpyridine ligands 32-35 in CDCl3 at 300 K. 
35 
34 
33 
32 
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Figure A2. 400 MHz 1H NMR spectra of BnMn(CO)5 (42) in CDCl3 at 300 K. 
 
 Figure A3. 400 MHz 1H NMR spectra of manganese
Figure A4. 1H NMR spectrum of 2(4
39 
38 
41 
40 
324 
(I) complexes 38-41
-hydroxyphenyl)pyridine(43) in CDCl
 in CDCl3 at 300 K 
 
3 at 300 K 
 Figure A5. 400 MHz 1H NMR spectrum of methyl [4
CDCl3 at 300 K
Figure A6.400 MHz 1H NMR spectrum of 
300 K 
325 
-(pyridin-2-yl)phenoxy]acetate
2-(4-hydroxymethyl-phenyl)pyridine
 
 (44) in 
 
 (50) in CDCl3 at 
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Figure A7. 1H NMR spectrum of tetracarbonyl (2-(4-hydroxyphenyl)κ,C2-pyridine-κ,N) 
manganese(I) (64) in CDCl3 at 300 K. 
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Figure A8. 1H NMR spectrum of tetracarbonyl (methyl [4-(pyridin-2-yl-κ,N)phen-κ,C2-
oxy]acetate) manganese(I) (45) in CDCl3 at 300 K. 
  
N
O
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O
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Figure A9. 1H NMR spectrum of methyl [4-(pyridin-2-yl)phenoxy]acetic acid (46) in DMSO-d6 
at 300 K. 
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Figure A10. 1H NMR spectrum of methyl tetracarbonyl (methyl [4-(pyridin-2-yl-κ,N)phen-κ,C2-
oxy]acetic acid) manganese(I) (47) in DMSO-d6 at 300 K. 
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Figure A11. 400 MHz 1H NMR spectrum of 2-[4-(prop-2-ynyloxy)phenyl]pyridine (51) in 
CDCl3 at 300 K. 
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Figure A12. 400 MHz 1H NMR spectrum of 2-(4-[(prop-2-ynyloxy)methyl]phenyl)pyridine (52) 
in CDCl3 at 300 K. 
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Figure A13. 400 MHz 1H NMR spectrum of 2-[4-(3-triisopropylsilyl-prop-2-
ynyloxy)phenyl]pyridine (57) in CDCl3 at 300 K. 
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Figure A14. 400 MHz 1H NMR spectrum of 2-(4-[(3-triisopropylsilyl-prop-2-ynyl-
oxy)methyl]phenyl) pyridine (58) in CDCl3 at 300 K. 
  
334 
 
 
Figure A15. 400 MHz 1H NMR spectrum of tetracarbonyl 2-[4-(3-triisopropylsilyl-prop-2-
ynyloxy)phenyl]κ,C2-pyridine-κ,N) manganese(I) (59) in CDCl3 at 300 K. 
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Figure A16. 400 MHz 1H NMR spectrum of tetracarbonyl 2-(4-[(3-triisopropylsilyl-prop-2-ynyl-
oxy)methyl]phenyl) κ,C2-pyridine-κ,N) manganese(I) (60) in CDCl3 at 300 K. 
  
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
ppm
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ppm
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Figure A17. 400 MHz 1H NMR spectrum of 2-[4-(prop-2-ynyloxy)phenyl] κ,C2-pyridine-κ,N) 
manganese(I) (62) in CDCl3 at 300 K. 
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Figure A18. 400 MHz 1H NMR spectrum of tetracarbonyl 2-(4-[(prop-2-ynyloxy)methyl]phenyl) 
κ,C2-pyridine-κ,N) manganese(I) (63) in CDCl3 at 300 K. 
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Figure A19. 400 MHz 1H NMR spectrum of 3-azido-1-propylamine (67) in CDCl3 at 300 K. 
 
Figure A20. 400 MHz 1H NMR spectrum of biotin-NHS(69) in DMSO-d6 at 300 K. 
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Figure A21. 400 MHz 1H NMR spectrum of biotinyl-azide(70) in d3-MeOD at 300 K. 
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Figure A22. 700 MHz 1H NMR spectrum of tetracarbonyl (2-[4-(([1-(4-carboxyphenyl)-1H-
1,2,3-triazol-4-yl]methoxy)methyl)phenyl κ,C2]pyridine κ,N) manganese(I) (65) in DMSO-d6 at 
300 K. 
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Figure A23. 400 MHz 1H NMR spectrum of CO-RM (71) in MeOD-d4 at 300 K 
 
Figure A24. 400 MHz 1H NMR spectrum of CO-RM L-75 in DMSO-d6 at 300 K 
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Figure A25. 400 MHz 1H NMR spectrum of azodye 76 in CDCl3 at 300 K 
 
Figure A26. 400 MHz 1H NMR spectrum of dye CO-RM 77 in CD2Cl2 at 300 K 
S
N
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13C NMR spectra of prepared compounds 
 
Figure A27. 100 MHz 13C NMR spectra of manganese complexes 32-35 in CDCl3 at 300 K 
N
Cl33 
32 
35 
34 
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Figure A28. 100 MHz 13C NMR spectra of manganese complexes 38-41 in CDCl3 at 300 K 
 
Figure A29. 121 MHz 13C NMR spectra of manganese complex 40 in CDCl3 at 298K with 10000 
scans to show metal carbonyl signals. 
115120125130135140145150155160165170175180185190195200205210215220
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Figure A30. 100 MHz 13C NMR spectrum of 2(4-hydroxy-phenyl)pyridine(43) in CDCl3 at 300 
K 
 
 
Figure A31.100 MHz 13C NMR spectrum of methyl [4-(pyridin-2-yl)phenoxy]acetate (44) in 
CDCl3 at 300 K. 
346 
 
 
Figure A32. 100 MHz 13C NMR spectrum of 2-(4-hydroxymethyl-phenyl)pyridine (50) in CDCl3 
at 300 K 
 
Figure A33. 100 MHz 13C NMR spectrum of tetracarbonyl (2-(4-hydroxy-phenyl)κ,C2-pyridine-
κ,N) manganese(I) (64) in CDCl3 at 300 K. 
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Figure A34. 100 MHz 13C NMR spectrum of tetracarbonyl (methyl [4-(pyridin-2-yl-κ,N)phen-
κ,C2-oxy]acetate) manganese(I) (45) in CDCl3 at 300 K. 
 
Figure A35. 100 MHz 13C NMR spectrum of methyl [4-(pyridin-2-yl)phenoxy]acetic acid (46) in 
DMSO-d6 at 300 K. 
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Figure A36. 100 MHz 13C NMR spectrum of tetracarbonyl (methyl [4-(pyridin-2-yl-κ,N)phen-
κ,C2-oxy]acetic acid) manganese(I) (47) in DMSO-d6 at 300 K. 
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Figure A37. 100 MHz 1H NMR spectrum of 2-[4-(prop-2-ynyloxy)phenyl]pyridine (51) in 
CDCl3 at 300 K. 
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Figure A38. 100 MHz 13C NMR spectrum of 2-(4-[(prop-2-ynyloxy)methyl]phenyl)pyridine (52) 
in CDCl3 at 300 K. 
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Figure A39. 400 MHz 1H NMR spectrum of 2-[4-(3-triisopropylsilyl-prop-2-
ynyloxy)phenyl]pyridine (57) in CDCl3 at 300 K. 
 
Figure A40: 100 MHz 13C NMR spectrum of 2-(4-[(3-triisopropylsilyl-prop-2-ynyl-
oxy)methyl]phenyl) pyridine (58) in CDCl3 at 300 K. 
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Figure A41. 100 MHz 13C NMR spectrum of tetracarbonyl 2-[4-(3-triisopropylsilyl-prop-2-
ynyloxy)phenyl]κ,C2-pyridine-κ,N) manganese(I) (59) in CDCl3 at 300 K. 
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Figure A42. 100 MHz 13C NMR spectrum of tetracarbonyl 2-(4-[(prop-2-
ynyloxy)methyl]phenyl) κ,C2-pyridine-κ,N) manganese(I) (60) in CDCl3 at 300 K. 
 
Figure A43. 100 MHz 13C NMR spectrum of 2-[4-(prop-2-ynyloxy)phenyl] κ,C2-pyridine-κ,N) 
manganese(I) (62) in CDCl3 at 300 K. 
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Figure A44. 100 MHz 13C NMR spectrum of tetracarbonyl 2-(4-[(prop-2-
ynyloxy)methyl]phenyl) κ,C2-pyridine-κ,N) manganese(I) (63) in CDCl3 at 300 K. 
 
Figure A45. 100 MHz 13C NMR spectrum of 3-aminopropylazide (67) in CDCl3 at 300 K. 
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Figure A46. 100 MHz 13C NMR spectrum of biotinyl-NHS(69) in DMSO-d6 at 300 K. 
 
Figure A47. 100 MHz 13C NMR spectrum of biotinyl-azide(70) in d3-MeOD at 300 K. 
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Figure A48. 176 MHz 13C NMR spectrum of tetracarbonyl (2-[4-(([1-(4-carboxy-phenyl)-1H-
1,2,3-triazol-4-yl]methoxy)methyl)phenyl κ,C2]pyridine κ,N) manganese(I) (65) in DMSO-d6 at 
299K. 
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Figure A49. 176 MHz 1H NMR spectrum of BB-CO-RM (71) in MeOD-d4 at 263 K with 22000 
scans. 
 
Figure A50. 100 MHz 13C NMR spectrum of azodye 76 in CDCl3 at 300 K 
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Figure A51. 100 MHz 13C NMR spectrum of CO-RM 77 in CD2Cl2 at 300 K 
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11 Abbreviations 
• CO-RM - Carbon monoxide-releasing molecule 
• CO - Carbon monoxide 
• NO - Nitric oxide 
• DMSO - Dimethyl sulfoxide 
• THF - Tetrahydrofuran 
• +ve - Positive 
• cGMP - Cyclic guanosine mono-phosphate 
• GTP - Guanosine triphospphate 
• HO - Haem oxygenase 
• Hb - Haemoglobin 
• Mb - Myoglobin 
• Lb - Leghaemoglobin 
• CO-Mb - Carboxy myoglobin 
• CO-Hb - Carboxy haemoglobin 
• NADPH - Nicotinamide adenine dinucleotide phosphate 
• UDP - Uridine diphosphate 
• VASP - Vasodilator-stimulated phosphoprotein 
• TNF - Tumor necrosis factor 
• NSAID - Non-steroidal anti-inflammatory drug 
• sGC - soluble guanylyl cyclase 
• EAE - Experimental allergic encephalomyelitis 
• IR - Infrared 
• NMR - Nuclear magnetic resonance 
• PLE - Pig liver esterase 
• 5-FU - 5-fluorouracil 
• MDM2 protein - mouse double minute 2 protein 
• DMF - N,N-dimethylformamide 
• MCF-7 - Michigan Cancer Foundation cell strain 7 
• LB medium - lysogency broth medium 
• DMEM - Dulbecco’s modified eagle medium 
• FCS - foetal calf serium. 
• PBS - Phosphate buffer saline 
• LDH - Lactate dehydrogenase 
• OD - optical density 
• s - singlet 
• d - doublet 
• t - triplet 
• q - quartet 
• qn - quintet 
• TMS - trimethylsilyl 
• TIPS - triisopropylsilyl 
• LDA - lithium diisopropylamide 
• ITC - isothermal titration calorimetry 
• ESI-MS - Electrospray ionisation mass spectrometry 
• BHI - Brain heart infusion 
• RPMI - Roswell Park Memorial Institute 
• µM - micromolar 
• nm - nanometres 
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• mM - millimolar 
• mm - millimetres 
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